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SUMMARY
The pharmacokinetics and serum thromboxane inhibition of four non-steroidal anti­
inflammatory drugs (NSADDs) were determined after administration to dogs by the 
intravenous, subcutaneous and oral routes.
Flunixin meglumine was first administered at three oral dose rates, 0.55, 1.10 and 1.65 
mg/kg, to determine a likely suitable dose rate by this route. At each dose rate the mean 
maximum plasma concentration of drug (Cmax ) occurred between 1 and 2 hours. After 
0.55, 1.10 and 1.65 mg/kg the Cmax increased approximately in relation to the dose rate 
and values were 2.77 ± 0.63,5.03 ± 0.99 and 8.17 ± 2.02 pg/ml respectively. The mean area 
under the plasma concentration versus time curve (AUC) was 9.01,14.62 and 25.98 |ig/ml.h after 
0.55,1.10 and 1.65 mg/kg. Maximum mean inhibition of serum thromboxane (TxB2) was 91.47,
98.84 and 97.31 % and occurred between 1 and 2 hours. The area under the TxB2 inhibition 
versus time curve was not linearly related to dose rate and was determined to be 5238, 
5952 and 6169 %.h respectively for 0.55, 1.10 and 1.65 mg/kg dose rates . On the basis of 
the findings from the oral experiments the 1.10 mg/kg dose rate was selected for study after 
intravenous and subcutaneous administration.
The decline in plasma concentration of flunixin meglumine after intravenous administration 
was best described by a bi-exponential equation. The mean half life of elimination (t V2B) in 
dogs was 2.97 hours and the mean volume of distribution at steady state (Vdss) was 
189.23 ± 46.70 ml/kg. The AUC from observed values after administration at a dose rate 
of 1.10 mg/kg was 20.47 ± 2.60 pg/ml.h.
Determination of the AUC after intravenous administration allowed calculation of the 
bioavailability (F) after oral administration. After normalisation for dose rate the 
bioavailability after oral administration of flunixin to dogs was 74.8,60.66 and 69.8 %.for 
the 0.55,1.10 and 1.65 mg/kg dose rates respectively, thus indicating that absorption was 
approximately linearly related to dose rate administered.
The maximum mean inhibition of serum TxB2 after intravenous administration was 99.87 
% (0.5 hours), and the area under the TxB2 inhibition versus time curve was 2148 %.h, 
approximately 36 % of the area under the TxB2 inhibition versus time curve obtained after 
the equivalent dose rate administered by the oral route.
After subcutaneous administration at a dose rate of 1.10 mg/kg the Cmax of flunixin in 
plasma was 6.36 |ig/ml, and this occurred at 0.92 hours. Bioavailability was excellent after 
subcutaneous administration, the AUC being 26.30 ± 4.73 |ig/ml.h (F=101.09 %).
viii
The maximum mean inhibition of TxB2 after subcutaneous administration was 
approximately equal to that after intravenous administration (99.73 % at 1 hour), as was 
the
area under the TxB2 inhibition versus time curve. This AUC was also approximately half 
of the AUC produced by the oral administration of the same dose rate.
No adverse reactions were observed after administration of flunixin meglumine to dogs.
After administration at a dose rate of 0.3 mg/kg by the intravenous route to dogs, the 
decline in plasma concentration of piroxicam was best described by a single exponential 
equation. The fit of the mathematically modelled best fit curve was very poor for all 
animals. The tV2^ was calculated to be 40.16 hours and the Vdss calculated from observed 
data was 178.37 ml/kg. The observed AUC of piroxicam after intravenous administration 
was 47.39 |ig/ml.h. The maximum mean inhibition of serum TxB2 was 96.85 % and this 
occurred at 0.25 hours after drug administration. The area under the mean TxB2 inhibition 
versus time curve was 5309 %.h.
The Cmax of piroxicam after oral administration at a dose rate of 0.3 mg/kg was 1.35 ± 
0.11 |ig/ml, and occurred at 3.33 (± 1.09 hours). The AUC was 46.77 |ig/ml.h showing 
that the oral bioavailability of piroxicam was excellent (F = 102.69 %). The mean 
maximum inhibition of serum TxB2 occurred at 1 hour and was lower than that measured 
after intravenous administration (72.45 ± 3.38 %). The AUC for mean TxB2 inhibition 
versus time was approximately 77 % of that after intravenous administration (4067 %.h). 
The intravenous administration of piroxicam was complicated by its poor aqueous 
solubility and the need to administer it in ethanol. Some symptoms typical of ethanol 
intoxication were noted after intravenous administration, however these did not persist 
beyond the first 30 minutes after drug administration.
Large decreases in the number of blood platelets were also detected in dogs after 
intravenous administration of piroxicam. Although some improvement was noted 
throughout the sampling times, numbers had not returned to normal by the final sampling 
times. It is unlikely that this effect was as a result of piroxicam administration as a similar 
effect was not observed after oral administration of the drug. It is possible that the decrease 
in platelet numbers was a result of ethanol administration. However, previously recorded 
ethanol induced thrombocytopenia has only been been associated with chronic alcohol 
consumption.
Piroxicam was otherwise well tolerated after administration to dogs by the intravenous and 
oral routes.
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Cinchophen was administered to dogs in combined preparations which contained 
prednisolone. Both intravenous and oral administration were at a dose rate of 12.5 mg/kg 
for cinchophen. As proportions of cinchophen and prednisolone differed in the intravenous 
and oral preparations, this resulted in dose rate of 0.15 and 0.06 mg/kg for prednisolone. 
The decline in plasma concentration of cinchophen after intravenous administration was 
best described by a bi-exponential equation for four of the six animals. The plasma 
concentration versus time curves for dogs 5 and 6  were best described by a single 
exponential equation. The profile of the curves however, suggested that a proportion of the 
drug may have been injected peri-venously although there was no indication of this at the 
time of drug administration. Pharmacokinetic values from these animals have been 
excluded from mean values. The tV2B of cinchophen after intravenous administration was
6.84 hours and the Vdss was 109.73 ± 6.88  ml/kg.The AUC calculated from observed 
values was 1067.76 (± 148.87) p.g/ml.h.
Mean maximum inhibition of TxB2 was 71.28 % and occurred at 10 minutes (0.17 hours). 
The area under the serum TxB2 inhibition versus time curve was 865 %.h.
After oral administration the Cmax of cinchophen was 80.54 (±5.96) |ig/ml and occurred at 
1.92 ± 0.49 hours. As a result of differences in the final sampling times after intravenous 
and oral administration it was necessary to calculate the bioavailability over a period of 48 
hours. The oral bioavailability of cinchophen based on data from four dogs was 95.93 (± 
14.65) %.
The maximum mean inhibition of serum TxB2 was considerably lower after oral 
administration than after intravenous administration (50.43 ± 9.29 %) and occurred at 1 
hour. Inhibition did not exceed 71 % in any sample. The mean area under the serum TxB2 
inhibition versus time curve was 636 %.h, approximately 73 % of that obtained after 
intravenous administration.
No adverse reactions were noted after administration of cinchophen by either route.
Tolfenamic acid was administered to dogs at a dose rate of 4.0 mg/kg by the intravenous 
and subcutaneous routes. After intravenous administration the decline in plasma drug 
concentration was best defined by a bi-exponential equation, however, in all animals this 
model was a poor fit. The tV2B was 5.91 hours and the observed AUC was 18.10 ± 4.12 
Hg/ml.h. A comparatively large Vdss was measured (1246.66 ± 293.34 ml/kg). The mean 
maximum TxB2 inhibition was 91.30 %, and the area under the serum TxB2 inhibition 
versus time curve after intravenous administration was 1857.02 %.h.
After subcutaneous administration a Cmax of 4.39 (± 0.55) pg/ml was measured at 1.40 (± 
0.24) hours and the observed AUC was 29.62 pg/ml.h. In all but one animal the 
bioavailability after subcutaneous administration was calculated to be in excess of 100 % 
and the mean value was 165.70 ± 3.10 %. The maximum mean TxB2 inhibition was 
slightly lower than that measured after intravenous administration (80.37 %). However, 
the overall area under the TxB2 inhibition versus time curve was approximately 1.5 times 
that after intravenous administration (2784.64 %.h).
The profiles of the plasma concentration versus time curves for flunixin, piroxicam, 
cinchophen and tolfenamic acid, were typical of those seen for drugs known to undergo 
enterohepatic circulation.
Serum protein binding of flunixin and meclofenamic acid was measured for dogs, goats 
and horses. A wide inter-species variation in protein binding was found. Inter-species 
variation was greatest for meclofenamic acid for which binding was 94, 84 and 100 % 
respectively for dogs, goats and horses. Protein binding for flunixin in these species was 
92, 87 and 87 % respectively.
In vitro inhibition of serum TxB2 production by flunixin and meclofenamic acid was 
determined using blood from dogs, goats and horses. Production of TxB2 was less 
sensitive to inhibition by flunixin in the dog than in the goat or horse and IC50 values of 
0.104, 0.018 and 0.036 pM, respectively, were measured. Overall, considerably higher 
concentrations were required to achieve the IC50 in these species using meclofenamic acid. 
The IC50 values calculated for this drug in vitro were 0.707, 0.757 and 0.299 pM 
respectively, for dog goat and horse.
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Chapter 1 
GENERAL INTRODUCTION
21.1 SOME HISTORIC ASPECTS OF INFLAMMATION
It is thought that the process of inflammation may have first been recognised almost 2000 
years ago. Early medical writings from Egypt dating from about 1650 B.C. include a 
word which can be translated as "inflammation” and which was used to describe 
wounds. These scrolls are thought to contain material first recorded in writings produced 
1000 years earlier. It was not, however, until sometime during the first century A.D. that 
the major signs of inflammation were set out by Cornelius Celsus, thereby providing an 
early clinical definition of inflammation.
The four "cardinal signs" - "rubor et tumor cum calor et dolore" (redness and swelling 
with heat and pain) remain the classical definition to this day. The only change being the 
addition of a fifth sign "functio laesa" ("disturbed function") by Rudolph Virchow during 
the 19th century.
Advances in science during the 19th century allowed some progress to be made towards 
understanding the tissue changes responsible for the appearance of the cardinal signs. 
The study of the microcirculation of frog mesentry after trauma led Cohnheim (1867) to 
recognise and describe its role in the pathology of inflammation.
1.2. CHANGES SEEN IN INFLAMMATION
The macroscopic changes - erythema, oedema, tenderness and pain seen as a response to 
tissue damage are a product of many underlying processes both vascular and cellular 
(figure 1.1). The precise nature of the processes is complex and is dependant to some 
extent upon whether the inflammation is acute or chronic.
During acute inflammation characteristic changes at the site of injury include dilation and 
increased permeability of the small blood vessels resulting in leakage of fluid into the 
interstitial spaces. Dilation of vessels at the site of injury has been shown to result in an 
increased blood flow of up to ten times normal levels (Ascheim and Zweifach, 1962) and 
this response may last for several hours. Small vessels are normally fully permeable to 
water but only slightly permeable to plasma proteins. As a result of increased 
permeability, passage of plasma proteins into the extravascular tissue increases (Majno 
and Palade, 1961) and leucocytes also pass through the walls of small blood vessels in 
the damaged area (Cohnheim, 1882). Initially, polymorphonuclear leucocytes (PMNs, 
neutrophils) are most abundant at the site of inflammation. These cells migrate in 
response to chemotactic factors released from injured cells which exist in a concentration 
gradient, increasing towards the site of injury. It is thought that PMNs are able to detect
3the concentration gradient of chemoattractants by spacial sensing (Zigmond, 1974), that 
is, by detecting the difference in concentration across the cell's own length. When cells 
are close to the source of chemotactic chemicals their movement becomes more random 
due to the absence of a gradient and, although movement continues, it acts to keep the 
PMNs moving within the area of injury. In addition to stimulation of chemotaxis, 
increased adhesiveness of PMNs is seen to occur at this time. This aids the escape of 
cells through vessel walls and later accumulation at the target site (Wilkinson, 1978). On 
arrival at the site of injury PMNs begin to phagocytose any particulate matter, such as 
bacteria, which may be present. It is thought that they may also secrete lysosomal 
contents directly into the area. Some lysosomal discharge can occur during phagocytosis, 
however even in the absence of phagocytosis secretion of lysosomal content has been 
noted. This phenomenon, sometimes referred to as 'reverse endocytosis' (Henson, 
1971a, Henson, 1972, Weissmann et al. 1972), may occur as a result of leucocyte 
exposure to immune complexes on a surface which is not capable of being phagocytosed 
by the cell (Hawkins, 1971, Henson 1971b). Release of lysosomal enzymes has also 
been noted when certain materials such as crystals of monosodium urate gain access to 
the vacuolar system of the cell resulting in cell damage and death (Allison, 1971). Such 
episodes are seen to appear in inflammation associated with acute gout (McCarty and 
Hollander, 1961). Release of lysosomal enzymes aids the digestion of dead tissue cells 
and the process of suppuration is the extensive manifestation of this process in one area. 
In addition to the possible benefits of this process, it is known to cause tissue damage 
and initiate the formation of tissue destructive free radicals of oxygen which in turn 
results in the formation of lipid peroxides (Oyanagui, 1976, McCord et al, 1979). These 
highly reactive substances are thought to stimulate the activity of phospholipases resulting 
in the release of arachidonic acid from phospholipid (Rainsford 1984a). Material which 
cannot be disposed of in this way is ingested and removed by macrophages. The overall 
increase in cells within the extravascular space due to vessel fenestration will also 
facilitate accumulation of cells at the site of inflammation. Additionally, it has been seen 
in vitro that damaged cells are able to stimulate chemotaxis of leucocytes by the release of 
chemotactic factors. Cytotoxins are released from viral infected cells (Ward et al. 1972) 
and actively phagocytosing leucocytes are known to release substances which attract 
other leucocytes (Keller and Borel, 1971). A further important function of PMNs is 
presentation of complement to the immune system (Unanue, 1972).
PMNs have a relatively short life span which has been estimated to be 3-13 days in blood 
and about 24-48 hours at the site of inflammation (Hurley, 1978).
After the initial acute phase of inflammation in which PMNs are dominant, mononuclear 
phagocytes (macrophages) and lymphocytes become the characteristic cell types. The
4profile of cell type at the site of inflammation is distinct and time related It is not clear if 
the delayed arrival of mononuclear phagocytes is due to their slower movement or a 
response to different chemoattractants. Mononuclear phagocytes are predominant in 
chronic inflammation or in acute inflammation which is resolving. Acute inflammation 
may be only a preliminary response followed by chronic changes, for instance in 
conditions such as rheumatoid arthritis. During chronic inflammation the affected area 
does not return to normal after the initial acute inflammatory response and the principal 
significant difference is characterised by a variety of immunological events and the 
production of fibrous tissue.
The precise mechanisms and triggers which result in the development of chronic 
inflammation are poorly understood. The three mechanisms considered by Dawson and 
Willoughby (1985) present the current accepted theories and it may be that chronic 
inflammation results from any one or a combination of these mechanisms. Firstly, it may 
be that the initial stimulus may be persistent and poorly removed from the body. 
Secondly, the regulatory substances normally released during the response to invasion or 
trauma may become abnormal, this may result in a perpetuating response. Finally, the 
modification of endogenous proteins by physical or chemical means (such as thermal 
damage or incomplete degradation during phagocytosis) could result in its perception as a 
foreign protein.
Large numbers of macrophages and lymphocytes at the site of inflammation are 
characteristic of chronic inflammation, whatever its cause, and consequent stimulation of 
the immune system occurs. Antigen is presented to T lymphocytes by the macrophages 
(Unanue, 1972) and proliferation and differentiation of T lymphocytes occurs. T helper 
cells thus produced, interact with B lymphocytes to produce plasma cells which are 
responsible for the production of antibody (Dawson and Willoughby, 1985). These 
events are regulated by Interleukins 1 and 2 which are produced by macrophages and T 
lymphocytes respectively. If conventional wisdom that inflammation is essentially a 
protective mechanism is accepted, then it seems likely that chronic inflammation, in many 
cases, may be a result of a breakdown of this mechanism.
The tissue and cellular changes seen in inflammation are largely mediated or modulated 
by chemical substances which are naturally produced within the body. The first discovery 
of the action of chemical mediators in the process of inflammation was made by Lewis 
and Grant (1924). These workers produced local irritation with vascular dilation and 
oedema by intra-dermal injection of histamine. More recently, work by Willis (1969) and 
Di Rosa et al (1971a) indicated that release of mediators in acute inflammation was a 
sequential process beginning with the release of the histamine and 5-hydroxytryptamine
5(5-HT). These amines are produced by enzymatic catalysis of amino acids, principally in 
mast cells (histamine) and platelets (5-HT), and are stored in intracellular granules 
(Bowman and Rand, 1984). The effect of these compounds is short lived and their 
release is followed by the generation of peptides such as bradykinin. Investigation has 
shown that antihistamines and 5-HT antagonists have little effect in the treatment of 
inflammation except during the first 90 minutes (Youlten, 1978). Bradykinin has a more 
prolonged effect, and Ferreira et al (1974) suggested that this step in the sequence may 
last for at least six hours after the initial damage has occurred.
There is little doubt that prostaglandins play a positive and direct role in inflammation. 
Inflammatory effects have been noted after intra-dermal, intravenous or intra-arterial 
injection of prostaglandin (PG) E2 and prostacyclin (PGI2) and large doses of PGE2 and 
PGF2aipha when given intramuscularly or subcutaneously cause local pain. A synergistic 
response to prostaglandins in the presence of bradykinin also has been demonstrated 
(Ferreira, 1972).
The time course of generation of prostanoids during inflammation has been investigated 
using equine models (Higgins et al. 1987). Maximum concentrations of PGE2 were 
detected at 12 hours, 6-keto-PGFiaipha (the stable derivative of PGI2) at nine hours and 
thromboxane B2 (TxB2 ), the stable derivative of thromboxane A2 (TXA2) at 6  hours.
In addition to histamine, 5-HT, kinins and prostaglandins a further group of pro- 
inflammatory substances has been identified. These substances are the leukotrienes (LTs) 
and LTB4 is thought to play a major role in the cellular chemotactic response which may 
lead to chronic inflammation. Leukotrienes are produced de novo by the action of 
lipoxygenase enzymes on the unsaturated carbons of arachidonic acid (Kitchen et al. 
1985) (figure 1.2).
Generation of LTs has been shown to be on a similar time scale to PGs. It has been 
demonstrated that concentrations of LTB4 reach a maximum at four to eight hours in 
inflammatory models using rats and ponies (Simmons et al. 1983; Higgins and Lees, 
1984a).
Subsequent to these initial cause and effect discoveries, world wide investigation over the 
last 20  years has resulted in a clear picture of the chemical structure and relationships of 
many of these substances and those produced as a result of arachidonic acid metabolism 
are shown in figure 1.2 .
Tissue injury results in the release of arachidonic acid (a 20-carbon unsaturated fatty acid) 
from cell membranes. The generation of arachidonic acid from cell membrane 
phospholipid is caused by the activation of membrane bound enzyme phospholipase
6(Hong and Levine, 1976a and 1976b; Bills et al. 1977). The cell wall associated enzyme 
may be activated as a result of changes which cause an alteration in permeability of the 
membrane to calcium ions (Borgeat and Samuelsson, 1979). Several phospholipase types 
including A2 (Hong and Deykin, 1981; McKean et al: 1981, Broekman, 1986) and C 
(Bell et al. 1979; Daniel et al. 1986) have been implicated in the release process. Much of 
the evidence suggested that phospholipase C was involved in phospholipase A2 activation 
(Lambert et al. 1986; Resink etal. 1987). However, studies by Hong and Deykin (1981) 
and Kaya et al (1989) have shown that activation of phospholipase A2 may be 
independent of phospholipase C in some systems and it now seems likely that 
phospholipase A2 activation may be mediated by G protein (Burch et al. 1986 and 
Burgoyne et al. 1987). Arachidonic acid is a pivotal precursor for the synthesis of a large 
number of substances (collectively known as eicosanoids) and acts as a substrate for 
cyclooxygenase and lipoxygenase enzymes. The term eicosanoid is derived from 
eicosatetraenoic acid (arachidonic acid). The action of cyclooxygenase results in the 
production of prostaglandins and thromboxane whilst the action of lipoxygenase 
produces leukotrienes (figure 1.2).
The pharmacological effects of eicosanoids are many and vary between tissues and 
species. The major effects of the eicosanoids produced by the arachidonic acid pathway 
are shown in table 1.1.
The biologically active products of the arachidonic acid pathway include the prostanoids 
(PGs and PGI2) and thromboxane. The most important pro-inflammatory PGs include 
PGE and PGF and these display a range of properties which are significant in 
inflammation (table 1.1). The principal prostanoid found in inflammatory exudate is 
PG Ej (Anggard and Jonsson, 1971; Greaves et al. 1971; Gould, 1976; Higgins and 
Lees, 1984b). Eicosanoids, are not stored in the body and many are highly unstable, for 
example TxA2 has a biological half life 32 seconds (Salmon and Flower, 1979).
Evidence exists that of the cyclooxygenase products generated by circulating leukocytes, 
thromboxane is predominant (Morley et al. 1979). Platelets are a major source of 
thromboxane in clotting blood but are not thought to contribute significantly to the 
cyclooxygenase products found in experimentally produced inflammation (Higgs et al 
1983). It has been shown however, that the presence of thromboxane in inflammatory 
exudates relates to the presence of migrating leukocytes which are also a lesser source of 
PGs (Higgs etal. 1983). PMNs are thought to be a major source of PGs in inflammation 
(Higgs et al. 1975) and are also thought to be a lesser source of thromboxane production 
(Higgs et al. 1976). The fact that leukocytes are capable of both leukotriene and 
prostaglandin production has led Higgins (1985) to suggest that this may indicate some
7sort of regulatory and perpetuating role in inflammation by the production of substances 
from each pathway.
Leukotriene B4  is the principal biologically active product of the lipoxygenase pathway. 
It is a highly potent chemotactic agent and has been shown to cause PMN accumulation in 
vivo following intra-peritoneal, intra-dermal or intra-ocular administration (Bhattacherjee 
et al. 1981; Higgs et al. 1981a). LTB4 has also been reported to be equipotent to PGs in 
enhancing exudation of plasma in the presence of bradykinin (Bray et al. 1981) and to 
have a direct effects on vascular permeability (Higgs e ta l. 1981b).
1.3. EARLY ATTEMPTS TO CONTROL PAIN
The relief of pain must have been one of man's earliest therapeutic quests, and opium has 
long been used to this end. Such drugs act on the central nervous system, being agonists 
of the opioid receptor types (mu, kappa and delta) which are present at various sites 
within the spinal and other nervous tissue. The quest for the euphoric state induced by 
these drugs has, however, led to widespread abuse of opium and other narcotic 
morphine-like drugs. Serious addictions have resulted from repeated administration and 
as a result use is now restricted to short term relief of severe acute pain, and to patients 
who have little prospect of recovery.
The first non-narcotic substances used to control pain were salicylates. In Greek and 
Roman times tree bark was chewed to give pain relief and by the 19th century salicylic 
acid had been isolated from various plants including the bark of Willow and Poplar trees. 
Acetylsalicylic acid (ASA) was the first commercially available non-steroidal anti­
inflammatory drug (NS AID) and was produced by Hofmann of the Bayer Pharmaceutical 
Co. in 1893.
1.4. PRESENT DAY ATTEMPTS TO CONTROL PAIN
1.4.1 NON-STEROIDAL ANTIINFLAMMATORY DRUGS
Following the production of salicylic acid and appreciation of its desirable properties, 
the search began for more potent analgesics with less toxic side effects. This resulted 
in the development of pyrazolone derivatives such as phenylbutazone, which was 
produced in 1946. These drugs were supplemented in the 1960s by indomethacin (an 
acetic acid derivative) and the propionic acid derivatives such as ibuprofen. Figure
1.3 shows the major groups of NSAIDs available today. The term NSAID or "aspirin
8like drug" is used to describe the group of drugs which are mainly organic acids and 
which possess anti-inflammatory, anti-pyretic and analgesic properties.
Not all NSAIDs are equipotent anti-inflammatory, anti-pyretic and analgesic agents. 
Paracetamol (acetaminophen) has traditionally been considered to be equipotent to 
ASA in its ability to control pyrexia and pain, however it had generally been 
considered to have little or no anti-inflammatory activity (Lee et al. 1976; Flower et 
al, 1985). More recent studies (Mburu et al. 1988; Mburu, 1991) have cast doubt on 
this and have demonstrated that paracetamol may be effective in reducing post­
operative swelling and pain in dogs. Similar findings have been reported for human 
subjects after oral surgery (Skjelbred et al. 1977). These discrepancies may well 
reflect the variety of mechanisms involved in inflammation and it may be that re- 
evaluation of individual NSAIDs for use in specific situations could allow a better 
correlation of dose and effect produced.
Although a large number of NSAIDs have been developed few of these are licensed 
or marketed for use in domestic animal species. Greater affluence within developed 
countries and increasing concern for animal welfare has resulted in an increased 
interest in the control of pain, particularly in companion animals. In addition, 
financial interests motivate the exploitation of animals involved in racing and other 
pursuits where their athletic ability is important This has fuelled research on drugs 
which effectively limit reduced performance associated with inflammatory and painful 
conditions.
The pharmacokinetics and efficacy of many NSAIDs have been well defined for man. 
However, it is well known that large inter-species variations exist in 
pharmacokinetics, efficacy and toxicity and this may affect the usefulness of these 
drugs in domestic animals (Lees et al. 1991). It is essential that potentially useful 
drugs are investigated in each new target species to determine the appropriate 
minimum dose rate and inter-dosing interval to achieve maximum efficacy, whilst 
avoiding adverse reactions or toxicity.
The non-steroidal agents currently licensed for anti-inflammatory use in animals in the 
United Kingdom are phenylbutazone, meclofenamic acid, flunixin meglumine, 
naproxen (until recently), cinchophen, carprofen, ketoprofen, dipyrone, isopyrin and 
meloxicam (table 1.2 .)
Several physiochemical properties are shared by non-steroidal anti-inflammatory 
drugs. They are acidic compounds, generally with a pKa of 4.5 or lower (Brune, 
1974; Brune et al. 1976) and as a result tend to be highly protein bound (95-99%).
9The structures of NSAIDs currently licensed or about to be licensed in the United 
Kingdom are given in figures 1.4a and 1.4b and a brief description of the major 
drugs now follows.
The pyrazolone group, includes phenylbutazone, dipyrone and isopyrin. 
Phenylbutazone is a relatively lipophilic NSAID and as a result is extensively 
metabolised prior to excretion; in the horse less than 2% is excreted unchanged 
(Maylin, 1974; Lees et al. 1983). Oxyphenbutazone, the major metabolite of 
phenylbutazone, has also been shown to exhibit some anti-inflammatory activity 
(Domenjoz, 1960). The half-life of elimination of phenylbutazone has been found to 
be dose dependent (Pipemo et al. 1968) and has been reported to range from 3.5 to
10.9 hours in the horse (Pipemo et al. 1968; Norheim et al. 1978). It was first used 
in human medicine in the late 1940s in the treatment of rheumatic disorders and 
became available to the veterinary profession in the 1950s. It is thought to be the most 
widely used NSAID in equine medicine (Tobin, 1981; Lees and Higgins, 1985). 
Phenylbutazone has been rated amongst the more effective anti-inflammatory and 
analgesic NSAIDs (Menasse et al. 1978). The principal adverse reaction to 
phenylbutazone in the horse is the appearance of intestinal lesions (Snow et al. 
1981a), however renal papillary necrosis and neutropenia have also been observed 
(McKay et al. 1983; Snow and Douglas, 1983). Other pyrazolones are marketed in 
preparations which contain more than one drug. Dipyrone is marketed as Buscopan 
(Boehringer Ingelheim), a product which also contains the spasmolytic hyoscine and 
isopyrin is produced in combination with phenylbutazone as Tomanol (Intervet). In 
addition, a combination of dipyrone and the spasmolytic methindizate was marketed 
as Isaverin (Bayer), this product has been withdrawn.
Meclofenamic acid is a member of the fenamate group of carboxylic acids, and was 
synthesised as a result of the search for new NSAIDs following the discovery of the 
anti-inflammatory activity of phenylbutazone. It is highly ionised at physiological pH 
and is highly lipophilic. The marketed preparation contains the sodium salt which has 
good bioavailability and is rapidly absorbed after oral administration (Glazko et al. 
1978). Meclofenamic acid is generally considered to be amongst the most potent 
inhibitors of cyclooxygenase in some animal models (Scheirer, 1985) and is widely 
used for the treatment of inflammatory conditions in the horse.
Tolfenamic acid is also a member of the fenamic acid group of NSAIDs. Produced in 
the early 1980s, its anti-inflammatory and analgesic activity was studied by 
Yamashita et al (1981a, 1981b). These studies found it to be a more potent anti­
inflammatory agent than mefenamic acid, phenylbutazone and aspirin and almost
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equipotent to diclofenac sodium and indomethacin. Its analgesic activity was 
estimated to be up to six times greater than phenylbutazone and aspirin and equal to 
that of mefenamic acid and diclofenac sodium. These authors also found tolfenamic 
acid to be less ulcerogenic than its comparitors and they suggested that it would be 
suitable for the treatment of acute and chronic inflammation.
Tolfenamic acid has been licensed in France for use in the dog. It is recommended 
that it be administered at a dose rate of 4 mg/kg/day, given as a divided dose by the 
intravenous or subcutaneous route.
There are two features which are thought to be common among but unique to 
fenamates. Firstly, the ability of to inhibit prostaglandin synthesis is enhanced in the 
presence of certain enzyme co-factors (Egan et al. 1978). Inhibition is positively 
correlated to co-factor concentration and can be increased by up to 100  times. 
Secondly, at physiological concentrations fenamates have been shown to directly 
inhibit some actions of PGs (Collier and Sweatman, 1968)
Cinchophen is the only quinolone to have been used in veterinary medicine. It was 
first synthesised by Dobner and Gieseke in 1887 and was developed for use in man 
during the 1940s for the treatment of gout. It has not been used in man in recent 
years, and little is known of its pharmacology. It became available for veterinary use 
in the late 1960s and is still available for use in animals. Cinchophen has been 
marketed as a combined pharmaceutical preparations containing prednisolone, a 
steroidal anti-inflammatory (Prednoleucotropin), phenylbutazone (Butaleucotropin), 
and hexamine and quinine (Leucotropin), although this latter preparation has been 
withdrawn. At therapeutic dose rates cinchophen and phenylbutazone have been 
shown to produce a similar clinical response and similar numbers of adverse reactions 
in dogs with degenerative joint disease (McKellar et al. 1991)
Naproxen is a highly lipid soluble propionic acid derivative which was produced in 
the late 1960s as a result of research which sought to synthesize a compound with 
similar anti-inflammatory potency to phenylbutazone but which displayed fewer side 
effects. The raw product comprises two enantiomers of which d-naproxen displays 
the greatest anti-inflammatory activity and least adverse effects. The two enantiomers 
are separated after synthesis, and d-naproxen used to formulate the pharmaceutical 
product. Naproxen is considerably more effective than phenylbutazone in some 
inflammatory models; it produces dose related anti-pyresis, and is an effective 
analgesic (Roszkowski et al. 1971). It has been found to have a long half life of 
elimination in dogs which may be due to enterohepatic circulation (Runkel et al. 1973; 
Frey and Rieh, 1981). Gastrointestinal side effects have been noted with daily dose
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rates as low as 5 mg/kg (Hallesy et al. 1973).
Flunixin is a comparatively new fenamate belonging to the carboxylic acid group of 
NSAIDs. The pharmacological preparation which is used for its anti-inflammatory 
and analgesic properties is the N-methyl-d-glucamine (meglumine) salt. Its efficacy at 
clinical dose rates has been shown to be equivalent to phenylbutazone for the 
treatment of canine inflammation and musculoskeletal pain (Kelly and Benitz, 1988). 
Despite a relatively short half life of elimination in the dog, reported as 3.5 hours 
(Hardie et al. 1985), the persistence of flunixin in active concentrations in 
inflammatory exudate, has been demonstrated for 24 hours (Higgins et al. 1986). 
Clinical effectiveness in lameness models in horses has been demonstrated to persist 
for 24 hours (Houdeshell and Hennessey, 1977) allowing a daily dosing frequency 
of 24 hours.
Carprofen is a propionic acid of the carboxylic acid group and was first synthesised 
during attempts to produce a NSAID which had similar anti-inflammatoiy activity to, 
but fewer adverse effects than, indomethacin. It is a racemic mixture in which the 
S(+) isomer is thought to be more biologically active and less toxic (Gaut et al. 
1975). Analgesic activity for carprofen has been shown to occur at similar dose rates 
to indomethacin, whilst its ulcerogenicity is less than indomethacin but greater than 
phenylbutazone and acetylsalicylic acid in rats (Maeda et al. 1977). Carprofen 
obtained a United Kingdom product licence for use in the dog in 1991.
Carprofen is a comparatively poor inhibitor of cyclooxygenase (Strub et al. 1982), 
and has been shown to be ineffective as an inhibitor of lipoxygenase (Baruth et al. 
1986). Despite this it has been demonstrated to have good anti-inflammatory activity 
using in vivo laboratory models (Maeda e tal. 1977).
Developed in the 1970s during attempts to find successor to indomethacin, the 
propionic acid derivative ketoprofen is an effective inhibitor of PG synthesis (Patrono 
et al. 1976), but has little or no anti-pyretic activity (Kandasamy et al. 1975). 
Ketoprofen, a racemic mixture, is highly protein bound and has a tV2B of 1.5 hours 
in man (Delbarre et al. 1976; Ishizaka et al. 1980; Stafanger et al 1981). Recent 
studies in the horse have examined the pharmacokinetics of the two enantiomers of 
ketoprofen. The tV2& of each enantiomer was found to be similar, approximately 25 
minutes (Jaussaud et al. 1993).
1.4.2 STEROIDAL ANTIINFLAMMATORY AGENTS
In addition to NSAIDs a large number of compounds with steroidal structure are used 
for their anti-inflammatory activity.
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The production of these drugs has its basis in the discovery and understanding of the 
functions of the steroid hormones produced by the adrenal cortex. The secretion of 
these adrenocorticoids is under the control of adrenocorticotrophic hormone (ACTH), 
and as a result of their different principal activities these hormones are classified 
mineralocorticoids, glucocorticoids and adrenal sex hormones. Of these groups the 
glucocorticoids are of interest in the control of inflammatory disease. In addition to 
their anti-inflammatory properties, these naturally occurring glucocorticoids play a 
role in the metabolism of carbohydrate, protein and lipids within the body. They are 
also known to be inhibitory to immune reactions and to have toxic effects on the 
gastro-intestinal tract. Naturally occurring glucocorticoids such as hydrocortisone do 
exhibit some mineralocorticoid activity, and this has led to development of synthetic 
compounds such as betamethasone and dexamethasone which are largely free of these 
properties.
1.4.3 OTHER COMPOUNDS
In addition to the drugs described, other compounds exist which are also non­
steroidal and anti-inflammatory. The chemistry and mode of action of these 
compounds in no way resembles the conventional NSAIDs. Examples of these 
compounds, which occur naturally in the body, include orgotein, hyaluronic acid and 
glycosaminoglycan polysulphate esters.
1.5 MODE OF ACTION OF DRUGS USED TO CONTROL 
INFLAMMATION AND PAIN
1.5.1 CONVENTIONAL NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS
It was first suggested twenty years ago that the ability of NSAIDs to control 
inflammation and pain was related to their ability to inhibit the production of 
prostaglandins within the body (Ferreira et al. 1971: Vane, 1971). Although it is now 
known that this is an important aspect of their mechanism of action, it is clear that the 
action of NSAIDs is more complex. Higgs et al. (1980) demonstrated that the dose 
required to produce a response in 50% of subjects tested (ED50) for treatment of 
some gross changes seen in inflammation (leucocyte infiltration and swelling) can be 
higher than the dose required to inhibit cyclooxygenase production by 50% (IC50). In 
addition, NSAIDs have been shown to inhibit aggregation and movement of 
neutrophils and the generation of superoxide radicals (Di Rosa etal. 1971b; Kaplan £t 
al, 1984). Some NSAIDs and corticosteroids are able to inhibit the secretion of
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neutral proteinases from neutrophils (Perper and Oronsky, 1974). These neutral 
proteinases are known to be responsible for the activation of complement (Goldstein 
and Weissmann, 1974) and kinin systems (Movat et al 1972) and to be capable of 
directly causing degeneration of tissue (Oronsky et al.1973).
Stimulated lymphocytes have been shown to generate substances which result in the 
release of inflammatory mediators, such as acid hydrolases and collagenase, from 
macrophages (Perper and Davies, 1977). Since the ability to induce release of acid 
hydrolases and the production of chronic inflammation have been shown to be related 
(Davies and Allison, 1976), it has been suggested that inhibition of acid hydrolysis 
release may be a site of action for some NSAIDs.
The actions of NSAIDs which result in suppression of production of prostaglandins 
are a result of their inhibitory actions on the conversion of arachidonic acid to the 
endoperoxide PGG2. This reaction is catalysed by the cyclooxygenase enzyme 
system. A variety of inhibition mechanisms exist, some being of a competitive nature, 
others irreversible. Aspirin is known to acetylate a serine which interferes with the 
site of cyclooxygenation (Roth and Siok, 1978). Platelets, being anucleate, are unable 
to regenerate cyclooxygenase resulting in permanent acetylation, thus inhibiting the 
activity of the enzyme for the life of the platelet (about 10 days).
Some members of the fenamate group of NSAIDs, including tolfenamic acid have 
been shown to inhibit the synthesis of, and be antagonistic to, the actions of PGs 
(Collier and Sweatman, 1968; Vapaatalo et al. 1977). This may explain the poor 
correlation which has been noted for inhibition of prostaglandin synthetase and in 
vivo anti-inflammatory activity by fenamates.
The search for new NSAIDs has recently led to the production of a group of 
compounds which are known as dual inhibitors. These substances are able to inhibit 
the activity of both the cyclooxygenase and lipoxygenase enzyme systems, and it may 
be that this property will result in even greater anti-inflammatory activity than is 
possessed by current NSAIDs. One such compound, BW 755C (3-amino-l-[m- 
(trifluoromethyl)-phenyl]-2 -pyrazoline) has been shown to inhibit both enzyme 
systems and to produce a reduction in experimentally produced oedema. It is thought 
that inhibition of leukocyte migration may result from the ability of these compounds 
to reduce the production of chemotactic hydroxy acids. Although Higgs e ta l (1979), 
have shown this compound to be highly effective in reducing the PG concentration in 
inflammatory exudate, it was less effective than a conventional NSAID 
(indomethacin). However, it did have significantly greater effect on leukocyte 
migration. These workers also compared BW755C with a steroidal anti-inflammatory
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drug (dexamethasone). The dual inhibitor was found to be equipotent to the steroid in 
its ability to reduce PG concentration and reduce leukocyte migration.
Research has also shown tolfenamic acid and sodium meclofenamate, two widely 
utilised NSAIDs, to be dual inhibitors in some biological systems (Alanko, 1990; 
Boctor et al. 1986).
1.5.2 ALTERNATIVE NON-STEROIDAL ANTIINFLAMMATORY DRUGS
Orgotein (superoxide dismutase) is a metalloprotein which exists as an intracellular 
enzyme with a role in the protection of the body against naturally produced 
superoxide radicals and has been shown to be a potent anti-inflammatory agent in the 
horse (Ahlengard et al. 1978). Superoxide radicals are produced naturally within the 
body by neutrophils and macrophages as a defensive mechanism. Any excess which 
is produced may result in damage to tissue and the phagocytes themselves. Orgotein 
scavenges these excess superoxide radicals, reducing damage and extending 
phagocyte viability (Salin and McCord, 1975).
Hyaluronic acid is a component of normal synovial fluid and articular cartilage. It 
comprises variable length chains of glucuronic acid or glucuronate sodium with N- 
acetyl glucosamine and is used as an intra-articular therapy. It has lubricant properties 
within the joint and has been shown to be effective in the treatment of osteoarthritis in 
the dog (Schiavinato et al. 1989). It is also thought to inhibit chemotaxis and 
phagocytosis of leukocytes (Wigren e ta l. 1976; Swanstrom, 1978), thereby reducing 
the potential for joint damage by neutral proteases which may be released after the 
ingress of leukocytes.
Glycosaminoglycan polysulphate esters (GAGPs) stimulate synthesis of 
glycosaminoglycan in chondrocytes (Nevo and Dorfman, 1972) and inhibit enzymes 
(such as hyaluronidase and collagenase) which are important in the degeneration of 
cartilage (May et al. 1988). Their use has been shown to be effective as a protection 
for cartilage exposed to experimentally induced osteoarthritis (Altman et al. 1988; 
Altman et al. 1989).
1.5.3 STEROIDAL DRUGS
The anti-inflammatory mechanisms of steroidal drugs are not yet fully understood. 
Some possible actions summarised by Malseed (1990) include: stabilisation of 
lysosomal membranes resulting in decrease in tissue damage by lysosomal enzymes, 
reduction of leukocyte migration and phagocytosis and decreased permeability and 
dilation of small blood vessels.
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Despite their potent anti-inflammatory activity glucocorticoids have been shown to be 
without effect on cyclooxygenase (Ferreira et al. 1971; Vane, 1971; Lewis and Piper, 
1975). The discovery by Flower and Blackwell (1979) that these drugs stimulated the 
production of a substance which inhibits phospholipase A2, and thereby prevents 
prostaglandin generation resulted in further investigation of this mechanism. Research 
by Danon and Assouline (1978) led to the discovery of the role of RNA and protein 
synthesis in the action of corticosteroids and is the basis of our current understanding 
of their principal mode of anti-inflammatory action.
Corticosteroids circulate in plasma and enter cells to bind with specific intra-cellular 
receptors. This results in a change in configuration of the receptors, revealing sites to 
which nuclear material is able to bind. On entry into the cell nucleus this complex 
interacts with sites on specific genes resulting in an increase in transcription and 
mRNA synthesis. Production of specific proteins (lipocortins) is stimulated by this 
process, resulting in the inhibition of the enzyme phospholipase A2 and 
consequently, arachidonic acid release. Prevention of the release of arachidonic acid 
blocks the synthesis of a large number of the identified mediators of inflammation, 
significantly, those produced by the action of cyclooxygenase (eg PGE2 and PGI2) 
and lipoxygenase (leukotrienes). These biochemical actions result in the changes that 
are seen in response to steroidal anti-inflammatory therapy including reduction of 
PMN migration and phagocytic activity, and inhibition of deposition of fibrin.
1.6 ADVERSE REACTIONS TO ANTI-INFLAMMATORY DRUGS
1.6.1 NON-STEROIDAL ANTIINFLAMMATORY DRUGS
Prolonged use of NSAIDs in human subjects has led to the discovery of a wide range 
of adverse effects. The most widely reported side effects, both in man and animals, 
affect the gastrointestinal tract. These include gastric discomfort, emesis, ulceration 
and gastrointestinal bleeding. It has been shown that in animals duodenal ulceration is 
common. In man gastric ulceration appears to be the more common result of chronic 
NSAID therapy (Piper et al. 1981) while ulceration of the large intestine is a more 
common feature in horses (Brodie et al. 1970; Snow et al. 1981a). This may be 
caused by a number of factors relating to species or drug studied. Lees and Higgins 
(1985) have suggested that drug may be bound to components of the diet such as the 
cellulose and fibre in hay and therefore be less available to cause damage in the 
proximal regions of the gut. As digestion and fermentation occurs, drug may be 
released in the more distal sections of the gut where ulceration results. This would 
indicate that similar problems might be expected to occur in all herbivore species
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where the dietary components and gut fermentation are similar.
There is no clear picture of the exact mechanism of gastrointestinal ulceration which 
results from NSAID therapy. Many factors are thought to contribute, however, the 
temporal nature of their action and interactions between these factors is as yet poorly 
defined. Those mechanisms currently considered to be relevant are now considered.
The majority of NSAIDs are acidic drugs with pKa values of 3 - 6 . Local effects have 
been observed in the gut which are likely to be a result of the direct physical 
properties of the drug, notably damage to and loss of the gastrointestinal mucosal 
surface (Cooke, 1976; Rainsford, 1984b). The damaged mucosa has also been 
shown to allow increased back diffusion of H+ ions which may contribute to this 
damage (Cooke, 1976).
It is likely that one action of this trauma is an increase in the local release of histamine 
resulting from degranulation of mast cells (Johnson, 1966; Johnson and Overholt, 
1967; Parmar and Ghosh, 1981). In addition, it is known that PGE and PGA can 
inhibit basal and stimulated gastric secretion (Classen e tal. 1971; Wilson e ta l. 1971). 
If this is the basis of an inbuilt control mechanism, inhibition of prostaglandins may 
result in an abnormally large response to stimulation by histamine coupled with an 
increased basal level of secretion. Several workers ( Ashley et al. 1985; Gana et al. 
1987; Kitahora and Guth, 1987) have suggested that a NSAID induced reduction in 
blood flow occurs in areas of mucosa which subsequently ulcerate. Ischemia 
reperfusion experiments using animal gastrointestinal tracts have shown that 
endothelial injury occurred after neutrophil adherence and activation which followed 
the production of inflammatory mediators (Hernandez et al. 1987; Granger et al. 
1989). Wallace and Granger (1992) have summarised a range of work which 
suggests that a similar sequence of events occurs following NSAID administration. It 
may be that ulceration occurs due to physical occlusion of the microcirculation by 
adhering neutrophils, however, the protective effect of antioxidant enzymes 
(Vaananen et al. 1991) indicates that damage may be as a result of tissue-destructive 
proteases and highly reactive oxygen metabolites released by neutrophils.
In general, NSAIDs inhibit the metabolic pathways which lead to the production of 
adenosine triphosphate (ATP) (Smith, 1966; Whitehouse, 1968; Smith and 
Dawkins, 1971; Glenn et al. 1979). Inhibition of ATP may influence regulation of 
xanthine dehydrogenase by adenine nucleotide resulting in its conversion to the 
oxidase form which is capable of producing superoxide radicals (Granger et al. 
1981), thereby creating the potential for greater tissue damage. Borg (1965) has also 
shown that free radicals may be generated from salicylate at an acidic pH such as that
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which occurs in the stomach.
Lowered ATP levels may also lead to reduced synthesis of gut mucosa (Rainsford, 
1984c) and one study has shown that aspirin, indomethacin and phenylbutazone are 
capable of decreasing the rate of gastric mucus secretion in the dog (Menguy, 1969).
Prostaglandin E2 and PGI2 are the principal prostaglandins synthesised by gastric 
mucosa and are responsible for the inhibition of acid secretion and production of 
cytoprotective mucus. It has been shown experimentally that these eicosanoids play a 
protective role in preventing mucosal damage produced by NSAIDs (Robert, 1981). 
In addition, it has been suggested that accumulation of drug may occur in acid 
secreting parietal cells (Rainsford, 1984c). This may be due to the acidic nature of 
NSAIDs which are highly unionised within the acidic environment of the stomach, 
providing suitable conditions for passage into the mucosal membranes and beyond. 
Following entry into the less acidic environment within the mucous and parietal cells 
the drugs loose protons and remain ionised and are therefore, trapped. Any 
concentration within these cells may lead to an amplification of the range of effects 
already described. Blood loss into the interstitial tissues or gut lumen may be 
exacerbated by impaired platelet aggregation resulting from the inhibition of 
thromboxane production.
Non-steroidal anti-inflammatory drugs are known to cause inhibition of the 
cytoprotective prostanoids - prostaglandins and PGI2 (Konturek et al. 1981; Cifone gt 
al, 1982). Rainsford (1985) has suggested that this may result in impaired blood flow 
through the stomach. It is known that hydrogen ions diffuse back into the mucosa 
(Kivilaasko and Silen, 1979), any decrease in blood flow in this area will result in a 
reduction in the removal of these hydrogen ions resulting in damage to the mucosa. A 
change in mucus synthesis (Rainsford, 1978) may also occur.
Elevation of AMP levels following tissue injury results in conversion of xanthine 
dehydrogenase, an enzyme normally abundant in the gastro-intestinal tract, to 
xanthine oxidase. The oxidase form of this enzyme is capable of producing free 
radicals of oxygen which are known to be tissue destructive (Granger et al.1981: 
McCord, 1982; Parks et al 1982). It has been suggested (Rainsford,1984c) that a 
similar enzyme conversion may occur if AMP is elevated following NSAID 
disruption of oxidative phosphorylation and that the resultant free radical production 
may contribute to mucosal injury.
Sensitivity to NSAID induced gastrointestinal lesions has been shown to vary widely 
between species (Hallesy et al 1973; Adams et al. 1970; Joulou et al. 1976). The
1 8
minimal ulcerogenic dosage of indomethacin was found to range from 0.5 mg/kg/day 
in dogs to 20 mg/kg/day in rabbits (Peck, 1968). Sensitivity to drug induced 
intestinal lesions has also been shown to be linked to the extent of biliaiy excretion of 
drug (Hucker et al. 1966; Yesair et al. 1970).
Pharmacokinetic and plasma drug profiles which suggest enterohepatic cycling of 
NSAIDs in dogs have been reported for indomethacin (Duggan et al. 1975), 
diclofenac (Tsuchia, 1980), naproxen (Frey and Rieh, 1981) and ibuprofen (Rubin 
and Papich, 1989). Biliary excretion of drug results in exposure of the gut mucosa to 
drug or metabolite even after parenteral administration. Gut ulceration has been 
observed after parenteral administration of NSAIDs and this has been linked to the 
inhibition of synthesis of prostaglandins by gastric mucosa (Whittle and Vane, 1983; 
Meschter et al. 1984).
Brodie et al (1970) found that intestinal sensitivity resulting from orally administered 
drug was. greatly reduced or almost abolished after fasting and bile duct ligation 
respectively. It may be that a reduction of ulcerogenic effect could be achieved by 
administration of drug on an empty stomach and by withholding food for a period 
afterwards, thereby reducing biliary flow which is stimulated by consumption of 
food. Pierson et al (1961) have demonstrated that gastric bleeding was not 
significantly different in patients given aspirin alone, with food, milk or if buffered or 
as an enteric coated preparation.
In addition to the gastrointestinal side effects seen after administration of NSAIDs, a 
wide range of other toxic effects of varying severity have been noted in human 
subjects. Many of these are not predominant, or have not been identified in the dog.
One other major toxic side effect which has been noted in the dog is renal toxicity 
(Nash et al. 1987). Renal toxicity is generally associated with higher doses of NSAID 
(Shelly, 1978). For aspirin it has been found that the drug accumulates in the kidney, 
especially the outer cortical regions (Rainsford et al. 1981; Rainsford et al. 1983), 
and it has been suggested that this may be due to normal mechanisms which 
concentrate anions within the kidney. Some NSAIDs cause acetylation of proteins, 
lipids and glycoproteins in the kidney (Rainsford et al. 1981; Rainsford et al. 1983) 
and stimulate the production of tissue destructive lysosomal enzymes. Recent work 
by Mathews et al (1990) suggests that there may be a risk of renal toxicity at lower 
NSAID dose rates when used in combination with some general anaesthetics. These 
workers reported nephrotoxicity in dogs after administration of flunixin meglumine at 
a dose rate of 1 mg/kg during anaesthesia with methoxyflurane. It has been 
established that methoxyflurane is nephrotoxic in man (Hook, 1971). Free fluoride
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ions produced during the metabolism of methoxyflurane have adverse effects on 
ADH receptor sites in distal tubules. Toxicity has been directly related to 
concentrations of these free fluoride ions in serum (Hook, 1971). Mathews et al 
(1990) suggested that the nephrotoxic effects reported for methoxyflurane and 
flunixin co-administration may be the result of any one or a combination of effects. 
Firstly, the reduction in production of vasodilatory prostaglandins (PGE2 and PGI2), 
resulting from the inhibition of cyclooxygenase. This would suppress the protective 
role of these substances which act to oppose vasoconstrictor effects which may occur 
during anaesthesia. Secondly, there may be competition between methoxyflurane and 
flunixin for plasma protein binding sites. As a result the circulating concentration of 
unbound flunixin and methoxyflurane would be higher than when either drug is 
present alone. This may result in a more rapid metabolism of methoxyflurane and a 
higher concentration of free fluoride. Also, a higher concentration of unbound 
flunixin may result in a greater inhibition of cyclooxygenase and a further reduction in 
prostaglandin production. Finally, it has been suggested that release of free fluoride 
may occur during metabolism of flunixin (which contains three fluoride atoms per 
molecule), and that the total concentration of free fluoride may cause greater toxicity 
than has been described for methoxyflurane alone. McNeil (1992) has also 
highlighted the increased risks associated with the use of flunixin after general 
anaesthesia when reporting the death of a dog which was administered flunixin and 
antibiotics post-operatively. These studies are consistent with studies of Stoff and 
Clive (1983) who suggested that high concentrations of angiotensin II and 
catecholamines produced during anaesthesia had the potential to produce 
vasoconstriction. They considered that this effect would be counteracted by the 
production of the vasodilatory prostanoids, the beneficial effects of which would be 
lost if the action of cyclooxygenase inhibitors reduced or abolished the production of 
these substances. There is little evidence to suggest that renal toxicity is likely to be a 
problem in normal patients not requiring general anaesthesia.
Non-steroidal anti-inflammatory drugs inhibit platelet cyclooxygenase (Gallus, 1979; 
Roth et al. 1975), with consequent reduction in Cyclic endoperoxides and therefore 
TxA2 (Roth and Majerus, 1975). Thromboxane A2 is a potent vasoconstrictor and 
platelet aggregator (Hamberg et al. 1975). Prolonged bleeding time has been widely 
reported for acetylsalicylic acid (Ivy et al. 1941; Meilke et al. 1969) and results from 
this inhibition of cyclooxygenase (and reduction of Tx production). This side effect 
can be of major significance in individuals with bleeding disorders (haemophilia) or 
in cases where NSAID use has resulted in gastric bleeding. It is interesting to note 
that this property of aspirin has been used constructively in the prevention of 
thrombosis in heart disease (Patrono, 1989).
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NSAIDs are known to uncouple oxidative phosphorylation (Adams and Cobb, 1958; 
Whitehouse and Haslam, 1962). It is thought that uncoupling is a result of the ability 
of these drugs to defeat the proton gradient which must exist across the mitochondrial 
membrane for oxidative phosphorylation to occur. Uncoupling results in a reduced 
production of ADP and ATP in the cell. While normal hydrolysis and pyrophosphate 
cleavage continues in the cell, the quantity of ATP and ADP decline and the AMP 
present in the cell increases. In addition, reduction in the release of ADP from 
platelets, which is normally stimulated by substances such as adrenaline and collagen, 
may result in inhibition of platelet aggregation. This has implications for the 
prolongation of bleeding time as described previously.
A wider range of toxic effects of NSAIDs have been reported in man. In addition to 
gastrointestinal irritation and renal toxicity, hepatic damage has been reported after 
administration of various NSAIDs including phenylbutazone and naproxen (Juul, 
1965; Bass, 1974), and a wide range of NSAIDs are thought to cause bone marrow 
aplasia (Davies, 1985).
1.6.2 STEROIDAL DRUGS
There are numerous side effects produced by steroidal anti-inflammatory drugs which 
are related to both their mineralocorticoid and glucocorticoid activities. These include 
water and electrolyte retention, muscle wasting, delayed wound healing and with 
prolonged usage, osteoporosis as a result of alteration of metabolism of calcium. In 
addition, the use of these drugs results in suppression of the secretion of ACTH from 
the pituitary gland which may cause atrophy of the adrenal cortex after prolonged use. 
Sudden termination of administration may result in adrenal insufficiency.
1.7 STUDY OBJECTIVES
The objectives of this study were, firstly to determine the pharmacokinetics of tolfenamic 
acid, flunixin, cinchophen and piroxicam in dogs after administration by various routes. 
Secondly, to assess the pharmacodynamics of these NSAIDs by measurement of TxB2 
inhibition, clotting time and detection of occult blood in faeces. Thirdly, to develop an in 
vitro method for assessing cyclooxygenase inhibition, and to use this to compare in vitro 
TxB2 inhibition when examined as response curves produced by NSAIDs in different 
species. Finally to determine the extent of protein binding of NSAIDs used in the in vitro 
assessment of inhibition of TxB2 in different species.
1.8 TABLES AND FIGURES
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E ic o s a n o i d  
T h r o m b o x a n e  A 2  ( T x A 2 )
Prostacyclin (PGI2)
P r o s t a g l a n d i n s  (P G s )  
P G E
P G F
P G D
L e u k o t r i e n e  B 4  (L T B 4 )  
L e u k o t r i e n e  C 4  (L T C 4 )
F u n c t i o n
P la te le t agg rega tion ,
S m o o th  m usc le  co n trac tio n , V aso co n stric tio n , 
T h ro m b o s is
Inh ib its  p la te le t agg rega tion ,
S m ooth  m usc le  re laxa tion , V asod ila tion ,
A cid  Secretion ,
C y top ro tec tion
S m o o th  m u sc le  co n trac tio n , V asod ila tion , 
B ronchodila tion ,
In h ib ition  o f  g astric  secre tion ,
C y top ro tec tion
S m o o th  m usc le  co n trac tio n ,
V asoconstric tion
B ronchoconstric tion ,
V asod ila tion .
V asod ila tion ,
B ronchoconstrction ,
Increased  vascu lar perm eability ,
L eukocy te  chem otax is .
S m ooth  m uscle  con traction , Increased  vascu la r 
p erm eab ility ,
Table 1.1 Some functions of major eicosanoids.
ANTIINFLAMMATORY AGENT L I C E N S E D  S P E C I E S
P heny lbu tazone H orses , D ogs
D ipyrone H orses , D ogs, C a ts
Isopyrin H orses, D o g s, C a ts
M eclofenam ic A cid H orses
F lu n ix in H orses , D ogs, C a ttle
C in ch o p h en  (in  co m b ina tion  w ith D o g s, C a ts
stero idal an ti-in flam m atory)
N aproxen H orses
C arprofen D o g s, H orses
K etoprofen H orses, D ogs
M eloxicam D ogs
Table 1.2 Non-steroidal anti-inflammatory drugs licensed in the 
United Kingdom for use in animals.
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INJURY
Phospholipase
Arachidonic Acid
Lipoxygenase
Products
Prostaglandins
Histamine
5HT
Kinins
Complement
Vasodilation
Increased
Vascular
Permeability
Collagenases
Neutral
ProteasesFree Radicals 
EnzymesOedema
Swelling
Pain
TISSUE
DAMAGE
Figure 1.1 The body's response to injury at the cellular level.
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Figure 1.4a Structure of some non-steroidal anti-inflammatory drugs
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Figure 1.4b Structure of some non-steroidal anti-inflammatory drugs
Chapter 2
GENERAL M ATERIALS AND METHODS
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2.1 COLLECTION OF BLOOD SAMPLES, PREPARATION AND 
STORAGE
2.1.1 SAMPLES FOR DRUG ANALYSIS
Samples for drug analysis were collected into 10 ml Monovettes (Sarstedt Ltd) 
containing 150 i.u. lithium heparin. They were then centrifuged at 1500 g and 4°C 
for 15 minutes, the plasma recovered and stored at -20°C until analysis.
Prior to analysis samples were placed in a refrigerator at 4°C overnight and allowed 
to defrost. They were then brought to room temperature by standing on the bench for 
one hour before use.
2.1.2 SAMPLES FOR ESTIMATION OF PLATELET NUMBERS
Samples for the estimation of the number of platelets in blood were collected into a 10 
ml sterile disposable syringe using a 20 g 1 inch needle (Beckton-Dickenson Ltd). 
The syringe was removed from the needle and a small volume of blood was 
immediately added to vials containing potassium-EDTA (Sarstedt Ltd.) to produce a 
concentration of 2 mg EDTA per millilitre of blood. Care was taken to ensure that the 
maximum recommended volume of blood was not exceeded and that the sample was 
thoroughly but gently mixed with the anticoagulant.
Platelet numbers were estimated microscopically after the addition of one percent 
ammonium oxalate. It was possible in most cases to carry out platelet determination 
within a few hours of collection of the sample. However, for a few samples which 
were taken late in the day or outwith normal working hours, it was necessary to carry 
out the procedure on the following day. When required, the samples were stored at 
4°C until counted. All platelet counts were carried out within 24 hours of sample 
collection.
Platelets were counted in the haematology laboratory of the department of Veterinary 
Pathology at Glasgow University Veterinary School.
2.1.3 SAMPLES FOR THE ESTIMATION OF CYCLO-OXYGENASE 
INHIBITION
The blood remaining in the syringe after the collection of sample for platelet counts 
(approximately 9 ml) was retained and placed in a 15 ml sterile glass test tube. The 
tube was stoppered and immediately placed in a water bath at 37°C where it was 
allowed to incubate without agitation for 90 minutes. After this time the tube was
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centrifuged at 900 g and 4°C for 15 minutes. The serum supernatant was collected 
and stored in glass screw-top vials at -20°C until thromboxane analysis.
2.1.4 SAMPLES FOR THE ESTIMATION OF CLOTTING TIME
The needle used for blood collection was retained in situ. After ensuring that the 
blood was flowing freely three unheparinised glass capillary tubes were filled and 
immediately placed in a container suspended in a water bath at 37°C. The time was 
noted and each tube was tested by gentle inversion at intervals of 30 seconds to 
determine if the blood was free flowing or clotted. The time taken for each tube to clot 
was noted and the mean clotting time of the three tubes was considered to be the 
clotting time for that animal on that sampling occasion.
2.2 COLLECTION OF FAECAL SAMPLES AND TESTING OF 
OCCULT BLOOD
Whenever available, faecal samples were gathered daily throughout each experiment from 
each pen in which the dogs were housed. As each pen contained two dogs it was not 
possible to determine the individual dog from which the faecal stool originated. On 
occasions where two separate faecal stools were found in a single pen it was assumed 
that they were from different animals.
Testing of faeces for occult blood was carried out at the time of collection using a Colo­
rectal test system (Hoffman la Roche). The peroxidative activity of haemoglobin present 
in the faecal sample oxidises a chromatographic paper impregnated with ’gum guaiac’ in 
the presence of alcoholic hydrogen peroxide. Appearance of a blue colour indicates a 
positive result. The test is sensitive to 2 ml of blood mixed homogeneously with 100 g 
faeces. Since intestinal bleeding would not result in a homogeneous mixture the test must 
be considered qualitative, not quantitative.
2.3 ESTIM ATION OF THROMBOXANE B2 IN SERUM BY 
RADIOIMMUNOASSAY (RIA)
Estimation of TxB2 in serum samples collected from dogs after oral administration of 
flunixin was carried out at London University by Professor Peter Lees using an in-house 
radioimmunoassay validated for dogs. The technique (Higgins and Lees , 1984b) was 
based on a modification of the methods of Salmon (1978) and Higgs and Salmon (1979)
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Thromboxane estimation for serum samples collected during all other experiments was 
performed using a commercial radioimmunoassay test kit (TRK 780 test system, 
Amersham International (UK) Ltd.). The Technical Services Department of Amersham 
International confirmed that although intended for use in humans, the kit was suitable for 
use in animal species. Nevertheless, prior to use, the system was validated by 
comparison with the in-house method of Professor Lees (see 2.3.3).
2.3.1 ASSAY METHOD
Competition for binding between unlabelled TxB2 and a fixed amount of tritium 
labelled TxB2 to a fixed quantity of an antibody provides the basis of the assay. 
Quantification (by scintillation counting) of the radioactivity of antibody bound TxB2 
allowed calculation of the amount of unlabelled TxB2 in the sample.
The amount of radioactive TxB2 (3H) bound to the antibody is inversely proportional 
to the concentration of non-radioactive TxB2 in the system as the quantities of 3H 
TxB2 and antibody are fixed (see figure 2 .1).
2.3.2 MODIFICATIONS OF THE METHOD
The TRK 780 test kit is designed for use with human samples and is therefore 
suitable for samples containing 0.05 - 3.0 ng TxB2 per millilitre of sample. The mean 
serum TxB2 concentration in normal dogs is 0.89 |ig/ml (SEM 0.12 |!g/ml) 
(McKellar et al. 1990) and therefore direct measurement of the samples was often not 
possible.
Three possible modifications to the assay method were considered:
Firstly, dilution of the sample with buffer prior to assay. Secondly, dilution of the 
sample with serum from which TxB2 had been remove ('stripped serum1), and 
finally reduction of the volume of serum used in the assay.
The following system was used to assess dilution with buffer -
A Tris : HC1 buffer (pH 7.4) was prepared as follows :-
To 800 ml of distilled water were added -
6.61 g Trizma HC1 (Sigma Chemical Co.)
0.97 g Trizma Base (Sigma Chemical Co.)
1.00 g Gelatine (B.D.H. Ltd.)
33
0.10 g Sodium Azide (B.D.H. Ltd.)
The mixture was stirred and gentle heat applied until all ingredients had dissolved. 
After cooling to room temperature the solution was made up to one litre with distilled 
water. If necessary the pH was adjusted to pH 7.4 using 1M sodium hydroxide. This 
buffer was used as a diluent for samples tested during the validation of the Amersham 
test system. The dilution required varied from sample to sample but for normal dog 
samples a standard dilution of 1 in 1000 was found to be appropriate.
Stripped serum was prepared as follows -
Flunixin meglumine was administered orally to dogs at a dose rate of 1.65 mg/kg. 
Blood was collected after one hour and serum harvested as described earlier. To 100 
ml of the serum 10 g of charcoal was added. The mixture was stirred overnight at 
4°C then centrifuged for one hour at 5000 g. The resulting supernatant was passed 
through a 3|im filter (Millipore Ltd.) to remove any remaining charcoal. This 
procedure was designed to produce serum which was free of TxB2- Thromboxane 
present in the serum collected after administration of flunixin was absorbed onto the 
charcoal.This 'stripped serum' was used as a diluent for samples tested in the 
validation of the Amersham test system.
The process of preparing 'stripped serum' was lengthy and required withdrawal of 
blood from animals. In addition, the effectiveness of the stripping process would 
have been difficult to standardise. As there appeared to be little advantage in the use 
of 'stripped serum' as a diluent when compared to assay buffer (table 2 .1) the use of 
assay buffer as a sample diluent was adopted.
Reduction of sample volume was not tested since it was calculated that in some cases 
the volume of serum would require to be reduced by 1000 times to permit assay of 
TxB2 concentrations. It was considered impractical to accurately measure such 
volumes.
2.3.3 VALIDATION
Prior to use of the Amersham test system it was necessary to establish that results 
obtained by this method were comparable to those obtained previously. A comparison 
of results obtained for samples analysed by both methods showed good correlation 
(table 2.1). Small variations in results between methods were considered to be of little 
importance since the difference in concentration of thromboxane between samples
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was important in the present series of experiments, rather than the absolute 
concentration in any one sample.
2.4 PHARM ACOKINETIC ANALYSIS
Pharmacokinetic analysis of plasma drug concentration versus time data was carried out 
using a computer programme, CSTRIP, (Sedman & Wagner, 1976) using an ICL main 
frame computer. This programme is designed to determine the best fit theoretical curve to 
suit the observed data, and uses up to three exponents (Bl, B2, B3) and y-axis intercepts 
(Al, A2, A3) to generate the equation. A correlation coefficient (r2) is calculated for each 
theoretical curve generated, and in addition the goodness of fit for each of the theoretical 
curves (using one, two or three exponents) was verified by means of Akaike's 
Information Criterion (AIC) (Yamaoka et al. 1978).
Care was taken to examine the number of observations used to compute each exponent 
and to disregard any fitted curve which contained an exponent which had been calculated 
on the basis of only two observations. Having applied this criterion in the selection of the 
best fit theoretical curve it was found that the correlation coefficient and AIC were 
generally in agreement. If AIC and r2 values were contradictory the best fit curve as 
indicated by AIC was used.
In general, mathematical modelling of plasma concentration versus time data for 
intravenous experiments produced theoretical curves which were closely correlated to the 
observed values. The number of exponents in the computed curve which best described 
the data was not always in agreement for all animals within each experiment 
The values of slope and intercept for each animal derived from the mathematical 
modelling of intravenous data were used to calculate the disposition kinetics of each drug 
in the plasma of dogs. Equations used to generate this information were obtained from 
Baggot (1977), Gibaldi and Perrier (1982), Sams (1987), Rowland and Tozier (1989) 
and Gibaldi (1991).
Where possible pharmacokinetic parameters were also calculated from observed data and 
these figures are included.
Mathematical models of plasma concentration versus time data following administration 
of drugs by routes other than intravenous were generally not well correlated with 
observed data therefore kinetic parameters for these routes have been calculated from 
observed data.
Pharmacokinetic parameters were calculated as follows, and the equations are given in 
table 2 .2 .
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The theoretical concentration of a drug in plasma at time zero after intravenous 
administration (CpO, |ig/ml) was calculated as the sum of zero time y-intercepts 
('equation' 1).
Area under the plasma concentration time curve (AUC0bs» M-g/ml-h) was determined for 
observed data by the trapezoidal rule and was calculated for time zero to infinity. The area 
under the curve described by the triangle between zero time and the first measured 
concentration (xi) was determined from the mean of the estimated concentration at zero 
time (CpO) and the first measured concentration multiplied by the time of the first 
measurement (ti) ('equation' 2). The area under the curve described by the triangle 
between the last measured concentration (xw) (if not zero) and zero concentration was 
determined from the last measured concentration divided by the slope of the final 
exponent (Bl) ('equation' 3). The AUC (jig/ml.h) for computed data was calculated as 
the sum of the ratio of appropriate y-axis intercepts and slopes ('equation' 4).
The area under the first moment curve (AUMC) is the area under the product of the 
plasma concentration and time plotted against time (|ig.h2/ml). This was also calculated 
from observed and computed data. For observed data this was calculated by means of the 
trapezoidal rule as in the AUC calculation. AUMC for computed data was calculated by 
substituting the square of the appropriate slope in equation 4 ('equation' 5).
Calculation of mean residence time (MRT) allowed an estimate of the time taken to 
eliminate 63.2% of a drug from the body. This was determined from the ratio of the 
AUMC and AUC and was calculated for both observed and computed values ('equation' 
6). The mean absorption time (MAT) was calculated as the difference between the MRT 
following extravascular administration and the MRT following intravenous administration 
('equation'7). The time taken (hours) for the plasma concentration to fall to 50% of the 
concentration at time zero, the half life of elimination (tV2B) was calculated using the 
equation 0.693/slope of the terminal exponent (Bl) ('equation' 8)
Having calculated CpO it was possible to calculate the volume of the central compartment, 
Vc (ml/kg) from the ratio of the dose of drug administered and CpO (mg/kg) ('equation' 
9).
The volume of distribution (V d a re a )  o f a drug (ml/kg) is the direct measurement of the 
distribution of a drug in the body and was calculated from the dose divided by the 
product of the AUC and the slope of the final intercept (Bl) ('equation' 10). The apparent 
volume of distribution can be directly influenced by the rate of elimination of a drug from 
plasma. A drug having a very rapid elimination rate will have undergone significant 
elimination during the period normally attributed to distribution in the body. In addition, 
if elimination from plasma is rapid drug will be removed from plasma at a rate greater
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than that required for re-equilibration. These factors may result in an apparently high 
volume of distribution. This anomaly can be addressed by determining the volume of 
distribution at steady state (Vd^). Vdss (ml/kg) is purely a measure of distribution since it 
reflects the state in the body when the arrival of drug in the body matches the rate of 
elimination and this can be calculated after intravenous administration of the drug. 
Estimates of Vdss were calculated for both observed and computed data from the ratio of 
the product of dose and AUMC to the square of the appropriate AUC ('equation' 11).
The rate at which a drug is removed from the body by metabolism or excretion is termed 
the rate constant for elimination kei (hours) and was estimated from the ratio of the 
clearance rate (determined from the ratio of AUC and dose, ('equation' 12)) and the 
volume of the central compartment ('equation' 13). The rate constants for drug leaving 
the central compartment and entering the peripheral compartment /  leaving peripheral 
compartment and entering the central compartment are k \2 and k2 i respectively and are 
also measured in hours. These parameters were calculated from the ratio of the sum or 
product of the exponents Bl and B2 and the rate constant of elimination, ('equations’ 14 
and 15) as appropriate.
The bioavailability (F) of a drug was determined as a percentage of the ratio of the AUC 
for observed data after intravenous and oral, intramuscular or subcutaneous 
administration after correction for dose ('equation' 16). It was assumed that the clearance 
rate remained constant after administration by each route.
2.5 STA TISTICAL ANALYSIS
Statistical analysis of data was performed using Statworks (v 1.1), a statistical package 
for micro-computers (Cricket Software, Pensylvania, USA.).
Wilcoxon matched-pairs signed-ranks test, a non-parametric test for two related samples 
was used to identify significant differences in TxB2 inhibition between intravenous 
administration and oral, intramuscular or subcutaneous administration of each drug in 
individual animals. Comparison of TxB2 inhibition in each animal after administration of 
all drugs by all routes was carried out by Friedman two-way analysis of variance for 
three or more related samples.
Samples were considered to be significantly different when p < 0.05.
For validation of methods, drug peak height and concentration data were plotted using a 
computer programme (Cricket Graph, v 1.3.2, Cricket Software, Pensylvania, USA.) 
which allowed computation of lines of best fit and correlation coefficients
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Drug concentration versus serum TxB2 inhibition data obtained from in vitro studies were 
adjusted using a logistic transformation. This data was then also computed to produce 
best-fit straight lines and correlation coefficients as for method validation.
2.6 TABLES
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Am ersham
Sam ple M ethod of Lees A m ersham  Stripped Serum
N um ber & Co-w orkers Buffer M ethod M ethod
1 0 .02 0.03 0.03
2 6.40 5.82 ND
3 0.04 0.06 0.05
4 8 .00 9.06 9.10
5 0.04 0.03 ND
6 8 .00 7.56 ND
7 0.05 0.03 ND
8 6.40 5.76 5.88
ND - Concentration of TxB2 not determined.
Amersham Buffer Method - samples pre-diluted in assay buffer.
Amersham Stripped Serum Method - samples pre-diluted in 'stripped serum'.
Table 2.1 Concentration Qig/ml) of TxB2 in serum of dogs analysed by three 
different methods.
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1 . CpO = A l + A2
2. AUC first triangle = (Xl+CpO) tl
( 2 )
3. AUC last triangle = X£Q
Bl
4. AUC = A2 + A !
B2 Bl
5. AUMC = A2 + A l
(B2)2 (B l)2
6. MRT = AUMC
AUC
7 . MAT = MRT (extravascular) - MRT (intravenous)
8 .  t V o f i  =  0 . 6 9 3
Bl
9. Vr = dose
CpO
1 0 .  V d  area =  d o s £
AUC.B1
11. Vdss = dose.AUMC
(AUC)2
1 2 . Cl = dose
AUC
13- Kel = £ i
Vc
14. K 12 = ( k 2 i + k e l )  - (B1+B2)
15. Koi = (B1.B21
Kel
16 F = AUC (non intravenous! X 100
AUC (intravenous)
Table 2.2 Pharmacokinetic equations
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S a m p l e  or S ta n d a rd  Ant ibody  (ab)
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Figure 2.1 Representation of radioimmunoassay for measurement of TxB2 
in serum.
Chapter 3 
STUDIES W ITH FLUNIXIN
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3.1 INTRODUCTION
Flunixin (3-pyridine carboxylic acid, 2[(2-methyl-3-trifluoromethyl) phenyl] amine) is 
a carboxylic acid belonging to the fenamate group of anti-inflammatory drugs. It has 
found clinical use as the meglumine (N-methyl-d-glucamine) salt, and is available as 
preparations suitable for intravenous, intramuscular and oral administration. The 
recommended dose rate in the dog is 1.1 mg/kg for up to three days, and the dose can 
be repeated weekly.
Flunixin has been established as an effective analgesic for horses (Houdeshell and 
Hennessey, 1977). When used in the treatment of equine colic a good response was 
recorded for 93 % of flatulent and 72 % of spastic cases. A feature of this treatment was 
the rapid onset of action with 40 % of cases having some improvement within 15 
minutes and a duration of action of up to eight hours (Vemimb and Hennessey, 1977). 
Flunixin was found to be four times more effective than phenylbutazone in the 
treatment of lameness and swelling in horses; 30 hours after flunixin treatment, 
lameness was improved by 71 % and swelling by 31 % (Houndeshell and Hennessey, 
1977).
Endotoxic shock is the clinical manifestation of the body's response to harmful 
lipopolysaccarides (endotoxins) which are released by gram-negative bacteria. The 
damage caused to vascular endothelium by these substances results in an activation of 
the arachidonic acid cascade and a release of eicosanoids. Experiments by Templeton et 
al (1983) have shown that flunixin prevented the increase of PGI2 and thromboxane 
normally associated with endotoxic shock in ponies, its use increased the survival rate 
from 25 to 75 % seven days after exposure to endotoxin. Pre-treatment with flunixin 
has also been shown to prevent the onset of some changes which are a feature of this 
condition (eg hypoxaemia, lactic acidosis and colic) in the horse (Moore at al. 1981). 
Similar results have also been reported for flunixin treatment of experimentally induced 
endotoxic shock in ponies ( Bottoms et al. 1981; Fessler et al. 1982).
The elimination half life of flunixin in the horse has been shown to be around 2 hours 
(Houdeshell and Hennessey, 1977; Semrad et al. 1985; Lees et al. 1987). Onset of 
action, assessed by improvement in lameness and reduction in swelling, occured by 2 
hours with maximum effects between 2 and 16 hours and a duration of up to 30 hours 
(Houdeshell and Hennessey, 1977). This long duration of action is somewhat surprising 
in view of the short half life. Lees and Higgins (1987a) were unable to detect drug in 
plasma after 12 hours following intravenous administration of flunixin at a dose rate of
1.1 mg/kg, although inhibition of TxB2 was recorded for up to 30 hours. However 
values had returned to normal by 48 hours indicating that this was not caused by 
irreversible inhibition.
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The fact that the duration of clinical efficacy of flunixin exceeds its measurable 
duration in plasma has been attributed to accumulation and persistence of drug in 
inflammatory exudate (Lehmann et al. 1981; Lees et al. 1986).
Flunixin caused dose related inhibition of equine and canine neutrophils when 
examined in vitro (Dawson et al. 1987; Strom et al. 1990). In each case flunixin was 
found to be a more potent inhibitor than phenylbutazone and indomethacin. Persistence 
of this activity was reported by Strom et al (1990). These workers noted that flunixin 
continued to cause inhibition of PMN migration at 24 hours when drug was not 
detected in plasma, and have suggested that prolonged duration of action may result 
from flunixin binding irreversibly to PMN in blood and bone marrow.
After intravenous administration at a dose rate of 1.1 mg/kg to horses, 13.8 % of the 
total administered dose had been excreted in urine by 24 hours, and at one hour, the 
concentration in urine was 37 times that present in plasma.
Flunixin toxicity has been reported in ponies (Trillo et al. 1984; Webbon and 
Wooliscroft, 1984). Administration of 3 mg/kg flunixin twice daily for five days 
resulted in anorexia, oral ulceration, depression, hypoproteinaemia and neutropenia. 
Gastric and colonic ulcers were found to be present at the time of post-mortem. This 
was a dose of more than five times the recommended dose rate. Houdeshell and 
Hennessey (1977) observed no clinical or biochemical signs of toxicity after 
intravenous administration at three and five times the normal dose rate for 10 and five 
days respectively.
Other work has examined the pharmacokinetic and pharmacodynamic characteristics of 
flunixin in the dog (Hardie et al 1985a), the use of which is now approved in the U.K. 
The elimination half life of flunixin was found to be approximately three hours, 
irrespective of dose rate. Similar kinetics were observed in dogs suffering septic 
peritonitis (Hardie et al. 1985b). Its use has been shown to increase the survival time in 
these cases (Hardie et al. 1983) although the significance of these studies is 
questionable since long term survival was not assessed.
Flunixin has also been shown to be effective in the treatment of endotoxic shock in this 
species (Bottoms et al. 1983).
3.2 EXPERIMENTAL OBJECTIVES
The objectives of this work were, to investigate suitable oral dose rates for flunixin 
meglumine treatment of dogs by examination of the pharmacokinetic profile and the 
pattern of serum thromboxane inhibition.
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To compare the kinetics and serum thromboxane inhibition of flunixin when the 
established dose rate was administered to dogs by the intravenous, subcutaneous and 
oral routes.
3.3 MATERIALS AND METHODS
3.3.1 ANALYSIS OF FLUNIXIN
Analysis of flunixin meglumine was carried out by high performance liquid 
chromatography (H.P.L.C.) using spectrophotometric detection.
3.3.1.1 REAGENTS
1. Flunixin meglumine (Schering Inc., U.S.A.)
2. Diethyl ether, redistilled grade (Rathbum Chemicals)
3. Methanol 'Analar' (B.D.H. Ltd), redistilled prior to use
4. Disodium hydrogen orthophosphate Analar' (B.D.H.Ltd)
5. Citric acid 'Analar' (B.D.H.Ltd)
6 . Citrate/phosphate buffer pH 5.0 was produced by mixing the following 
solutions:
49.3 ml M/5 Na2HP04 + 50.7 ml M/10 citric acid, to give 100 ml of
buffer.
7. Perchloric acid 70 % 'Analar' (B.D.H.)
8 . Water, redistilled in the presence of potassium permanganate prior to use.
9. H.P.L.C. mobile phase comprised 85 : 15, methanol: water, containing 50 fil 
of 1 in 55 aqueous solution of perchloric acid per 100 ml mobile phase.
3.3.1.2 H.P.L.C. EQUIPMENT 
P u m p G i l s o n  301 
D e te c to r S p e c t ra p h y s ic s  100
Column 100 mm X 8 mm containing 5 |i O.D.S. Hypersil
(Shandon Southern).
W a v e le n g th 320 nm
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A b s o r b a n c e 0.05 AUFS
Flow rate of mobile phase 1 ml/min.
Retention time of flunixin under these conditions was 3.5 minutes.
3.3.1.3 SAMPLE PREPARATION
A 2 ml aliquot of each plasma sample was placed in a 50 ml ground glass tube. 
To this was added 0.6 ml of citrate /  phosphate buffer (pH 5.0), followed by 20 
ml diethyl ether. The tube was stoppered and the mixture shaken for 10 minutes 
by inversion on a slow rotary mixer. Fifteen millilitres of ether were removed 
from the upper layer and placed in a 50 ml glass test tube. A further 20 ml 
diethyl ether was added to the sample mixture prior to shaking for a second 
period of 10 minutes, after which 20  ml of the upper ether fraction was removed 
and combined with the 15 ml previously recovered.
The tube containing the combined ether extracts was placed in a Dri-Block 
(Techne Ltd) at 50 °C  under a stream of air and allowed to evaporate until 
approximately 5 ml remained. This remaining diethyl ether was transferred to a 
10 ml conical glass tube. The 50 ml glass tube was rinsed three times with 
approximately 1 ml of diethyl ether which was then added to the conical tube. 
The ether extract was evaporated to dryness at 50 °C  under a stream of air. A 
final 1 ml of ether was run down the walls of the conical tube to ensure that all 
residue present was in the base of the tube. The extract was returned to the .Dri- 
Block and allowed to evaporate to dryness. Sample tubes were covered with 
clingfilm and stored overnight at 4 °C  if necessary. Prior to injection into the 
HPLC system the residues were reconstituted in methanol. An appropriate 
known volume (not less than 150 |il) of methanol was added to the bottom of 
the conical tube which was then tilted and rotated in an ultrasonic bath for 1 
minute. A 20 |il injection loop was used for injection, the loop was loaded with 
15 jil of sample.
The concentration of flunixin in each sample was determined by reference to a 
calibration curve prepared for each analysis. This was generated by fortifying 
blank plasma with known amounts of flunixin to produce the appropriate range 
of concentrations. A number of fortified plasma aliquots treated in this way 
were processed in an identical manner to that described for unknown samples. 
In addition, standard solutions of flunixin were injected directly onto the HPLC. 
These standard solutions allowed equipment performance to be monitored and 
were also used to calculate the concentration of flunixin measured in the
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fortified samples. From these figures it was possible to calculate the percentage 
recovery of flunixin after extraction.
Unknown sample concentrations were calculated by reference to the standard 
drug solutions. These concentrations were then adjusted to 100 % to allow for 
extraction losses by comparison to the recoveries obtained for the fortified 
samples.
A typical chromatogram is shown in figure 3.1
3.3.1.4 RECOVERY, PRECISION, LINEARITY AND SENSITIVITY
Recovery of drug from plasma samples was approximately 90 %. Typical 
recovery of flunixin, inter-assay and intra-assay variations are shown in 
appendix 1.1.
Calculation of the inter-assay coefficient of variation for recovery of flunixin 
from fortified plasma allowed an assessment of the precision of the assay to be 
made (appendix 1.1). The mean intra-assay variation was found to be 3.2 % 
mean inter-assay variation was 5.8 %.
Simple regression was used to determine the linearity of concentration with 
respect to peak height for fortified samples. The correlation coefficient (r) for 
concentrations ranging from 0.1 - 5.0 |ig/ml of flunixin in plasma was 0.999.
The sensitivity of the assay was determined with respect to the background 
fluctuation recorded on the trace produced from the HPLC system. The 
minimum peak height which could be reliably recorded was estimated from 
standard solutions in replicate analyses. This was determined as being at least 
twice the maximum overall background fluctuation and was set at one unit. A 
peak height of one unit of flunixin, under the HPLC conditions described, 
corresponded to 0.05 |ig drug per millilitre of plasma.
3.3.1.5 OTHER ANALYSES AND METHODS USED.
Methods for the estimation of serum TxB2 concentration, platelet numbers in 
blood, blood clotting time and detection of occult blood in faeces are described 
in the general material and methods section. Statistical and pharmacokinetic 
analysis including equations are also outlined in that section.
The estimation of serum TxB2 in samples taken after oral administration of 
flunixin was carried out by Professor Peter Lees and colleagues at the 
University of London.
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3.4 EXPERIMENTS WITH FLUNIXIN
Three male and three female Beagle dogs were used for all experimental work. All 
animals were approximately 1-2 years of age at the beginning of experimental work.
Animals were housed in pairs and fed a complete cereal diet once daily, water was 
available ad libitum.
3.4.1 EXPERIMENTAL DESIGN
Flunixin was administered to each of the six dogs by oral intravenous and 
subcutaneous routes.
Oral administration of flunixin was carried out using a three way crossover 
experimental design. Animals were allocated to groups of two and each group was 
given a different dose rate on each occasion. Dose rates used were 0.55, 1.10 and
1.65 mg/kg body weight. Intravenous and subcutaneous administrations were 
performed as separate experiments and in these studies each dog was administered 
flunixin at a dose rate of 1.10 mg/kg by the appropriate route. There was a 
minimum wash out period of seven days between each drug administration. Dogs 
were weighed immediately prior to each experiment and the dose of flunixin to be 
administered calculated from this weight.
3.4.2 DRUG ADMINISTRATION
Flunixin meglumine was administered orally as tablets (Banamine; Schering Inc., 
USA). Tablets containing 5 and 20 mg of drug were used and when an exact dose 
could not be prepared from whole tablets they were supplemented with powdered 
tablet administered in a gelatine capsule. The dose rate administered to each animal 
on each occasion is shown in appendix 2 .1.
A 50 mg/ml injectable solution of flunixin meglumine (Finadyne, Kirby-Warrick), 
was used for intravenous administration. The drug was administered into the right 
cephalic vein over a period of 30 seconds.
Finarine (Rigaux Galena, France), a 10 mg/ml solution of flunixin meglumine was 
used for subcutaneous administration. This was administered under the loose skin at 
the back of the animal’s neck.
In each experiment, administration of drug was carried out one hour prior to feeding
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3.4.3 SAMPLING REGIMEN
Blood was collected from the jugular vein into suitable tubes prior to and at: 0.5, 1, 
2, 4, 8 , 12, 24, 48, 72, 96 and 168 hours after oral administration; 0.25,0.5, 1, 2, 4, 
6 , 8 , 12, 24, 48 and 72 hours after intravenous administration and 0.25,0.5, 1, 2, 4, 
8 , 12, 24, 48, 72, 96 and 168 hours after subcutaneous administration. The 
appropriate sample was used for drug analysis, haematology and serum TxB2 
estimation, as described previously.
In addition, samples for estimation of clotting time were collected into capillary 
tubes at 1 ,2 , 4, 6 , 8 , 24, 48 and 72 hours after intravenous administration and at 
0.25, 0.5, 1, 2, 4, 6 , 8 , 48, 72 and 168 hours after subcutanous administration of 
drug.
Faecal samples were collected throughout the experiment and an estimate of the 
presence of occult blood was made.
3.5 RESULTS OF ORAL EXPERIMENTS WITH FLUNIXIN
The concentration of flunixin in the plasma of each dog after oral administration of 
flunixin meglumine at a dose rate of 0.55, 1.10 and 1.65 mg/kg body weight are shown 
in appendix 2.2 to 2.4. Mean (± SEM) concentrations after each dose rate are shown in 
table 3.1 and figure 3.2. The main pharmacokinetic variables for each dose rate are 
shown in table 3.2.
3.5.1 FLUNIXIN CONCENTRATION AFTER ORAL ADMINISTRATION
3.5.1.1 ORAL ADMINISTRATION OF 0.55 mg/kg FLUNIXIN
Flunixin was detected in the plasma of all animals with the exception of dog 1 at 
0.5 hours post drug administration. In three of the animals (dogs 4, 5 and 6) this 
was also the maximum concentration detected in plasma. Concentrations 
measured at this sample time varied widely over the range 0.11 - 3.69 |ig/ml. In 
two animals, the maximum plasma concentrations were measured at one hour 
(dogs 2 and 3). No drug was detected in any sample from dog 1 until four hours, 
this was the only time at which drug could be measured in this animal. The 
inter-animal variation in maximum concentration was large (0.67 - 5.23 |ig/ml).
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3.5.1.2 ORAL ADMINISTRATION OF 1.10 mg/kg FLUNIXIN
Plasma from all animals was found to contain flunixin at 0.5 hours post drug 
administration. In dog 1 this was also the time at which the maximum 
concentration of drug was detected in plasma. Concentrations at this sample 
time varied more widely than after 0.55 mg/kg and were in the range 0.06 - 4.39 
p.g/ml. Maximum plasma concentrations of flunixin in plasma were measured at 
one hour in four animals (dogs 2, 4, 5 and 6). One animal (dog 3) had the 
maximum plasma concentration of drug at 2 hours. Inter-animal variation in 
maximum concentration was large with values ranging from 2.15 to 9.21 pg/ml.
3.5.1.3 ORAL ADMINISTRATION OF 1.65 mg/kg FLUNIXIN
Plasma from all animals was found to contain flunixin at the first sample time of 
0.5 hours. Concentrations measured at this sample time varied widely over the 
range 0.40 - 7.20 pg/ml. In four animals the maximum plasma concentrations 
were measured at one hour (dogs 3, 4, 5 and 6). Maximum concentrations for 
dogs 1 and 2 were detected at four hours and two hours respectively. The inter- 
animal variation in maximum concentration was large (1.67 - 16.59 (ig/ml).
3.5.2 PHARMACOKINETICS OF FLUNIXIN AFTER ORAL 
ADMINISTRATION
The mean Cmax values of flunixin in plasma of dogs following oral administration 
at dose rates of 0.55, 1.10 and 1.65 mg/kg were 2.77 (± 0.63), 5.03 (± 0.99) and 
8.17 (± 2.02) fig/ml respectively and these were observed at 1.25 (± 0.56), 1.08 (± 
0.20) and 1.67 (± 0.49) hours.
The area under the plasma concentration versus time curves (AUC) showed a large 
inter-animal variation after all dose rates the ranges being 2.01 -19.78 (mean 9.01), 
5.58 - 25.16 (mean 14.62) and 9.32 - 37.98 pg/ml.h (mean 25.98) after 0.55, 1.10 
and 1.65 mg/kg respectively. These figures are approximately linearly related to the 
dose rate administered.
Wide inter-animal variations in AUMC and MRT were also noted. Persistence of 
flunixin as measured by the MRT value was between 1.37 and 5.05 hours after 0.5 
mg/kg, 1.95 and 6.86  hours after 1.1 mg/kg and 3.13 and 8.20 hours after 1.65 
mg/kg. Estimated tV2B calculated from the MRT for each dose rate gave mean 
values of 3.06, 2.66 and 3.87 hours for 0.55, 1.10 and 1.65 mg/kg dose rates 
respectively. The relative differences between lowest and highest AUMC measured 
after each dose rate was calculated. This difference was smallest after
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administration of 1.65 mg/kg (seven times) and highest after 0.55 mg/kg (18 times). 
Mean absorbance time values were found to be negative in several animals after 
oral administration of flunixin, mean values being -0.62, -1.12 and 0.38 hours after 
0.55,1.10 and 1.65 mg/kg dose rates.
3.5.3 SERUM THROMBOXANE INHIBITION AFTER ORAL 
ADMINISTRATION OF FLUNIXIN.
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 2.5 and percentage inhibition of TxB2 in table 3.3.
At the first sample time (0.5 hours), inhibition of serum TxB2 was found to be 
between 52.50 and 98.96 % after a dose rate of 0.55 mg/kg, between 8.43 to 99.80 
% after 1.10 mg/kg and ranged from zero to more than 99.92 % after the 1.65 
mg/kg dose rate.
After oral administration of 0.55 mg/kg, maximum inhibition was greater than 95 % 
in five animals (dogs 2-6) and occurred at 0.5 - 1 hour. In one animal (dog 1) the 
maximum inhibition was 84.38 % and this was measured at 4 hours.
In three animals, inhibition decreased to zero at one sample time, and was measured 
at approximately 30 % at the next sample time (24 hours later). In these three dogs 
(numbers 2 ,4  and 6), inhibition continued thereafter and was 25 % or greater in the 
final sample (168 hours). In one animal (dog 5) no inhibition of serum TxB2 was 
detected in any sample after 24 hours. The maximum mean inhibition of serum 
TxB2 was 91.47 % and occured at 1 hour.
At 0.5 hours after oral administration of flunixin at a dose rate of 1.10 mg/kg 
inhibition of 97 % or greater was measured in samples from four dogs (dogs 1, 2, 5 
and 6). In dog 3, the inhibition in this first sample was 69 %, the sample from dog 4 
showed only 8.4 % inhibition.
The maximum inhibition was greater than 99 % in five dogs, and serum from all 
animals had a maximum inhibition greater than 97 %. In four animals (dogs 2,3,4 
and 6 ), the inhibition of serum TxB2 decreased to zero at one sample time prior to 
rising again in the next sample. No inhibition was detected in any sample from dog 
4 after 8 hours. In all other animals some degree of inhibition was measured in the 
final sample (168 hours). The maximum mean inhibition was greater than 98.84 % 
and was measured at 1 hour.
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After oral administration of flunixin at 1.65 mg/kg, inhibition of serum TxB2 
ranging from 69.05 to more than 99.92 % was detected in serum from five dogs at 
the first sample time. In the other animal (dog 6) no inhibition was detected at this 
time, although inhibition of serum TxB2 was measured as 99.84 % at the next 
sample time (1 hour). In one animal, (dog 1) inhibition was zero at 12 hours, 
however at 24 hours (the next sample time) inhibition was found to be 41.67 % 
This animal also had erratic levels of inhibition at later time points. In dog 2, no 
inhibition was measured after 24 hours and in dog 6 , no inhibition was measured 
after 12 hours. The maximum mean inhibition of serum TxB2 was 97.31 % and was 
measured at 2  hours.
The mean maximum inhibition of serum TxB2 was 99.11, 99.24 and 99.67 % after 
0.55, 1.10 and 1.65 mg/kg respectively. The area under the serum TxB2 inhibition 
versus time curves were 5238, 5952 and 6169 %.h respectively.
3.5.4 PLATELET NUMBERS AFTER ORAL ADMINISTRATION OF 
FLUNIXIN.
Platelet numbers for each dog on each sampling occasion are given in appendix 2.6. 
Throughout the experiments platelet counts were frequently found to be above the 
normal range expected for dogs. This was particularly a feature of dogs 1 and 2 and 
appeared to occur irrespective of dose rate.
3.5.5 OCCULT BLOOD IN FAECES AFTER ORAL ADMINISTRATION OF 
FLUNIXIN.
Gastrointestinal blood loss determined throughout each experiment by Colo-Rectal 
test is shown in appendix 2.7.
Traces of occult blood were detected in faeces from dog 1, 48 hours after 
administration of the 0.55 mg/kg dose rate and from dog 5, 72 hours after 
administration of the 1.65 mg/kg dose rate.
A definitive positive reaction indicated the presence of blood in faeces from dog 1 
at 48 hours after administration of 1.65 mg/kg flunixin
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3.6 RESULTS OF INTRAVENOUS EXPERIMENTS WITH FLUNIXIN
3.6.1 FLUNIXIN CONCENTRATION AFTER INTRAVENOUS 
ADMINISTRATION.
The concentration of flunixin in the plasma of each dog after intravenous 
administration of flunixin meglumine at a dose rate of 1.10  mg/kg is shown in 
appendix 3.1. Mean (± SEM) concentrations are shown in table 3.4 and figure 3.3. 
The main pharmacokinetic variables are shown in table 3.5.
The mean concentration of flunixin measured in plasma of dogs at 0.25 hours post 
drug administration was 12.80 ± 1.05 |Xg/ml. As shown by the standard error the 
inter-animal range in concentration was quite large (9.91 - 16.78 fig/ml) and this 
was generally the case at each sampling time. The concentration of drug declined 
rapidly and in one dog (dog 1) no drug could be detected at 8 hours. Flunixin was 
detected in plasma from two dogs at 48 hours (dogs 4 and 6 ), and at 72 hours was 
only detected in plasma from dog 4. Mean concentration of flunixin in plasma was 
0.22 (± 0.11) (J.g/ml at 12 hours and 0.09 (± 0.03) |ig/ml at 24 hours.
The \}/2& of flunixin after intravenous administration at a dose rate of 1.1 mg/kg 
was found to be in the range 0.90 - 25.10 hours. The mean tV2B was 2.97 hours. 
Two animals (dogs 4 and 6) had particularly large tV2B values (25.10 and 23.18 
hours respectively). These variable values for tV2B were matched by the values for 
MRT calculated from computed data. Examination of MRT values calculated from 
observed data shows a much smaller inter-animal variation (1.13 - 9.95 hours). 
When tV2B values were calculated from these data a mean figure of 3.56 hours was 
obtained.
The inter-animal variation of persistence of flunixin in plasma is also reflected in 
the large inter-animal variation in computed and observed AUCs. These ranged 
from 13.93 - 34.70 |ig/ml.h for computed data and 11.23 - 29.31 |ig/ml.h for 
observed data . The mean observed AUC after administration of flunixin at a dose 
rate of 1.10 mg/kg by the intravenous route was 20.47 |ig/ml.h.
The area under the first moment curve for observed values had an extremely wide 
inter-animal variation. The mean observed AUMC was 117 (± 39) |ig/ml.h2. In the 
case of two animals (dogs 4 and 6) the AUMC value was much greater if calculated 
from computed best fit curve values. Inclusion of the estimated last triangle did not 
greatly affect the AUMC values. Mean body clearance of drug was 47.85 ± 7.34 
ml/kg.h when calculated from computed values and 48.83 ± 6.37 ml/h.kg when 
calculated from observed values for the same period. The volume of distribution at
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steady state (Vdss) was 326 ± 105  ml/kg for values from the computed best fit 
curves and 189 ± 46 ml/kg for observed data.
3.6.2 SERUM THROMBOXANE INHIBITION AFTER INTRAVENOUS 
ADMINISTRATION OF FLUNIXIN.
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 3.2, and percentage inhibition of TxB2 in table 3.6.
Inhibition of TxB2 was greater than 99 % in all animals at 0.25 and 0.5 hours after 
drug administration. In one dog (dog 1) inhibition had decreased to 97.9 % at one 
hour, however the mean inhibition at this time was still greater than 99 %. Mean 
inhibition remained above 90 % at four hours and still exceeded 70 % at 12 hours. 
At 24 hours TxB2 concentrations had returned to near pre drug administration 
values. The area under the serum TxB2 inhibition versus time curve after 
intravenous administration at a dose rate of 1.1 mg/kg was 2148 ± 283 %.h.
3.6.3 PLATELET NUMBERS AFTER INTRAVENOUS ADMINISTRATION OF 
FLUNIXIN.
Platelet numbers for each dog on each sampling occasion and mean (±SEM) platelet 
numbers are given in appendix 3.3. On several occasions throughout the experiment 
samples were noted to contain lower than normal platelet counts. This was not seen 
to be a consistent feature and was not considered to be associated with drug 
administration.
3.6.4 CLOTTING TIMES AFTER INTRAVENOUS ADMINISTRATION OF 
FLUNIXIN.
Clotting times for each animal at each sampling time and mean clotting times are 
shown in appendix 3.4. These values remained within the expected range at all 
sample times with the exception of the eight hour sample from dog 1 which was 
lower than expected (0.59 minutes).
3.6.5 OCCULT BLOOD IN FAECES AFTER INTRAVENOUS 
ADMINISTRATION OF FLUNIXIN.
Gastrointestinal blood loss determined throughout the experiment by Colo-Rectal 
test is shown in appendix 3.5. Blood was detected in one faecal sample collected 
from pen 3 at 24 hours and pen 1 at 168 hours.
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3.7 RESULTS.OF SUBCUTANEOUS EXPERIMENTS W ITH 
FLUNIXIN.
3.7.1 FLUNIXIN CONCENTRATION AFTER SUBCUTANEOUS 
ADMINISTRATION.
The concentration of flunixin in the plasma of each dog after subcutaneous 
administration of flunixin meglumine at a dose rate of 1.10  mg/kg is shown in 
appendix 4.1. Mean (± SEM) concentrations are shown in table 3.4 and figure 3.4. 
The main pharmacokinetic variables are shown in table 3.7
The mean concentration of flunixin measured in plasma of dogs at 0.25 hours post 
drug administration was 3.15 ± 0.35 |lg/ml. A small inter-animal range in 
concentration (1.94 - 4.14 |ig/ml) was found to be typical of this and other sample 
times until 12 hours. The maximum mean concentration (6.31 ± 0.63 |ig/ml) 
occured at one hour after drug administration and flunixin was detected in the 
plasma of all animals at 12 hours (mean concentration 0.34 ± 0.13 Jig/ml). Flunixin 
could be detected in the plasma of two dogs (dogs 4 and 6) at 48 hours and in 
plasma of one animal (dog 6 ) 0.14 p.g/ml was measured at 96 hours after 
administration. Examination of the drug concentration versus time profile for dog 6 
shows that after declining to a concentration of 0.11 |ig/ml at 48 hours a higher 
concentration of 0.21 |J.g/ml was measured at 72 hours. The mean maximum 
concentration of 6.36 |ig/ml was measured at 0.92 hours.
The inter-animal variation for persistence of flunixin in plasma is reflected in the 
large intra-animal variation in AUCs which ranged from 9.95 - 41.23 |Xg/ml.h.and in 
the MRT which ranged from 2.48 hours in dog 5 to 32.64 hours in dog 6 . 
Calculation of an estimated tV2fi from MRT values gave a figure of 6.9 hours. The 
mean AUC after administration of flunixin at a dose rate of 1.10 mg/kg by the 
subcutaneous route was 26.30 (ig/ml.h indicating that drug was well absorbed from 
the injection site. Examination of MAT values showed a large inter-animal variation 
with several animals having negative values, the mean value was 4.13 hours. The 
mean value for AUMC was 304 (± 210) jig/ml.h2.
3.7.2 SERUM THROMBOXANE INHIBITION AFTER SUBCUTANEOUS 
ADMINISTRATION.
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 4.2, and percentage inhibition of TxB2  in table 3.6.
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Inhibition of TxB2 was greater than 98 % in all animals at 0.25 and 0.5 hours after 
drug administration. Mean inhibition remained above 90 % at four hours and still 
exceeded 70 % at 12 hours.
In four animals (dogs 1, 2, 4 and 6) the inhibition of TxB2 decreased to zero, after 
which some degree of inhibition was measured at the next sample time, 24 hours 
later.
At 48 hours mean serum TxB2 concentrations had returned to near control 
values.The area under the serum TxB2 inhibition versus time curve after 
subcutaneous administration at a dose rate of 1.1 mg/kg was 2741 ± 540 %.h.
3.7.3 PLATELET NUMBERS AFTER SUBCUTANEOUS ADMINISTRATION
Platelet numbers for each dog on each sampling occasion and mean (±SEM) platelet 
numbers are given in appendix 4.3. On several occasions throughout the experiment 
samples were noted to contain lower than normal platelet numbers. This was seen to 
be a consistent feature in one animal (dog 4), however the platelet count in the pre 
drug administration sample was also somewhat low for this animal. Platelet counts 
were not considered to be sufficiently low on a consistent basis to affect 
concentrations of thromboxane produced in serum.
3.7.4 CLOTTING TIMES AFTER SUBCUTANEOUS ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times are 
shown in appendix 4.4. These values remained within the expected range at all 
sample times with the exception of the 0.5 hour sample from dog 1 which was 
lower than expected (0.96 minutes).
3.7.5 OCCULT BLOOD IN FAECES AFTER SUBCUTANEOUS 
ADMINISTRATION.
Gastrointestinal blood loss determined throughout the experiment by Colo-Rectal 
test is shown in appendix 4.5.
No blood was detected in any sample collected during this experiment.
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3.8. DISCUSSION
No adverse effects were seen in any animal after oral administration of flunixin. With 
only one exception (dog 1 at 0.55 mg/kg) drug was detected in the plasma of all 
animals at 0.5 hours after administration thus indicating that this oral preparation of 
flunixin is rapidly absorbed. Examination of results for individual animals shows wide 
variations in concentrations and this was particularly apparent at the 0.55 mg/kg dose 
rate where drug was only detected in plasma at 4 hours for one animal (dog 1). It is 
likely that this variation reflects the innate inter-animal variation in absorption rate as it 
was not a consequence of concurrent feeding. Each dog was in a similar state of fasting 
prior to administration of the drug and food was not available to any animal until one 
hour after drug administration. The AUC for individual animals after oral 
administration also reflects this variation. Persistence of drug in plasma as measured by 
MRT was significantly different amongst the dose rates (p = 0.01). This was shown to 
be due to the MRT being significantly higher after administration of the 1.65 mg/kg 
dose rate than after the 1.10 mg/kg dose rate. A visual examination of the plasma 
concentration versus time curves produced after each oral dose rate also indicated that a 
general similarity existed in the pharmacokinetics of flunixin at the three dose rates. 
This is in agreement with the findings for the pharmacokinetics of flunixin in sheep 
after intravenous administration at dose rates of 1.0 and 2.0 mg/kg (Welsh et al. 1993). 
As expected the Cmax increased with increasing dose rates, however similar values for 
tm a x  were seen after each dose rate thus indicating that rate of oral absorption is not 
affected by dose rate within the range 0.55-1.65 mg/kg.
The maximum mean inhibition of TxB2 exceeded 90 % after each oral dose rate, 
however, after the 1.10 and 1.65 mg/kg dose rates the mean maximum inhibition 
achieved was greater than 99 %. A significant difference was found (p = 0.039) when 
these maxima were compared statistically using Friedman's test. However, differences 
were not found to be significant on examination of data as pairs using Wilcoxon Signed 
Ranked Test. This may have been a result of small sample numbers. At the higher oral 
dose rates of 1.10 and 1.6 mg/kg, each animal had a TxB2 inhibition of 97 % or greater 
on at least one sampling occasion after drug administration. The maximum inhibitions 
achieved with the 0.55 mg/kg dose rate were more variable and in dog 1 the maximum 
achieved was as low as 84 %. Flunixin is known to be highly bound to plasma proteins 
(perhaps 99 %) (Soma et al. 1988). In several samples where drug concentrations were 
as low as 0.1 fig/ml, inhibition of TxB2 to a level of around 50 % was detected. Since 
this concentration represents the total concentration of flunixin in plasma the 
concentration of unbound drug could be estimated to be in the order of 0.001 p.g/ml, 
indicating that the drug is extremely potent in producing inhibition of platelet
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cyclooxygenase. In all cases at 24 hours the inhibition of TxB2 had greatly declined, 
thus indicating that flunixin is a reversible inhibitor of platelet cyclooxygenase and 
confirming the findings of Lees et al. (1987).
The the area under the TxB2 inhibition versus time curve was 5238, 5952 and 6169 %.h 
after 0.55, 1.10 and 1.65 mg/kg respectively. The increase in the area under the TxB2 
inhibition versus time curve between the 0.55 and 1.10 mg/kg dose rates was 13 %, 
whereas the increase between 1.10 and 1.65 mg/kg was 3 %. This, together with the fact 
that the maximum TxB2 inhibition was greater after 1.10 and 1.65 mg/kg than after 
0.55 mg/kg, but was similar after 1.10 and 1.65 mg/kg, led to the conclusion that there 
was little apparent benefit in the use of the highest dose rate. Accordingly, a dose rate 
of 1.10 mg/kg was used in the intravenous and subcutaneous studies with flunixin.
Lees and Higgins (1984) have shown, for cattle and horses, that the concentration of 
flunixin in plasma may not be an accurate indicator of its clinical efficacy, since the 
drug accumulates in inflammatory exudate. Concentrations of up to four times those in 
plasma have been measured in inflammatory exudate from horses after intravenous 
administration of flunixin (Lees and Higgins, 1984 ; Higgins et al. 1986), and inhibition 
of TxB2 and PGE2 production in exudates is more persistent than in plasma. It seems 
likely that this situation will also apply for the dog.
Platelet numbers were within the normal range for beagle dogs throughout these 
experiments and the changes in TxB2 concentrations were not associated with changes 
in platelet numbers. In addition, although occult blood was detected in faeces from dogs 
on some occasions this was not persistent. Monitoring of dogs outwith experimental 
periods indicated that blood was passed in faeces occasionally and was not associated 
with flunixin administration. It is likely that in NSAID toxicity the amount of blood 
passed in faeces would be much greater and that it would be a consistent feature.
The plasma concentration versus time curve for flunixin after intravenous 
administration was best described by a biexponential equation in all animals, however, 
the second exponent of the equation for data from dog 2  contained only two data points 
indicating that this description was unsound. These findings are in agreement with 
studies on dogs (Hardie et al. 1985a), horses (Chay et al. 1982) and cattle (Benitz, 
1984; Hardee et al. 1985). However, a recent study on the pharmacokinetics of flunixin 
in sheep at dose rates of 1.0 and 2.0  mg/kg dose rates found the plasma concentration 
versus time curve to be best described by a triexponential equation (Welsh et al. 1993). 
It is possible that the identification of a third exponent is a result of the greater 
sensitivity of the assay method used by Welsh. The low background absorbance of 
plasma samples from sheep allowed an increase in the sensitivity for the measurement
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of flunixin of approximately five times, and in the study in sheep, flunixin was detected 
in plasma at 33 hours after administration. In the present study the concentration of 
flunixin in plasma remained above 0.3 |ig/ml for eight hours in all but one animal (dog 
1), but was below the limit of detection in two animals at 12 hours after administration.
No adverse effects were seen in any animal after intravenous administration of flunixin.
The half life of elimination of flunixin was seen to vary widely between animals. These 
values may be associated with enterohepatic cycling . Half lifes of elimination can be 
greatly influenced by sampling times and limit of detection for a drug. A low limit of 
detection and appropriately spaced sampling times can result in an apparently longer 
half life. There is no way of determining the exact time at which drug can no longer be 
detected in plasma, this time point may occur at any time between the last positive 
sampling time, and the first negative sampling time and as a result these figures may 
also have a marked effect on the calculated half life of elimination. The tV2^ in the 
present study was approximately 3 hours. This is similar to the values previously 
reported for dogs (3.7 hours, Hardie et al. 1985), sheep (3.4 - 3.8 hours, Welsh et al. 
1993) and lactating cattle (3.1 hours, Anderson, 1990). Other studies in cattle have 
reported tV2B values which are considerably longer (approximately 8 hours, Hardee et 
al. 1985) and the tV2C reported by Chay et al (1982) for horses was considerably 
shorter (1.6 hours). A factor which may hamper the comparison of tV2B values is the 
method of expression. In the present study all values for tV2B have been expressed as 
harmonic mean values. Calculation of the harmonic mean requires that values are 
expressed as the inverse of the sum of the inverse individual values divided by the 
number of observations, and is considered to be the most appropriate method of 
describing rates (Moroney, 1963). Conversion of this value to an arithmetic mean 
produces a ri/2B of approximately 10 hours. Without full knowledge of the method of 
calculation of t1/ ^  and the ability to express data in the same way it is impossible to 
make accurate comparisons of these figures.
The mean Vdss calculated from observed data was 189 ml/kg and the Clb was 48.83 
ml/h/kg. These figures, together with the other main pharmacokinetic parameters, are in 
good agreement with the findings of Hardie et al (1985a) who studied mixed breed 
dogs. This indicates that there is likely to be little difference in pharmacokinetics 
between breeds of dogs although differences between individuals are large.
It is difficult to draw conclusions from the data obtained for MAT as in many cases 
these values were negative, indicating that theoretically drug was more rapidly 
available after oral administration than intravenous administration. As this is not 
possible these results must be due to the errors inherent in comparing the intravenous
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and oral concentration versus time curves. This does, however suggest that absorption 
is very rapid after oral administration.
The AUC values calculated for each animal reflect the inter-animal variation in 
persistence of drug concentrations in plasma. Enterohepatic cycling has been noted in 
dogs by several workers after the administration of NSAIDs (Duggan et al. 1975; 
Tsuchia, 1980; Frey and Rieh, 1981; Rubin and Papich, 1989) and it may be that 
although the characteristic peaks and troughs in drug concentrations were not seen, the 
persistence of drug in some animals was due to this phenomenon.
Bioavailability of drug after oral administration was calculated when the intravenous 
experiment had been performed. In the case of each dose rate the AUC after oral 
administration was compared with the intravenous AUC at the dose rate of 1.10 mg/kg. 
Observed values plus the theoretical last triangle were used in this calculation and 
results were in good agreement with those reported for mixed breed dogs by Hardie et 
al (1985a). In general, bioavailability at each dose rate was approximately equivalent 
when adjusted for the dose administered. However, at the lowest dose rate the inter­
animal variation was such that the lowest bioavailability was 27.94 % whilst the highest 
was 197.40 %. Inter-animal variation at the higher dose rates was smaller, the range 
being 50.42 - 113.23 % and 43.18 - 101.50 % after 1.10 and 1.65 mg/kg respectively. It 
is of interest to note that when these values for bioavailability are adjusted for a dose 
rate of 1.10 mg/kg the mean values would be 74.8, and 69.8 % and are similar to the 
value of 60.7 % obtained after oral administration of 1.10 mg/kg, thus reinforcing the 
theory that absorption is not related to dose rate. These estimates of bioavailability are 
somewhat lower than that reported for the horse by Soma et al (1988), who found the 
bioavailability of flunixin to be 85.8 % after administration to mares at a dose rate of
1.1 mg/kg.
The maximum inhibition of serum TxB2 production was generally higher after the 
administration of flunixin by the intravenous route than after any of the three oral dose 
rates. The high levels of inhibition were also maintained over a longer time scale, 
following intravenous administration. However, when the decline in inhibition occured 
it was rapid and by 72 hours only one animal (dog 3) had any inhibition and the area 
under the serum TxB2 inhibition versus time curve was 2148 %.h after intravenous 
administration, less than half that measured after oral administration at the same dose 
rate. As in the oral experiment the reversible nature of the cyclooxygenase inhibition 
was confirmed by the return to near normal values for the concentration of TxB2 in 
some dogs by 24 hours, after administration of flunixin.
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No adverse effects were seen in any animal after subcutaneous administration of drug 
and the administration did not appear to cause undue discomfort to any animal. 
Concentrations ranging from 1.94 - 4.14 |ig/ml (mean 3.15 ± 0.35 |ig/ml) of flunixin 
were detected in plasma at 0.25 hours after drug administration indicating that a rapid 
absorption occurs after subcutaneous administration. Drug concentrations were well 
maintained in most animals until 12 hours. A large inter-animal variation in persistence 
of drug was noted. Examination of the plasma drug concentration versus time profile 
for dog 6  showed a trough, followed by increased concentrations during the period 24 - 
96 hours and in this animal drug was detected in plasma until 96 hours. This profile 
would suggest that the drug may have undergone enterohepatic circulation. The 
persistence of flunixin in the plasma of dog 6  is also reflected in the larger AUC. This 
value is four times the smallest measured AUC (Dog 1,9.95 |ig/ml.h) and almost twice 
the mean AUC calculated for the other five animals. Mean residence times calculated 
after subcutaneous administration showed a large inter-animal variation, the mean value 
being 8.55 hours. An estimated tV2b calculated from this figure is 6.9 hours. The large 
difference in AUCs may also reflect the large inter-animal differences in absorbance of 
the drug (MAT 4.13 ± 3.82 hours).
Good inhibition of serum TxB2 occured after the subcutaneous administration of 
flunixin and this inhibition also mirrored the concentration of flunixin in plasma. At 12 
hours, the last sampling time at which flunixin could be detected in all animals, the 
mean inhibition was 78 %. At 24 hours, when drug could be detected in plasma from 
only two animals (dogs 4 and 6) this mean inhibition had decreased to 29 %. Maximum 
inhibition was similar to that measured after intravenous and oral administration of 
flunixin at the 1.10 mg/kg dose rate. High levels of inhibition were maintained for 
longer periods than after oral administration, however, the decline when it occured was 
rapid. The area under the serum TxB2 inhibition versus time curve was slightly larger 
than after intravenous administration and approximately half of that measured after oral 
administration at the 1.10 mg/kg dose rate.
Platelet numbers were, generally, within the normal range for beagle dogs throughout 
this experiment, samples from dogs 1 at two hours, dog 3 at eight hours and dog 4 at 
one and 24 hours being the exception to this. These samples contained low numbers of 
platelets, however since these occurrences were not part of a trend but were individual 
exceptions it seems likely that these figures may have resulted from clotting which had 
occured but was undetected in the sample. Clotting times were also generally 
considered to be normal with the exception of a single sample from dog 1 at 0.5 hours. 
Occult blood in faeces was not a consistent feature for any animal after the
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subcutaneous administration of flunixin. This further confirms the observations that 
dogs did not respond adversely to subcutaneous administration of the drug.
General
The dose rates and routes of administration of flunixin produced no adverse reactions in 
any dog, and this observation was borne out by the results obtained for platelet counts, 
clotting times and the occult blood test. Examination of the data produced by the oral 
study resulted in the selection of a dose rate of 1.10 mg/kg for the intravenous and 
subcutaneous experiments.
Comparison of a single oral dose of flunixin administered at three dose rates, showed 
that absorption and bioavailability are approximately linear through the range 0.55 to
1.65 mg/kg. Comparison of the data from the administration of 1.10 mg/kg flunixin by 
the oral route with that produced after administration of the same dose rate by the 
intravenous and subcutaneous routes showed that tV2^ estimates were slightly longer 
after oral than intravenous administration (3.12 and 2.97 hours respectively). The value 
estimated after subcutaneous administration was considerably longer at 6.91 hours. 
These observations would be expected, as the elimination phase of any plasma 
concentration versus time curve for a drug given by an extravascular route is a 
composite of absorption and elimination factors. The possibility of enterohepatic 
circulation having occured in these experiments has been discussed and it seems 
possible that the variations in tV2B may have resulted from this phenomenon. Large 
inter-animal variations in plasma concentration and tV2^ were noted in all experiments 
and this was particularly a feature after the 0.55 mg/kg oral administration and the 
intravenous administration. As all animals were in a similar state of fasting prior to the 
experiment, it is likely that the differences arose as a result of normal individual 
differences in absorption, distribution and excretion of drug. The extent of this variation 
may have serious implications for the inter-animal variation in efficacy and toxicity of 
flunixin if dosage regimens are based on mean data, or in cases of multiple 
administration over a period of days or weeks. Mean absorbance time was extremely 
short in all experiments and in some cases was calculated as a negative value. 
Theoretically this would only be possible only if a proportion of drug had not been 
delivered directly into the vein during the intravenous administrations. As there is no 
other evidence to support this it seems likely that a normally short MAT was 
augmented by extremely large inter-experimental variation in MRT which could result 
from enterohepatic circulation.
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Flunixin was found to be a potent, reversible inhibitor of cyclooxygenase activity. 
Examination of all available information suggests that a single daily administration of 
1.10 mg/kg flunixin should provide relatively safe and effective anti-inflammatory 
activity. The greater area under the serum TxB2 inhibition versus time curve after oral 
administration, coupled with the convenience of this route of administration indicates 
that this may be the route of administration of choice.
3.9. TABLES AND FIGURES
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Tim e Dose Rate Adm inistered (mg/kg)
(h) 0 .5 5 1 .1 0 1 .65
P re 0 0 0
0 .5 0 1.93 ± 0.63 1.95 ± 0.77 2.94 ± 1.30
1 . 0 0 2.40 ± 0.70 4.57 ± 1.12 7.42 ± 2.07
2 . 0 0 1.44 ± 0.62 2.83 ± 0.57 4.99 ± 1.11
4 .0 0 0.55 ±0.13 1.33 ±0.39 1.64 ±0.16
8 . 0 0 0.32± 0.18 0.44 ±0.16 0.60 ±0.13
1 2 . 0 0 0.17 ±0.08 0.22  ±0.16 0.31 ±0.10
2 4 .0 0 0 0.02  ± 0.02 0.07 ± 0.04
4 8 .0 0 0 0 0.02  ± 0.02
7 2 .0 0 0 0 0
9 6 .0 0 0 0 0
1 68 .00 0 0 0
Table 3.1 Mean concentration (|ig/ml) of .flunixin in plasma of dogs after administration 
of a single dose of flunixin by the oral route at a dose rate of 0.55, 1.10 and 
1.65 mg/kg body weight.
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Param eter Animal Num ber
U nits 1 2 3 4 5 6 Mean ± SEM
0 .5 5 mg/kg
Cmax tig/ml 0 .6 7 2 .25 5 .23 2 .5 2 3 .69 2 .2 4 2 .77 ± 0.63
tmax hours 4 .0 0 1 .0 0 1 .0 0 0 .5 0 0 .5 0 0 .5 0 1.25 ± 0 .5 6
A U C |lg/ml.h 2 .0 1 5.14 19.78 3 .98 14.89 8 .2 9 9.01 ± 2.83
A U M C pg/ml.h2 8.04 14.51 1 0 0 .0 0 5 .43 74 .51 3 7 .7 6 40 .0 4 ± 15.98
M R T hours 4 .0 0 2 .8 2 5 .05 1.37 5 .0 0 4 .5 6 3 .8 0 ± 0 .59
M A T hours 2 .8 7 -2 .58 3 .13 -1 .83 0 .0 6 -5 .39 -0 .62 ± 1.35
F % 2 7 .9 4 4 6 .2 6 197 .40 2 9 .2 2 90 .2 4 5 7 .9 8 7 4 .8 4 ± 26 .2 2
1 . 1 0  mg/kg
Cmax Mg/ml 4 .3 9 9.21 3 .4 2 2 .15 5 .6 2 5 .3 7 5.03 ± 0 .99
tmax hours 0 .5 0 1 .0 0 2 .0 0 1 .0 0 1 .0 0 1 .0 0 1.08 ± 0 .2 0
A U C pg/ml.h 7 .6 6 2 5 .1 6 10.59 5 .58 2 4 .3 4 14 .42 14.62 ± 3.43
A U M C pg/ml.h2 14.9 81.41 30 .27 13 .10 166 .42 36.71 57 .13 ± 24 .08
M R T hours 1.95 3 .24 2 .8 6 2 .35 6 .8 6 2 .5 5 3.31 ± 0.73
M A T hours 0 .8 2 -2 .16 0 .9 4 -0 .85 1.90 -7 .4 0 - 1 .1 2 ± 1.39
F % 53.23 113.23 52 .8 4 20 .4 8 7 3 .7 6 50 .4 2 60 .6 6 ± 12.61
1 .65  mg/kg
Cmax |ig/ml 1.67 9 .8 0 5 .6 0 7 .45 7.91 16.59 8 .17 ± 2 .0 2
tmax hours 4 .0 0 2 .0 0 1 .0 0 1 .0 0 1 .0 0 1 .0 0 1.67 ± 0.49
A U C pg/ml.h 9 .3 2 33 .83 2 0 .2 7 19.31 3 5 .2 0 37 .9 8 25 .9 8 ± 4 .6 4
A U M C [ig/ml.h2 33 .74 105.91 7 4 .1 6 61 .21 2 4 8 .0 0 31 1 .2 5 139.04 ± 4 6 .1 9
M R T hours 3 .6 2 3.13 3 .6 6 3 .17 7 .03 8 .2 0 4 .8 0 ± 0.91
M A T hours 2 .4 9 -2.27 1.74 -0 .03 2 .0 9 -1 .75 0 .38 ± 0 .8 4
F % 4 3 .1 8 101.50 6 7 .4 3 4 7 .2 6 71 .11 8 8 .5 3 69 .83 ± 9 .27
Table 3.2 Main pharmacokinetic variables in dogs after administration of flunixin at dose 
rates of 0.55, 1.10 and 1.65 mg/kg by the oral route.
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I . 5 5 m g / k g
T i m e A n im a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n
P r e 0 0 0 0 0 0 0
0 . 5 0 52 .5 0 64 .5 2 98 .9 6 9 8 .5 4 98 .0 4 9 6 .3 6 84 .82
1 . 0 0 58 .75 9 9 .1 9 99 .58 9 6 .3 4 98 .5 9 9 6 .3 6 91 .47
2 . 0 0 4 0 .0 0 > 8 2 .2 6 99 .24 98 .21 92 .83 78 .1 8 > 8 1 .7 9
4 . 0 0 84 .38 7 2 .5 8 91 .67 95 .61 9 0 .0 0 56 .3 6 81 .77
8 . 0 0 76 .25 29 .03 9 5 .4 2 26 .83 82 .17 4 1 .8 2 58 .59
1 2 . 0 0 3 0 .0 0 4 3 .5 5 91 .94 4 7 .9 7 80 .43 4 3 .6 4 56 .26
2 4 . 0 0 17 .50 4 6 .7 7 58.33 0 39 .13 5 .45 26 .1 0
4 8 . 0 0 3 5 .0 0 0 2 2 .2 2 3 6 .59 0 0 15.63
7 2 . 0 0 4 5 .0 0 29 .03 55 .55 6 5 .8 5 0 3 4 .54 30 .16
9 6 . 0 0 6 2 .5 0 19.35 0 7 2 .3 6 0 52 .73 34 .49
1 6 8 .0 0 0 25 .81 0 72 .3 6 0 4 3 .6 4 23 .63
[ .1 0  m g /k g
T i m e A n im a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n
Pre 0 0 0 0 0 0 0
0 .5 0 9 9 .1 2 97 .73 6 9 .23 8 .43 9 9 .8 0 99 .6 4 78 .99
1 .0 0 97 .43 9 9 .7 0 9 9 .94 97 .11 > 9 9 .9 5 9 8 .9 2 > 9 8 .8 4
2 .0 0 88 .8 2 9 7 .8 0 99 .1 0 9 3 .2 5 99 .7 5 9 3 .4 2 9 5 .3 6
4 .0 0 67 .65 > 9 9 .2 4 92 .82 0 9 8 .7 0 98 .1 4 > 7 6 .0 9
8 .0 0 4 8 .5 3 71.21 71 .79 10.84 9 7 .9 0 88 .57 64.81
1 2 .0 0 11.76 4 8 .4 8 0 0 9 3 .4 0 3 2 .8 6 31 .08
2 4 .0 0 11.76 1 2 .1 2 33 .33 0 5 7 .0 54 .29 28 .08
4 8 .0 0 23 .53 0 33 .33 0 6 9 .0 0 20 .98
72 .0 0 4 1 .1 8 3 7 .8 8 47 .43 0 6 6 .0 17 .14 3 4 .94
9 6 .0 0 70 .59 6 5 .1 6 42 .31 0 6 3 .0 2 .9 6 4 0 .6 5
168 .00 58 .8 2 5 1 .5 2 7 .69 0 5 4 .0 2 1 .4 3 3 2 .24
L.65 m g /k g
T im e A n im a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n
P r e 0 0 0 0 0 0 0
0 . 5 0 69 .0 5 9 8 .91 97 .25 88 .5 0 > 9 9 .9 2 0 > 7 0 .2 3
1 . 0 0 83 .93 9 8 .8 0 99 .69 9 9 .9 4 > 9 9 .9 2 9 9 .8 4 > 9 7 .0 2
2 . 0 0 99 .0 5 99 .5 7 98 .81 9 1 .5 0 9 9 .6 0 9 5 .3 2 97 .31
4 . 0 0 9 2 .8 6 97 .9 3 95 .87 76 .25 > 9 9 .1 9 91 .61 > 9 2 .2 9
8 . 0 0 7 8 .5 7 82.61 83 .75 78 .13 93 .71 6 1 .2 9 7 9 .6 8
1 2 . 0 0 0 4 3 .4 8 5 0 .0 0 5 7 .5 0 7 9 .03 3 .2 2 3 8 .8 7
2 4 . 0 0 4 1 .6 7 4 .3 5 51 .25 6 5 .0 0 7 9 .8 4 0 4 0 .3 5
4 8 . 0 0 7 .14 0 35 .00 5 5 .0 0 5 0 .0 0 0 2 4 .5 2
7 2 . 0 0 6 1 .9 0 0 38.75 76 .2 5 5 0 .0 0 0 3 7 .8 2
9 6 . 0 0 0 0 6 2 .5 0 56 .25 6 6 .1 3 0 30.81
1 6 8 . 0 0 19.05 0 70 .0 0 56 .25 7 2 .5 8 0 36.31
Table 3.3 Inhibition (%) of thromboxane B2 in serum of dogs after oral administration 
of flunixin at three dose rates.
6 8
Time Route of Adm inistration
(h) In travenous Subcutaneous
P re 0 0
0 .2 5 12.80 ± 1.05 3.15 ± 0.35
0 .5 0 8.71 ± 0.59 5.31 ± 0.58
1 . 0 0 5.28 ± 0.35 6.31 ± 0.63
2 . 0 0 2.16 ± 0.21 4.20 ± 0.78
4 .0 0 1.12 ±0.24 1.56 ± 0.36
6 . 0 0 0.51 ± 0.09 N S
8 . 0 0 0.34 ± 0.08 0.39 ± 0.07
1 2 . 0 0 0.22  ± 0.11 0.34 ±0.13
2 4 .0 0 0.09 ± 0.03 0.04 ± 0.03
4 8 .0 0 0.04 ± 0.03 0.03 ± 0.02
7 2 .0 0 0.02  ± 0.02 0.03 ± 0.03
9 6 .0 0 NS 0.02 ± 0.23
168 .00 N S 0
Table 3.4 Mean (±SEM) concentration (|ig/ml) of.flunixin in plasma of dogs after 
administration at a dose rate of 1.10 mg/kg by the intravenous 
and subcutaneous routes
Table 
3.5 
M
ain 
pharm
acokinetic 
variables in 
dogs after adm
inistration 
of flunixin 
at a 
dose 
rate 
of 
1.10 
mg/kg 
by 
the 
intravenous route.
69
+ c + | + > + >
n n
✓”*so S '
£L-w" crVS
II II CD CDELELop oELo o*cST ST
cd
CL CDO - ar sprr> o o
O 3*
s-1 cnV) V)
3 3oO
3
o<3*vs
"O CD
c 5
CDQ.
O JO
cdQ. Lat o i—»t o
< <
CJ Co
c C
CD CD
M vs
o  n n O r t n O o n C o o O C n o O O  as BBO'BMO’MMCrtJBCrO'MUO'Cr
“  c/s “  “  Vi to  to  to  “  “  Vi to
p o p  
t o  4 l  l a  N) WW
_  -o
. t O
F  -  l r  3  3  3  3
g  g  3  3 3  T
c/i JJT JJ; s o  cra cro l u  «  =r _n  n  m  m  n
r r r r i l l t  
=£, =r i r  =r =r
O n
- o - o O
JO
NO 0 0 k-^ —* >—> l _ _ k _ _
o o ON ON 4 l r ON O n ON LA - o NO 4 *
no 4 * NO NO O n NO
C© — t o ■-Pl o NO NO t o
o 4 * o 4 ^ ON
N* '- J  OO t o t o NO NO NO NO
NO ON 4L 4L.NO )C ) 0
o NO k j La
o La O
4l t o t o 1—> 1— i—t k—
La - o O n l—"* LA LA tO  tO t o i—-
p l a - o i"- L a 4 * NO tO O NO
C^N 4 l La —Jrv ■U O i _ 4L.
- o 0 0 o 4 ^ NO LA O t o
t o t o t o 1—k
4 ^ t o t o NO
OO L-> t o L a
t o >—1t o t o
^  U i k j  7^1 » l  \  ^  ^  k j  . w  w  t o  ^  t oP .  >"on . a N - ^ r r ^ ^ ' O . r ^ ^ o o o w N C c c N
^  ^  la ^J NONCg^£iooVONJto4Lk*-*H- -^to4»kON
O O O  5
O  o o  ON -o -o ~o
t o  NO 4 l  
La
^ O W ^ ^ - C V i g ^ ^ ^ O O O N O t O t J  O O O O W g f 3 v O O ° ^ ^ O V i O O O ^ O \
pi
3
CL
5T
O O O La4 * 4 ^
NO
LA
t o
t o
NO
4 *
La
NO
La
LA 4 *O O n
VO L o
t o
(Om h
ON ON 
ON 0 0  4 *  
4*. 4l ON oo-o-o
o n  r  .
'ao On n o  i  . .
NO ^  O n ON O
^  w w to ." 
 ►“ *
no  t o  o
NO NO NO t o
4 ^ O NO ) 0
NO ON b NO
NO NO o k—k
Pi
° 2 -  ON ON 
CD 
Pi O.O.
cd
CI­
ON t oLA t o  w  w > -  
P H P  o o  t o  l a  o o  no
~  NO OO 4 *  ON tO  ' g  g }  NO
t o  0 0
^ t o ? ° r J ^ o ' o ^ w. . r*r\ k % NL . . . .
A  ON LA LA t_A 
O  ON ON t o
NO NO -O NO
LA NO i—k t o  t o l—k k—k
LA t o o o _1 o o 4 *  ON O n 1—k ►—k
NO on NO rv k j 0 0  -O 0 0 ■ o
4 l 0 0 t o NO t o  b  '—1 t o t o►—k o t o 00 t o t o NO
t o NO t o t o
4 - O o o 4 ^
NO *-o ON 4L.
L a o o O t o
1+  1+  1+  1+ 1+  1+  1+  1+
t o  ~
p o o p O  ON o  c
►—‘ t o  b  b v  !: b  t o  r -  y
t o  ON no  o
LA O
N O O ^ ^ W ^ t O t O ^ ^ W W t O t O
0-0 0
LA
t o t o t o t o
NO LA 4 ^ O
b NO t o 4>.
o o O La -O
14- 14- 14- 14-
n o t o t o t o
45* t o k i ON
NO ON NO O
Param
eters 
A
nim
al N
um
ber
Units 
Dogl 
Dog2 
Dog 
3 
Dog 
4 
Dog 
5 
Dog 
6 
M
ean 
± 
SEM
70
In travenous
T i m e
( h )
1 2 3 4 5 6 M e a n ± S E M
0 0 0 0 0 0 0 0 -
0 . 2 5 9 9 .8 6 99 .9 2 99 .93 99 .91 9 9 .6 4 9 9 .8 0 99 .84 ± 0 .0 4
0 . 5 0 9 9 .9 0 99 .95 99 .88 9 9 .8 6 99 .93 99 .73 9 9 .8 7 ± 0.03
1 . 0 0 97 .9 3 99 .69 9 9 .6 6 9 9 .1 6 99 .88 9 9 .6 0 9 9 .3 2 ± 0 .2 9
2 . 0 0 9 6 .5 6 96.51 98 .87 9 6 .0 5 9 8 .4 7 9 8 .8 6 9 7 .5 5 ± 0 .5 4
4 . 0 0 9 6 .9 0 93 .1 0 94 .37 95 .3 7 9 6 .6 6 82 .29 93 .11 ± 2 .2 4
6 . 0 0 83 .91 86 .39 92 .48 86 .07 92 .43 71 .61 85 .48 ± 3 .13
8 . 0 0 57 .33 79 .22 87 .54 66 .6 7 94 .43 75 .8 4 76 .84 ± 5 .5 2
1 2 . 0 0 13.53 94 .44 87 .68 7 2 .9 6 95 .21 9 4 .2 2 76 .34 ± 13.02
2 4 . 0 0 5 .8 7 0 30 .74 25 .18 46 .4 4 0 18.04 ± 7 .78
4 8 . 0 0 0 30 .87 0 31 .25 17.13 4 .7 7 14.00 ± 5 .97
7 2 . 0 0  0  
Subcutaneous
0 2 .84 0 0 0 0 .4 7 ± 0 .47
T i m e
( h )
1 2 3 4 5 6 M e a n ± S E M
0 0 0 0 0 0 0 0 -
0 . 2 5 9 8 .8 6 99 .8 0 99 .84 9 9 .6 0 9 9 .2 6 99 .43 9 9 .4 6 ± 0 .15
0 . 5 0 9 8 .7 7 99 .9 0 99 .93 9 9 .8 6 9 9 .5 7 99 .85 99 .65 ± 0 .1 8
1 . 0 0 99 .8 5 9 9 .7 6 99 .73 99 .6 0 9 9 .7 2 99 .7 4 99 .73 ± 0 .03
2 . 0 0 93 .9 4 98.81 99 .88 99 .7 0 9 8 .8 0 99 .33 98 .41 ± 0.91
4 . 0 0 92 .8 8 9 6 .9 0 99 .29 9 8 .8 9 9 3 .6 2 7 7 .5 2 9 3 .1 8 ± 3.31
8 . 0 0 8 6 .74 87 .19 82 .88 8 8 .98 59 .84 82 .39 8 1 .34 ± 4 .4 2
1 2 . 0 0 74 .62 79 .90 86 .28 8 4 .3 7 4 7 .7 6 95 .51 78 .07 ± 6 .6 9
2 4 . 0 0 27 .2 7 29 .13 8.71 48 .51 4 .41 58 .88 29 .48 ± 8 .74
4 8 . 0 0 5 .0 5 0 0 16.88 0 3 5 .4 4 9 .5 6 ± 5 .8 2
7 2 . 0 0 10.38 8 .57 0 0 0 0 3 .1 6 ± 2 .0 1
9 6 . 0 0 0 0 0 4 .7 3 0 10.99 2 .6 2 ± 1.84
1 6 8 . 0 0 10 .76 0 0 7 .7 2 0 25 .71 7 .3 6 ± 4 .1 2
Table 3.6 Inhibition (%) of thromboxane B2 in serum of dogs after administration of 
flunixin at a dose rate of 1.10 mg/kg by the intravenous and subcutaneous 
routes.
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Param eter Animal N um ber
Uni t s 1 2 3 4 5 6 Mean ± SEM
C m a x | i g / m l 4 .1 2 6 .3 7 6 .9 6 8 .55 6 .5 0 5 .6 7 6 .3 6 ± 0 .6 0
t m a x h o u r s 0 .5 0 1 .0 0 1 .0 0 1 .0 0 1 .0 0 1 .0 0 0 .9 2 ± 0 .0 8
A U C p . g / m l . h 9 .9 5 24 .7 2 30 .17 34 .87 16.84 4 1 .2 3 2 6 .3 0 ± 4 .7 3
A U M C p g / m l . h 2 29.41 86 .93 106 .57 2 1 5 .4 6 4 1 .7 3 1345.58 3 04 .28 ± 2 10 .04
M R T h o u r s 2 .9 6 3 .5 2 3 .53 6 .1 8 2 .4 8 32 .64 8 .55 ± 4 .8 5
M A T h o u r s 1.83 - 1 .8 8 1.61 2 .9 8 -2 .46 2 2 .6 9 4 .13 ± 3 .82
F % 69 .14 111.25 150.55 128.01 57 .4 5 144 .16 101.09 ± 15.89
Table 3.7 Main pharmacokinetic variables in dogs after administration of flunixin at 
a dose rate of 1.10 mg/kg by the subcutaneous route.
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F L O W
A. Standard solution containing 1 p.g/ml of drug.
B. Plasma sample estimated to contain 0.94 }ig/ml of drug.
C. Blank dog plasma fortified with 1.0 p.g/ml drug.
D .Standard solution containing 1 Jig/ml of drug.
Figure 3.1 Typical chromatogram of flunixin in dog plasma
Figure 
3.2 
M
ean 
concentration 
(|ig/m
l) of flunixin 
in 
plasma 
of dogs after oral adm
inistration 
at three 
dose 
rates .
73
C o n c e n t r a t i o n  (ng/ml)
Figure 3.3 
M
ean 
(±SEM
) concentration 
(jig/m
l) of flunixin 
in 
plasma of dogs after intravenous adm
inistration 
at a 
dose 
rate 
of 
1.10 
m
g/kg.
74
C o n c e n t r a t i o n  (fig/ml)
o  (ji o  cn
o
oo
-vjro
Figure 
3.4 
M
ean 
(±SEM
) concentration 
(}ig/ml) of flunixin 
in 
plasma 
of dogs after subcutaneous adm
inistration 
at a 
dose 
rate 
of 
1.10 
mg/kg 
.
75
C o n c e n t r a t i o n  ( | ig/ml)
o  r o  g > o o
N>
ro
H
3o
CO
05
00
Chapter 4 
STUDIES WITH PIROXICAM
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4.1. INTRODUCTION
Piroxicam (4-hydroxy-2-methyl-N-2-pyridlyl-2H-1,2-benzothiazine-3-carboximide- 
1,1-dioxide) is a member of the oxicam group of NSAIDs which was first 
synthesised in the 1970s. It is currently only available for use in humans. The normal 
daily dose rate is 20 mg per adult, and this has been established to be effective and 
safe (Wiseman, 1985).
Piroxicam exhibits no opioid like analgesic activity, in hot plate and tail-flick tests 
(Brogden et al. 1981). However, in other experimental models such as the 
phenylquinone-induced writhing test it has shown substantial analgesic activity. At 
doses of 10 - 32 mg/kg orally, piroxicam inhibited phenylquinone-induced writhing 
in mice to a similar extent to the reduction observed after 320 mg/kg aspirin 
(Wiseman et al 1976). When using this pain model Milne and Twomey (1980) found 
1.85 mg/kg piroxicam to be less effective than indomethacin (0.39 mg/kg) but more 
effective than ibuprofen (4.9 mg/kg), naproxen (201 mg/kg) and phenylbutazone (32 
mg/kg) in reducing writhing frequency by 50 %. Schiantarelli and Cadel (1981) 
found piroxicam to be 70 times more effective in this model than phenylbutazone and 
Wiseman (1978) found it to be 11 times more effective than naproxen and 64 times 
more effective than aspirin. Piroxicam has been shown to give relief of post-operative 
pain one hour after oral administration (Jain et al. 1978) and to produce some 
improvement in pain from gout after 2 hours (Widmark, 1978). Other studies have 
shown that administration of 20 mg/kg orally produces true analgesic effects in man 
within 1-2 hours of administration, and maximal effects were observed at 3-4 hours 
(Pitts, 1982). With repeated daily doses, pain relief increases over a 6-8 day period 
(Tausch, 1982), and it is likely that this is due to increasing plasma drug 
concentrations until steady state is achieved.
Pitts (1982) reported that there was a difference in blood concentration of drug which 
produces analgesic and anti-inflammatory effects. Clinical analgesia was seen at 2 
pg/ml, however optimal anti-inflammatory effects in man were seen at blood 
concentrations of 5 |ig/ml.
Use of 10 mg/kg piroxicam was found to be as effective as 56 mg/kg aspirin in the 
inhibition of experimental pyrexia produced by the injection of Eschericha coli 
lipopolysaccharide.
Piroxicam has been shown to be effective in the treatment of inflammatory 
conditions such as rheumatoid arthritis and osteoarthritis. In osteoarthritis a dose of 
20 mg daily was found to produce maximal improvement (Zizic et al. 1978), and this 
dose was found to as effective as the standard dose of phenylbutazone in the 
treatment of ankylosing spondylitis (Pitts, 1982). In the treatment of rheumatoid
78
arthritis, piroxicam was equal to or superior to aspirin, naproxen, diclofenac, 
ketoprofen and indomethacin (Rohde et al. 1980; Finstad, 1981; Sydness, 1981; 
Villiaumey, 1981; Willkens et al.19821. and in the treatment of oesteoarthritis its 
effectiveness has equalled or exceeded that of aspirin, naproxen and indomethacin 
(Goldie, 1981; Abruzzo et al. 19821. Siegmeth (1980), found the clinical response to 
be related to plasma drug concentrations in rheumatoid arthritis.
Use in experimentally produced inflammation has shown piroxicam to be effective 
both topically and orally (Kandil et al. 1980; Larson and Lombardino, 1980). 
Radiographs of inflamed joints of arthritic rats indicated that piroxicam therapy 
resulted in large decreases in the deposition of granuloma tissue and a reduction in 
bony erosions (Ottemess et al. 1982).
Piroxicam has been shown to have a tV2& in man of approximately 45 hours (Nuotio 
and Makisara, 1978; Wiseman and Hobbs, 1982). Conflicting reports of 45 hours 
(Wiseman and Hobbs, 1982) and 17.3 hours have been given for the tV2B in dogs 
(Esteve et al. 1986). The markedly shorter tty^A found in rats (4-19 hours) (Esteve £t 
aL 1986) and monkeys (4.6 hours) (Wiseman, 1978), indicates that this value varies 
widely with species, and it has been demonstrated that sex related differences also 
occur in rats where the t l /28  was found to be longer in the female of the species 
(Hobbs and Twomey,1979; Esteve et al. 1986). In man, it has been shown that tV2^ 
is not related to dose rate (Wiseman and Chiaini, 1972; Hobbs and Twomey, 1979) 
and that concentrations in blood remain within the therapeutic range during the 24 
hour period following a single dose of 10-40 mg/kg (Wiseman, 1978). Steady state in 
blood is reached within 7 days when piroxicam is given once daily, and the long half 
life results in a slow decay of plasma concentrations when the drug is withdrawn 
(Nuotio and Makisara, 1978).
Piroxicam is rapidly absorbed after oral administration in man (Hobbs and Twomey, 
1979). Measurable concentrations were found in blood at 1-2 hours and maximum 
concentrations occured at 8 hours. It was also found to be rapidly absorbed after 
rectal administration, and bioavailability by this route was found to be similar to that 
after oral administration in rats, rabbits and man (Schiantarelli et al. 1981). A plasma 
concentration profile containing multiple drug peaks was found after administration 
of piroxicam in man (Hobbs and Twomey, 1979), this suggested that piroxicam may 
undergo enterohepatic recycling.
Patients with rheumatoid arthritis have been shown to have synovial fluid 
concentrations of drug which were approximately 40% of those in plasma 
(Bachmann, 1980).
It is likely that the anti-inflammatory activity of piroxicam is, at least in part, a result 
of its ability to inhibit cyclooxygenase enzymes and it has been established that it is a
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potent and reversible inhibitor of prostaglandin synthesis (Carty etal, 1980a and b). 
Estimation of serum PG E^ PGE2 and PGF2alpha concentrations in asthmatic 
patients showed reductions within 1-3 hours of administration of piroxicam (Spector 
e ta l. 1979).
The anti-inflammatory properties exhibited by piroxicam may also result from its 
effect on cells in inflamed tissue. A dose of 5 mg/kg piroxicam was reported to 
inhibit the increase in synovial pressure, and reduce the number of leukocytes in 
inflamed joints produced by injection of urate crystals into the knee joint of dogs 
(Wiseman et al. 1976). When administered at a dose rate of 20 mg/kg after the 
experimental induction of pleural inflammation in rats, there was an inhibition of 
pleural exudate production. The total leukocyte migration and the monocyte 
component of this was also reduced (Ottemess et al. 1982). In addition, it has been 
shown that migration of leukocytes into sponges implanted in rats was significantly 
reduced after oral administration of piroxicam at dose rates of 5 and 10 mg/kg, and 
that both mononuclear and polymorphonuclear leukocyte numbers were reduced 
(Schiantarelli et al. 1981). It has also been demonstrated that aggregation, secretion 
of lysosomal enzymes and generation of tissue destructive superoxide radicals by 
human neutrophils are inhibited by low concentrations of piroxicam (ID50  50 |XM, 
approximately 0.2 |ig/ml) (Edelson et al. 1982).
Piroxicam is extensively metabolised prior to excretion. Less than 10% of the 
administered dose was found to be excreted unchanged in urine (Wiseman, 1978; 
Brogden et al. 1981). A variety of metabolites are produced depending on species. 
However, for all species hydroxylation of the pyridyl ring is an important pathway 
(Wiseman, 1978), and metabolites thus produced have been found to be 1000 times 
less inhibitory to the production of prostaglandins than the parent drug (Wiseman and 
Boyle, 1980). In addition, metabolites have little or no anti-inflammatory activity in 
animal models studied (Spector et al. 1979).
Studies on piroxicam have shown it to be well tolerated, however, LD50  values have 
shown wide inter-species variation. Reported LD50  values after oral administration 
are 270 mg/kg in rats, 360 mg/kg in mice and more than 700 mg/kg in dogs, 
indicating that piroxicam has a good therapeutic index. Chronic administration at 
daily dose rates of 2.5,5 and 10 mg/kg to primates over a 12 month period resulted in 
no drug related toxicity (Wiseman, 1978). Gastrointestinal lesions and renal papillary 
necrosis were, however, seen in dogs, rats and mice after administration over periods 
of 12-18 months. At higher dose rates, these side effects were seen to be more severe 
in female compared to male rats (Wiseman, 1978). In clinical studies, 32 % of 3000 
patients being treated for inflammatory disorders manifested side effects. Of this 
total, 19 % were related to the gastrointestinal tract. However, unlike indomethacin
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there was no other single major group of side effects (Pitts, 1982). No evidence of 
organ toxicity was found by these workers although small reversible blood urea 
nitrogen elevations were measured. Such changes in blood urea nitrogen are thought 
to be common with NSAID administration, and Pitts (1982) has suggested that they 
may be a result of inhibition of renal prostaglandin biosynthesis. Piroxicam was 
found to be one third as ulcerogenic in the gastrointestinal tract as indomethacin in 
rats (Ohtsuki et al. 1981) and ibuprofen in man (Pitts, 1982) at their respective anti­
inflammatory dose rates. Although gastrointestinal side effects were the most 
common intolerance associated with piroxicam, such episodes were less frequent 
than after administration of therapeutically equivalent doses of aspirin, indomethacin 
and naproxen. Studies on reproductive effects in rats and rabbits have shown 
piroxicam to be non embryo or foeto-toxic, although in rats a dose related delay or 
inhibition of parturition was observed (Wiseman, 1978). Overall, Pitts (1982) has 
reported fewer side effects after administration of piroxicam than after aspirin, 
indomethacin and phenylbutazone and a comparable number to that produced after 
ibuprofen or naproxen administration.
Protein binding of piroxicam is high in all species. In dogs, binding was 93 % at 
serum drug concentrations of 5 |ig/ml and in man was 99 % at concentrations of 5 to 
50 |ig/ml indicating that the degree of protein binding is not concentration related 
(Hobbs and Twomey, 1979). Co-administration of aspirin was found to have no 
effect on the kinetics of piroxicam and did not cause displacement of bound drug 
(Hobbs and Twomey, 1979). This lack of displacement is not common in extensively 
protein bound drugs where competition for binding sites is high. In man, aspirin has 
been shown to reduce the plasma concentration of other NSAIDs such as naproxen 
(Segre et al. 1974) diclofenac (Muller et al. 1977) and indomethacin (Kaldestad et al. 
1975). It may be that the low doses used and resultant low concentrations of 
piroxicam do not result in the occupation of a significant number of binding sites.
4.2 EXPERIMENTAL OBJECTIVES
The objectives of this work were to examine the kinetics of piroxicam after 
administration at the recommended dose rate of 0.3 mg/kg body weight by the 
intravenous and oral routes and to quantify the inhibition of TxB2 in serum following 
administration of piroxicam by each route.
4.3 MATERIALS AND METHODS
4.3.1 ANALYSIS OF PIROXICAM
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Analysis of piroxicam was carried out by high performance liquid 
chromatography (H.P.L.C.) using spectrophotometric detection.
4.3.1.1 REAGENTS
1. Piroxicam (Sigma Chemical Co.)
2. Acetonitrile, redistilled grade (Rathbum Chemicals)
3. Orthophosphoric acid (BDH Ltd)
4. Potassium dihydrogen phosphate 'Analar' (BDH Ltd)
5. 1-Heptane sulphonic acid (Sigma Chemical Co.).
6. Water, redistilled in the presence of potassium permanganate prior to use.
7. H.P.L.C. mobile phase comprising 427.5 ml acetonitrile, 5.1 ml phosphoric 
acid, 1.72 g potassium dihydrogen phosphate and 0.564 g 1-heptane sulphonic 
acid per litre of water.
4.3.1.2 H.P.L.C. EQUIPMENT 
Pum p:- Gilson 301
Detector:- Spectraphysics 100
Column :- 100 mm X 8 mm containing 5 \i O.D.S. Hypersil
(Shandon Southern).
Wavelength:- 354 nm
Absorbance:- 0.01 AUFS
Flow rate of mobile phase :- 1.0 ml/min.
Retention time of piroxicam under these conditions was 2.3 minutes.
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4.3.1.3 SAMPLE PREPARATION
One millilitre of plasma was pipetted into a conical centrifuge tube and 1 ml 
of acetonitrile added. The tube was stoppered and the contents mixed by 
vortexing for 30 seconds. The sample was then centrifuged at 1500 g and 4 
°C  for 15 minutes and the resultant clear supernatant recovered into a clean 
stoppered tube prior to chromatography. Samples were chromatographed 
within five hours of preparation. A 100 pi stainless steel loop was used for 
injection, the loop was loaded with 50 pi of sample.
The concentration of piroxicam in each sample was determined by reference 
to a calibration curve for each analysis. This was prepared by fortifying blank 
plasma with known amounts of piroxicam to produce the appropriate range of 
concentrations. A number of fortified plasma aliquots treated in this way were 
processed in an identical manner to that described for unknown samples. In 
addition, standard solutions of piroxicam were injected directly into the 
HPLC. These standard solutions allowed equipment performance to be 
monitored and were also used to calculate the concentration of piroxicam 
measured in the fortified samples. From these figures it was possible to 
calculate the percentage recovery of piroxicam after extraction.
Unknown sample concentrations were also calculated by reference to the 
standard drug solutions. These concentrations were then adjusted to 100 % to 
allow for extraction losses by comparison to the recoveries obtained for the 
fortified samples.
A typical chromatogram is shown in figure 4.1
4.3.1.4 RECOVERY, PRECISION AND LINEARITY
Recovery of drug from plasma samples was approximately 70 %. Appendix
1.2 shows typical recoveries of piroxicam, inter-assay and intra-assay 
variation.
Calculation of the inter-assay coefficient of variation for recovery of 
piroxicam from fortified plasma allowed an assessment of the precision of the 
assay to be made. The mean inter-assay variation was found to be 10.3 % 
mean intra-assay variation was 2.5 %.
Simple regression was used to determine the linearity of concentration with 
respect to peak height for fortified samples. The correlation coefficient (r) for 
concentrations ranging from 0.1 |ig/ml to 2.0 |ig/ml of piroxicam in plasma 
was 0.998.
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4.3.1.5 OTHER ANALYSES AND METHODS USED.
The following techniques and methods were employed during the studies 
carried out on piroxicam. Estimation of serum TxB2 concentration, estimation 
of platelet numbers in blood, blood clotting time and detection of occult blood 
in faeces, pharmacokinetic and statistical analysis.These methods were also 
used in studies on other drugs included in this thesis and are included in the 
Materials and Methods section.
4.4 EXPERIMENTS W ITH PIROXICAM
Three male and three female Beagle dogs aged between 1 and 2 years were used for 
all experimental work.
Animals were housed in pairs and fed a complete cereal diet once daily, water was 
available ad libitum.
4.4.1 INTRAVENOUS ADMINISTRATION OF PIROXICAM
4.4.1.1 EXPERIMENTAL DESIGN
The six dogs were administered piroxicam at a dose rate of 0.3 mg/kg on a 
single occasion. The dogs were weighed immediately prior to the experiment 
and the dose of piroxicam to be administered calculated according to body 
weight. Weights ranged from 11.5-16.3 kg.
4.4.1.2 DRUG ADMINISTRATION
No intravenous preparation of piroxicam is commercially available therefore 
piroxicam powder (Sigma Chemical Co.) dissolved in ethanol was 
administered. A solution containing 1.33 mg/ml of piroxicam in ethanol was 
prepared and administered into the right cephalic vein at a dose rate of 0.3 
mg/kg over a period of thirty seconds. Administration of piroxicam was 
carried out one hour prior to feeding.
4.4.1.3 SAMPLING REGIMEN
Blood was collected from the jugular vein into suitable tubes for drug 
analysis, haematology and serum TxB2 estimation as described previously. 
Sampling was carried out prior to and at 0 .2 5 ,0 .5 ,1 ,2 ,4 ,6 , 8 ,12 ,24 ,48  and 
72 hours post drug administration.
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In addition samples of blood were taken into capillary tubes prior to drug 
administration and at 0.5, 1, 2, 4, 6, 8, 24,48 and 72 hours for estimation of 
clotting times.
The presence of occult blood was investigated in faecal samples which were 
collected throughout the experiment.
4.4.2 ORAL ADMINISTRATION OF PIROXICAM
4.4.2.1 EXPERIMENTAL DESIGN
The six dogs were administered piroxicam at a dose rate of 0.3 mg/kg on a 
single occasion. The dogs were weighed immediately prior to the experiment 
and the dose of piroxicam to be administered calculated according to body 
weight. Weights ranged from 11.7-16.5 kg.
4.4.2.2 DRUG ADMINISTRATION
Piroxicam (Feldene; Pfizer, UK) was administered orally in capsules at a dose 
rate of 0.3 mg/kg. In order to accurately achieve this dose rate, the contents of 
the commercial preparation were removed from their capsules and re-weighed 
into gelatine capsules thus providing the correct drug dosage for each animal. 
Administration of piroxicam was carried out one hour prior to feeding.
4.4.2.3 SAMPLING REGIMEN
Blood samples were collected from the jugular vein, prior to and at 0.5, 1, 2, 
4, 8, 12, 24, 48, and 72, hours following drug administration using suitable 
tubes for drug analysis, haematology and serum TxB2 estimation.
Blood samples were also collected in capillary tubes before drug 
administration, and at 0.5, 1, 2, 4, 8, 24, 48 and 72 hours after drug 
administration.
Faecal samples, which were collected throughout the experiment, were tested 
for the presence of occult blood.
4.5 RESULTS OF EXPERIMENTS WITH PIROXICAM
4.5.1 INTRAVENOUS ADMINISTRATION
4.5.1.1 PIROXICAM CONCENTRATIONS AND PHARMACOKINETICS 
AFTER INTRAVENOUS ADMINISTRATION
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Appendix 5.1 shows the concentration of piroxicam in the plasma of each dog 
after intravenous administration of piroxicam at a dose rate of 0.3 mg/kg. 
Individual concentrations are also given in figure 4.2, and mean (±.SEM) 
concentrations are shown in table 4.1 and figure 4.3. The main 
pharmacokinetic variables are shown in table 4.2.
The mean concentration of piroxicam measured in plasma of dogs at 0.25 
hours after drug administration was 1.11 ± 0.05 |Xg/ml and the inter-animal 
range in concentration was comparatively small (0.99 - 1.25 |ig/ml). The 
concentration of drug had declined in all animals at 0.5 hours. However, 
plasma concentrations of drug rose again in all animals. These second peaks 
of concentration were similar to those measured at 0.25 hours for dogs 1, 2 
and 6 and exceeded the earlier concentrations for the other animals. The 
second peaks occured between 2 and 8 hours. A further small peak in 
concentration was noted at 24 hours in samples from all dogs, with the 
exception of dog 1. Piroxicam was detected in the plasma of all animals at 72 
hours (mean concentration 0.30 ± 0.04 |ig/ml).
The inter-animal variation in computed t*/2 B was large, values ranged from 
30.54 to 53.72 hours, however, estimates of t*/2 B calculated from MRT 
values for observed data were somewhat lower than this (range 18.61 to 23.24 
hours). Similarly, the MRT value calculated from computed data (58.27 ± 
7.92) was approximately double the value calculated from observed data 
(26.78 ± 0.79 hours). The inter-animal variation in persistence of piroxicam in 
plasma was also greater for MRT values calculated from computed data, 
especially if the estimated last triangle of the AUC and AUMC were included.
Observed AUCs ranged from 34.63 to 63.69 |ig/ml.h. The mean observed 
AUC after administration of piroxicam at a dose rate of 0.3 mg/kg by the 
intravenous route was 47.39 ± 4.52 |ig/ml.h.
The area under the first moment curve for observed values had a wide inter­
animal variation. The mean observed AUMC was 1259 (±100) hours, with a 
range of 912 to 1499 fig/ml.h2. As with the MRT this value was much larger 
if calculated from computed best fit curve values and also if the calculated 
last triangle was included.
Mean body clearance of drug was 6.62 ± 0.62 ml/h.kg when calculated from 
observed values and 4.04 (± 0.58) hours when calculated for computed values 
for the same time period. The volume of distribution at steady state was 178
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(± 18) ml/kg, for observed data and 235 (± 38) ml/kg when calculated from 
parameters for computed theoretical best fit curves.
4.5.1.2 SERUM THROMBOXANE INHIBITION AFTER 
INTRAVENOUS ADMINISTRATION
Serum TXB2 concentrations for each animal at each time point are shown in 
appendix 5.2 and percentage inhibition of TxB2 in table 4.3.
Inhibition of TxB2 was greater than 90 % in all animals at 0.25 hours after 
drug administration (mean >96.85 %). The time at which maximum inhibition 
was detected varied widely between animals (range 0.25 - 4 hours). The mean 
maximum inhibition was greater than 98 % and was found to occur at 1.04 
hours. Inhibition of serum TxB2 exceeded 40 % in five animals at 72 hours 
(mean 50.21 %). The area under the serum TXB2 inhibition versus time curve 
after intravenous administration of piroxicam was 5310 %.h.
4.5.1.3 PLATELET NUMBERS AFTER INTRAVENOUS 
ADMINISTRATION
Appendix 5.3 shows platelet numbers for each dog on each sampling 
occasion. Samples from all dogs showed a marked decrease in platelet 
numbers 0.25 hours after administration of piroxicam and counts were found 
to be below pre drug administration levels throughout the experiment. Dogs 3, 
4, 5 and 6 had platelet counts of 30 x 109 per litre of blood or less at 0.25 
hours and dogs 4, 5 and 6 had counts of around 50 x 109 per litre at 0.5 hours.
4 .5 .1 .4  CLOTTING TIM ES A FTER INTRAVENOU S
ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times 
after administration of piroxicam by the intravenous route are shown in 
appendix 5.4. Several samples from dog 4 (at 2, 6 and 8 hours) and one 
sample from dogs 3 (4 hours), 5 (24 hours) and 6 (4 hours) were found to be 
slightly outwith the range established as normal for these dogs. No apparent 
pattern of altered clotting time was detected throughout the experiment.
4.5.1.5 OCCULT BLOOD IN FAECES AFTER INTRAVENOUS 
ADMINISTRATION
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Gastrointestinal blood loss determined throughout the experiment by Colo- 
Rectal test are contained in appendix 5.5. Blood was not detected in faecal 
samples with the exception of a single sample from pen 2 (dogs 3 and 4) at 72 
hours, in which blood was detected.
4.5.2 ORAL ADMINISTRATION
4.5.2.1 PIROXICAM CONCENTRATION AND PHARMACOKINETICS 
AFTER ORAL ADMINISTRATION 
Appendix 6.1 contains the concentration of piroxicam in the plasma of each 
dog after oral administration at a dose rate of 0.3 mg/kg. Mean (± SEM) 
concentrations are shown in table 4.1 and figure 4.4. The main kinetic 
variables are shown in table 4.4.
The first sample time after oral administration of piroxicam was 0.5 hours and 
at this time the mean concentration of drug in plasma was 0.77 ± 0.14 |ig/ml. 
As shown by the standard error the inter-animal range in concentration was 
large (0.27 - 1.27 |ig/ml). The maximum mean concentration (1.27 ±  0.14 
|xg/ml) occured at two hours after drug administration. Piroxicam was 
detected in the plasma of all animals at 72 hours (mean concentration 0.39 ± 
0.06 Jig/ml) and the Cmax was 1.35 |i.g/ml. There was a large inter-animal 
variation in time of maximum concentration (tmax 3.33 ±1.09 hours). In one 
animal (dog 6), the maximum concentration of drug occured at 1 hour and 
this concentration of drug was also detected in the 2 hour sample. In four 
animals, (dogs 2, 3, 5 and 6), the plasma concentration versus time graph 
showed a multi-peak profile
There was good inter-animal agreement in the persistence of piroxicam 
(MRT) after oral administration, the range being 26.31 to 29.62 hours for 
observed values (mean 28.42 ± 0.63 hours). The mean observed AUC after 
administration of piroxicam at a dose rate of 0.3 mg/kg by the oral route was 
46.77 |ig/ml.h. After addition of the estimated last triangle this figure was 
100.72 |xg/ml.h and the inter-animal variation was greatly increased. The area 
under the first moment curve for observed data ranged from 941 to 1751 
|ig/m l.h2, and this value, and the inter-animal variation, was also greatly 
increased by the addition of the estimated last triangle.
Bioavailability (calculated for the period 0 to 72 hours) showed a very wide 
inter-animal variation, range 76 to 160 pg/ml.h (mean 103 ± 12 pg/ml.h).
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4.5.2.2 SERUM THROMBOXANE INHIBITION AFTER ORAL 
ADMINISTRATION
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 6.2, and percentage inhibition of TxB2 in table 4.5.
Inhibition of TxB2 at the first sample time of 0.5 hours was greater than 70 % 
in only three animals (dogs 2, 3 and 4) and in one animal (dog 5) was found 
to be less than 45 % (mean inhibition 64.71 ± 5.34 %). In all but two animals 
(dog 2 and 3), inhibition had increased at 1 hour and the mean inhibition at 
this time was 72.45 ± 3.38 %. Maximum mean inhibition (74.35 ± 2.91%) 
occured at 8 hours, however the time at which maximum inhibition occured in 
individual animals varied widely (range 0.5 - 8 hours) and the mean 
maximum inhibition of 73.74 (± 1.66) % occured at 3.25 hours. The serum 
TxB2 inhibition versus time graphs showed a multi-peak profile, and one or 
more secondary peak in inhibition occured for each animal. In all but one 
animal (dog 1) inhibition remained greater than or close to 40% at 72 hours. 
The area under the serum TXB2 concentration versus time curve was 4067 
%.h.
4.5.2.3 PLATELET NUMBERS AFTER ORAL ADMINISTRATION
Appendix 6.3 gives platelet numbers for each dog on each sampling occasion 
after oral administration of piroxicam at a dose rate of 0.3 mg/kg. A large 
inter and intra-animal variation in platelet counts was observed throughout the 
experiment, however, in no animal was a consistent trend apparent.
4 5.2.4 CLOTTING TIMES AFTER ORAL ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times 
are shown in appendix 6.4. These values remained within the expected range 
at all sample times with the exception of the 1 hour sample from dog 3.
4.5.2.5 OCCULT BLOOD IN FAECES AFTER ORAL 
ADMINISTRATION
Faecal samples collected throughout the experiment were tested for the 
presence of gastro-intestinal blood by Colo-Rectal and the results are shown 
in appendix 6.5. No blood was detected in any faecal sample collected during 
the experiment.
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4.6. DISCUSSION
Piroxicam was well tolerated after intravenous and oral administration to dogs. 
However, clinical observations consistent with the administration of alcohol were 
recorded during the first 0.5 hours after intravenous administration. Peripheral 
vasodilation was noted and it is likely that some lowering of blood pressure would 
have been associated with this. The actions of alcohol are similar to those of general 
anaesthetics as it causes irregularly descending depression of the higher centres of the 
central nervous system. It is not surprising, therefore, that slight depression was noted 
in all animals after intravenous administration of the drug solution.
The plasma concentration versus time curves for the drug were characterised by 
successively lower peaks and troughs after both intravenous and oral administration. 
The intra-animal variation in plasma concentration of drug for each route of 
administration was generally small. In three animals (dogs 3 ,4  and 5) the maximum 
concentration of drug in plasma after intravenous administration occured at 4 hours 
and not at the first sample time (0.25 hours) as is normally observed after intravenous 
administration and this may indicate that some of the drug dose was injected peri- 
venously. However, concentration of drug was high in the first sample from these 
dogs (0.98 - 1.25 |Xg/ml) and was lower at the next sampling occasion (0.5 hours) 
indicating that it was unlikely that drug was being absorbed from surrounding tissue.
Concentrations of piroxicam detected in plasma at 0.5 hours after oral administration 
indicated that the drug had been rapidly absorbed. A pattern of secondary peaks and 
troughs, similar to that seen after intravenous administration was also seen. Plasma 
drug concentrations were generally well maintained for 24 hours at which time a 
mean concentration of 0.8 |ig/ml was detected.
The pattern of peaks and troughs in plasma drug concentration seen generally after 
each route of administration may be due to enterohepatic circulation. This is in 
agreement with the evidence presented by Dupont et al (1982) and Hobbs and 
Twomey (1979) who reported that a plasma profile consistent with enterohepatic 
cycling was seen after administration of piroxicam to human subjects. The 
occurrence of enterohepatic cycling can result in difficulty in producing reliable 
pharmacokinetic data.
Mathematical modelling of the drug concentration versus time curves produced after 
intravenous administration of piroxicam demonstrated that the data were best 
described by one exponent. This was confirmed by application of AIC and is in
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agreement with the findings of Esteve et al (1986). In the case of only one animal 
(dog 1), was the correlation (r2) of these best fit curves greater than 0.9, as a result 
there was considerable variation between kinetic values calculated from these best fit 
curves and those calculated from observed data. Mathematical modelling of the 
concentration versus time data obtained after oral administration was only possible in 
one animal (dog 1) for this animal the correlation was 0.97, accordingly all 
pharmacokinetic parameters are calculated from observed data.
Drug was detected in the plasma of all animals at 72 hours after administration of 
piroxicam in each experiment and this was reflected in the large AUC, AUMC and 
long tV2B (40.16 hours) calculated for these animals. The tV2B of piroxicam which 
was calculated after intravenous administration (40.16 hours) is similar to that 
previously reported in man and dogs (Wiseman and Hobbs, 1982). In the present 
study, the group of six dogs comprised three male and three female animals. 
Comparison of the U/2B from male and female animals showed no significant 
difference. The arithmetic mean obtained for males was, however, higher than that 
for females (46.31 vs 37.25 hours). This difference is the converse of the findings of 
Esteve et al (1986), who reported tl/2B values of 4.66 and 19.52 hours (respectively) 
for piroxicam in male and female rats. The overall U/2B value from this study has 
been expressed as the harmonic mean. Comparison of the harmonic mean U/2B 
values for male and female dogs in this study also shows good agreement between 
sexes (35.36 hours for male and 36.40 hours for female).
Piroxicam was found to have an excellent oral bioavailability (mean 102.69 %). In 
three animals (dogs 1, 2 and 6), this was found to be greater than 100% and in the 
case of one dog (animal 6), the bioavailability was calculated to be approximately 
160%. The cause of this overestimate remains unexplained. However, good oral 
absorption coupled with intra-animal experimental error seem unlikely explanations 
for such a large overestimate.
Mean absorption times (MAT) calculated from observed data varied widely amongst 
animals. The maximum value was calculated for dog 5 (6.08 hours) and a negative 
value was calculated for dog 1 (-0.01 hours). This negative value is theoretically 
impossible as it implies that drug entered the bloodstream faster after oral 
administration than after intravenous administration. It is likely that this phenomenon 
is a result of rapid absorption coupled with intra-animal variation which may have 
occured between the two experiments.
Comparison of bioavailability and MRT values calculated from observed data 
indicate that, in terms of availability of piroxicam in circulating plasma, there would
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be little to be gained from intravenous administration. However, comparison of oral 
data with data derived from the best fit mathematical model, which makes allowance 
for the section of the intravenous curve between CpO and the first sample time 
indicate that both mean AUC and mean MRT were considerably larger after 
intravenous administration.
The maximum inhibition of TxB2 after intravenous administration was greater than 
90 % for all animals and inhibition of greater than 80 % was observed in all but one 
sample for 8 hours. Platelet numbers were considerably lower than pre-treatment 
values throughout this experiment and since platelets are the principal source of 
TxA2 in the circulation it is possible that the reduction in TxB2 concentrations is 
related to reduced platelet numbers rather than cyclooxygenase inhibition. The cause 
of the thrombocytopenia observed during this experiment is unknown. All animals 
appeared clinically healthy throughout the experiment. Although thrombocytopenia 
has been recorded as a side effect of piroxicam (Bjomstad and Vik, 1986) it was not 
observed in these animals after administration of piroxicam at the same dose rate by 
the oral route. In addition, some increase in platelet numbers was observed after 0.5 
hours and on this time scale it is unlikely that recovery could be explained by the 
production of new platelets. The presence of ethanol in the circulation is a 
complicating factor. The likely concentration of ethanol in blood of these animals 
would have been around 200 milligrams per one hundred millilitres of blood 
(approximately equivalent to a human subject having consumed six pints of beer), a 
figure which is frequently exceeded in man, in whom thrombocytopenia (and other 
blood disorders) have been linked with alcoholism (Lindenbaum and Hargrove, 
1968; Post and Desforges, 1968a; Cowan and Hines, 1971) even in the absence of 
nutritional deficiency (Lindenbaum and Leiber, 1969). However, such studies have 
observed the onset of thrombocytopenia over a longer period of exposure to alcohol, 
for example 20 days at blood alcohol levels up to 125 mg/100 ml (Lindenbaum and 
Leiber, 1969). In addition, it has been observed that mice exposed to alcohol vapour 
(10-25 mg/litre air) for 20 or more days also developed blood disorders, including 
thrombocytopenia and at higher vapour concentrations (25-38 mg/litre), similar 
abnormalities were observed after 24 hours.(Malik and Wickramasinge, 1986). 
Thrombocytopenia was not detected by Cowan and Hines (1971) after the 
intravenous administration of ethanol to man and in a similar study by Haut and 
Cowan (1974) which produced blood alcohol concentrations of around 200 mg/100 
ml blood no thrombocytopenia was reported. This is in contrast to an earlier study 
reported by Post and Desforges (1968a) where patients were administered 2,000 ml 
of 5 % ethanol in dextrose by intravenous infusion at a rate of 11 ml/minute. These 
workers recorded a fall in platelet count at 4 - 6 hours after the start of infusion, a
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recovery in platelet numbers began to be apparent several hours after administration 
was discontinued. The thrombocytopenia associated with alcohol consumption is 
generally characterised by a reduction in platelet lifespan. In one case the longevity 
of the platelets was found to be reduced by 50 % or more (Cowan, 1973 ). However, 
the speed of recovery of platelet counts noted by Post and Desforges (1968b) 
indicates that the mechanism of recovery is not replacement by new platelets. These 
workers also investigated the possibility of splenic or hepatic sequestration of 
platelets after intravenous administration of ethanol. Platelets carrying a radioactive 
label were introduced into the patient prior to alcohol administration and the 
radioactivity present in the spleen and liver subsequendy monitored. No increase in 
the number of labelled platelets was found in these organs.
In the present experiment, the platelet counts varied widely between sample times 
and did not appear to follow a time related course. It is not possible to determine if 
this effect was due to piroxicam or ethanol administration or to some other 
unidentified cause.
The maximum inhibition of serum TxB2 was considerably less after administration of 
piroxicam by the oral route. The maximum mean inhibition was 74.3 % and occured 
at 8 hours, at no time did the inhibition exceed 82 % in any animal. In addition, there 
was wider inter and intra-animal variation in inhibition after oral than after 
intravenous administration. No inhibition of TxB2 was measured in the serum of dog 
1 at 72 hours.
Comparison of the area under the serum TxB2 inhibition versus time curve after 
intravenous and oral administration of piroxicam showed that the AUC after oral 
administration was 77% of that obtained after intravenous administration.
Statistical examination was also carried out on the maximum inhibition produced by 
each route of administration and on the inhibition measured at each time point. The 
mean maximum inhibition was 98.00 and 75.88 % after intravenous and oral 
administration respectively and these figures were found to be significantly different 
(p = 0.014). In addition TxB2 inhibition was significantly greater at all common time 
points (p < 0.05) after intravenous administration than after oral administration, with 
the exception of 72 hours.
The presence of relatively high concentrations of piroxicam in plasma (up to 0.56 
jig/ml) at 72 hours after the administration of a single dose of 0.3 mg/kg by the oral 
route suggests that daily administration would result in accumulation of the drug. The 
estimated tV20 of around 40 hours, in conjunction with the extent of serum TxB2 
inhibition at 72 hours (up to 64%) suggests that an appropriate dosage interval for
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oral administration may be 48 hours. This is supported by reports on the clinical 
efficacy of this drug (S. Carmichael, personal communication).
In man, during administration of 10, 20 or 30 mg once daily, steady state conditions 
are achieved after approximately 7 days (Nuotio and Makisara, 1978) and further 
studies are required to determine the extent of accumulation of drug prior to the 
attainment of steady state in the dog. The extent to which this species will tolerate 
repeated dosing also requires to be determined. Alternate day administration of a 
drug in veterinary therapy is likely to lead to problems of owner compliance. It may 
be that a dosage regimen designed to produce steady state levels followed by a lower 
daily maintenance dose may be more beneficial. However, as a single oral dose of 0.3 
mg/kg gave a mean TxB2 inhibition which did not exceed 75 % this strategy may 
result in a poorer clinical response. Further studies to examine thromboxane 
inhibition and clinical response after a variety of dosage regimens would be required 
to determine the optimum strategy for clinical use of piroxicam.
There was no apparent overall change in blood clotting times after administration of 
piroxicam and gastrointestinal blood loss was not found to be a consistent feature. 
This, together with other data presented, suggest that piroxicam is a safe and 
efficacious NSAID for use in dogs and that further investigation of this drug would 
be justified.
4.7. TABLES AND FIGURES
Time Route of Adm inistration
(h) In travenous Oral
P re 0 0
0 . 2 5 1.11 ±0.05 NS
0 .5 0 0.86 ± 0.04 0.77 ±0.14
1 .0 0 0.93 ±0.11 1.21 ±0.15
2 . 0 0 0.98 ± 0.14 1.27 ±0.14
4 . 0 0 1.12 ±0.15 1.25 ±0.13
6 . 0 0 1.06 ±0.12 NS
8 .0 0 0.94 ± 0.05 1.00 ±0.10
1 2 .0 0 0.78 ± 0.04 0.77 ± 0.08
2 4 . 0 0 0.82 ± 0.08 0.80 ± 0.06
4 8 .0 0 0.45 ± 0.03 0.44 ± 0.03
7 2 . 0 0 0.30 ± 0.04 0.39 ± 0.06
Table 4.1 Mean (±SEM).concentration of piroxicam in plasma of dogs after 
administration at a dose rate of 0.3 mg/kg by the intravenous 
and oral routes.
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Time Animal Number
(h) 1 2 3 4 5 6 Mean
Pre 0 0 0 0 0 0 0
0.25 93.41 94.08 >99.49 >99.38 96.20 98.50 >96.85
0 . 50 88.04 90.77 >99.49 99.20 97.52 97.67 >95.45
1.00 89.55 85.86 >99.49 99.38 97.96 93.59 >94.31
2 .00 89.55 60.68 96.59 93.52 96.50 83.44 86.72
4 . 00 86.68 >99.10 97.25 89.44 93.72 86.02 >92.03
6 . 00 89.27 80.24 92.90 95.30 97.52 89.52 89.79
8 . 00 89.33 87.86 98.77 94.94 93.43 89.52 92.31
12 .0 0 81.23 81.85 NS NS NS NS 81.54
24 .00 76.91 68.00 91.81 83.85 79.42 82.86 80.48
48 .00 62.76 54.16 90.36 81.81 72.85 64.23 71.03
72 .00 53.60 36.61 50.65 55.10 58.39 46.92 50.21
NS = No sample
Table 4.3 Inhibition (%) of thromboxane B2 in serum of dogs after administration 
of piroxicam at a dose rate of 0.3 mg/kg by the intravenous route.
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Tim e
(h) 1 2 3
Animal
4
1 N um ber 
5 6 Mean ± SEM
P re 0 0 0 0 0 0 0
0 .5 0 54.48 78.67 72.13 75.17 44.95 62.92 64.72 ± 5.35
1 . 0 0 63.53 76.45 60.37 78.40 79.45 76.53 72.45 ± 3.38
2 . 0 0 68 .00 78.95 67.14 74.29 77.20 66.39 72.00 ± 2.25
4 .0 0 60.82 81.35 65.30 72.20 76.54 68.95 70.86 ± 3.05
8 . 0 0 71.92 82.02 61.78 77.52 78.94 73.93 74.35 ± 2.91
1 2 . 0 0 53.26 76.00 64.57 75.62 65.65 61.18 66.05 ± 3.56
2 4 .0 0 49.07 65.70 53.91 63.52 67.68 54.37 59.04 ± 3.09
4 8 .0 0 51.03 63.36 41.00 62.44 66.59 54.42 56.47 ± 3.91
7 2 .0 0 0 39.31 63.67 45.22 39.87 43.80 34.70 ± 7.73
Table 4.5 Inhibition (%) of thromboxane B2 in serum of dogs after administration 
of piroxicam at at a dose rate of 0.3 mg/kg by the oral route.
1 0 0
F L O W
A. Standard solution containing 1 jig/ml of drug.
B. Plasma sample estimated to contain 0.99 |ig/ml of drug.
C. Blank dog plasma fortified with 1.0 M-g/ml drug.
D .Standard solution containing 1 fig/ml of drug.
Figure 4.1 Typical chromatogram of piroxicam in dog plasma
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STUDIES W ITH CINCHOPHEN
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5.1. INTRODUCTION
Cinchophen (2-phenyl quinoline-4-carboxylic acid) was synthesised in 1887 by 
Dobner and Giesecke. The initial preparation of cinchophen was yellowish in colour 
and this was thought to be due to the presence of impurities (Hueper, 1948). The pure 
compound is a white odourless powder which is insoluble in water but somewhat 
soluble in hot alkali and boiling organic solvents such as alcohol and acetone (Hueper, 
1948).
Cinchophen found its first therapeutic application in 1911 for the treatment of gout 
(Weintraud, 1911 and 1912). This resulted from the discovery of its ability to increase 
the excretion of uric acid (Nicolairer and Dohm, 1908). The substance was marketed 
as Atophan and the recommended human therapeutic dose rate was 22 mg/kg daily. 
The discovery of its more general anti-inflammatory and analgesic properties (Smith 
and Hawk, 1915) resulted in a wider range of uses, as did the discovery that it 
produced anti-pyretic effects when given intravenously or subcutaneously (Fuerst, 
1925).
Cinchophen, and the corticosteroid prednisolone, have been available for more than 20 
years as a combined preparation for anti-inflammatory treatment of small animals. 
Despite this there is little literature relating to the clinical efficacy or pharmacokinetics 
of cinchophen. An oral cinchophen/prednisolone combination preparation has been 
found to give good improvement in osteoarthritic dogs and its effectiveness was shown 
to be similar to that produced by phenylbutazone (Pearson, 1989).
Little is known about the precise nature of the metabolism and excretion of cinchophen, 
however it has been shown (Hueper, 1948) that the urinary metabolites differed in man 
and dog since 2-o-oxyphenylquinoline-4-carboxylic acid is produced in man but not in 
the dog. Lichtman (1931) also found that 7-21 % of an administered dose of 
cinchophen was excreted as oxycinchophen in normal human patients.
Biberfield (1913) reported yellow atrophy of the liver after administration of 5 g of 
cinchophen twice daily to dogs, and by 1948 there had been 230 documented cases of 
jaundice associated with its use (Hueper, 1948), however hepatotoxicity appeared to be 
a feature of prolonged use only.
Although a high incidence of gastrointestinal complaints were noted when cinchophen 
was used clinically in man (Westfall, 1926), it was not until 1932 that Van Wagoner 
and Churchill discovered the ulcerogenic action of cinchophen whilst attempting to 
study its hepatotoxicity. Further studies by these authors (Van Wagoner and 
Churchill, 1932a and b) showed that gastric ulcers were produced in dogs after daily
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oral administration of up to 27 times the therapeutic oral dose for man. In 1938, 
Boilman et al also reported chronic peptic ulceration in man and dogs after 
administration of cinchophen at a dose rate of 100-200 mg/kg, with food. In addition, 
duodenal ulcers were observed in this study, but these were found only to be present in 
conjunction with gastric ulcers. Cinchophen has also been shown to cause gastric 
ulceration in cats (Hanke, 1934; Schwartz and Simonds, 1935), however neither Shoji 
(1933) nor Schwartz and Simonds (1935) were able to produce gastric ulceration in 
rabbits by oral or parenteral administration of cinchophen. Gastric ulceration is not 
necessarily a feature of a local toxic action of this drug. This was shown by Churchill 
and Manshardt (1933) who found that gastric ulcers were produced after daily injection 
of cinchophen into an isolated loop of jejunum. In addition, Hanke (1934) observed 
gastric ulcers after subcutaneous administration to cats. In an attempt to understand the 
mechanism of cinchophen induced ulceration, Stalker et al (1937) showed that there 
was no increase in gastric acidity associated with cinchophen administration, however 
overall gastric secretion was increased. There is some evidence to suggest that the more 
refined (white) cinchophen which became available is less ulcerogenic than the original 
preparation (Simonds, 1938).
Little clear evidence of other side effects exists. Annegers et al (1943), studied human 
subjects to whom he administered cinchophen at the normal dose rate for up to 39 
weeks. No evidence of any changes were seen in the liver, although peptic ulceration 
was noted.
The occurrence of skin disorders after administration of cinchophen has been recorded 
(Hueper, 1948), and the frequency of these side effects has been reported as 0.5 % to 
20 % of cases studied. This large range in number of skin side effects may have 
resulted from the fact that cutaneous hypersensitivity in the form of itching and skin 
rashes has been reported to occur a few hours after initial medication in some cases and 
only after prolonged periods of medication in others (Hueper, 1948).
The LD50 of cinchophen after subcutaneous administration has been shown to be in the 
region of 1 g/kg for rats, mice and guinea pigs (Barbour and Lozinsky, 1923; Risi, 
1932; Hueper, 1948) and a litde lower (0.62 g/kg) for dogs (Risi, 1932).
5.2. EXPERIM ENTAL OBJECTIVES
The objectives of this work were, to examine the kinetics of cinchophen after 
administration of a combined preparation containing cinchophen and prednisolone 
(PLT) at the recommended dose rate of 12.5 mg cinchophen per kilogram of body 
weight by the intravenous and oral routes. Also to investigate the pharmacodynamics
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by quantifying the inhibition of TxB2 in serum following administration of PLT by 
each route.
5.3. MATERIALS AND METHODS
5.3.1 ANALYSIS OF CINCHOPHEN
Analysis of cinchophen was carried out by high performance liquid 
chromatography (H.P.L.C.) using spectrophotometric detection.
5.3.1.1 REAGENTS
1. Cinchophen (C-VetLtd.)
2. Diethyl ether, redistilled grade (Rathbum Chemicals)
3. Acetonitrile, redistilled grade (Rathbum Chemicals)
4. Orthophosphoric acid (BDH Ltd)
5. Potassium dihydrogen phosphate Analar' (BDH Ltd)
6 . 1-Heptane sulphonic acid (Sigma Chemical Co.).
7. Disodium hydrogen orthophosphate Analar1 (BDH Ltd)
8. Citric acid Analar' (BDH Ltd)
9. Citrate/phosphate buffer pH 3.0 was produced by mixing 20.5 ml M/5 
Na2HP04 and 79.5 ml M/10 citric acid to give 100 ml of buffer.
10. Water, redistilled in the presence of potassium permanganate prior to use.
11. H.P.L.C. mobile phase comprising 427.5 ml acetonitrile, 5.1 ml 
phosphoric acid, 1.72 g potassium dihydrogen phosphate and 0.564 g 1- 
heptane sulphonic acid per litre of water.
5.3.1.2 H.P.L.C. EQUIPMENT 
Pum p:- Gilson 301
Detector:- Spectraphysics 100
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Column 100 mm X 8 mm containing 5 p. O.D.S. Hypersil
(Shandon Southern).
W a v e l e n g t h 262 nm
A b s o r b a n c e 0.02 or 0.05 AUFS
Flow rate of mobile phase 1 ml/min.
Retention time of cinchophen under these conditions was 4.0 minutes.
5.3.1.3 SAMPLE PREPARATION
For samples from the intravenous experiment a 1 ml aliquot of each plasma 
sample was placed in a 50 ml ground glass tube. To this was added 1.0 ml of 
citrate /  phosphate buffer (pH 3.0), followed by 20 ml diethyl ether. For 
samples from the oral experiment the volume of sample and buffer were 
increased to 2 ml. The tube was stoppered and the mixture shaken for 10 
minutes by inversion on a slow rotary mixer. Fifteen millilitres of ether was 
removed from the upper layer and placed in a 50 ml plain glass tube. A further 
20 ml diethyl ether was added to the sample mixture prior to shaking for a 
second period of 10 minutes. Twenty millilitres of the upper ether fraction was 
removed and combined with the 15 ml previously recovered.
The tube containing the combined ether extracts was placed in a Dri-Block 
(Techne Ltd) at 50 °C  under a stream of air and allowed to evaporate until 
approximately 5 ml remained. This remaining diethyl ether was transferred to a 
10 ml conical glass tube. The 50 ml glass tube was rinsed three times with 
approximately 1 ml of diethyl ether which was then added to the conical tube. 
The ether extract was evaporated to dryness at 50 °C under a stream of air. A 
final 1 ml of ether was run down the walls of the conical tube to ensure that all 
residue present was in the base of the tube. The extract was returned to the Dri- 
Block and allowed to evaporate to dryness.
Sample tubes were covered with clingfilm and stored overnight at 4 °C  if 
necessary.
Prior to injection into the HPLC system the residues were reconstituted in 
methanol. An appropriate known volume (not less than 150 |il) of methanol 
was added to the bottom of the conical tube which was then tilted and rotated in 
an ultrasonic bath for 1 minute. A 20 p.1 injection loop was used for injection, 
the loop was loaded with 15 (il of sample.
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The concentration of cinchophen in each sample was determined by reference to 
a calibration curve prepared for each analysis. This was prepared by fortifying 
blank plasma with known amounts of cinchophen to produce the appropriate 
range of concentrations. A number of fortified plasma aliquots treated in this 
way were processed in an identical manner to that described for unknown 
samples. In addition, standard solutions of cinchophen were injected directly 
into the HPLC. These standard solutions allowed equipment performance to be 
monitored and were also used to calculate the concentration of cinchophen 
measured in the fortified samples. From these figures it was possible to 
calculate the percentage recovery of cinchophen after extraction.
Unknown sample concentrations were also calculated by reference to the 
standard drug solutions. These concentrations were then adjusted to 100 % to 
allow for extraction losses by comparison to the recoveries obtained for the 
fortified samples.
A typical chromatogram is shown in figure 5.1
5.3.1.4 RECOVERY, PRECISION AND LINEARITY
Recovery of drug from plasma samples was approximately 90 %. Typical 
recovery of cinchophen, inter-assay and inter-assay variations are shown in 
appendix 1.3.
An assessment of the precision of the assay was made by estimation of the 
inter-assay coefficient of variation for recovery of cinchophen from fortified 
plasma (appendix 1.3). The mean inter-assay and intra-assay variations were 
found to be 4.5 % and 4.8 % respectively.
Linearity of concentration was determined by the use of simple regression for 
peak height of samples fortified with known concentrations of drug. The 
correlation coefficient (r) for concentrations ranging from 1 - 5 0  |ig/ml of 
cinchophen in plasma was 0.997.
The sensitivity of the assay was determined with respect to the background 
fluctuation recorded on the trace produced from the HPLC system. The 
minimum peak height which could be reliably recorded was estimated from 
standard solutions in replicate analyses. This was determined as being at least 
twice the maximum overall background fluctuation and was set at one unit. A 
peak height of one unit of cinchophen, under the HPLC conditions described, 
correspond to 0.03 jig drug per millilitre of plasma.
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5.3.1.5 OTHER ANALYSES AND METHODS USED.
Methods for the estimation of serum TxB2 concentration, platelet numbers in 
blood, blood clotting time and detection of occult blood in faeces are described 
in the general material and methods section. Statistics and pharmacokinetic 
analysis, including equations are also outlined in that section.
5.4. EXPERIM ENTS W ITH CINCHOPHEN
Three male and three female Beagle dogs aged between 2 and 3 years were used for all 
experimental work.
Animals were housed in pairs and fed a complete cereal diet once daily, water was 
available ad libitum.
5.4.1 INTRAVENOUS ADMINISTRATION OF CINCHOPHEN
5.4.1.1 EXPERIMENTAL DESIGN
The six dogs were administered cinchophen at a dose rate of 12.5 mg/kg of 
cinchophen on a single occasion. Animals were weighed immediately prior to 
the experiment and the dose rate of cinchophen to be administered calculated 
according to body weight. Weights ranged from 12.0 -17.5 kg
5.4.1.2 DRUG ADMINISTRATION
An injectable preparation containing cinchophen (80 mg/ml) and prednisolone 
(1 mg/ml) (PLT, C-Vet Ltd.) was used. The preparation was administered into 
the right jugular vein over a 30 second period at a dose rate of 12.5 mg/kg 
cinchophen, and 0.15 mg/kg prednisolone.
Administration of PLT was carried out one hour prior to feeding.
5.4.1.3 SAMPLING REGIMEN
Blood samples were collected from the left jugular vein into suitable tubes for 
drug analysis, haematology and serum TxB2 estimation as described 
previously. Sampling was carried out prior to and at 0.08, 0.17, 0.33, 0.5, 
0.75, 1, 2, 4, 8, 12, 24, 30, 48 and 55 hours after drug administration. No 55 
hour sample was collected for measurement of TxB2 inhibition or platelet 
numbers.
I l l
Samples of blood were also taken into capillary tubes prior to drug 
administration and at 0.5,1, 2,4, 8, 24, 30 and 48 hours. These were used for 
the estimation of clotting times.
Faecal samples were collected throughout the experiment and an estimate of the 
presence of occult blood was made.
5.4.2 ORAL ADMINISTRATION OF CINCHOPHEN
5.4.2.1 EXPERIMENTAL DESIGN
The dogs were weighed immediately prior to the experiment and the dose of 
cinchophen to be administered calculated according to body weight Weights 
ranged from 12.0 - 16.0 kg. The six dogs were administered cinchophen at a 
dose rate of 12.5 mg/kg of cinchophen on a single occasion.
5.4.2.2 DRUG ADMINISTRATION
An oral preparation containing cinchophen (200 mg/tablet) and prednisolone (1 
mg/tablet) (PLT, BK Ltd.) was used. Where the dose to be administered did 
not equal an exact number of tablets, a tablet was shaved with a scalpel blade to 
reduce the weight to that required. The target dose rate for cinchophen was
12.5 mg/kg and all administered doses were within 0.2 % of this. The resulting 
dose of prednisolone was 0.06 mg/kg.
Administration of the preparation was carried out one hour prior to feeding.
5.4.2.3 SAMPLING REGIMEN
Blood samples were collected into suitable tubes for drug analysis, 
haematology and TxB2 estimation, as described previously.. Sample times 
were prior to and 0.08, 0.17, 0.33, 0.5, 0.75, 1, 2, 4, 8,12, 24, 30, 48 and 50 
hours post drug administration.
In addition, samples of blood were taken into capillary tubes prior to drug 
administration and at 0.5, 1, 2, 4, 8, 24, 30 and 48 hours for estimation of 
clotting times.
Faecal samples, collected throughout the experiment, were used to estimate the 
presence of occult blood.
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5.5. RESULTS OF EXPERIMENTS W ITH CINCHOPHEN
5.5.1 INTRAVENOUS ADMINISTRATION
5.5.1.1 CINCHOPHEN CONCENTRATIONS AND 
PHARMACOKINETICS AFTER INTRAVENOUS ADMINISTRATION 
The concentration of cinchophen in the plasma of each dog after intravenous 
administration at a dose rate of 12.5 mg/kg is shown in appendix 7.1. Figure
5.2 shows individual concentrations. Mean (± SEM) concentrations are shown 
in table 5.1 and figure 5.3. The main pharmacokinetic variables are shown in 
table 5.2
The mean concentration of cinchophen measured in plasma of dogs at the first 
sample time (0.08 hours) after drug administration was 120.24 ±  15.09 |ig/ml. 
The inter-animal range in concentration was large 61.58 - 159.01 |xg/ml. 
Decreasing concentrations of cinchophen were then measured in plasma of 
dogs 1 to 4, as is typical of an intravenous administration. In dogs 5 and 6 this 
typical pattern was not observed and concentrations were found to be higher 
than the 0.08 hour value at some sample times during the early part of the 
sampling period. These later peaks in concentration occured at 0.50 hours for 
dog 5 (91.97 }ig/ml) and 0.75 hours for dog 6 (92.09 Jig/ml) and were greater 
than the concentration measured for these animals in the first sample after drug 
administration. In addition, dog 5 had a smaller peak in drug concentration at 4 
hours (70.36 }ig/ml). A likely explanation for the difference in plasma 
concentration versus drug concentration profiles for these animals is that not all 
drug was injected intravenously. As a result of this possibility the values for 
pharmacokinetic parameters calculated for these animals have been excluded 
from the calculation of pharmacokinetic mean values. Secondary peaks in 
concentration were also measured in dogs 1, 2 and 4, these were lower than the 
concentration measured in the first sample and occured at 0.5 (dog 1) and 0.75 
hours (dogs 2 and 4) respectively. Drug was present in five animals at the final 
sample time and the maximum concentration in any animal at this time was 1.04 
pg/ml (dog 2). The mean concentration at this time was 0.72 ± 0.20 pg/ml.
The tV2B of cinchophen after intravenous administration at a dose rate of 12.5 
mg/kg was found to be in the range 7-8 hours for dogs 2-4, however dog 1 had 
a shorter half life of 4.66 hours. The overall mean t V2B in four animals was 
6.54 hours.
113
The range of MRT calculated from observed values for dogs 1-4 was 6.38-
10.76 hours. Using these figures to calculate an observed tV2B, resulted in 
figures which were not substantially different from the computed values (range 
5.14 - 8.68 hours)
Observed AUCs ranged from 694 - 1324 |ig/ml.h and the mean observed AUC 
for cinchophen in dogs 1-4 after intravenous administration at a dose rate of
12.5 mg/kg was 1068 ± 149 |xg/ml.h..
The AUMC computed from figures produced by fitting the theoretical curves 
showed very large inter-animal variation. A similar variation was seen when 
AUMC was calculated from observed data and in neither case did inclusion of 
the estimated first and last triangles decrease this variation to an appreciable 
extent The mean AUMC for observed data from dogs 1-4 was 10315 (± 2225) 
|ig/ml.h2.
Mean body clearance of drug was similar when calculated from observed or 
computed values (12.59 ± 2.07 ml/kg.h for values from observed data, and
12.77 ± 2.02 ml/kg/h for computed values), once more the inter-animal 
variation was large. Volume of distribution at steady state was in good 
agreement whether calculated from observed or computed values and the inter- 
animal variation was not large. The mean Vdss calculated from observed data 
was 109.60 ± 6.77 ml/kg and 113.44 ± 5.99 ml/kg for computed values. The 
volume of the central compartment showed an almost two fold variation 
between animal 4 and animals 5 and 6. This supports the suggestion that a 
proportion of the drug was injected peri-venously. Data from animals 1-4 are in 
the range 74.7 - 92.6 ml/kg.
5.5.1.2 SERUM THROMBOXANE INHIBITION AFTER INTRAVENOUS 
ADMINISTRATION
Appendix 7.2 contains the serum TxB2 concentrations for each animal at each 
time point. Percentage inhibition of TxB2 is shown in table 5.3.
Inhibition of TxB2 was between 45 and 84 % in all animals at 0.08 hours after 
drug administration (mean 69.04 ± 6.19 %). Four animals (dogs 1 to 4) had 
maximum inhibition in excess of 80 %, however in dogs 5 and 6 the maximum 
inhibition was 76 and 60 % respectively, and may be further evidence to suggest 
that a proportion of the drug was injected peri-venously in these animals. The 
serum TxB2 inhibition for dogs 3 and 6 was less than 25 % at 0.5 and at 0.75 
hours for dog 6, however inhibition was greater at 0.75 hours for dog 3 (82.19
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%). At 1 hour after drug administration, mean inhibition had decreased to 43.41 
% and mean inhibition remained around 40 - 50 % until 8 hours. With the 
exception of dogs 5 and 6, inhibition of serum TxB2 was greater than 50 % at 
most sampling times up to 4 hours and at 30 hours inhibition was only detected 
in the sample from one animal (dog 1). The area under the serum TxB2 
inhibition versus time curve was 865 %.h.
5.5.1.3 PLATELET NUMBERS AFTER INTRAVENOUS 
ADMINISTRATION
Platelet numbers for each dog on each sampling occasion are given in appendix
7.3.
Dog 4 was found to have platelet numbers outwith the normal range quoted for 
dogs, that is below 200 X 109/litre, at most samples times after drug 
administration. In addition, low platelet numbers were also recorded in dog 2 at 
48 hours and dog 6 at 12 hours. Platelet numbers above the normal range were 
measured in dog 1 prior to and at 8 hours post administration and in dog 2 prior 
to and at 8 and 12 hours.The cause of these variations is unknown, however, it 
was not considered likely that these results would affect the overall pattern of 
TxB2 production.
5.5.1.4 CLOTTING TIMES AFTER INTRAVENOUS ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times are 
shown in appendix 7.4.
In general, these values remained within the expected range, however it was 
noted in five animals (dogs 2 - 6), that the clotting times were longer at one 
hour than the values obtained prior to drug administration. This was found to 
be a statistically significant difference (p < 0.05). No general pattern of increase 
or decrease was noted thoroughout the experiment and it was therefore 
considered that this had occured by chance.
5.5.1.5 OCCULT BLOOD IN FAECES AFTER INTRAVENOUS 
ADMINISTRATION
Gastrointestinal blood loss determined throughout the experiment by Colo- 
Rectal test is shown in appendix 7.5.
Blood was not detected in any faecal sample collected during the experiment
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5.5.2 ORAL ADMINISTRATION
5.5.2.1 CINCHOPHEN CONCENTRATION AND 
PHARMACOKINETICS AFTER ORAL ADMINISTRATION
The concentration of cinchophen in the plasma of each dog after oral 
administration at a dose rate of 12.5 mg/kg is shown in appendix 8.1. Mean (± 
SEM) concentrations are shown in table 5.1 and figure 5.4 
The main kinetic variables are shown in table 5.4
Cinchophen was present in the plasma of only two dogs on the first sampling 
occasion (0.17 and 0.06 |ig/ml, dogs 2 and 4 respectively). The mean 
concentration of cinchophen measured in plasma of dogs at 0.17 hours post 
drug administration was 5.63 ± 3.69 |Xg/ml. As shown by the standard error 
the inter-animal range in concentration was large at this time (0.07 - 21.21 
|ig/ml) and this was generally the case at each sampling time. The maximum 
mean concentration (70.20 ± 8 .15  |Xg/ml) occured at two hours after drug 
administration and cinchophen was detected in the plasma of all animals at 50 
hours (mean concentration 2.05 ± 0 .8 1  |ig/ml). Concentrations of drug 
detected in dogs 1, 5 and 6 at several time points up to one hour were 
considerably lower than concentrations detected in the other three animals.
The mean observed AUC after administration of cinchophen at a dose rate of
12.5 mg/kg by the oral route was 1010 |ig/ml.h. Inter-animal variation in the 
persistence of cinchophen was determined as the MRT was greater than two 
fold, the range being 7.62-16.44 hours (mean 12.53 ± 1.48). The AUMC for 
observed values was in the range 3,500 to 24,500 |ig/ml.h2 and the mean value 
was 10944 ± 3637 |i.g/ml.h2. The final blood sample was collected at 50 hours 
after oral administration of cinchophen, however after intravenous the final 
sample time was 55 hours. The bioavailability was calculated on concentrations 
measured up to and including 48 hours and varied by more than a factor of 
two. The mean value was 64.15 %.
5.5.1.2 SERUM THROMBOXANE CONCENTRATION AFTER ORAL 
ADMINISTRATION
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 8.2, and percentage inhibition of TxB2 in table 5.5
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There was a very large inter-animal variation in serum TxB2 inhibition at most 
sampling times. Inhibition of TxB2 was measured in only three animals on the 
first sampling occasion and in all animals there was no inhibition detected on at 
least one sampling occasion during the first 12 hours. The maximum inhibition 
was in the range 60 - 70 % for four animals (dogs 2, 3 ,4  and 6). Dogs 1 and 5 
had lower maximum inhibition values (58.03 and 42.23 % respectively). In 
five animals maximum inhibition occured between 0.333 and 2 hours, however 
in one animal (dog 5) the maximum inhibition of TxB2 occured at 8 hours. The 
maximum mean inhibition was 50.43 ± 9.29 % and occured at 1 hour, at all 
other sampling times the mean inhibition was 35 % or less. Inhibdon of TxB2 
was detected in only two animals (dogs 1 and 5) at 50 hours. The area under 
the serum TxB2 inhibition versus time curve was 636 %.h.
5.5.1.3 PLATELET NUMBERS AFTER ORAL ADMINISTRATION
Platelet numbers for each dog on each sampling occasion are given in appendix
8.3.
Platelet numbers were found to be outwith the normal range in many samples. 
This was particularly a feature of dog 1 (which was high) and dog 4 (which 
was low), however in these animals the platelet numbers in the sample taken 
prior to drug administration were also outwith the normal range.
5.5.1.4 CLOTTING TIMES AFTER ORAL ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times are 
shown in appendix 8.4.
In general, these values remained within the expected range, however it was 
noted that the clotting times were shorter (p < 0.001) at 24 hour than the values 
obtained prior to drug administration. No general pattern of increase or 
decrease was noted thoroughout the experiment and as a result it was concluded 
that this difference had occured by chance.
5.5.1.5 OCCULT BLOOD IN FAECES AFTER ORAL ADMINISTRATION
Gastrointestinal blood loss determined throughout the experiment by Colo- 
Rectal test is shown in appendix 8.5.
Blood was not detected in any faecal sample collected during the experiment
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5.6. DISCUSSION
Cinchophen was well tolerated and achieved high concentrations in the plasma of dogs 
after intravenous administration of a preparation containing cinchophen and 
prednisolone. It is unfortunate that the relative proportions of cinchophen and 
prednisolone were different in the intravenous and oral preparations available. As a 
result of this it is not possible to be entirely sure that any of the similarities and 
differences between the intravenous and oral administrations were real or were a 
consequence of the presence of prednisolone. This is particularly true in the case of 
inhibition of TxB2 , where inhibition was considerably greater after intravenous 
administration than after oral administration in which the prednisolone content of the 
preparation administered was less than half of that in the intravenous administration.
For both intravenous and oral routes of administration the plasma concentration versus 
time profile for cinchophen was characterised, in most animals, by at least one 
secondary peak. These secondary peaks may have resulted from enterohepatic 
circulation of drug which has been noted by several workers after administration of 
NSAIDs (Dupont et al. 1982; Hobbs and Twomey 1979). In the case of animals 5 and 
6 after intravenous administration this may have been contributed to by the continuing 
absorbtion of drug from around the injection site as it seems likely that some drug had 
been administered peri-venously. Mathematical modeling of plasma concentration 
versus time curves revealed that best fit theoretical curves for intravenous data were 
produced by 2 exponents for animals 1-4,. It was not possible to describe the data 
obtained from dogs 5 and 6 by anything other than a curve using a single exponent, 
and as a result the pharmacokinetic variables have been calculated accordingly. It is 
assumed that this discrepancy may have resulted from the incomplete intravenous 
administration discussed earlier. The plasma concentration versus time profile for dog 
6 after intravenous administration was not typical of an intravenous administration. The 
concentration of drug in plasma increased between the first sample time at 0.08 hours 
and 0.33 hours, the maximum concentration occured at 0.75 hours. This pattern 
suggests that some drug had been deposited peri-venously, although there was no 
indication of this at the time of drug administration, that any drug had been deposited 
peri-venously. Drug was detected in the plasma of all but one animal on the last 
sampling occasion after intravenous administration (55 hours) and in all animals on the 
last sampling occasion after oral administration (50 hours).
Mathematical fitting of best theoretical curves for the concentration data generated by 
the oral administration resulted in a very poor correlation with observed data, only two 
animals had correlations of greater than 0.9. As a result pharmacokinetic variables were
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calculated from observed data. A wide inter-animal variation in the concentration of 
cinchophen was noted in each experiment and the tmax after oral administration varied 
from 0.75 - 4 hours.
Preparations containing cinchophen and prednisolone have been marketed in the UK 
for more than 20 years, yet there is a paucity of information regarding their 
pharmacokinetics and suitable therapeutic plasma concentrations. It has been 
established (Hart, 1983) that prednisolone is well absorbed after oral administration. In 
addition, Graham et al. (1977) have shown that concurrent administration of aspirin 
and corticosteroid decrease salicylate levels due to an increase in salicylate metabolism. 
It is therefore possible that the presence of the prednisolone component and the fact that 
it was administered at different dose rates may have affected the kinetics of 
cinchophen. The tV2B of cinchophen was found to be 6.84 hours after administration 
of the intravenous product. Calculation of an approximate tV2^ for cinchophen from 
the MRT value after oral administration showed that the tV2B was 10.06 hours and was 
therefore somewhat longer than after intravenous administration. Cinchophen achieved 
larger AUCs when combined with the higher dose rate of prednisolone indicating that it 
was unlikely that any increase in the rate of metabolism had occured.
Cinchophen was found to have widely variable bioavailability (range 54-120 %) after 
oral administration, although in general it was well absorbed. In two animals (dogs 2 
and 3) the bioavailability was greater than 100 % (119 and 116 % respectively). This 
may have resulted from good absorption coupled with intra-animal variation and 
experimental errors. In addition, it is possible that this is an anomaly as a result of the 
need to calculate the bioavailability over a restricted time period, however the 
bioavailability for dog 2 was in excess of 100 % whether or not it was calculated using 
AUCs measured after intravenous administration which had been adjusted to include 
the theoretical first and last triangles of the plasma concentration time curves.
Mean absorption times varied widely between animals and one animal (dog 4) had a 
negative value (range -1.55 - 5.68). It is not possible to explain this negative value, 
which theoretically implies that oral absorbance was more rapid than the injection of an 
intravenous bolus of drug. It may be that the rapid absorption rate was complicated by 
the occurrence of inter-animal variation between intravenous and oral experiments.
The inability to produce accurate theoretical curves for the data produced after the oral 
administration of cinchophen and the presence of drug in plasma at the final sampling 
times means that comparison of MRT values cannot be straightforward and it is not 
possible to accurately calculate the last triangle of the AUC for the oral administration. 
Comparison of MRT values based on observed data indicate that for each animal the
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MRT is considerably longer after oral administration. Inclusion of the AUCs of the 
calculated first and last triangles for the intravenous data makes little difference to the 
overall MRT values, since the AUC of these triangles is small in comparison to the 
total AUC. The concentration of drug in the plasma at the last sample time was similar 
after intravenous and oral administration. It is therefore likely that the contribution to 
the total AUC by the inclusion of the last triangle for the oral AUC would make little 
difference to the overall MRT value.
Maximum inhibition of serum TxB2 was generally in the range 75-90 % after 
intravenous administration of cinchophen, however for one animal (dog 6) the 
maximum inhibition was only 60 %. This lower level of inhibition is more typical of 
the inhibition measured after oral administration where maximum values were generally 
in the range 40-60 %. In most animals inhibition of 50 % or greater was maintained for 
4-8 hours after intravenous administration, however one animal (dog 6) had an 
inhibition greater than 50 % at only one sample time (0.333 hours).
Comparison of the AUC of TxB2 inhibition versus time curve after intravenous and 
oral administration of cinchophen showed that the AUC after oral administration was 
73 % of that obtained after intravenous administration. Statistical examination was also 
carried out on the maximum inhibition produced by each route and the inhibition 
measured at each time point. The mean maximum inhibition was 78.17 and 59.91 % 
after intravenous and oral administration respectively and these figures were found to 
be significantly different (p = 0.02). In addition, TxB2 inhibition was significantly 
higher at all time points until 1 hour (p < 0.05) after intravenous administration than 
after oral administration. After both intravenous and oral administration of cinchophen 
the graph of inhibition of TxB2 was characterised by peaks and troughs. This pattern 
was somewhat similar to that seen in the plasma concentration versus time graph 
although the time of appearance of peaks and troughs was not synchronised. This 
feature was very striking in the case of the data for inhibition after oral administration 
where in many cases the inhibition fell to zero prior to rising again. The occurrence of 
much smaller peaks and troughs in the plasma concentration versus time curves, which 
may have been caused by enterohepatic circulation, may explain this. However, this 
seems unlikely as high concentrations of cinchophen were required to produce 
substantial inhibition in TxB2 production, and it seems unlikely that the small increases 
in drug concentration which were detected could produce relatively large increases in 
TxB 2 inhibition unless the dose response curve is very steep. The presence of 
prednisolone in the administered preparations is a complication. Although the 
recognised mode of action of corticosteroids does not include inhibition of 
cyclooxygenase, it is possible that drug interference at the level of phospholipase may
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have resulted in TxB2 inhibition. However, Seppala et al (1985) have demonstrated 
that a single 20 mg dose of prednisolone does not significantly reduce the concentration 
of PGE2, 6-keto-PGFialpha or TxB2 in synovial fluid of arthritic patients. In this 
study, fluctuations in inhibition were greatest after oral administration and the dose rate 
of prednisolone administered orally was less than 50 % of that administered 
intravenously. This factor suggests that the erratic levels of inhibition of serum TxB2 
were not as a result of the prednisolone component.
Platelet numbers were found to be outwith the expected range (both high and low) on a 
number of occasions after both intravenous and oral administration of drug. In no 
animal did this appear to be a feature associated with drug administration. Also, the 
variation in platelet numbers does not mirror the unusual pattern of serum TxB2 
inhibition, indicating that it is unlikely that poor inhibition was an anomaly caused by 
low production of TxB2 resulting from a decreased number of platelets.
It is interesting that the blood clotting times recorded at one hour after intravenous 
administration of cinchophen were significantly longer than those measured prior to 
drug administration. Some NSAIDs have been shown to prolong bleeding time (Meilke 
et al. 1969, Hirsch et al. 1973). This is thought to be linked to inhibition of 
cyclooxygenase and the resulting reduction in the production of platelet TxA2 
(Buchanan, et al. 1983). Clotting times measured at 24 hours after the oral 
administration of cinchophen were found to be significantly shorter than those recorded 
prior to drug administration. In light of this, and the fact that significant alteration in 
clotting times was not a consistent feature in either experiment, it seems unlikely that 
cinchophen had any clinically significant effect on blood clotting times after a single 
administration at the dose rate studied.
The continued use of this drug combination over a period of 20 years indicates that it is 
relatively safe and the observations of this study support this.
Baggot (1982) has suggested that the dosage interval for most analgesics used in 
veterinary medicine should be twice the half life and since the half life for cinchophen 
was found to be approximately 6.5 hours, a twice daily dosage interval would be 
appropriate. This half life also indicates that drug accumulation during prolonged 
therapy is unlikely. Examination of the serum TxB2 inhibition data demonstrates that 
this dosage strategy is unlikely to maintain inhibition of greater than 50 %. The 
presence of prednisolone in the preparation means that it is not possible to predict the 
efficacy of treatment on the basis of serum TxB2 inhibition alone. A clinical trial using 
the oral preparation given twice daily at a dose rate of between 25 and 44 mg/kg daily 
over a period of 14 days showed it to have similar efficacy to phenylbutazone in the
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treatment of osteoarthritis. In this study dogs treated with the combined preparation 
showed almost twice the incidence of adverse reactions than was noted in the group 
treated with phenylbutazone (Pearson, 1989).
Further studies using each drug independently would be required to establish the 
contribution of each component to the efficacy of the preparation and to confirm the 
kinetics and serum TxB2 inhibition of cinchophen in the absence of prednisolone. It is 
apparent, however, that cinchophen is a relatively poor and reversible inhibitor of 
serum TxB2 inhibition. In light of the fluctuation in platelet numbers and the occasional 
significant change in blood clotting times it would also be of interest to examine these 
parameters for each drug individually.
TABLES AND FIGURES
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Time Route of A dm inistration
(h) In travenous Oral
Pre 0 0
0 .0 8 120.24 ± 15.09 0.04 ± 0.03
0 .1 7 116.16 ± 12.53 5.63 ± 3.69
0 .3 3 112.39 ± 9.90 23.08 ± 14.29
0 .5 0 107.35 ± 8.24 40.97 ± 17.93
0 .7 5 104.44 ± 7.84 45.45 ± 18.64
1 .00 99.93 ± 8.13 54.85 ± 15.46
2 .0 0 84.00 ± 5.15 70.20 ± 8.15
4 .0 0 67.72 ± 4.96 57.96 ± 7.07
8 .0 0 45.67 ± 4.88 39.40 ± 6.02
12 .00 33.48 ± 4.41 29.20 ± 4.89
2 4 .0 0 11.26 ± 2.37 13.14 ± 3.40
3 0 .0 0 7.50 ± 1.70 10.34 ± 3.42
4 8 .0 0 1.34 ± 0.34 2.85 ± 1.03
5 0 .0 0 NS 2.05 ± 0.81
5 5 .0 0 0.72 ± 0.20 NS
Table 5.1 Mean (±SEM) concentration (jig/ml) of cinchophen in plasma 
of dogs after administration at a dose rate of 12.5 mg/kg by the 
intravenous (in combination with 0.15 mg/kg prednisolone) and 
oral (in combination with 0.06 mg/kg prednisolone) routes.
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T i m e  A n i m a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n ± S E M
P r e 0 0 0 0 0 0 0 ± -
0 . 0 8 8 4 .0 0 78 .65 55.91 77 .27 7 3 .3 5 4 5 .0 4 69 .0 4 ± 6 .1 9
0 . 1 7 88 .39 75 .89 8 2 .2 6 8 3 .1 2 6 4 .0 3 3 4 .0 2 7 1 .2 8 ± 8 .2 0
0 . 3 3 7 4 .5 0 8 1 .4 2 74 .18 66 .0 7 6 2 .3 8 57 .91 69 .41 ± 3 .59
0 . 5 0 80 .4 6 7 5 .8 0 18.41 68 .51 7 5 .9 4 2 3 .7 7 57 .15 ± 11.53
0 . 7 5 75 .1 0 7 2 .6 0 8 2 .1 9 4 5 .1 3 6 8 .7 5 10 .47 59 .0 4 ± 10.99
1 . 0 0 75 .77 60 .59 54 .4 2 9 .7 4 35 .61 2 4 .3 2 43 .41 ± 10.04
2 . 0 0 5 6 .0 2 58 .8 2 61 .1 5 54 .2 2 4 8 .8 2 4 0 .4 6 53 .25 ± 3 .0 8
4 . 0 0 51 .67 51.51 56 .5 9 57 .63 2 5 .4 7 0 4 0 .4 8 ± 9 .4 2
8 . 0 0 57 .23 13.83 64 .6 7 6 2 .8 2 2 8 .8 9 6 0 .5 2 4 7 .9 9 ± 8 .7 0
1 2 . 0 0 36.01 0 .95 19.91 17.86 0 0 12.45 ± 6 .0 1
2 4 . 0 0 48 .1 3 0 N S 4 6 .5 9 2 7 .8 3 0 24 .51 ± 10 .62
3 0 . 0 0 23 .83 0 0 0 0 0 5 .9 6 ± 5 .9 6
4 8 . 0 0 N S NS N S N S N S 0 0 ±
Table 5.3 Inhibition(%) of thromboxane B2 in serum of dogs after administration of 
cinchophen (in combination with 0.15 mg/kg prednisolone) at a dose rate 
of 12.5 mg/kg by the intravenous route.
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T i m e  A n i m a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n ± S E M
P r e 0 0 0 0 0 0 0 ± -
0 . 0 8 3 1 .8 6 0 0 27 .23 0 12 .72 11 .97 ± 5 .9 4
0 . 1 7 20.21 0 4 .5 8 0 2 1 .1 9 7 .6 5 19 .36 ± 9.31
0 . 3 3 5 .9 6 23 .0 8 5 .0 9 62 .53 12 .34 0 14 .26 ± 5 .93
0 . 5 0 5 .7 6 31 .84 4 1 .6 8 39 .08 0 11.74 2 2 .5 2 ± 7 .8 0
0 . 7 5 0 64 .3 9 70 .71 4 4 .1 2 0 .3 7 2 6 .8 7 2 7 .0 6 ± 13.51
1.00 50 .0 0 6 3 .8 9 66 .81 0 5 .7 2 61 .5 7 5 0 .4 3 ± 9 .2 9
2.00 58 .03 5 4 .0 6 5 5 .3 5 54 .57 14 .28 30 .67 3 5 .4 0 ± 9 .9 7
4 . 0 0 34 .54 16.54 0 0 3 7 .3 2 2 1 .4 6 18 .30 ± 6 .6 0
8.00 4 4 .6 5 8 .05 0 0 4 2 .2 3 0 15 .82 ± 8.83
12.00 6 .5 6 0 0 0 3 8 .0 7 17.43 13 .20 ± 5 .9 0
2 4 . 0 0 3 .48 18 .30 2 .6 3 17.17 0 1.84 9 .5 4 ± 5 .0 7
3 0 . 0 0 25 .8 4 0 0 30 .97 0 2 4 .1 5 14.99 ± 7 .0 4
4 8 . 0 0 12.25 0 0 39 .59 11.97 0 4 .0 4 ± 2 .5 5
5 0 . 0 0 12.18 0 0 0 1 0 .56 0 4 .5 5 ± 2 .8 0
Table 5.5 Inhibition(%) of thromboxane B2 in serum of dogs after administration of 
cinchophen (in combination with 0.06 mg/kg prednisolone) at a dose rate 
of 12.5 mg/kg by the oral route.
 > -
FLOW
A. Standard solution containing 5 |ig/ml of drug.
B. Blank dog plasma fortified with 20 |ig/ml drug.
C. Plasma sample estimated to contain 10.17 fig/ml of drug. 
D .Standard solution containing 5 }ig/ml of drug.
Figure 5.1 Typical chromatogram of cinchophen in dog plasma
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.
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Chapter 6
STUDIES W ITH TOLFENAMIC ACID
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6.1. INTRODUCTION
Tolfenamic acid (N-(2-methyl-3-chlorophenyl) anthranilic acid) is a member of the 
fenamic acid group of NSAIDs. It is structurally similar to other substituted anthranilic 
acids, particularly mefenamic acid and flufenamic acid, which have analgesic and 
antiinflammatory properties (Bamaido et al. 1966). Individual members of this group 
differ only by the presence or absence of methyl and chloro groups in the basic 
structure. Tolfenamic acid, manufactured by GEA Ltd (Denmark), is marketed for 
human use under the trade name Clotam. The normal human therapeutic dosage 
regimen is 100-200 mg three times daily. It is also available for use in small animals 
(dogs and cats) in France where is is marketed as Tolfedine by Vetoquinol Ltd 
(France).
In general, fenamic acids have a pKa of 3-4 (tolfenamic acid pKa 4.3) and are thus 
almost completely ionised at physiological pH, however they are very lipophilic for 
this class of drug and as a result, are likely to be present in reasonable concentrations in 
lipid fractions of the body (Schemer, 1985).
Numerous clinical trials have been carried out comparing tolfenamic acid to other 
NSAIDs. Kajander etal (1972) compared tolfenamic acid at dose rates of 300 and 600 
mg daily with acetylsalicylic acid at 300 mg per day for four days, and found the 
higher dose rate of tolfenamic acid to give significantly better analgesia. Yamashita etal 
(1981a) confirmed the analgesic superiority of tolfenamic acid when compaired to 
phenylbutazone and also found it to be two to six times as potent as aspirin and 
equipotent to mefenamic acid and diclofenac. Tolfenamic acid has also been 
demonstrated to have good analgesic efficacy in the treatment of dysmenorrhea 
(Kauppila and Ylikorkala, 1977) and migraine (Hakkarainen et al. 1979). In patients 
with rheumatoid arthritis, 600 mg of tolfenamic acid was more effective than 300 mg 
phenylbutazone using subjective and objective evaluation (Rejholec et al. 1979b). A 
comparative study of tolfenamic acid, aspirin and a placebo in the treatment of 
osteoarthritis of the knee showed no significant difference between drug or placebo 
when range of movement and other objective perameters were measured (Zachariae and 
Sylvest, 1972). The analgesic efficacy (as measured by patient preference) was, 
however, equal to aspirin.
A tV2B of 2.5 hours after intravenous and oral administration has been established in 
human subjects (Pentikainen et al. 1981) and this was also shown to be independant 
of dose rate over the range examined (100-800 mg). This is in the same range as tV2B 
values obtained for other chemically similar NSAIDs such as flufenamic acid (tV2& 3.0 
hours) and mefenamic acid (t1^  1-8 hours) (Von Dell et al. 1977; Adamska- 
Dyniewska et al. 1979). A slightly lower t1^  of 1.7 hours was established for
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tolfenamic acid when administered to patients with cirrhosis of the liver (Stenderup et 
al, 1985).
After oral administration, tolfenamic acid was found to be rapidly absorbed. Maximum 
concentrations in plasma occurred by 2  hours, and bioavailability was reported to be 60 
% (Pentikainen et al. 1981). In the same study, maximum plasma concentration and 
AUC were also found to be linearly correlated with dose. Pentikainen et al (1981) have 
suggested that the comparatively low bioavailablility may be due to a combination of 
incomplete gastric absorbtion and first pass metabolism.
Tolfenamic acid is highly bound to plasma proteins in vivo (99.7 %) and the extent of 
binding has been shown to be independent of plasma concentration (Pentikainen et al. 
1981). This figure also correlated well with the value of 99.7 % determined in vitro for 
protein binding. High protein binding is typical of many NSAIDs and this figure 
equals or exceeds the degree of binding established for fenoprofen, ibupnofen, tolmetin 
and naproxen (Brogden et al. 1979). Pentikainen et al (1981), have established that 
tolfenamic acid does not saturate binding sites in the normal therapeutic concentration 
range.
In line with other NSAIDs it has been established that tolfenamic acid inhibits 
cyclooxygenase activity in vivo and in vitro (Linden et al. 1976; Vapaatalo et al. 1986). 
In vitro, it has been found to be as effective as indomethacin and to be effective at 
lower concentrations than acetylsalicylic acid in inhibiting the synthesis of PGE2 in 
rabbit kidney medulla microsomal fractions. In addition, tolfenamic acid is similar to 
indomethacin and acetylsalicylic acid as a competitive inhibitor of PG synthesis 
(Linden et al. 1975 and 1976). Alanko and co-workers (1989,1990) measured a 31 % 
decrease in PGE2 produced by PMNs, and a 70 % decrease in TxB2 production by 
platelets after administration of tolfenamic acid to human subjects. It has been 
established that plasma drug concentrations produced by the administration of three 
lOOmg doses of tolfenamic acid per day exceed the concentrations required to produce 
a 50 % inhibition of PG synthesis in an experimental model using rabbit kidney 
medullamicrosomes (Lindenetal. 1976).
An interesting feature of tolfenamic acid is its additional ability to inhibit the synthesis 
of LTs in man at clinically achievable concentrations (Moilanen et al. 1988; Alanko et 
al, 1989). Oral administration of tolfenamic acid has been shown to reduce the 
production of LTB4 in human PMN by 26 % and of LTC4 by 33 % (Alanko, 1990) 
and this inhibition has shown a positive correlation with drug concentration. More 
recently, Kankaanranta et al (1993) demonstrated that tolfenamic acid was 
approximately ten times less effective (on a molar basis) than flunixin in inhibiting
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serum TxB2 production. However it was capable of inhibiting LTB4 synthesis and 
PMN migration at clinically achievable concentrations. Inhibition of LT synthesis has 
also been shown for flufenamic acid and meclofenamic acid (Fruchtmann, 1984; 
Boctor, 1986). Compounds capable of inhibiting the production of both PGs and LTs 
(so called dual inhibitors), have been shown to be more effective antiinflammatory 
agents than classic NSAIDs (Moncada, 1986). A further distinctive property of 
fenamates is the influence of co-factors on the ability of these drugs to inhibit 
cyclooxygenase. Many of the cofactors (such as phenols and indoles) are substances 
which may be present naturally at the site of activity. Enhancement of activity by as 
much as 100 fold has been reported (Egan et al. 1978), and it has been sugested 
(Scherrer, 1985) that the local presence of such natural co-factors may result in an 
action of fenamates which is tissue selective.
Fenamates differ from other NSAIDs since they may block prostaglandin receptors. 
This was initially reported by Collier and Sweatman (1968), and later confirmed by 
Zor et al (1976). When tested on two in vitro smooth muscle preparations, tolfenamic 
acid was 20  times more effective than mefenamic acid in the inhibition of PGF2aipha 
contraction of rat uterus, and equal to mefenamic acid in the inhibition of PGF2aipha 
contraction of guinea pig trachea (Vapaatalo et al. 1977). Concentrations required to 
cause this effect are 30 times higher than those required to cause inhibition of 
prostaglandin synthesis, however they are still within the range which may be achieved 
during clinical use.
Bennett et al (1980a , 1980b), investigating the action of various PGs in gut 
preparations, found that sodium meclofenamate antagonised the stimulation of 
gastrosecretion induced by PGF2alpha but not the inhibitory effect of PGE2. The ability 
of fenamates to antagonise PG induced contractions varied with species and tissue, and 
these workers suggested that the apparent anomolies were a result of the existence of 
several types of PG receptors.
Yamashita et al (1981b) have shown tolfenamic acid to be superior to mefenamic acid, 
diclofenac and indomethacin in inhibiting the in vitro migration of leukocytes and to be 
almost as potent as diclofenac and indomethacin in the inhibition of platelet 
aggregation. This is in line with previous findings for fenamic NSAIDs (O’Brien, 
1986).
Studies by Pentikainen et al (1981) indicated elimination of tolfenamic acid in human 
subjects is predominantly by extrarenal mechanisms. This is similar to the chemically 
related compounds mefenamic and flufenamic acid which are removed by hepatic 
metabolism (Glazko, 1967). There is good correlation between elimination rate
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constants or plasma clearances of tolfenamic acid and liver function in patients with 
cirrhosis of the liver (Stenderup et al. 1985). It has been well documented that other 
fenamates are extensively metabolised to hydroxylated derivatives with only a small 
percentage of initial dose being excreted in the urine as unaltered drug or glucuronide 
(Glazko, 1967). Pentikainen et al (1981, 1982) have shown that less than 10 % of an 
intravenous dose is detected in urine as unchanged drug or glucuronide when given to 
healthy patients. These workers have also identified two major metabolites of 
tolfenamic acid in urine and have established that these are both hydroxylated 
derivatives. Studies conducted by Kuninaka et al (1981) on humans, rats and rabbits 
indicated that the major metabolites present in urine were glucuronides and these 
metabolites have been found to be less potent antiinflammatory agents than the parent 
compound.
In general, clinical use of tolfenamic acid has been found to produce few side effects 
(Kajander et al. 1972; Zachariae and Sylvest, 1972; Axelsson et al. 1977), even after 
administration for several months (Rejholec et al. 1979b). Gastrointestinal irritation has 
been noted in some studies (Sorensen and Christiansen, 1977; Rejholec et al. 1979a) 
although not all (Axelsson et al. 1977) and administration of 10 times the human dose 
to dwarf pigs over a period of six weeks resulted in no adverse effects on gastric 
mucosa (Axelsson et al. 1977). Slight dysuria, particularly in male patients was noted 
in some studies (Sorensen and Christiansen, 1977; Rejholec et al. 1979a). Tolfenamic 
acid has been shown to have a better therapeutic index than mefenamic acid, 
indomethacin, diclofenac and phenylbutazone (Rejholec et al. 1979a). Axelsson (1977) 
reported that tolfenamic acid produced significantly fewer cases of gastritis than 
acetylsalicylic acid, and studies carried out in Japan suggest that tolfenamic acid may be 
up to five times less ulcerogenic than mefenamic acid when administered to rats 
(Yamashita et al. 1981a).
6.2 EXPERIM ENTAL OBJECTIVES
The objectives of this work were to examine the kinetics of tolfenamic acid after 
administration at the recommended dose rate of 4.0mg/kg body weight by the 
intravenous and subcutaneous routes in dogs, to investigate the pharmacokinetics and 
to quantify the inhibition of TxB2 in serum following administration of tolfenamic acid 
by each route.
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6.3 MATERIALS AND METHODS
6.3.1 ANALYSIS OF TOLFENAMIC ACID
Analysis of tolfenamic acid was carried out by high performance liquid 
chromatography (H.P.L.C.) using spectrophotometric detection.
6.3.1.1 REAGENTS
1. Tolfenamic acid (Sigma Chemical Co.)
2. Diethyl ether, redistilled grade (Rathbum Chemicals)
3. Methanol 'Analar' (BDH Ltd), redistilled prior to use
4. Disodium hydrogen orthophosphate 'Analar1 (BDH Ltd)
5. Citric acid ’Analar' (BDH Ltd)
6 . Citrate/phosphate buffer pH 3.0 was produced by mixing the following 
solutions
20.5 ml M/5 Na2HP0 4  + 79.5 ml M/10 citric acid,to give 100 ml of 
buffer.
7. Perchloric acid 70 % ’Analar’ (BDH Ltd)
8 . Water, redistilled in the presence of potassium permanganate prior to use.
7. H.P.L.C. mobile phase comprised 80 : 20, methanol: water containing 50 
fj.1 of 1 in 55 aqueous solution of perchloric acid per 100 ml mobile phase.
6.3.1.2 H.P.L.C. EQUIPMENT 
P u m p G i l s o n  301 
D e te c to rS p e c tra p h y s ic s  100
C o l u m n 100 mm X 8 mm containing 5 1x O.D.S. Hypersil (Shandon 
Southern).
W a v e le n g th 342 nm
A b s o r b a n c e 0.02 AUFS
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Flow rate of mobile phase 1.5 ml/min.
The retention time of tolfenamic acid under these conditions was 3.5 minutes.
6.3.1.3 SAMPLE PREPARATION
A 2 ml aliquot of each plasma sample was placed in a 50 ml ground glass tube. 
To this was added 2 ml of citrate /  phosphate buffer (pH 3.0), followed by 20 
ml diethyl ether. The tube was stoppered and the mixture shaken for 10 minutes 
by inversion on a slow rotary mixer. Fifteen millilitres of ether was removed 
from the upper layer and placed in a 50 ml glass test tube. A further 20 ml 
diethyl ether was added to the sample mixture and shaken for a second period 
of 10 minutes after which 20  ml of the upper ether fraction was removed and 
combined with the 15 ml previously recovered.
The tube containing the combined ether extracts was placed in a Dri-Block 
(Techne Ltd) at 50 °C under a stream of air and allowed to evaporate until 
approximately 5 ml remained. The remaining diethyl ether was transferred to a 
10 ml conical glass tube. The 50 ml glass tube was rinsed three times with 
approximately 1 ml of diethyl ether which was then added to the conical tube. 
The ether extract was evaporated to dryness at 50 °C under a stream of air. A 
final 1 ml of ether was run down the walls of the conical tube to ensure that all 
residue present was in the base of the tube. The extract was returned to the Dri- 
Block and allowed to evaporate to dryness. Sample tubes were covered with 
clingfilm and stored overnight at 4 °C if necessaiy. Prior to injection onto the 
HPLC system the residues were reconstituted in methanol. An appropriate 
known volume (not less than 150 |il) of methanol was added to the bottom of 
the conical tube which was then tilted and rotated in an ultrasonic bath for 1 
minute A 20 |il injection loop was used for injection, the loop was loaded with 
15 |il of sample.
The concentration of tolfenamic acid in each sample was determined by 
reference to a calibration curve prepared for each analysis. This was prepared 
by fortifying blank plasma with known amounts of tolfenamic acid to produce 
the appropriate range of concentrations. A number of fortified plasma aliquots 
treated in this way were processed in an identical manner to that described for 
unknown samples. In addition, standard solutions of tolfenamic acid were 
injected directly onto the HPLC. These standard solutions allowed equipment 
performance to be monitored and were also used to calculate the concentration
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of tolfenamic acid measured in the fortified samples. From these figures it was 
possible to calculate the percentage recovery of tolfenamic acid after extraction.
Unknown sample concentrations were calculated by reference to the standard 
drug solutions. These concentrations were then adjusted to 100 % to allow for 
extraction losses by comparison to the recoveries obtained for the fortified 
samples.
A typical chromatogram is shown in figure 6.1
6.3.1.4 RECOVERY, PRECISION, LINEARITY AND SENSITIVITY
Recovery of drug from plasma samples was approximately 70 %. Typical 
recovery of tolfenamic acid, inter-assay and intra-assay variation are shown in 
appendix 1.4.
Calculation of the inter-assay coefficient of variation for recovery of tolfenamic 
acid from fortified plasma allowed an assessment of the precision of the assay 
to be made (appendix 1.4). The mean inter-assay variation was found to be 5.2 
% and the mean intra-assay variation was 5.5 %.
Simple regression was used to determine the linearity of concentration with 
respect to peak height for fortified samples. The correlation coefficient (r) for 
concentrations ranging from 0.1 - 5.0 pg/ml of tolfenamic acid in plasma was 
0.999.
The sensitivity of the assay was determined with respect to the background 
fluctuation recorded on the trace produced from the HPLC system. The 
minimum peak height which could be reliably recorded was estimated from 
standard solutions in replicate analyses. This was determined as at least twice 
the maximum overall background fluctuation and was set at one unit. A peak 
height of one unit of tolfenamic acid, under the HPLC conditions described, 
corresponded to 0.05 |ig drug per millilitre of plasma.
6.3.1.5 OTHER ANALYSES AND METHODS USED
Estimation of serum TxB2 concentration, estimation of platelet numbers in 
blood, estimation of occult blood in faeces, pharmacokinetic analysis, statistical 
analysis
are described in the general Materials and Methods section.
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6.4 EXPERIM ENTS W ITH TOLFENAMIC ACID
Three male and three female Beagle dogs aged between 2.0 and 2.5 years were used 
for all experimental work. The animals were housed in pairs and fed a complete cereal 
diet once daily, water was available ad libitum.
6.4.1 INTRAVENOUS ADMINISTRATION OF TOLFENAMIC ACID
6.4.1.1 EXPERIMENTAL DESIGN
Tolfenamic acid, at a dose rate of 4.0 mg/kg, was administered to the six dogs 
on a single occasion .The dogs were weighed immediately prior to the 
experiment and the dose of tolfenamic acid to be administered calculated 
according to body weight Weights ranged from 13.1-16.9 kg.
6.4.1.2 DRUG ADMINISTRATION
A 40 mg/ml injectable solution (Tolfedine, Vetoquinol) was administered into 
the right cephalic vein over a 30 second period.
Administration of tolfenamic acid was carried out one hour prior to feeding.
6.4.1.3 SAMPLING REGIMEN
Blood was collected by jugular venipuncture into suitable tubes for drug 
analysis, haematology and serum TxB2 estimation as described previously. 
Sampling was carried out sequentially prior to and at 0.08, 0.17, 0.33, 0.50, 
0.75, 1, 2, 4, 8,12, 24,48 and 72,96 and 168 hours after drug administration. 
The first sample time for serum TxB2 inhibition was 0.5 hours and no sample 
was taken at 0.75 hours. Addition samples of blood were taken into capillary 
tubes prior to drug administration and at 0 .5 ,1, 2, 4, 8,12, 24, 48, 72, 96 and 
168 hours after drug administration. These were used for the estimation of 
blood clotting time.
Faecal samples were collected throughout the experiment and an estimate of the 
presence of occult blood was made as described in the general material and 
methods section.
6.4.2 SUBCUTANEOUS ADMINISTRATION OF TOLFENAMIC ACID
6.4.2.1 EXPERIMENTAL DESIGN
The six dogs were administered tolfenamic acid at a dose rate of 4.0 mg/kg on a 
single occasion. The dogs were weighed immediately prior to the experiment
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and the dose of tolfenamic acid administered calculated according to body 
weight. Weights ranged from 12.3 - 16.3 kg.
6.4.2.2 DRUG ADMINISTRATION
A 40 mg/ml injectable solution of tolfenamic acid (Tolfedine, Vetoquinol) was 
used. The drug was administered under the loose skin at the back of the neck. 
Administration of tolfenamic acid was carried out one hour prior to feeding.
6.4.2.3 SAMPLING REGIMEN
Samples were taken for drug analysis, haematology and serum TxB2 estimation 
as described previously. Sampling was carried out prior to and at 0.25,0.5,1, 
2, 4, 8 , 12, 24, 48, 72, 96 and 168 hours after drug administration. Samples 
of blood also taken into capillary tubes prior to drug administration and at 0.5, 
1, 2, 4, 8 , 24, 48, 72, 96 and 168 hours after drug administration for 
estimation of clotting time.
An estimate of the presence of occult blood was made from faecal samples 
which were collected throughout the experiment
6.5 RESULTS OF EXPERIMENTS W ITH TOLFENAM IC ACID
6.5.1 INTRAVENOUS ADMINISTRATION
6.5.1.1 TOLFENAMIC ACID CONCENTRATION AND 
PHARMACOKINETICS AFTER INTRAVENOUS 
ADMINISTRATION 
The concentration of tolfenamic acid in the plasma of each dog after intravenous 
administration of tolfenamic acid at a dose rate of 4.0 mg/kg is shown in 
appendix 9.1. Figure 6.2 shows individual concentrations. Mean (±SEM ) 
concentrations are shown in table 6.1 and figure 6.3. The main 
pharmacokinetic variables are shown in table 6 .2 .
The mean concentration of tolfenamic acid measured in plasma of dogs at 0.08 
hours after drug administration was 25.41 ± 4.50 |ig/ml and a large inter- 
animal range in concentration was noted (14.50 - 44.13 |ig/ml). Concentration 
of drug declined rapidly and in two dogs (dog 1 and 2 ) no drug could be 
detected at 2 hours. Tolfenamic acid was detected in plasma from two dogs at 
48 hours (dogs 3 and 4), and at 96 hours was only detected in plasma from dog
4. Mean concentration of tolfenamic acid in plasma was 0.28 ±  0.06 |i.g/ml at 
12 hours and 0.07 ± 0.03 fig/ml at 24 hours.
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Two animals showed plasma concentration versus time profiles containing 
several peaks and troughs. Drug could not be detected in plasma from dogs 1 
and 2 at 2 hours post administration, however, at 4 hours concentrations of 
0.20 fig/ml and 0.32 jig/ml (respectively) were measured. Drug was then 
detected in samples from these animals until 12 hours (dog 2) and 24 hours 
(dog 1).
A large inter-animal variation in tV2 B was observed over the range 3.91 to 
16.38 hours. The inter-animal variation of persistence of tolfenamic acid in 
plasma is reflected in the large variation in MRT values calculated from 
observed data (range 1.32 to 19.27 hours). In addition, observed AUCs ranged 
from 9.70 - 35.05 jig/ml.h. The mean AUC after administration of tolfenamic 
acid at a dose rate of 4.0 mg/kg by the intravenous route was 18.10 |i.g/ml.h.
The area under the first moment curve also varied widely between animals. The 
mean AUMC was 193 (±111) jig/ml.h2, range 17.34 - 727.41 jig/ml.h2.
Mean body clearance of drug was 230 ± 41 ml/h/kg, range 106 ml/h/kg (dog4) 
to 351 ml/h/kg (dog 1) and Vdss was 1247 (± 293) ml/kg, range 396 (dog 5) to 
2058 ml/kg (dog 1).
6.5.1.2 SERUM THROMBOXANE INHIBITION AFTER INTRAVENOUS 
ADMINISTRATION
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 9.2, and percentage inhibition of TxB2 in table 6.3.
Inhibition of TxB2 was between 84 and 96 % in all animals at 0.5 hours after 
drug administration (mean 91.30 %). Inhibition exceeded 70 % in only three 
animals (dogs 2, 3 and 6) at one hour and serum TxB2 was near to control 
concentrations during the period 2 to 4 hours in several animals. However, all 
animals showed a secondary peak in inhibition at some point during the 
sampling times from 4 hours onwards. The area under the serum TxB2 
inhibition versus time curve was 1857 %.h.
6.5.1.3 PLATELET NUMBERS AFTER INTRAVENOUS 
ADMINISTRATION
Platelet numbers for each dog on each sampling occasion are given in appendix
9.3. Dogs 2, 4, and 5 were found to have platelet numbers outwith the range 
quoted for dogs prior to drug administration, that is below 200 X 109/litre. 
Low counts were recorded for dog 4 at each sampling time until eight hours,
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from which time platelet counts were within the normal range until 72 hours. 
Blood samples taken from dog 6  at 2 hours and dog 2 at 8 hours were also 
found to be outwith the normal range. No time related pattern of increase or 
decrease was noted throughout the experiment.
6.5.1.4 CLOTTING TIMES AFTER INTRAVENOUS 
ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times are 
shown in appendix 9.4. These values remained within the expected range at all 
sample times with the exception of the two hour sample from dog 1 and 3, the 
4 hour sample from dog 4 and the 96 hour sample from dog 3 which were 
slightly lower than expected. No pattern of increase or decrease was noted 
thoroughout the experiment
6.5.1.5 OCCULT BLOOD IN FAECES AFTER INTRAVENOUS 
ADMINISTRATION
Colo-Rectal tests were used throughout the experiment to determine gastro­
intestinal blood loss (appendix 9.5). Blood was not detected in the faeces 
samples with the exception of the single sample from pen 3 (dogs 5 and 6) at 
72 hours in which a trace of blood was detected.
6.5.1 SUBCUTANEOUS ADMINISTRATION
6.5.1.1 TOLFENAMIC ACID CONCENTRATION AND 
PHARMACOKINETICS AFTER SUBCUTANEOUS 
ADMINISTRATION
The concentration of tolfenamic acid in the plasma of each dog after 
subcutaneous administration at a dose rate of 4.0 mg/kg is shown in appendix
10.1 and figure 6.4. Mean (± SEM) concentrations are shown in table 6.1 and 
figure 6.4. Figure 6.5 shows individual concentrations and the main kinetic 
variables are shown in table 6.4.
Plasma concentrations after subcutaneous administration of tolfenamic acid 
were determined for only five of the six dogs to which drug had been 
administered. This was due to loss of samples in storage.
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The mean concentration of tolfenamic acid measured in plasma of dogs at 0.25 
hours after subcutaneous administration of drug was 1.11 ± 0.35 |ig/ml. As 
shown by the standard error the inter-animal range in concentration was large at 
0.25 hours and from 8 hours onwards. The maximum mean concentration 
(4.05 ± 0.65 |ig/ml) occured at 2 hours after drug administration and 
tolfenamic acid was detected in the plasma of all animals at 12 hours (mean 
concentration 1.17 ± 0.28 |ig/ml). Tolfenamic acid could be detected in the 
plasma of two dogs (dogs 1 and 6 ) at 48 hours. Examination of the drug 
concentration versus time profile shows that for all but one dog (dog 5), after 
an initial decline, concentrations rose again. The profile for dog 1 showed two 
such secondary peaks and the concentration of drug detected rose again from 
below the limit of detection at 24 hours to 0.06 |ig/ml at 48 hours, before 
falling below the limit of detection once more at 72 hours.
As in the intravenous experiment, the inter-animal variation in persistence of 
tolfenamic acid in plasma is reflected in the large variation in MRT values 
calculated from observed data (3.89 - 11.06 hours). In addition, observed 
AUCs ranged from 12.53 - 41.47 (Ig/ml.h. The mean observed AUC after 
administration of tolfenamic acid at a dose rate of 4.0 mg/kg by the 
subcutaneous route was 29.62 jig/ml.h. The area under the first moment curve 
ranged from 49 to 429 jig/ml.h2 (mean 246 jig/ml.h2).
6.5.1.2 SERUM THROMBOXANE CONCENTRATION AFTER 
SUBCUTANEOUS ADMINISTRATION
Serum TxB2 concentrations for each animal at each time point are shown in 
appendix 10.2, and percentage inhibition of TxB2 in table 6.5
Inhibition of TxB2 ranged from 32 - 99 % at 0.25 hours and from 54 -90 % at 
0.5 hours after drug administration. Maximum inhibition was greater than 80 % 
in each animal and the maximum mean inhibition of 80 % occured at 2  hours. 
Twelve hours after drug administration inhibition of TxB2 had declined to 50 % 
or less in four animals (dogs 2, 3, 5 and 6 ), and at 24 hours concentrations 
were near pr- drug administration values in dogs 2 and 5. The area under the 
serum TxB2 inhibition versus time curve was 2785 %.h.
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6.5.1.3 PLATELET NUMBERS AFTER SUBCUTANEOUS 
ADMINISTRATION
Platelet numbers for each dog on each sampling occasion are given in appendix
10.3. In general, throughout the experiment these remained within the range 
considered to be normal for dogs. However, decreased platelet numbers were 
detected in samples collected at 48 and 96 hours from dog 4 and at one and 96 
hour from dog 6 .
6.5.1.4 CLOTTING TIMES AFTER SUBCUTANEOUS 
ADMINISTRATION
Clotting times for each animal at each sampling time and mean clotting times are 
shown in appendix 10.4. These values remained within the expected range at 
all sample times with the exception of the 1 hour sample from dog 1 and the 96 
hour sample from dog 4, which were lower than expected.
6.5.1.5 OCCULT BLOOD IN FAECES AFTER SUBCUTANEOUS 
ADMINISTRATION
Gastro-intestinal blood loss determined throughout the experiment by Colo- 
Rectal test is shown in appendix 10.5. No blood was detected with the 
exception of faeces from pen 2 (dogs 3 and 4) and pen 3 (dogs 5 and 6) at 48 
hours. These samples showed a trace and definite reaction respectively.
6 .6  DISCUSSION
Tolfenamic acid was well tolerated after intravenous and subcutaneous administration 
to dogs.
The general pattern of plasma drug concentration versus time after intravenous and 
subcutaneous administration indicated that enterohepatic circulation had occured, to 
some extent, in most dogs after drug administration. This is in keeping with findings 
for other NSAIDs (Hobbs and Twomey, 1979; Dupont et al. 1982)
Concentrations of tolfenamic acid in plasma of dogs after intravenous administration 
were found to have a wide inter-animal variation and to decline rapidly. This was most 
notable in animals 1 and 2 in which no drug was detected at two hours. Inter-animal 
variations in drug concentration were particularly apparent at 0.25 hours and from eight 
hours onwards after subcutaneous administration. A pattern of troughs and secondary
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peaks in concentration similar to that noted in the intravenous experiment was observed 
in most animals after intravenous and subcutaneous administration.
Large inter-animal variation in observed AUC (9.70 - 35.05 |ig/ml.h intravenous and 
12.53 - 41.47 pg/ml.h subcutaneous) and MRT (1.32 - 19.27 hours intravenous and 
3.89 - 11.06 hours subcutaneous) was observed after both intravenous and 
subcutaneous administration of drug. It is possible that the plasma concentration profile 
may have played a part in the wide variation of tV2B and enterohepatic cycling may 
occur to varying degrees in different animals. The presence of this phenomenon makes 
it extremely difficult to accurately determine pharmacokinetic variables for this drug. 
Mathematical modelling of the concentration versus time data obtained after intravenous 
administration of tolfenamic acid was best described by two exponents. This was 
found to be a reasonably accurate description of drug disposition, a correlation of 
greater than 0.95 was obtained between observed and estimated values for a 
biexponential curve in all animals. For comparative purposes, pharmacokinetic values 
calculated directly from observed data were also computed.
Mathematical modelling of the concentration versus time curves obtained after 
subcutaneous administration demonstrated that the data was best described by two 
exponents. Goodness of fit of mathematically derived model curves was generally 
poor. The correlation (r2) of observed to estimated drug concentrations was found to 
be lower than 0.90 for all but one animal (dog 6 ). As a result the kinetic information 
obtained from directly observed data is likely to be a more accurate indication of the 
disposition of the drug and therefore observed data was used to calculate kinetic 
parameters. Comparison of computed tV2B with half lifes estimated from observed 
MRT data indicated that all computed tV2b values were an overestimate, in some cases 
by more than 50%.
It is apparent that the mean AUC obtained after subcutaneous administration was 
considerably greater than after intravenous administration (29.62 vs 18.10 |ig/ml.h). 
Expression of these figures as bioavailability (F) indicates that in all but one animal 
(dog 5) the bioavailability was greater than 100 %. This result may be due to the errors 
in estimating values for AUCs, particularly for that section of the AUC from the time 
of injection to the first sample. Drug concentrations detected at the earlier sampling 
times do, however, indicate that tolfenamic acid may be well absorbed after 
subcutaneous administration.
Mean absorption times (MAT) were in good agreement (2.57 -3.82) hours for dogs 1, 
2 and 5. Dog 6  had a longer MAT of 8.14 hours and dog 4 had a negative MAT, 
indicating that the MRT was longer after intravenous than after subcutaneous
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administration. This is theoretically only possible if some of the drug administered 
during an intravenous infusion does not enter the vein and is deposited subcutaneously 
or intramuscularly. The occurence of a comparatively small degree of enterohepatic 
circulation of a drug can result in a large increase in the calculated AUMC. If 
enterohepatic circulation were more apparent after subcutaneous than after intravenous 
administration this may result in a small increase in AUC, however the increase in 
AUMC could outweigh this resulting in a value for the AUMC which is smaller after 
intravenous than after subcutaneous administration of the drug.
Comparison of bioavailability and MRT indicates that there is no advantage to be 
derived by intravenous administration.
The inhibition of serum TxB2 after intravenous administration was initially higher than 
after subcutaneous administration but was of shorter duration. Mean inhibition of TxB2 
0.5 hours after intravenous administration of tolfenamic acid was greater than 90 %. 
The pattern of inhibition versus time reflected the apparently erratic plasma drug 
concentrations with a lower mean inhibition measured at 2 hours (inhibition 23.36 % at 
drug concentration 0.41 ± 0 .20  |ig/ml tolfenamic acid) than at four hours (inhibition 
31.78 % at drug concentration 0.62± 0.30 pg./ml tolfenamic acid). At one hour the 
mean inhibition had decreased to 54.47 % although some individual animals had 
inhibition of greater than 50% at time points thereafter.The maximum inhibition of 
TxB2 after subcutaneous administration of tolfenamic acid (99.78 %) was detected in 
dog 3 at 0.25 hours, however the general level of inhibition during the period up to 
two hours was in the range 70 - 90 % and this was reflected in the mean values. The 
pattern of increasing and decreasing inhibition related to drug concentrations at these 
time points is apparent in samples from some animals (eg dog 1 at 24 and 48 hours, 
dogs 2 and 4 at 8 and 12 hours) but is not reflected in mean figures due to inter-animal 
variation.
Calculation of the area under the serum thromboxane inhibition versus time curve 
confirmed the wide inter-animal variation in inhibition achieved after drug 
administration. The mean AUC obtained was greater after subcutaneous 
administration, however this difference was not found to be statistically significant. 
Statistical examination was also carried out on the maximum inhibition produced by 
each route of administration and on inhibition measured at each time point The mean 
maximum inhibition was found to be 91.30 and 88.12 % after intravenous and 
subcutaneous administration respectively. There was no significant difference between 
these observations. Mean TxB2 inhibition was found to be significantly higher after 
subcutaneous administration at 2 and 8 hours post drug administration.
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A number of low platelet counts were seen at various time points during the 
intravenous and subcutaneous experiments and in three animals (dogs 2, 4, and 5) 
prior to intravenous administration of the drug. The pattern of these did not suggest 
that they were in any way associated with the administration of tolfenamic acid and 
were not a consistent feature of drug administration. It is therefore considered unlikely 
that reduced concentrations of TxB2 in serum were due to low platelet numbers.
The blood clotting times after administration of tolfenamic acid indicated that there was 
no apparent change in clotting times which could be associated with drug 
administration.
Whilst blood was occasionally detected in faecal samples collected throughout the 
course of each experiment this was never a consistent feature and appeared not to 
present likely complications associated with the administration of tolfenamic acid at this 
dose rate.
These results suggest that subcutaneous administration would be an appropriate route 
for the administration of tolfenamic acid. Intravenous administration appears to confer 
no advantage in terms of plasma concentration nor TxB2 inhibition and there is some 
evidence that TxB2 inhibition may be superior after subcutaneous administration. The 
difference in tl/28  measured for dogs in this study (5.9 hours), when compaired with 
that reported in man (2.5 hours) (Pentikainen et al. 1981), underlines the need for 
examination of individual drugs in each species. Greater inhibition of TxB2 was noted 
in this study than that reported in man (Pentikanen et al. 1981; Alanko et al. 1989), 
where tolfenamic acid has been shown to be a superior analgesic than phenylbutazone. 
The 12 hour persistence of this inhibition and the relatively short tl/2B, suggest that a 
twice daily oral dosage regimen may be appropriate to maintain good levels of TxB2 
inhibition in the dog. However, further studies are required to confirm the time taken to 
achieve steady state and confirm the safety of drug concentrations achieved.
It is of interest to note that Espinasse et al. (1992) found good inhibition of PGE2 
production, by lower dose rates of tolfenamic acid, in experimental models of 
inflammation. These workers administered tolfenamic acid intramuscularly at a dose 
rate of 2  mg/kg to cattle. Good inhibition of PGE2 in tissue cage exudates was 
measured at 24 hours (88 %) and inhibition was greater than 50 % at 48 hours. This 
indicates that as good or better levels of inhibition of PGs may be expected in the dog, 
and that 4 mg/kg would be an appropriate dose for further testing in clinical trials or 
inflammatory models. Recent studies in dogs using tissue cages as the inflammatory 
model confirm this observation (McKellar, Lees and Gettinby, personal 
communication).
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The comparatively large volume of distribution which was measured after the 
intravenous administration of tolfenamic acid to dogs is in contrast to that reported in 
humans (Vdss 0.16 litres/kg) by Pentikainen et al (1981). A small volume of 
distribution is generally indicative of extensive binding of drug to plasma proteins and 
is a common feature of NSAIDs, having been reported in several studies (Pentikainen, 
et al. 1981; Snow et al. 1981ab Rainsford, 1985). It is, however, of interest to 
consider the findings of Pentikainen et al and Snow et al as these workers also 
examined the extent of binding of drug to plasma protein. Tolfenamic acid was shown 
to be 99.7 % bound to human plasma protein and Snow e ta l found meclofenamic acid 
to be more than 99 % bound to plasma protein in the horse and to have a volume of 
distribution of 0.13 litres/kg. The fact that the volume of distribution in this study was 
almost ten times higher than these reported figures suggests that the plasma protein 
binding of tolfenamic acid in the dog is considerably lower than that in man, and 
indeed lower than normal for NSAIDs. A lower percentage of drug bound could result 
in a higher circulating concentration of unbound (potentially pharmacologically active) 
drug. If this were the case then it might be expected that high levels of inhibition of 
serum TxB2 would have been observed. In fact levels of inhibition generally did not 
exceed 90 % and it must therefore be assumed that the degree of inhibition of serum 
TxB2 is not dependant on unbound drug, or that in the case of tolfenamic acid the drug 
leaves the circulation and is bound within the tissues. The possibility exists that lower 
plasma protein binding of tolfenamic acid would result in a lower accumulation of this 
drug in inflammatory exudates, as suggested by Higgins et al (1986). However if 
tissue binding had occurred, then it is possible that physical or chemical changes 
resulting from tissue damage or the inflammatory process could free drug which had 
been bound, and result in increased localised concentrations of free drug. One possible 
factor which may be involved in such a process is the action of tissue destructive free 
radicals.
Further studies to examine the concentrations of drug, degree of protein binding and 
level of serum TxB2 and tissuePGE2 inhibition in experimental models of 
inflammations are required to provide a greater insight into the action of tolfenamic acid 
in the dog.
6.7 TABLES AND FIGURES
Time Route of A dm inistration
(h) In travenous Subcu taneo i
P re 0 0
0 .0 8 25.41 ± 4.50 NS
0 .1 7 18.18 ± 3.28 NS
0 .2 5 NS 1.11 ±0.35
0 .3 3 9.92 ± 1.78 NS
0 .5 0 4.98 ± 1.32 2.16 ±0 .32
0 .7 5 3.47 ± 0.66 NS
1 . 0 0 1.61 ±0.31 4.04 ± 0.50
2 . 0 0 0.41 ± 0.20 4.05 ± 0.65
4 .0 0 0.62 ± 0.30 1.60 ±0.38
8 . 0 0 0.50 ±0.14 0.72 ± 0.20
1 2 . 0 0 0.28 ± 0.06 1.17 ± 0.28
2 4 .0 0 0.07 ± 0.03 0.11 ±0.07
4 8 .0 0 0.04 ± 0.02 0.03 ± 0.02
7 2 .0 0 0.01 ± 0.01 0
9 6 .0 0 0.02  ± 0.01 0 .02  ± 0 .02
168 .00 0 0
NS = No sample
Table 6.1 Mean (±SEM) concentration (|!g/ml) of tolfenamic acid in
plasma of dogs after administration at a dose rate of 4.0 mg/kg 
by the intravenous and oral routes.
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Tim e Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 0 0 0 0 0 0 0 -
0 .5 0 85.50 95.25 94.60 84.63 91.25 96.56 91.30 ± 2.10
1 . 0 0 12.83 76.27 73.37 66.67 26.17 71.53 54.47 ± 11.26
2 . 0 0 0 46.40 0 31.07 35.36 27.36 23.36 + 7.83
4 .0 0 7.62 50.25 70.73 55.83 0 6.28 31.78 ± 12.49
8 . 0 0 8.03 47.74 37.92 42.40 0 20.52 26.10 ± 7.98
1 2 . 0 0 20.70 50.25 50.41 13.11 7.80 16.26 26.42 ± 7.75
2 4 .0 0 0 48.35 21.14 22.33 15.25 14.45 20.25 ± 6.49
4 8 .0 0 34.69 24.62 17.00 0 29.38 18.14 20.63 ± 4.95
7 2 .0 0 0 17.42 0 0 36.05 26.73 13.37 ± 6.44
9 6 .0 0 12.42 14.52 15.08 0 39.78 45.57 21.21 ± 7.16
1 6 8 .0 0 0 0 0 0 0 17.66 2.94 ± 2.94
Table 6.3 Inhibition (%) of thromboxane B2 in serum of dogs after administration 
of tolfenamic acid at a dose rate of 4.0 mg/kg by the intravenous route.
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Tim e
(h) 1 2 3
Animal
4
Number
5 6 M ean ± SEM
Pre 0 0 0 0 0 0 0 -
0 .2 5 74.12 68.61 99.78 91.11 62.68 32.30 71.43 ± 9.68
0 .5 0 87.30 82.79 90.29 87.92 66.40 54.58 78.21 ± 4.98
1 . 0 0 89.35 81.15 84.39 85.37 77.51 57.23 79.17 ± 4.68
2 . 0 0 83.33 75.31 78.49 79.42 82.90 82.79 80.37 ± 1.30
4 .0 0 71.04 39.85 63.22 50.97 52.17 56.48 55.62 ± 4.39
8 . 0 0 60.41 42.46 45.88 78.74 21 .02 51.07 49.93 ± 7.85
1 2 . 0 0 59.33 48.49 50.73 79.31 0 28.27 44.35 + 11.15
24 .00 20.83 9.21 30.60 45.30 8.43 14.80 21.53 ± 5.82
48 .0 0 35.81 21.92 0 21.67 29.14 16.52 20.84 ± 4.99
7 2 .0 0 29.17 0 0 21.67 29.14 16.52 16.08 ± 5.45
9 6 .00 49.51 0 0 8.83 0 14.45 12.13 ± 7.86
168 .00 21.13 15.00 0 2.45 24.86 8.87 12.05 ± 4.09
Table 6.5 Inhibition (%) of thromboxane B2 in serum of dogs after administration of 
tolfenamic acid at a dose rate of 4.0 mg/kg by the oral route.
FLOW
A. Blank dog plasma fortified with 1.0 |ig/ml drug.
B. Plasma sample estimated to contain 0.96 Jig/ml of drug.
C. Standard solution containing 5 }ig/ml of drug.
Figure 6.1 Typical chromatogram of tolfenamic acid in dog plasma.
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Chapter 7
PROTEIN BINDING OF FLUNIXIN M EGLUM INE AND 
MECLOFENAMIC ACID
161
7.1. IN TR O D U C TIO N
Serum albumin is the most abundant protein in plasma (Doolitde, 1979) and performs 
several important physiological roles. It is responsible for the maintenance of the 
osmotic pressure of blood, the transport of fatty acids and the sequestration and 
transport of bilirubin. It is a simple protein, comprised of a single polypeptide chain 
containing 585 amino acids and has a molecular weight of 66500 (Behrens et al. 1975: 
Meloun et al. 1975). Albumin is unique amongst the major plasma proteins in having 
no carbohydrate component (Peters, 1975). The albumin molecule is hydrophilic and is 
highly soluble in aqueous media, this results from the presence of more than 200 
positive and negative charges which are distributed over its surface (Peters, 1975). 
Serum albumin has been shown to have a repeating loop structure which is comprised 
of two large and one small loop in each of three separate areas, these are formed by the 
presence of disulphide bonds (Brown and Shockley, 1982).
The liver is the primary site of albumin production (Miller et al. 1951). Here, synthesis 
occurs on ribosomes attached to endoplasmic reticulum. Albumin is secreted from 
ribosomes to the rough endoplasmic membrane and subsequently through the smooth 
endoplasmic reticulum to the golgi complex, after which it passes through the cell 
membrane (Peters et al. 1971; Redman and Cherian, 1972; Jamieson and Ashton, 
1973). The average time for this process is about 30 minutes.
The normal half life of circulating albumin is about 19 days in man (Schultze and 
Heremans, 1966; Peters, 1970) and the horse (Kaneko, 1989) and approximately 8 
days in the dog (Kaneko, 1989) and it appears to be directly correlated to body size. 
About 10 % of plasma albumin is generally lost in the gut (Jeffries et al. 1962). A 
small proportion is not reabsorbed after glomerular filtration and is lost in urine. It is 
thought that the balance of catabolism results from the small, but continual, uptake into 
cells by pinocytosis of microscopic droplets of circulating plasma (Cushman, 1970).
In man only 40% of albumin is in the circulation at any given time. Five percent of 
circulating albumin passes from the blood into interstitial fluid each hour, and returns 
during the subsequent 24-28 hours via the thoracic duct (Peters, 1975). There is 
albumin present in almost eveiy body fluid and in most body secretions (Schultze and 
Heremans, 1966).
Serum albumin plays an important role in the binding of drugs within the body. It is 
the serum protein primarily involved in the binding of drugs, although many basic 
drugs are known to bind to acid glycoproteins and lipoproteins (Riviere, 1988). Drug 
protein binding (in blood and tissue proteins) is an important factor for regulation of 
drug distribution within the body, and it has been widely accepted that only unbound
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drug is able to exert any pharmacological action. Monitoring of drug concentration in 
plasma has become standard practice and for most drugs clinical response is more 
closely correlated with plasma drug concentrations than with dose administered 
(Booker and Darcy, 1973; Borga, 1980; Levy, 1980; Kilpatrick et al. 1984). The 
monitoring of plasma concentrations is of particular importance for drugs with narrow 
therapeutic indices, drugs with concentration dependant kinetics, or in patients for 
whom the risk of toxicity is abnormally high (eg with impaired renal function). Most 
analytical procedures used for therapeutic monitoring measure total drug concentration 
in plasma or serum and, unless information on the binding of drug is available, these 
results may be misleading.
In general, drugs are reversibly bound to proteins and this may involve a combination 
of a variety of bonds including van der Waals and electrostatic forces (Perrin, 1985). 
Initial studies on human serum albumin suggested that the conformational flexibility of 
the molecule results in the existence of a number of relatively non-selective sites and 
this was proposed as an explanation for its ability to bind a wide variety of substances 
with different chemical structures (Nilsen, 1976; Muller and Wollert, 1979). Although 
the situation has not yet been fully elucidated, it is now clear that a relatively small 
number of specific binding sites exist on the molecule (Sudlow et al. 1976; Fehske et 
al, 1981). A number of these sites have been localised, and two of the most important 
sites have been named I and II. Sudlow et al (1976) were able to characterise these 
sites according to the properties of the drugs which they generally bind. Site I binds 
hydrophilic drugs, generally aromatic acids which are ionised at physiological pH. Site 
II attracts more hydrophobic compounds, these are also generally aromatic acids but 
tend to be larger heterocyclic molecules. Table 7.1 shows some drugs which have been 
shown to bind to sites I and II.
NSAIDs have been shown to be extensively bound to plasma protein (Glazko et al. 
1978; Brune and Lanz, 1985) and this has resulted in considerable interest in the 
binding of this group of drugs. Table 7.2 shows the extent of protein binding in man 
for some common NSAIDs.
Although plasma binding of drugs may differ considerably between species (Sturman 
and Smith, 1967; Borga et al. 1968 ), intra-species protein binding is thought to vary 
little in healthy individuals, and in man it is rare to see a variability in free drug 
concentration of greater than two fold (Routledge, 1985). There are, however, some 
circumstances under which the free fraction of drug in blood is known to vary. 
Physical factors including temperature and pH are important (Chignell, 1977), 
although there is limited variation in these parameters in vivo. The variability of the
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concentration of free drug is also related to changes in albumin concentration, and the 
effect of this will be most profound in cases where protein binding is high (Routledge,
1985). In cases of chronic renal failure the extent of protein binding has been found to 
be lower than that predicted from the albumin concentration of the patient (Boobis, 
1977), and protein binding of salicylates was found to be significantly decreased in 
children with Kawasaki disease (a disease of unknown origin, most common in 
children, characterised by high fever, conjunctivitis, skin rash and swelling of glands) 
compared with normal controls (Koren et aL 1991). It has been suggested that this may 
be due to structural changes in the protein which reduce its ability to bind ligands, or to 
the production of unidentified endogenous inhibitors of drug binding (Sjoholm et al. 
1976; Boobis, 1977).
A further factor which affects the binding of drugs to albumin is the presence of other 
drugs. It is known that drugs are able to compete for binding sites on albumin, and 
some of the most active displacing substances are acidic compounds such as NSAIDs 
(Sellers and Koch-Weser, 1971). There are some circumstances under which these 
displacement reactions are of great importance. When a drug with high protein affinity 
is given as a bolus injection displacement may be almost instantaneous, and the 
concentration of free displaced drug may be significantly increased. Under normal 
conditions the rates of displacement and re-equilibration of a drug within the body 
preclude excessive elevations of free (pharmacologically active) concentrations of drug 
in plasma. However, if the re-distribution of free drug is delayed or does not occur 
uniformly, or if the safe therapeutic range is narrow this may result in toxic effects. 
Also, since plasma drug monitoring generally assumes that the ratio of free and bound 
drug remains constant, it is possible for total plasma concentrations to be 
misinterpreted if the overall concentration of drug in plasma has decreased, due to a 
reduction in only the bound component (D'Arcy and McElnay, 1985).
In addition to displacement interactions it is also thought that the presence of one drug 
may alter the ability of protein to bind another drug. Acetylsalicylic acid has been 
shown to acetylate serum albumin and it is thought that this results in the modification 
of the binding sites (Erill and Calvo, 1985). Binding of acetrizoate was enhanced after 
treatment with acetylsalicylic acid (Farr et al. 1966; Hawkins et al. 1968), however the 
binding decreased when treatment was replaced by sodium salicylate (Hench and Farr, 
1967). Other binding changes which have been shown to occur after treatment with 
acetylsalicylic acid include increased binding of phenylbutazone and decreased binding 
of flufenamic acid (Chignell and Starkweather, 1971). For some chiral drugs the 
enantiomers exhibit different protein binding. Binding of the R(-) enantiomer of 
ibuprofen and flurbiprofen is lower than that of the S(+) enantiomer, and binding was
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found to be influenced by the presence of the optical antipode (Evans et al. 1989; 
Knadler et al. 1989).
Although albumin is the most abundant of the serum proteins, blood plasma contains 
numerous other proteins, and many of these proteins also bind drugs. Globulins are 
known to bind sex hormones and may also have a binding capacity for 
pharmacological agents (Routledge, 1985). Another important group of blood proteins 
are the lipoproteins. These are macromolecular complexes which transport plasma 
lipids in the circulation and are generally grouped, according to density, into four main 
classes named chylomicrons. A wide variety of hydrophobic drug groups have been 
shown to bind to lipoproteins, including non-ionisable neutral compounds (eg 
Probucol) (Urien, et al. 1984), acidic mucopolysaccharides (eg heparin) (Mahley etal. 
1979), acidic drugs (eg diclofenac) (Chamouard et al. 1985), steroids (Counsell, and 
Pohland, 1982), basic compounds (eg tetracycline) (Powis, 1974) and peptides (eg 
cyclosporin A) (Lemaire and Tillement, 1982). A large variety of drugs including 
acepromazine, propranolol and warfarin, are also known to bind to alphai-acid 
glycoprotein. Current evidence suggests that these, and other drugs, compete for a 
single binding site on this plasma protein (Muller, et al. 1985)
Approximately 45% of the volume of circulating blood is composed of blood cells and 
of this 95% comprises erythrocytes. The remaining 5% contains blood leucocytes and 
thrombocytes and this small proportion is generally ignored when binding to blood 
cells is measured. The terms erythrocyte and blood cells are therefore used 
synonymously in this area of research. The size of an erythrocyte is many hundreds of 
times larger than an albumin molecule and the major protein constituent of erythrocytes 
(haemoglobin) is approximately 8 times more abundant in blood than albumin on a 
molar basis, although the molecular weight of 64500 is similar to that of albumin. 
Phenothiazines and pentobarbital are amongst the drugs known to bind to haemoglobin 
(Wind et al. 1973; Ehmebo, 1980).There is some evidence to suggest that binding is 
linearly related to the concentration of drug, and that there is competition between 
plasma proteins and blood cells for the binding of free drug available in whole blood 
(Ehmebo, 1985). The equilibration rate of drug and blood cells is highly variable and 5 
minutes and 90 minutes have been reported in vitro for diphenylhydantoin and 
chlorthalidone (a more hydrophobic drug), respectively (Beermann et al. 1975; 
Ehmebo and Odar-Cederlof, 1977). It has also been demonstrated that drug binding 
may be reversible and competitive with other drugs (Ehmebo and Odar-Cederlof, 
1977).
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Drug binding is also known to occur in tissues (D'Arcy and McElnay 1982; McElnay 
and D'Arcy, 1983). It was thought that tissue binding was principally the result of 
drug binding to the extravascular fraction of albumin (Jusko and Gretch, 1976). 
However, more recently drugs have been shown to bind to a variety of structures in 
tissues (Kurz and Fichtl, 1983).
Fichtl and Schuhmann (1985) studied the relationship between tissue and plasma 
binding of 44 drugs in the rabbit and rat. These workers reported a poor intra-species 
correlation in binding between plasma and tissue for a given drug. However, they 
found good correlation in binding to different tissue types, and this correlation was 
found to extend to a number of unrelated drugs. It was also found that there was a 
close correlation for binding of drugs to muscle of rat, rabbit and man and it has been 
suggested that tissue binding may be governed by similar mechanisms in different 
species. In this respect tissue binding in one species may serve as a model for others. 
Examination of published data for 29 drugs in different species led Fichtl and 
Schuhmann (1985) to conclude that inter-species differences in the distribution volume 
of drugs principally result from inter-species differences in binding of drugs in plasma 
and not to binding in tissue.
Binding has a marked effect on the distribution, metabolism and excretion of drugs 
(Routledge, 1985). Protein binding plays a major role in glomerular filtration and may 
be of some importance in tubular secretion (Balat, 1985). Only free drug is filtered into 
the Bowman's capsule and tubular secretion may depend on the rate of dissociation of 
bound drug. Studies on the plasma protein binding of propranolol in man, dog, rat and 
monkey have shown the volume of distribution to be inversely related to plasma 
protein binding (Evans et al. 1973).
Drug retention in plasma is regulated by a number of factors which include the ability 
to pass through vascular membranes, and lipid solubility. In addition, drug is retained 
in plasma when the capacity of plasma to bind the drug is greater than that of the 
tissues. The resultant trapping of drug in plasma and restricted diffusion into tissues is 
seen as high concentrations of drug in blood and a low volume of distribution. This 
predominantly occurs for acidic drugs which are highly ionised at the physiological pH 
of plasma. Tissue retention of drug occurs when the binding capacity in plasma is low 
relative to that in the tissues. In this situation, which is most common for basic drugs, 
the plasma concentration is often lower than that in tissues and the volume of 
distribution of the drug is large (Houin, 1985).
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Current interpretation of drug behaviour in the body is largely based on the widely held 
belief that only the unbound fraction of a drug can reach its target site and be 
pharmacologically active. However it has been suggested that the major biologically 
active fraction of a drug is that bound to protein, and that drug bound to protein is 
available for transport to tissues (Pardridge, 1985). Some drugs have been shown to 
leave the blood stream many times faster than the plasma proteins (Dewey, 1959; 
Pardridge et al. 1985), indicating that transport of protein bound drugs into tissues 
involves enhanced dissociation of drug from plasma protein. One possible explanation 
for this is that the enhanced dissociation from plasma protein may be the result of 
interaction with, as yet, unidentified endogenous substances within the 
microcirculation (Pardridge and Landaw, 1984).
7.2 EXPERIM ENTAL OBJECTIVES
The objectives of this work were - to examine the protein binding of two common 
NSAIDs, flunixin and meclofenamic acid, in the serum of dogs, goats and horses.
7.3 MATERIALS AND METHODS
7.3.1 DIALYSIS EXPERIMENTS WITH MECLOFENAMIC ACID AND 
FLUNIXIN
7.3.1.1 ANIMALS
All animals used throughout the experiment were housed indoors. Animals 
used in the study appeared to be clinically normal and had no recent history of 
any clinical abnormality.
7.3.1.2 SERUM COLLECTION
One hundred millilitres of blood were collected into unheparinised glass 
Vacutainers (Becton Dickinson Ltd) from each of three dogs, goats and horses. 
The blood was allowed to clot for 24 hours at room temperature and the clot 
gently eased from the side of the tube by means of a glass rod prior to removal. 
The serum fraction was separated from the resultant liquor by centrifugation at 
4°C and 3000g for 15 minutes. Serum from each animal was pooled to give 
one sample for each species and this was stored frozen in glass universal 
bottles at -20 °C until use. Prior to use the serum was defrosted overnight and 
allowed to equilibrate to room temperature.
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7.3.1.3 DRUG PREPARATION
On the day of use a 300 ng/ml solution of each drug (flunixin meglumine and 
meclofenamic acid) was prepared using 0.85 % aqueous sodium chloride as 
solvent. The solution was sonicated in an ultrasonic bath for 5 minutes to 
ensure complete dissolution and was then stored at room temperature until use.
7.3.1.4 FORTIFICATION OF SERUM WITH DRUG
Thirty millilitres of serum of a single species were placed in a glass beaker and 
stirred constandy at a slow speed with a magnetic stirrer. To this was added, 
dropwise over a period of one minute, 0.5 ml of the appropriate 300 (ig/ml 
drug solution, to produce a final concentration of 5 |ig/ml of drug in serum. 
The serum was then left to mix at room temperature for 30 minutes.
7.3.1.5 PREPARATION OF DIALYSIS TUBING
Seamless cellulose visking tubing (25 mm diameter) which was permeable to 
water and had a molecular cut off in the range 12,000 - 14,000 (BDH Ltd) was 
cut into a number of 12 inch lengths and pre-wetted in distilled water. To 
ensure removal of impurities the lengths were boiled twice for 1 minute in a 
solution containing 5 mM EDTA and 200 mM sodium bicarbonate (prepared 
using distilled water). The tubing was thoroughly rinsed with distilled water 
after each boiling. The lengths of visking tubing were prepared on the day prior 
to use and stored at 4 °C overnight, in a covered beaker containing distilled 
water. On the day of use the tubing was transferred to a beaker containing fresh 
distilled water and allowed to equilibrate to room temperature prior to use.
7.3.1.6 DIALYSIS
Fifteen millilitres of fortified serum were transferred into dialysis tubing which 
had been prepared as described above. After securing, this was placed in a 
large dialysis tank containing 25 litres of 0.85 % sodium chloride. The tank 
was maintained undisturbed at room temperature (18 °C) for 18 hours.
The balance of the fortified serum was transferred to a universal bottle and 
stored at -20 °C until drug analysis was performed.
After dialysing for 18 hours the equilibrated serum was removed from the 
dialysis tubing and transferred to a universal bottle for storage in a similar 
manner to the undialysed aliquot.
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Preparation and dialysis for flunixin was carried out for all three species on a 
single occasion. A similar procedure was performed for meclofenamic acid on a 
separate occasion.
7.3.2 ANALYTICAL METHODS
7.3.2.1 ANALYSIS OF FLUNIXIN
Analysis of flunixin was carried out by H.P.L.C. using spectrophotometric 
detection according to the method described for experiments with flunixin in 
chapter 3.
The concentration of flunixin in each sample was determined by reference to 
aliquot of the sample of serum which had been fortified with drug prior to 
dialysis. These samples were processed in an identical manner to that described 
for the dialysed samples. In addition, standard solutions of flunixin were 
injected directly onto the H.P.L.C.. These standard solutions allowed 
equipment performance to be monitored. Before and after injection of each 
sample an injection was made of standard drug solution of known 
concentration. The concentration (20 pg/ml) was chosen to produce a peak 
height on the final trace which was similar to that expected from the samples. 
For each sample the quantity of drug detected was expressed as a ratio of peak 
height of sample : peak height of standard. The ratios calculated for dialysed 
and undialysed samples were compared and the difference expressed as a 
percentage. This allowed the calculation of the degree of protein binding.
No calculation of actual percentage extraction of drug from serum was made 
nor were extraction losses assessed as these were assumed to be constant 
between the analysis of dialysed serum samples and the samples of undialysed 
fortified bulk serum to which they were compared.
7.3.2.2 ANALYSIS OF MECLOFENAMIC ACID
Analysis of meclofenamic acid was carried out by high performance liquid 
chromatography (H.P.L.C.) using spectrophotometric detection.
1 3 2 3  REAGENTS
1. Meclofenamic acid, sodium salt (Sigma Chemical Co.)
2. Chloroform, H.P.L.C. grade (Rathbum Chemicals Ltd)
3. Methanol 'Analar' (B.D.H. Ltd), redistilled prior to use
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4. Disodium hydrogen orthophosphate 'Analar' (B.D.H. Ltd)
5. Citric acid 'Analar* (B.D.H. Ltd)
6 . Citrate/phosphate buffer pH 3.0 was produced by mixing the following 
solutions :-
20.5 ml M/5 Na2HPC>4 + M/10 citric acid
7. Water, redistilled in the presence of potassium permanganate prior to use.
8 . Perchloric acid, 70 % 'Analar* (B.D.H. Ltd)
9. H.P.L.C. mobile phase comprising 80 : 20, methanol: water containing 50 
pi of 1 in 55 aqueous solution of perchloric acid per 100 ml mobile phase.
7.3.2.4 H.P.L.C. EQUIPMENT 
Pump:- Gilson 301
Detector:- Spectraphysics 100
Column:- 100mm X 8mm containing 5p O.D.S. Hypersil
(Shandon Southern)
Wavelength:- 287nm
Absorbance:- 0.05 AUFS
Flow Rate:- 1.5 ml/min.
The retention time of meclofenamic acid under these conditions was 5 minutes.
7.3.2.4 SAMPLE PREPARATION
A 1 ml aliquot of each serum sample was placed in a 50 ml ground glass tube. 
To this was added 0.3 ml of citrate/phosphate buffer (pH 3.0), followed by 6 
ml chloroform. The tube was stoppered and the mixture shaken for 10 minutes 
by inversion on a slow rotary mixer. Four millilitres of the chloroform were 
recovered and placed in a 10 ml conical glass tube. These tubes were placed in 
a Dri-Block (Techne Ltd) at 50 °C under a stream of air and allowed to 
evaporate to dryness. A final 1 ml of chloroform was run down the walls of the 
conical tube to ensure that all residue present was in the base of the tube. The
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tube was returned to the Dri-Block and allowed to evaporate to dryness. 
Samples were covered with clingfilm and stored overnight at 4 °C if necessary. 
Prior to injection onto the H.P.L.C. system the residues were reconstituted in 
methanol. An appropriate volume (not less than 150 |il) of methanol was 
added to the bottom of the conical tube which was then tilted and rotated in an 
ultrasonic bath for 1 minute. A 20 fil injection loop was used for injection, the 
loop was loaded with 15 |il of sample.
The procedure for comparison of dialysed and undialysed samples, and the 
calculation of percentage binding was as described for flunixin. A typical 
chromatogram is shown in figure 7.1.
7.4 RESULTS OF DIALYSIS EXPERIM ENTS W ITH FLUNIXIN AND 
MECLOFENAMIC ACID
The ratio of peak height of drug in sample : peak height of drug in standard for each 
species are shown in appendix 11.1 for flunixin and 11.2 for meclofenamic acid. The 
percentage binding for each drug in each species is shown in table 7.3.
As can be seen from the standard error (appendix 11.1 and 11.2) the inter sample 
variation within each species was small. Serum protein binding of flunixin was 92.0, 
87.0 and 86.6 % in dog, goat and horse, respectively. The inter-species variation in 
binding was not large. Protein binding of meclofenamic acid in serum showed larger 
inter-species variation.The extent of binding was 93.8, 84.2 and 100.0 % for dog, 
goat and horse respectively.
7.5 DISCUSSION
The binding study was restricted to only two drugs because of the insolubility of other 
NSAIDs in suitable aqueous solvents and the unsuitability of non aqueous solvents for 
use in protein binding studies. Drugs which were considered for use, and which had 
limited solubility in saline were piroxicam, tolfenamic acid, carprofen, and 
phenylbutazone. Each of these appeared to dissolve in saline to produce a concentration 
of 1 |ig/ml. However, analytical methods sensitive enough to accurately determine the 
degree of dissolution at this concentration were not available. Also, the addition of a 
drug solution of this concentration to serum would have resulted in a final 
concentration below the limit of analytical detection and outwith the in vivo circulating 
concentrations generally targeted for these drugs.
The concentration of drug used to fortify serum in this study was targeted to be within 
the range of blood concentrations achieved during normal clinical use. As a result of
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the high degree of binding normally reported for NSAIDs (Brune and Lanz, 1985), 
coupled with the comparatively low concentration of drug studied, it was anticipated 
that the total concentration of unbound drug in serum would be small. The reliable limit 
of detection of available methods for the quantification of drug did not permit the 
measurement of unbound drug, consequently estimation of the extent of binding was 
based on the concentration of bound drug detected following dialysis.
Estimation of the concentration of unbound drug would have been possible by 
increasing the total concentration of drug used to fortify the serum by a factor of 5 or 
10. It would then have been possible to employ a system of ultrafiltration using 
centrifugation to collect the unbound fraction. The concentration of drug in this fraction 
could then have been determined by the analytical methods employed in this study to 
quantify the bound fraction. Such an increase in the concentration of drug with which 
the serum was fortified would only have been justified if additional studies had been 
carried out to establish that the binding of drug to serum protein was linear throughout 
the concentration range in each species. Such studies were not performed for the drugs 
studied as they were examined at a single concentration targeted to be within the normal 
therapeutic range.
The results of this study are in agreement with the general findings that most NSAIDs 
are highly protein bound (Brune and Lanz, 1985). Binding estimations have generally 
been carried out in human serum or plasma. In this study, the binding of flunixin to 
serum proteins was very similar between horse and goat (8 6 .6  and 87.0 % 
respectively), however a higher degree of binding was measured for flunixin in the dog 
(92 %). In all cases the extent of binding was lower than that reported for mares by 
Soma et al (1988). Using a micropartition centrifugation method, these workers 
determined the binding of flunixin to serum proteins to be greater than 99 % in samples 
which contained known concentrations of flunixin, and also in serum which had been 
fortified with flunixin.
Blood protein binding of meclofenamic acid has been reported to be 99.8 % in man 
(Glazko et al. 1978). A similar degree of binding (>99 %) was reported in horses 
(Snow et al. 1981b), however this figure was determined from samples containing a 
high total drug concentration. These figures are similar to the results obtained for horse 
serum in this study, where binding was determined to be 100 %. The extent of binding 
for meclofenamic acid in serum from dogs was determined as 93.8 %, the variation in 
these figures, coupled with the considerably lower estimate of binding in the goat (84.2 
%) indicates that blood protein binding of this drug may vary considerably between 
species. The present results confirm the findings of Sturman and Smith (1967) and
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Borga et al (1968) and indicate that significant variations in binding of some NSAIDs 
may occur between species. It is interesting to note that in this study the variation does 
not appear to show any correlation with respect to species and drug. For flunixin the 
binding is similar between horse and goat, whereas for meclofenamic acid binding is 
similar between horse and dog. It would appear, therefore, that it is necessary to 
establish the degree of blood protein binding separately for each drug and each species.
Fichtl and Schuhman (1985) were unable to demonstrate a correlation between plasma 
and tissue binding of drug. In a study relating to 29 drugs these workers concluded 
that there was a close correlation between tissue binding in different species and 
accordingly hypothesised that the inter-species difference in distribution volume of 
these drugs was due to species differences in drug binding in plasma. If this proves to 
be generally correct it may be possible to estimate plasma protein binding in a target 
species from a knowledge of the plasma and tissue binding in any species together with 
a knowledge of the volume of distribution of the drug in the target species. In addition, 
as the concentration of NSAID at target tissues may be more important than the 
concentration in blood, it may be possible to determine the concentration of a drug in 
the tissues of all species by investigation of a single model species.
Examination of figures, from the present study, for protein binding show maximum 
inter species differences of 5 % and 16 % respectively for flunixin and meclofenamic 
acid. However if we consider that the ’active* portion of any drug dose is generally 
thought to be the unbound drug then these differences are seen to be more extreme. 
Table 7.4 shows the concentration of unbound drug which would exist in each species 
when the total blood concentration of drug is 5 flg/ml. From these figures it is apparent 
that, in percentage terms, these differences are large. For example there would be 162 
% more unbound flunixin and 255 % more meclofenamic acid circulating in the blood 
of goats than dogs. These very large differences may go some way towards explaining 
the many anomalies which are seen in NSAID use. It is interesting that estimations in 
these experiments indicated that all meclofenamic acid in the serum of horse is bound to 
protein. This may simply reflect inaccuracies in the technique. It is apparent, however, 
that the percentage of this drug which exists in the unbound state in the horse will be 
very low. As this is undoubtedly an efficacious drug, this raises questions as to its 
ability to be active in the bound state or at extremely low concentrations of free drug.
It may be that some anti-inflammatory and analgesic therapies are characterised by 
accumulation (or decreased rate of removal) of drug at the site of action (Higgins et al.
1986). In inflammatory exudates, where the protein concentration is initially relatively 
low, this accumulation may be partly founded on free drug available, and large inter­
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species variations in binding could result in significantly different degrees of efficacy. 
Higgins et al (1986) have shown that in experimentally produced equine inflammation 
the concentration of albumin in inflammatory exudate increases during the course of the 
inflammatory process. Dissociation of bound drug at the site of inflammation as a 
result of equilibration would continue to ensure that the concentration of unbound drug 
remains higher in species with a lower binding ratio.
Pardridge (1985) has suggested that there may be some process by which protein 
bound drugs undergo enhanced dissociation, thereby enabling free access to tissues. 
This possibility does of course require that the accepted theory of access of many drugs 
to their target sites be re-evaluated. The existence of such a mechanism may explain the 
ability of meclofenamic acid to act as an effective NSAID in horses, when it is 
apparently totally bound to serum protein. It is interesting to note that the concentration 
of flunixin in experimentally produced inflammatory exudate decreases more slowly 
than in plasma during the period 3 to 12 hours after drug administration (Higgins et 
aj.,1986). However, during this time it was also noted that the total protein 
concentration in exudate was increasing and it is therefore not clear if the maintained 
drug concentrations result from this protein accumulation or some other mechanism.
Studies on the extent, nature and relevance of protein binding of drugs require to be 
continued until the significance and the interaction of the many unexplained factors 
have been clarified. These studies are of particular importance for NSAIDs which are 
highly bound to blood protein and are widely used in both veterinary and human 
medicine.
7.6 TABLES AND FIGURES
Site I Site II
Warfarin Flufenamic acid
Phenylbutazone Ibuprofen
Oxyphenbutazone Naproxen
(Data from Sudlow et al. 1976 & Birkett and Wanwimolruk, 1985 )
Table 7.1 Some drug ligands known to bind at sites I and II on the 
serum albumin molecule.
Drug Protein Binding (%)
Acetylsalicylic Acid >70
Carprofen 99.9
Ibuprofen 99
Ketoprofen 99
Indomethacin 99
Piroxicam 99
Meclofenamic Acid 99.8
(Data from Brune and Lanz, 1985 and Glazko et al. 1978)
Table 7.2 The extent of plasma protein binding in man for some 
common NSAIDs.
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Species
Drug Dog G oat H orse
F lunixin 92.0 87.0 86 .6
Meclofenamic Acid 93.8 84.2 100
Table 7.3 Binding (%) of flunixin and meclofenamic acid to serum protein of 
three animal species.
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S pecies
D rug Dog G oat H orse
Flunixin 0.40 (0.81) 0.65 (1.32) 0.67 (1.36)
Meclofenamic Acid 0.31 (0.97) 0.79 (2.47) 0
Table 7.4 Concentration (|ig/ml) of unbound flunixin and meclofenamic acid
in blood of dogs, goats and horses when the total blood concentration 
of drug is 5 |ig/ml. Figures in parenthesis show micromolar 
concentrations (jiM ).
A  B  . C  j >
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F L O W
A. Standard solution containing 20pg/ml of drug
B. Blank dog serum which has been fortified with 5}ig/ml drug
C. Blank dog sserum which has been dialysed after fortification 
with 5fig/ml drug
D. Standard solution containing 20pg/ml drug
Figure 7.1 Typical chromatogram of meclofenamic acid in dog plasma.
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STUDIES ON THE INHIBITION OF IN VITRO PRODUCTION O F SERUM 
THROMBOXANE BY NON-STEROIDAL ANTI-INFLAMMATORY
D R U G S.
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8.1 INTRODUCTION
Chemical or mechanical injury to the body tissues results in the release of eicosanoids. 
These are not stored in the body, but are produced de novo on the occasion of each 
stimulation (Piper and Vane, 1971). The formation of these important mediators of the 
inflammatory process, which include PCs, Txs, PGI2 and LTs, is a result of the activity of 
cyclooxygenase or lipoxygenase enzymes which cause oxygenation of arachidonic acid 
(Samuelsson et al. 1978; Samuelsson et al. 1980). Within the cyclooxygenase pathway 
dioxygenase enzyme acts initially on arachidonic acid to produce PGG2, from which PGH2 
and prostaglandins A, B, C, D, E, and F are formed (Ramwell et al. 1980), PGI2 and the 
thromboxanes are formed from PGH2. Thromboxanes are not true prostaglandins as they 
do not have the cyclopentane ring typical of the group. However, they are the only 
members of the so called endoperoxides formed by the cyclooxygenase pathway which are 
known to have biological activity (Ramwell et al. 1980).
Some of the general properties of eicosanoids have been discussed earlier and little doubt 
remains that they exhibit a range of activities which are significant in the inflammatory 
process. The discovery of the pro-inflammatory role of eicosanoids resulted in the search 
for compounds which could inhibit their action. Early work by Ferreira et al (1971) and 
Vane (1971) identified this to be the mechanism of action of aspirin. Later studies also 
suggested that this inhibitory process was the basis of many of the undesirable side-effects 
which result from the usage of anti-inflammatory drugs (Vane, 1976).
A variety of techniques have been developed to test and compare existing and novel 
NS AIDs. Some of these techniques are based on the ability of the drug to provide analgesia 
under experimental conditions, for example in phenylquinone-induced writhing in mice 
(Roszkowski et al. 1971). Others require the production of experimental inflammation in 
which the response to the introduction of a pro-inflammatory substance, such as 
carrageenan, is studied. Such tests are often performed in small laboratory animals, for 
example carrageenan is used in the production of rat paw oedema (Vinegar et al. 1969). 
Carrageenan may also be used to produce skin blisters, or in conjunction with implanted 
tissue cages for the collection of inflammatory exudate in some domestic animal species 
(Higgins e ta l. 1984a). In addition, NSAIDs have been studied in clinical trials where their 
true clinical efficacy could be assessed. In each of these cases there are ethical and practical 
difficulties. The use of animals for experimental purposes has become increasingly 
unacceptable to society and this is particularly true where there is a requirement to inflict
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discomfort or pain. Although tests such as the production of oedema can be carried out in 
small animals, the implantation of devices to collect inflammatory exudate is generally only 
practical in larger animals, and as a result economic factors also become important. 
Experimentally induced inflammation has been used, in various species, to study the active 
factors present in inflammatory exudate (Willis, 1969; Velo et al. 1973; Higgs et al. 1983; 
Higgins et al. 1984b). These sttidies indicate that eicosanoid content of carrageenan-induced 
inflammation shows inter-species similarities. Prostaglandin E2 concentration has been 
shown to become elevated in experimentally produced inflammatory exudates from rats, 
horses and ponies (Willis, 1969; Higgs at al. 1983; Higgins et al. 1984b; Higgins and Lees 
1984b), and smaller increases in TxB2 and 6-keto-prostaglandin Fiaipha concentration have 
also been demonstrated in rats and ponies (Higgs et al. 1983; Higgins and Lees, 1984b). 
The discovery of these changes in the concentration of eicosanoids in experimentally 
produced exudate led to their use as monitors of the action of NSAIDs. As the increase in 
concentration of these substances is inhibited by the administration of NSAIDs, quantitative 
and qualitative changes in exudate eicosanoid composition are used to evaluate and compare 
the potential efficacy of NSAIDs
The use of clinical studies is, of course, important in determining the efficacy of proven 
NSAIDs in specific situations. However, there is little moral justification for initiating 
clinical trials to test a compound until some positive indication of its efficacy has been 
established.
In vitro testing of NSAIDs has been carried out using a variety of species and tissues 
(Flower et al. 1972; Flower and Vane 1972; Giyglewski, 1974), and has often been based 
on the inhibition of PGE2 synthesis. This technique employs the collection of fresh tissue 
from clinically normal animals which are known to be free from interfering substances and, 
therefore, generally uses purpose killed experimental animals. From these tissues (eg dog 
spleen, guinea pig lung and bovine seminal vesicles) homogenates containing microsomes 
are prepared and these are incubated under controlled conditions in the presence or absence 
of inhibitors of eicosanoid synthesis. Supernatants from these incubations are then 
compared for prostaglandin -like activity in a bioassay system (eg using rat fundic strips).
The search for a test, to assess NSAIDs, which was inexpensive and which conformed to 
current moral guidelines, resulted in the development of an ex vivo TxB2 assay. Lees and 
co-workers (1987a) employed this method to assess the inhibition of production of 
thromboxane in clotting blood by measuring differences in the concentration of the 
relatively stable endoperoxide TxB2. Using this technique it is possible to compare the
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concentration of TxB2 generated in animals to which NSAID has been administered with 
control animals, or to compare TxB2 concentration in the same animal prior to and after 
NSAID administration.
Thromboxane A2 is a product of the arachidonic cascade and therefore its generation can be 
reduced by cyclooxygenase inhibitors (Lees et al. 1987). The half life of eicosanoids has 
been shown to be short, PGI2 has a half life of about 4 minutes (Salmon and Flower, 
1979). An even shorter in vitro half life for TxA2 of 32 seconds (Salmon and Flower, 
1979) has been determined, and as a result measurement of this compound is quite 
impractical. Thromboxane A2 is hydrolysed to TxB2 (Hamberg et al. 1975) which is 
relatively stable, having a half life of 20-30 minutes (McCann et al. 1981). As a result, the 
measurement of TxB2 by radioimmunoassay is accepted as an indicator of the production of 
TxA2 (Fitzpatrick et al. 1977) and the accuracy of this technique has been verified by gas 
liquid chromatography-mass spectrometry (Granstrom et al. 1976; Fitzpatrick et al. 1977).
The principal effects of TxA2 are its potent induction of platelet aggregation and its action as 
a vasoconstrictor (Hamberg etal. 1975; Svensson et al. 1975). The primary source of TxA2 
within the body is blood platelets (Hamberg et al. 1975) although migrating leucocytes are 
also known to be a source (Higgs et al. 1983). In addition, it is thought that TxA2 may be 
produced by migrating macrophages (Humes et al. 1977). The major endogenous 
antagonist of TxA2 induced platelet aggregation is PGI2 (Gorman, 1982). This substance 
not only inhibits platelet aggregation but also promotes vasodilation and is produced in the 
cells of the blood vessel walls.
The technique initially used to measure TxB2 ex vivo has been adapted to develop a 
technique which may be used to monitor the effects of NSAIDs in vitro. Since the major 
source of thromboxanes in the body is blood platelets, it is possible to study inhibition of 
thromboxane production in blood which has been removed from the body and maintained 
under controlled conditions. Normal concentrations of TxB2 in human blood are in the 
range 7-300 pg/ml (Fitzgerald et al. 1983). Blood platelets generate increased quantities of 
TxB2 during the clotting process, and this increase is time related (Lees et al. 1987). By 
ensuring rigourous control of the conditions under which this clotting occurs it is possible 
to use this as the basis of a test system. The addition of a cyclooxygenase inhibitor to 
samples of clotting blood can be used to create a dose response curve for the inhibition.
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8.2 EXPERIMENTAL OBJECTIVES
To utilise an in vitro test system for measurement of TxB2-to determine and compare the 
inhibition of cyclooxygenase by two NSAIDs (flunixin and meclofenamic acid) in three 
different species, namely dogs, goats and horses.
8.3 MATERIALS AND METHODS
8.3.1 REAGENTS
1. Sodium chloride 'Analar' (BDH Ltd)
2. Water, redistilled in the presence of potassium permanganate prior to use.
3. Disodium hydrogen orthophosphate 'Analar' (BDH Ltd)
4. Sodium dihydrogen orthophosphate 'Analar' (BDH Ltd)
5. Ethanol 'Analar' (BDH Ltd)
6 . Flunixin meglumine (Schering Inc., USA)
7. Meclofenamic acid, sodium salt (Sigma Chemical Co. Ltd)
8.0.85 % Sodium chloride
9. Phosphate buffer pH 7.0 was produced by mixing the following solutions:-
195 ml of 28.392 g/litre disodium hydrogen orthophosphate + 305 ml of 31.202 
g/litre sodium dihydrogen orthophosphate + 8.5 g sodium chloride per litre of 
water.
10. Phosphate buffer pH 7.5 was produced by mixing the following solutions
80 ml of 28.392 g/litre disodium hydrogen orthophosphate + 420 ml of 31.202 
g/litre sodium dihydrogen orthophosphate + 8.5 g sodium chloride per litre of 
water.
11. Phosphate buffer pH 8.0 was produced by mixing the following solutions:-
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26.5 ml of 28.392 g/litre disodium hydrogen orthophosphate + 473.5 ml of 31.202 
g/litre sodium dihydrogen orthophosphate + 8.5g sodium chloride per litre of 
water.
8.3.2 EXPERIMENTS TO MEASURE THE INHIBITION OF TxB2  USING THE 
IN VITRO DRUG TEST SYSTEM
8.3.2.1 ANIMALS
Blood from three species : dogs, goats and horses, was used in these experiments. 
In all cases three or more individual animals of each species were studied. All 
animals within a species were of one breed, that is Beagle dogs, Saanen goats and 
Thoroughbred horses. All dogs and goats were aged between 1 and 3 years. Horses 
were 19, 17, 8 and 11 years old (horse 1, 2, 3 and 4 respectively). Animals were 
maintained indoors for a period of at least one week prior to experimental work and 
appeared to be clinically normal, none had a recent history of any clinical 
abnormality.
8.3.2.2 DESIGN OF THE TEST SYSTEM
One millilitre of blood was added to a fixed volume of 0.85 % NaCl containing the 
desired concentration of drug. This was achieved by the initial production of 
solutions containing 400, 40, 4. 0.4 and 0.04 p,g/ml of flunixin meglumine or 
meclofenamic acid in 0.85 % NaCl. An appropriate volume of the drug solution was 
then added to a glass test tube. The final volume was made up to 0.5 ml by the 
addition of 0.85 % NaCl, and the solution thoroughly mixed by vortexing. Final 
concentrations of drug which were tested were in the range 0.0005 -10.0 |ig/ml for 
flunixin and 0.0005 - 133.33 jig/ml for meclofenamic acid. These concentrations 
fall within the range likely to be achieved in plasma after administration at the 
recommended dose rates (Snow et al. 1981b; Hardie et al. 1985a; Lees et al. 1987; 
Soma et al. 1992). Tubes containing each concentration of drug were produced in 
duplicate and layed out so that duplicate concentrations were placed distant from 
each other in the assay design. In addition, tubes containing blank 0.85 % NaCl 
were included as every tenth tube. This arrangement was employed so that the mean 
of the results obtained for each concentration and blank would minimise any 
differences in TxB2 concentration which may have occured due to the time taken to 
pipette each blood sample.
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The necessity to work to a tight time schedule for a large number of samples 
required that the inhibition experiments were performed on blood from only one 
animal on any given day.
8.3.2.3 SAMPLES FOR THE ESTIMATION OF THROMBOXANE IN 
SERUM BY RADIOIMMUNOASSAY
All necessary equipment was set up in an area immediately adjacent to the animal. 
Blood was drawn into a 20 ml disposable syringe (Plastipack, Beckton Dickenson 
Ltd.) from the jugular vein, via a 20 g one inch needle (Becton Dickenson Ltd.). If, 
for any reason, the entire 20  ml collection could not be completed without delay the 
collection was abandoned and begun again using a fresh needle and syringe. After 
collection of 20  ml of blood, the needle was removed from the syringe and the 
blood gently ejected into a 50 ml glass beaker which was suspended in a water bath 
at 37 °C. One millilitre aliquots of this blood were then pipetted, using an automatic 
pipette, into glass test tubes which were also suspended in the 37 °C water bath. 
Each tube contained a test solution. The disposable tip on the automatic pipette was 
not changed between each pipetting. The content of each tube was immediately 
mixed by gentle shaking, the time was noted and the tubes covered with aluminium 
foil to prevent accidental contamination. This process was repeated until the required 
number of 1 ml aliquots had been dispensed. Each set of tubes was incubated in the 
water bath at 37 °C for 90 minutes, after which they were centrifuged and serum 
harvested, as described in the general material and methods section.
8.3.3 EXAMINATION OF THE EFFECT OF A RANGE OF SOLUTIONS ON 
THE INHIBITION OF TxBo
As a result of the low aqueous solubility of piroxicam it had been necessary to employ a 
solution in ethanol for the study of this drug in which intravenous administration was 
required. It was not clear if the presence of ethanol in the solution administered had 
influenced the inhibition of thromboxane which was subsequently measured. Many 
other NSAIDs are poorly soluble in water and consequently the possibility of 
employing other solvents for use in in vitro studies had been considered. A study was 
therefore carried out to establish the effect on thromboxane generation of a range of 
solutions. The test system as described above was utilised, however, in each tube 0.85 
% NaCl was replaced by the solution for which the inhibitory properties were to be
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tested. Solutions tested in this way were pH 7.0, 7.5 and 8.0 phosphate buffered 
saline, and a range of concentrations of ethanol (0.01 - 10 %) prepared in 0.85 % NaCl. 
The inhibition of serum TxB2 which occured in the presence of these solutions was 
measured in comparison with that which occured in the presence of 0.85 % NaCl. A 
.. significant (p<0.05) inhibition of serum TxB2 was measured in the presence of all test 
solutions with the exception of 0.01,0.1 and 1.0 % ethanol when compared with 0.85 
% NaCl (table 8.1).
8.3.4 CURVE FITTING AND ESTIMATION OF IC™
Non-linear curve fitting was carried out by means of the computer package Sigmaplot 
(Jandel Scientific, Germany). This package uses the Marquaidt-Levenberg algorithm in 
an iterative process. Least squares are calculated and used to minimise the sum of 
squares of differences between equation values and experimental values. The IC50 is 
then calculated from the best fit curve.
8.4. RESULTS
8.4.1 IN VITRO EXPERIMENTS WITH FLUNIXIN
The concentration of TxB2 generated from serum of dogs, goats and horses in vitro in 
response to inhibition by flunixin is shown in appendices 12.1-12.3. From this data it 
was possible to calculate the difference between TxB2 generated in the presence of a 
range of concentrations of flunixin with that generated in control samples. The results 
are expressed as a percentage with respect to control values (tables 8.2 - 8.4). Mean (± 
SEM) inhibition of TxB2 production is shown in table 8.5 and figure 8.1.
8.4.1.2 DOGS
The mean inhibition of TxB2 in serum of dogs at the minimum concentration of 
flunixin tested (0.0005 |ig/ml) was 9.57 ± 4.94 %. The inter-animal range in 
inhibition was large at this, and many of the other concentrations tested, and at this 
concentration there was no inhibition of TxB2 production in one animal (dog 4). 
Inhibition of approximately 50 % was measured at flunixin concentrations of 0.05 
and 0.075 |ig/ml. At each of these concentrations inhibition did not exceed 50 % of 
control in all animals. In one animal (dog 3), inhibition was 48.81 % at 0.05 |ig/ml 
and in dogs 2 and 3 inhibition was 34.01 and 49.87 % respectively at 0.075 pg/ml. 
A concentration of 0.1 |ig/ml flunixin produced inhibition of TxB2 greater than 50
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% in all dogs, and at this concentration the mean inhibition was 63.87 ± 4.18 %. 
Production of TxB2 was reduced by 90 % or more in all animals at concentrations 
of 1.0 |ig/ml of flunixin, and the mean inhibition at this concentration was 94.48 ± 
1.40 %. At all higher concentrations tested, the inhibition of TxB2 production 
exceeded 90 % in all animals, and at the maximum concentration tested (10 |xg/ml), 
inhibition exceeded 95 % in all animals (mean 97.71 ± 0.51 %). The maximum 
mean inhibition was 98.11 %, this was produced by a solution of 5.0 pg/ml 
flunixin.
8.4.1.3 GOATS
The mean inhibition of TxB2 in serum from goats at the minimum concentration of 
flunixin tested (0.0005 jig/ml) was 8.52 ± 3.64 %. Although the inter-animal range 
in inhibition was large, some degree of inhibition of TxB2 production was detected 
in all goats at this drug concentration. Inhibition in excess of 50 % were measured at 
flunixin concentrations of 0.02 |ig/ml and above (mean inhibition 64.74 ± 5.92 %). 
Production of TxB2 was reduced by more than 90 % (94.82 %) in one animal (goat 
3) at a drug concentration of 0.05 pg/ml, and inhibition in excess of 90 % was 
measured in blood from all animals at drug concentrations of 0 .10  |ig/ml and above 
(mean inhibition at 0.10 |i.g/ml was 95.98 ± 1.43 %). At the maximum drug 
concentration tested (10 jig/ml), inhibition of serum TxB2 exceeded 98 % in all 
animals (mean 99.42 ± 0.36 %).The maximum mean inhibition was 99.63 %, this 
was produced by a solution of 5.0 |ig/ml flunixin.
8.4.1.4 HORSES
The mean inhibition of TxB2 in serum from horses at the minimum concentration of 
flunixin tested (0.0005 fig/ml) was 11.41 ± 5.78 %, however in one animal (horse 
3) no inhibition of TxB2 production was detected. The mean inhibition exceeded 50 
% at a flunixin concentration of 0.025 |Xg/ml (60.28 ± 8.64 %), however in one 
animal (horse 3) the inhibition of TxB2 at this drug concentration was only 38.56 
%. A concentration of 0.05 |ig/ml flunixin produced inhibition of TxB2 greater than 
60 % in all horses at which concentration the mean serum TxB2 inhibition was 
76.26 ± 7.10 %. Production of TxB2 was reduced by 90 % or more in all animals at 
concentrations of 0.75 |!g/ml of flunixin, and the mean inhibition at this 
concentration was 97.55 ± 0.42 %. At all higher concentrations tested the inhibition 
of TxB2 production exceeded 90 % in all animals and at the maximum concentration
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tested (10 |ig/ml) inhibition exceeded 97 % in all animals (mean 98.57 ± 0.57 
%).The maximum mean inhibition was 99.66 %, this was produced by a solution of
2.5 |ig/ml flunixin.
8.4.2 IN VITRO EXPERIMENTS WITH MECLOFENAMIC ACID
The concentration of TxB2 generated from serum of dogs, goats and horses in vitro in 
response to inhibition by meclofenamic acid is shown in appendix 12.4-12.6. From 
these data it was possible to calculate the difference between TxB2 generated in the 
presence of a range of concentrations of meclofenamic acid with that generated in 
control samples. The results are expressed as a percentage with respect to control values 
(tables 8.6  - 8.8). Mean (± SEM) inhibition of TxB2 production is shown in table 8.9 
and figure 8.2
8.4.2.1 DOGS
The mean inhibition of TxB2 in serum of dogs at the minimum concentration of 
meclofenamic acid tested (0.0005 |Xg/ml) was 22.46 ± 3.96 %. A mean inhibition 
greater than 50 % (61.98 %) was measured at 0.2 pg/ml meclofenamic acid, 
however this result is misleading as it is based on values from only two animals 
(dogs 1 and 2) for which inhibitions of 94.06 and 29.90 %, respectively, were 
measured. Inhibition did not exceed 50 % in all animals sampled until 2.5 |ig/ml 
(mean 81.22 ± 0.72 %) and at the next highest concentration of drug (5.0 pg/ml) 
the inhibition measured for dog 3 was again below 50 % (43.28 %). At 10 |Xg/ml 
meclofenamic acid, the maximum drug concentration which was tested in all three 
dogs, inhibition exceeded 88 % in all animals and the mean inhibition of TxB2 at 
this concentration was 95.55 %. In one animal (dog 3), drug concentrations of up to 
38.55 |ig/ml were tested. At this concentration the inhibition measured was little 
more than that produced by 10 p.g/ml meclofenamic acid in blood from dog 2 (98.77 
%), and was less than that produced by 10 Hg/ml in dog 1 (99.09 %). The 
maximum mean inhibition was 98.98 %, this was produced by a solution of 38.55 
pg/ml meclofenamic acid.
8.4.2.2 GOATS
The mean inhibition of TxB2 in serum of goats at the minimum concentration of 
meclofenamic acid tested (0.001 |ig/ml) was 6.52 ± 6.06 %. There was large inter­
animal range in inhibition, and at this concentration there was no inhibition of TxB2
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production in one animal (goat 2). The first drug concentration at which inhibition in 
all animals exceeded 50 % was 0.25 |J.g/ml (mean inhibition 64.82 ± 2.84 %), 
however one animal (goat 2) had 51.92 % inhibition at a drug concentration of 0.1 
p.g/ml. Production of TxB2 was reduced by 90 % or more in all animals at 
concentrations of 1.0 |ig/ml of meclofenamic acid, and the mean inhibition at this 
concentration was 93.92 ± 1.29 %. At all higher concentrations tested, the 
inhibition of TxB2 exceeded 90 % and at the maximum concentration tested in all 
animals (10 |Xg/ml) inhibition exceeded 99 % in all goats (mean 99.78 ± 0.06 %). 
Higher drug concentrations which were tested in two animals (goats 2 and 3) 
produced inhibition up to a maximum of 99.94 %.
8.4.2.3 HORSES
The mean inhibition of TxB2 in serum of horses at the lowest concentration of 
meclofenamic acid tested (0.001 Jig/ml) was 19.10 ± 14.62 %. No inhibition of 
TxB2 production was detected for the serum from one animal (horse 2) at this 
concentration and this illustrates the large inter-animal variation which was 
recorded. A mean inhibition in excess of 50 % was produced by 0.25 |ig/ml 
meclofenamic acid (69.81 ± 5.70 %), however inhibition in excess of 50 % had 
been noted with drug concentrations of 0.05 and 0.1 jig/ml for horse 1. A mean 
inhibition in excess of 90 % was measured for drug solutions of 0.75 |ig/ml. 
However, at this concentration one animal (horse 3) had an inhibition of 86.20 %. 
Production of TxB2 was reduced by 90 % or more in all animals at concentrations 
of 1.00 |ig/ml of meclofenamic acid, and the mean inhibition at this concentration 
was 96.03 ± 1.84 %. At all higher concentrations tested the inhibition of TxB2 
production exceeded 95 % in all horses, and at the maximum concentration tested in 
all animals (20 |ig/ml) inhibition exceeded 99 % (mean 99.73 ±  0.10 %). Drug 
concentrations of 38.55 and 133.33 |ig/ml were also tested in two animals (horses 2 
and 3).The maximum inhibition detected from these higher concentrations was 
99.91 % by 38.55 |ig/ml meclofenamic acid in blood from horse 2.
8.5 DISCUSSION
There are a number of advantages to the use of this in vitro test system. Firstly, it fulfils the
previously stated criteria of being comparatively non-invasive. Secondly, it does not require
the monitoring of inflicted pain or discomfort Thirdly, it is based on the quantification of a
compound, the assay of which has been fully validated, and requires no subjective
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judgements such as those often required in clinical trails. Finally, it is a comparatively 
simple and cost effective process by which inter-species and inter-drug comparisons can be 
made.
A large inter-animal variation in serum TxB2 inhibition was noted in all species and for both 
drugs. This was particularly apparent at lower concentrations of drug and it may be due to 
the difficulty of accurately measuring small degrees of inhibition. This variation may also 
have been caused by the existence of a threshold of activity for drug concentrations below 
which no inhibition occured and which showed inter-animal variation.
Examination of the raw data for individual animals and mean values showed that 
approximately 10-20 % inhibition of serum TxB2 occured in most species in the presence of 
0.001 pg/ml of either drug (ie approximately 0.002 pM flunixin and 0.003 pM 
meclofenamic acid). The exception to this was in the goat where 0.003 |iM of meclofenamic 
acid produced a mean inhibition of only 6.52 %. At a drug concentration of 10 pg/ml 
(20.37 pM flunixin and 31.4 pM meclofenamic acid), inhibition exceeded 95 % for both 
drugs in goats and horses. In dogs, inhibition at 10 |ig/ml meclofenamic acid ranged from 
88-99 %. Examination of the concentration at which inhibition equalled or exceeded 50 % 
(IC50) showed a variation between drugs and within species. Based on mean data the 
concentration of flunixin which produced 50 % or more inhibition of serum TxB2 was 
0.025, 0.020 and 0.025 pg/ml (0.051, 0.041 and 0.051 pM) for dog, goat and horse 
respectively. For meclofenamic acid the corresponding concentrations were 0.20,0.25 and 
0.25 pg/ml (0.628, 0.785 and 0.785 pM) and statistical examination of data shows that 
flunixin meglumine was significantly more effective in inhibiting serum TxB2 than 
meclofenamic acid at a number of the concentrations tested (appendix 12.7). Computation 
of IC50 values from best fit curves for this data resulted in somewhat different values which 
are shown in table 8 .10, this served to highlight the difficulties of making estimates from 
raw data. Figures for IC50 derived from the best fit curve showed that on a molar basis 
flunixin was a considerably poorer inhibitor of serum TxB2 in vitro in dogs than in the two 
other species examined. It was 5.8 times more effective in producing inhibition of TxB2 in 
the goat than in the dog, twice as effective an inhibitor in the goat than in the horse and 2.9 
times more effective in the horse than the dog. Meclofenamic acid was equipotent in its 
actions in the blood of dogs and goats, however it was approximately 5.5 times more 
effective as an inhibitior of TxB2 in the serum of horses.
Comparison of the in vitro inhibition of serum TxB2 by each drug within species also 
revealed some major differences. In all cases flunixin produced superior inhibition of TxB2.
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In dogs and horses it was found to be approximately 7-8 times more effective on a molar 
basis than meclofenamic acid, and when tested in the blood of goats flunixin was more than 
40 times more effective than meclofenamic acid.
Some studies, such as those described in earlier chapters of the present thesis, have 
examined drug induced inhibition of TxB2 ex vivo. Soma et al (1992) administered flunixin 
intravenously at a dose rate of 1.1 mg/kg to sedentary horses and horses in training. This 
work showed that approximately 50 % inhibition of TxB2 was detected when the 
concentration of flunixin in plasma was around 0.9 |ig/ml. A study reported by Lees et al 
(1987), in which the same intravenous dose rate was administered to ponies, showed an 
inhibition of TxB2 of about 50 % in the presence of less than 0.05 |Xg/ml of flunixin. It is 
difficult to draw comparison from these figures with those found in the present study. In 
both cases the blood platelets had been exposed to a much higher concentration of drug 
which was diminishing with time. In the present study the platelets were exposed to a 
single, stable, concentration of drug. It may be that the effects observed at specific time 
points in ex vivo studies are complicated by inhibitory effects produced by previous 
exposure to higher drug concentrations. Since the inhibitory effects of flunixin and 
meclofenamic acid on platelet cyclooxygenase are reversible, it is possible that the inhibition 
observed in the ex vivo study is a result of the combined effect of previous exposure and 
the concentration of drug to which the platelets are exposed at the time of sampling.
Large inter-species variations in the effectiveness of flunixin and meclofenamic acid to 
inhibit serum TxB2 were demonstrated and these differences were significant at several 
concentrations of each drug (appendix 12.8 and 12.9). The results published by Lees et al 
(1987) were closer to those in this study than were the results of Soma et al (1992). This is 
interesting in view of the fact that both this study and the work of Soma et al (1992) used 
thoroughbred horses, where as the work of Lees et al (1987) was canied out in Welsh 
Mountain and New Forest ponies. All studies measured TxB2 which had been generated in 
clotting blood, however, Soma et al (1992) used an incubation time of one hour, whereas 
both this study and that published by Lees et al (1987) used an incubation time of 90 
minutes. In addition, Lees et al (1987) have demonstrated that blood which is incubated for 
one hour produces only 77 % of the TxB2 which is produced if a 90 minute incubation is 
used. If this does in fact form the basis of the difference between the results of the two 
previous studies, then it seems likely that the similarity between the inhibition of TxB2 
measured in thoroughbreds in this study and ponies in the work of Lees et al (1987) 
indicates that the inter-species differences demonstrated may not extend to breeds.
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A more recent study (Kankaanranta et al. 1993) has examined the in vitro inhibition of 
TxB2 by flunixin and tolfenamic acid for human platelets. These workers reported that the 
IC 50 values for serum TxB2 inhibition using these drugs were 0.28 and 2.6 |J.M 
respectively for flunixin and tolfenamic acid. This was approximately 2, 15 and 8 times 
higher concentrations of flunixin than were required in the present study in the dog, goat 
and horse, respectively. Once more it is not possible to determine if this reflects true 
variation between man and other species or if these large differences are due to the short 
incubation period (30 minutes) which was used in the human study. It is likely that rather 
than producing higher IC50 values, a short incubation period would produce relatively 
lower IC50 concentrations since the interaction of drug with cyclooxygenase enzyme is 
rapid and a constant rate of inhibition would be expected after equilibration had occured.
There is little doubt that, despite the ambiguity introduced by different methodology in other 
studies, this work has shown that large inter-species variations exist in the inhibition of 
serum TxB2 by NSAIDs. One explanation for this may be differences in affinity of the drug 
for enzymes in each species. This might result from intra-species structural differences in 
the cycloxygenase enzyme. Some evidence to support this theory exists in work on other 
enzymes such as phosphodiesterase and monoamine oxidase (Fuller, 1972; Horovitz et al. 
1972; Squires, 1972; Yodim, 1972), where differential sensitivity of enzymes to drugs has 
been documented. Rower and Vane (1972) have reported that paracetamol showed widely 
differing activities against synthetase enzymes from dog spleen and rabbit brain, and it has 
been shown that antisynthetase activity to vary up to 1000 fold depending on the anatomical 
source of the same enzyme. These, and other unpublished studies, led Rower and Vane
(1984) to speculate that at least one component protein of prostaglandin synthetase exists in 
more than one molecular form (isoenzymes) within an animal. Also, that each may catalyze 
a similar type of reaction, but has its own distinct biochemical and pharmacological profile, 
and this may relate to the function of prostaglandins in that specific tissue type. It is 
generally accepted, for the horse, that meclofenamic acid is more effective in the control of 
pain associated with movement and joints (eg laminitis) where as flunixin is more effective 
against pain associated with colic. These observations reinforce the case for the existence of 
different forms of cyclooxygenase in different tissues, as they may result from a differential 
sensitivity to particular NSAIDs amongst enzyme forms. In addition, recent work by Hla 
and Neilson (1992) has shown that expression and differential regulation of human 
cyclooxygenase in various cell types is encoded by two or more genes.
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It has been reported (Egan et al. 1978) that the potency of fenamates in inhibiting 
cyclooxygenase is influenced by the presence of co-factors. The presence of these 
substances (such as phenol) has been shown to increase potency by up to 100 times, and it 
has been suggested that differential presence of naturally occuring co-factors in tissues may 
explain the tissue selective activity which has been reported for these drugs. In addition, 
fenamates are known to directly inhibit the action of some PGs (Collier and 
Sweatman,1968). These actions do not extend uniformly to all actions of a particular PG, 
and in addition the situation varies between species. This ability to inhibit some actions of 
PG could also explain inter-tissue differences in efficacy.
Another possible explanation for the different activity of flunixin and meclofenamic acid in 
different species is the variation in drug protein binding. Calculation of the likely 
concentration of unbound drug present at the IC50 concentrations of flunixin and 
meclofenamic acid in this study, based on work on protein binding described in chapter 7, 
resulted in the values shown in table 8.11. It is apparent from these figures that the inter- 
species differences in inhibition of meclofenamic acid and flunixin on the production of 
serum TxB2 cannot simply be explained on the basis of the concentration of unbound drug. 
At the IC50, the concentration of unbound flunixin is approximately 30 times less than the 
concentration of unbound meclofenamic acid for serum from goats. In dogs there is 
approximately 5 times less free flunixin. The concentration of flunixin required to produce 
the IC50 is approximately 40 times lower in the goat, and approximately 7 times lower in 
the dog than is required for meclofenamic acid. It is difficult to draw a similar comparison 
for these drugs in the horse as meclofenamate was estimated to be 100 % bound to serum 
protein. However, since less than 0.1 % meclofenamic acid was estimated to be unbound 
drug, then the concentration of unbound flunixin in serum from horses was more than 10 
times greater than the concentration of unbound meclofenamic acid, on a molar basis. 
Examination of the recommended dose rates for flunixin and meclofenamic acid in the horse 
(1.1 and 2.2 mg/kg respectively) indicates that the relative clinical efficacy of flunixin in this 
species is twice that (three times on a molar basis) of meclofenamic acid. If the IC50 were 
determined simply on the basis of the concentration of free drug, then the results of the 
present study indicate that the dose rate of meclofenamic acid required to provide equivalent 
clinical efficacy would be approximately 10 times greater than the dose of flunixin. A 
further complication is the apparent differential effectiveness of these two drugs in different 
clinical situations, as outlined above.
8.6 TABLES AND FIGURES
Phosphate Buffer 
pH 7.0 pH 7.5___________ pH 8.0
0.85% NaCl p<0.01 p<0.01 p<0.01
Ethanol Solution
0.01%  0.1%  1.0%  5.0% ______ 10%
0.85% NaCl p>0.05 P>0.05 p>0.05 p<0.05 p<0.05
Table 8.1 Level of significance in differences in inhibition of in vitro serum 
TxB2 produced by a range of buffers and ethanol solutions.when 
compared with 0.85 % NaCl.
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>rug Cone. Animal Num ber
(jig /m l) 1 2 3 4
0 - - - -
0 .0 0 0 5 16.50 NS 12.20 0
0 .0 0 1 0 10.54 17.56 14.06 0
0 .0 0 5 0 30.61 28.65 16.45 17.98
0 .0 0 7 5 22.28 17.19 6.90 12.12
0 .0 1 0 0 34.35 19.22 15.38 10.91
0 .0 2 0 0 54.44 9.61 23.87 25.86
0 .0 2 5 0 55.95 35.86 25.20 24.65
0 .0 5 0 0 69.39 51.39 48.81 50.71
0 .0 7 5 0 78.57 34.01 49.87 57.37
0 .1 0 0 0 75.51 59.89 56.23 63.84
0 .2 0 0 0 97.96 80.78 54.11 74.75
0 .2 5 0 0 95.58 74.31 77.98 78.79
0 .5 0 0 0 97.96 89.46 85.15 91.52
0 .7 5 0 0 95.41 88.17 96.29 92.53
1 .0 0 0 0 98.13 92.05 95.23 92.53
2 .5 0 0 0 98.81 96.12 96.82 96.57
5 .0 0 0 0 99.15 98.15 97.35 97.78
7 .5 0 0 0 99.15 96.67 98.67 97.37
1 0 .0000
NS = No sample
99.15 97.04 97.69 96.97
Table 8.2 Inhibition (%) of thromboxane B2 production in the serum of dogs.
Blood clotting occured in the presence of flunixin.
►rug Cone Animal Num ber
(Hg/ml) 1 2 3
0 - - -
0 .0005 3.70 15.65 6.21
0 .0 0 1 0 6.76 14.54 11.97
0 .0 0 5 0 39.84 36.53 53.23
0 .0 0 7 5 38.66 42.43 48.02
0 .0 1 0 0 40.59 45.65 43.67
0 .0 2 0 0 59.62 58.05 76.55
0 .0 2 5 0 66.68 76.01 86.05
0 .0 5 0 0 81.75 87.25 94.82
0 .0 7 5 0 84.93 89.14 95.55
0 .1 0 0 0 96.93 93.16 97.84
0 .2 0 0 0 91.52 98.46 96.77
0 .2 5 0 0 91.69 98.12 98.08
0 .5 0 0 0 96.40 99.40 99.15
0 .7 5 0 0 98.92 99.66 98.51
1 .0000 98.42 99.74 99.82
2 .5 0 0 0 98.96 99.91 99.73
5 .0 0 0 0 99.15 99.90 99.85
7 .5 0 0 0 99.03 99.95 99.70
10 .0000 98.70 99.81 99.76
Table 8.3 Inhibition {%)  of thromboxane B2 production in the serum of goats.
Blood clotting occured in the presence of flunixin.
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►rug Cone. Animal Num ber
(jig /m l) 1 2 3 4
0 - - - -
0 .0005 NS 18.64 0 15.60
0 .0 0 1 0 3.89 27.09 0 32.39
0 .0 0 5 0 13.04 12.27 13.67 34.83
0 .0 0 7 5 NS 20.45 17.56 28.21
0 .0 1 0 0 72.54 51.45 30.22 54.23
0 .0 2 0 0 NS 58.55 24.22 58.97
0 .0 2 5 0 80.55 58.55 38.56 63.46
0 .0 5 0 0 93.14 66.00 63.11 82.78
0 .0 7 5 0 92.68 74.00 62.00 80.85
0 .1 0 0 0 97.71 83.36 79.00 76.84
0 .2 5 0 0 97.25 93.59 90.61 85.02
0 .5 0 0 0 98.63 97.18 96.22 71.18
0 .7 5 0 0 98.33 98.14 96.56 97.18
1 .0000 98.33 98.07 96.62 97.58
2 .5 0 0 0 99.66 NS NS NS
5 .0 0 0 0 99.68 NS 98.64 97.25
10 .0000 99.71 NS 98.29 97.85
NS = No sample
Table 8.4 Inhibition (%) of thromboxane B2 production in the serum of horses.
Blood clotting occured in the presence of flunixin.
2 0 0
D rug
C one.
Dog
M ean SEM
G oat
Mean SEM
H orse
M ean SEM
(Hg/ml)
0
0 .0 0 0 5 9.57 4.94 8.52 3.64 11.41 5.78
0 .0 0 1 0 10.54 3.79 11.09 2.28 15.84 8.13
0 .0 0 5 0 23.42 3.62 43.20 5.10 18.45 5.47
0 .0 0 7 5 14.62 3.31 43.04 2.71 22.07 3.18
0 .0 1 0 0 19.96 5.09 43.30 1.47 52.11 8.67
0 .0 2 0 0 28.44 9.39 64.74 5.92 47.25 11.53
0 .0 2 5 0 35.41 7.31 76.25 5.59 60.28 8.64
0 .0 5 0 0 55.07 4.80 87.94 3.78 76.26 7.10
0 .0 7 5 0 54.95 9.26 89.87 3.08 77.38 6.42
0 .1 0 0 0 63.87 4.18 95.98 1.43 84.23 4.69
0 .2 0 0 0 76.90 9.05 95.58 2.08 NS -
0 .2 5 0 0 81.66 4.74 95.96 2.13 91.62 2.58
0 .5 0 0 0 91.02 2.67 98.32 0.96 90.80 6.56
0 .7 5 0 0 93.10 1.83 99.03 0.33 97.55 0.42
1 .0000 94.48 1.40 99.33 0.45 97.65 0.38
2 .5 0 0 0 97.08 0.59 99.53 0.29 99.66 -
5 .0 0 0 0 98.11 0.38 99.63 0.24 98.52 0.70
7 .5 0 0 0 97.96 0.57 99.56 0.27 NS -
10 .0000 97.71 0.51 99.42 0.36 98.57 0.57
NS = No sample
Table 8.5 Mean inhibition (%) of thromboxane B2 production in the serum of dogs, 
goats and horses. Blood clotting occured in the presence of flunixin.
'rug Cone. Animal Number
(lig/m l) 1 2 3
0 - - -
0 .0 0 0 5 32.19 19.12 22.07
0 .0 0 1 0 35.84 26.96 16.03
0 .0 0 5 0 NS 14.95 33.79
0 .0075 29.45 19.85 7.59
0 .0 1 0 0 34.70 20.34 5.69
0 .0 2 0 0 81.96 12.50 24.31
0 .0 2 5 0 NS NS 10.52
0 .0 5 0 0 NS 21.57 17.41
0 .0 7 5 0 22.15 31.37 0
0 .1 0 0 0 58.68 25.25 24.31
0 .2 0 0 0 94.06 29.90 NS
0 .2 5 0 0 98.86 32.11 NS
0 .5 0 0 0 NS 64.71 32.59
0 .7 5 0 0 86.07 72.06 45.17
1 .0000 96.35 NS NS
2 .5 0 0 0 NS 82.11 80.34
5 .0 0 0 0 NS 97.30 43.28
7 .5 0 0 0 NS 98.53 76.55
10 .0000 99.09 98.77 88.79
2 0 .0000 NS NS 95.00
3 8 .5 5 0 0 NS NS 98.97
NS = No sample
Table 8.6 Inhibition (%) of thromboxane B2 production in the serum of dogs. 
Blood clotting occured in the presence of meclofenamic acid.
Drug Cone. Animal Num ber
(tig/m l) 1 2 3
0 - - -
0 .0 0 1 0.92 0 18.63
0 .0 0 5 0 6.76 35.17
0 .0 1 0 0 18.27 0
0 .0 5 0 24.00 22.85 20.10
0 .1 0 0 30.47 51.92 39.29
0 .2 0 0 15.61 NS NS
0 .2 5 0 64.36 69.95 60.14
0 .5 0 0 84.51 86.39 82.13
0 .7 5 0 89.89 90.34 83.87
1 .0 0 0 91.73 96.19 93.85
2 .5 0 0 99.20 99.11 97.99
5 .0 0 0 99.60 99.74 99.30
7 .5 0 0 99.67 99.76 99.50
10 .000 99.88 99.78 99.68
2 0 .0 0 0 NS 99.82 99.88
3 8 .5 5 0 NS NS 99.94
133 .330 NS NS 99.94
NS = No sample
Table 8.7 Inhibition (%) of thromboxane B2 production in the serum of goats.
Blood clotting occured in the presence of meclofenamic acid.
Drug Cone. Animal Num ber
(pg/m l) 1 2 3
0 - - -
0 .0 0 1 47.78 0 9.52
0 .0 0 5 49.28 0 13.99
0 .0 1 0 30.78 0 3.83
0 .0 2 0 37.98 38.50 12.15
0 .0 5 0 57.67 46.86 24.35
0 .1 0 0 54.56 47.70 34.25
0 .2 5 0 77.75 72.92 58.76
0 .5 0 0 89.13 86.19 81.42
0 .7 5 0 92.16 92.43 86.20
1 .000 95.01 99.60 93.47
2 .5 0 0 97.95 98.50 97.47
5 .0 0 0 99.19 99.29 98.62
7 .5 0 0 99.15 98.58 98.54
10 .000 99.49 99.56 99.16
2 0 .0 0 0 99.74 99.91 99.55
3 8 .5 5 0 NS 99.91 99.63
133 .330 NS NS 99.86
NS = No sample
Table 8.8 Inhibition (% )  of thromboxane B2 production in the serum of horses.
Blood clotting occured in the presence of meclofenamic acid.
2 0 4
Drug
C one.
Dog
Mean SEM
Goa t
Mean SEM
H orse
Mean SEM
(Hg/ml)
0
0 .0005 22.46 3.96 NS - NS -
0 .0 0 1 0 26.28 5.74 6.52 6.06 19.10 14.62
0 .0 0 5 0 24.35 9.48 13.98 10.78 21.09 14.68
0 .0075 18.96 6.33 NS - NS -
0 .0 1 0 0 20.24 8.38 6.09 6.09 11.54 9.70
0 .0 2 0 0 39.59 21.48 NS - 29.54 8.71
0 .0 2 5 0 10.52 - NS - NS -
0 .0 5 0 0 19.49 2.09 22.32 1.16 42.96 9.82
0 .0 7 5 0 17.84 9.32 NS - NS -
0 .1 0 0 0 36.08 7.99 40.56 6.23 45.50 5.97
0 .2 0 0 0 61.98 32.16 15.61 - NS -
0 .2 5 0 0 65.48 33.47 64.82 2.84 69.81 5.70
0 .5 0 0 0 48.64 16.11 84.34 1.23 85.58 2.25
0 .7 5 0 0 67.77 12.01 88.03 2.09 90.26 2.03
1 .0000 96.35 - 93.92 1.29 96.03 1.84
2 .5 0 0 0 81.22 0.72 98.77 0.39 97.97 0.30
5 .0 0 0 0 70.29 27.09 99.55 0.13 98.73 0.21
7 .5 0 0 0 87.54 11.02 99.64 0.08 98.76 0.20
10.0000 95.55 3.38 99.78 0.06 99.40 0.12
20 .0000 95.00 - 99.85 0.03 99.73 0.10
3 8 .5500 98.98 - 99.94 - 99.77 0.14
133 .3300 NS 99.94 99.86 .
NS = No sample
Table 8.9 Mean inhibition (%) of thromboxane B2 production in the serum of 
dogs, goats and horses. Blood clotting occured in the presence of 
meclofenamic acid.
2 0 5
Species
Dog
Goat
Horse
Prag
Flunixin
Meclofenamic Acid 
Flunixin
Meclofenamic Acid 
Flunixin
Meclofenamic Acid
Computed I C ^  
0.051|ig/ml (0.104|xM) 
0.225|ig/ml (0.707pM) 
0.009pg/ml (0.018(iM) 
0.241pg/ml (0.757|iM) 
0.018ng/ml (0.036|iM) 
0.095|ig/ml (0.299jiM)
Table 8.10 Computed IC50 values for flunixin and meclofenamic acid inhibition
of serum thromboxane B2 production in vitro for dogs, goats and horses.
D rug Species
_______ Dog______________ G oat_____________ H orse
Flunix in  0.008 0.003 0.005
M eclofenam ic 0.044 0.098 0
Acid
Table 8.11 Estimation of the unbound concentration (|iM) of flunixin and 
meclofenamic acid in test solutions which produced in vitro IC50 
values for serum thromboxane B2 generation in three animal species.
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Chapter 9 
GENERAL DISCUSSION
2 1 0
The principal therapeutic uses for NSAIDs are in the control of pain and inflammation. 
Recently, as our understanding of the mechanism of action of these compounds has 
expanded, additional uses have included the control of platelet aggregation and the 
treatment of endotoxic shock. The ethical issues involved in the therapeutic use of any 
foreign substance, such as a drug, are increasingly under general discussion, and this 
issue is particularly emotive when it involves the use of drugs in animals. The debate 
surrounding the ethics of using NSAIDs in domestic animals where the control of pain 
and inflammation may prolong or enhance the competitive ability of an animal has been 
particularly heated (for example horse racing). The ability to recognise pain and 
discomfort in animals presents many difficulties, and our perception of these states in an 
animal is frequently based on comparable human experience. There is little doubt, 
however, that the ability of NSAIDs to relieve suffering is desirable, although the control 
of pain and inflammation should be used in support of a regimen which also addresses the 
underlying cause of these symptoms.
A wide variety of NSAIDs are available for use in humans. The development of these 
drugs has been encouraged by the enormous commercial return which can be derived 
from the production of a successful drug. The commercial value of veterinary drugs is 
considerably less, and as a result NSAIDs licensed for use in animals are fewer in number 
and frequently their use is restricted to a few specific species. The increasing concern for 
animal welfare, and a greater general affluence has gone some way towards changing this 
situation. As a result there is greater interest in exploring the possible uses of NSAIDs 
which were developed for human use. Inter-species, and occasionally age or sex related, 
differences in pharmacokinetics and disposition of NSAIDs and other drugs result in the 
necessity to elucidate the properties of a drug in each target species.
The good efficacy of any drug must be assessed in conjunction with the risks associated 
with drug therapy. It is now recognised that the mechanisms of action of NSAIDs are also 
the mechanisms responsible for adverse effects, the nature and extent of which also show 
inter-species variation. The adverse side effects of some NSAIDs have been discussed in 
some detail in previous chapters. The most common side effects of therapy with these 
drugs is gastrointestinal toxicity, frequently ulceration, and renal papillary necrosis. The 
duration of NSAED therapy is generally in the order of days, rather than weeks or months, 
and as a result the risk to life and the risk of permanent damage is outweighed by the 
benefit to be derived from their use.
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The present studies have examined the pharmacokinetics and pharmacodynamics of four 
NSAIDs in dogs. Two of the drugs (flunixin and cinchophen) are currently licensed for 
veterinary use. The pharmacokinetics of the drugs studied varied widely, as can be seen 
from the estimates of tV2& After intravenous administration the tV2B of flunixin was 
shortest (2.97 hours), cinchophen and tolfenamic acid had slightly longer tV2B values 
(6.84 and 5.91 hours respectively). The t 1^  of piroxicam after intravenous 
administration (40.16 hours) was more than ten times greater than that of flunixin and 
approximately six times longer than the t 1^  of cinchophen and tolfenamic acid. 
Comparison of the tV2B estimates for NSAIDs in dogs in these studies with tV2B values 
reported in other species (eg for piroxicam in rats and man (Esteve et al. 1986; Nuotio and 
Makisara, 1978)) confirmed that large inter-species differences may occur and that it is 
necessary to determine the pharmacokinetics of each drug in the target species.
Very large differences also existed between the volumes of distribution for these drugs. 
The Vdss of cinchophen was smallest (110 ml/kg), flunixin and piroxicam had similar 
Vdss values (190 and 178 ml/kg respectively). The Vdss of tolfenamic acid was 1247 
ml/kg - more than six times that of the other drugs and considerably larger than the figure 
of 160 ml/kg estimated for tolfenamic acid in man (Pentikaainen et al. 1981). Drugs, such 
as NSAIDs, which are highly protein bound typically have low volumes of distribution, 
and in man this figure is less than 200 ml/kg for many such drugs (Rowland and Tozer, 
1989). The binding of tolfenamic acid in man, has been reported to be in excess of 99 % 
(Pentikaainen et al. 1981), which is similar to or higher than that for other NSAIDs. 
Examination of the serum protein binding of two NSAIDs in these studies have shown 
that there may be large inter-species variations. It may be that the level of binding of this 
drug is considerably lower in dogs. However, the binding of meclofenamic acid in this 
species was shown to be greater than 90 % and it seems likely that the chemically related 
tolfenamic acid would not exhibit a substantially different degree of binding although this 
remains to be proven.
In an attempt to determine the likely efficacy of the four drugs studied, inhibition of serum 
TxB2 production was measured after intravenous administration. Comparison of drugs in 
these intravenous and other experiments was complicated by the preparation o f  
cinchophen which was available. This drug was formulated in conjunction with the 
steroidal anti-inflammatory drug prednisolone. The possibility that the presence of 
prednisolone may have altered the pharmacodynamic properties of chinchophen cannot be 
ruled out. Although prednisolone does not directly inhibit cyclooxygenase, it may have
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reduced serum TxB2 production by inhibition of phospholipase. However, Seppala et al
(1985) have shown that a single 20 mg dose of prednisolone did not significantly reduce 
the concentration of PGE2, 6-keto-PGFiaipha or TxB2 in synovial fluid of patients with 
rheumatoid arthritis. Also, it was of interest to compare the effects of the combined 
preparation after intravenous and oral administration, to those obtained after 
administration of preparations containing only NSAID. Maximum inhibition of serum 
TxB2 after intravenous administration was greater than 90 % for flunixin, piroxicam and 
tolfenamic acid (99.9,96.8 and 91.3 % respectively). However, the maximum inhibition 
of TxB2 after intravenous administration of cinchophen was only 71 %. Although the 
maximum inhibition produced by these drugs is important, their overall clinical usefulness 
is also linked to the duration of efficacy. The last time at which inhibition of TxB2 was 50 
% or greater was used to give some indication of this duration. The shortest duration was 
measured for tolfenamic acid and cinchophen (1 and 2 hours respectively). Flunixin had a 
duration of inhibition in excess of 50 % of 12 hours and the maximum duration was 
measured for piroxicam where 50 % inhibition was measured at 72 hours after drug 
administration. This approach can give only a very rough indication of the useful time 
scale for each drug as flunixin had 76 % inhibition at 12 hours but this had decreased to 
18 % at the next sampling time of 24 hours. In addition the total area under the serum 
thromboxane inhibition versus time curve was measured for each drug after each route of 
administration. Although this does not give a direct measurement of duration of action, it 
does allow comparison of the likely overall effectiveness of the drugs when administered 
on a single occasion. The area under the TxB2 inhibition curve was greatest after 
intravenous administration of piroxicam. This value was approximately twice that 
calculated for flunixin and tolfenamic acid, and was six times higher than that measured 
after intravenous administration of cinchophen. This indicates that piroxicam may be the 
drug of choice for single intravenous administration, although it has not been established 
if the area under the TxB2 inhibition curve is positively correlated with the incidence of 
side effects of NSAIDs.
In many clinical situations the use of the intravenous route of administration for NSAIDs 
is impractical, and medication must be administered on more than one occasion. This can 
be achieved for some drugs by the use of oral preparations which can be administered by 
the owner of the animal. Alternatively, extended persistence of effect may be achieved by 
the use of intramuscular or subcutaneous preparations. Of the drugs considered in the 
present studies, flunixin, piroxicam and cinchophen were available as oral preparations.
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Tolfenamic acid was available as a subcutaneous preparation and a preparation containing 
flunixin was also available for administration by this route.
Maximum concentrations of flunixin and cinchophen in plasma were measured between 1 
and 2 hours after oral .administration. The maximum concentration of piroxicam occured 
after approximately 3 hours. Mean residence time for plasma drug concentration after oral 
administration agreed with the ranking of tV2^ values calculated for intravenous 
administration, that is flunixin had the shortest MRT, piroxicam had a considerably longer 
MRT and the values for cinchophen fell within these two extremes. The bioavailability of 
flunixin and cinchophen after oral administration was approximately 60 %. However, 
piroxicam had a much greater bioavailability of around 100 %.
Examination of the maximum serum TxB2 inhibition and duration of inhibition may be 
used to assess the potency of each drug as a cyclooxygenase inhibitor in plasma. 
Flunixin, given orally at a dose rate of l.lmg/kg, produced a maximum TxB2 inhibition 
of 99 %. This is comparable to that produced by the same dose rate after intravenous 
administration and is considerably greater than the maximum inhibition measured after 
oral administration of piroxicam (74 % ) and cinchophen (50 %). In the case of flunixin 
and cinchophen, these maximum values were measured at 1 hour after administration of 
the drug. Maximum inhibition of serum TxB2 production after oral administration of 
piroxicam did not occur until 8 hours.
The last time at which inhibition of TxB2 was 50 % or greater may be used to give an 
indication of the duration of action of drug. In all cases this duration of inhibition was 
shorter after oral than after intravenous administration. Cinchophen had the shortest 
duration of 1 hour, flunixin (1.1 mg/kg) was intermediate at 8 hours and piroxicam had 
the longest oral duration at 48 hours. Comparison of the area under the serum TxB2 
inhibition versus time curve for drugs administered orally demonstrated that flunixin (1.1 
mg/kg) (5952 %.h) was was more effective than piroxicam (4067 %.h). The area 
measured after oral administration of cinchophen (636 %.h) was approximately 10 % of 
that for flunixin, indicating that flunixin had the greatest effect following oral 
administration.
It is of interest to note that despite the presence of prednisolone in the preparation of 
cinchophen which was administered, the level and duration of TxB2 inhibition after both 
routes of administration indicate that it was a poor inhibitor of platelet cyclooxygenase. 
The clinical effectiveness of cinchophen may be attributable to other properties and it
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would be of interest to examine the inhibition of TxB2 following the separate 
administration of the two component drugs.
Subcutaneous administration of flunixin (1.1 mg/kg) and tolfenamic acid produced values 
for maximum inhibition of serum TxB2 of 99.and 80 % respectively. These maxima 
occured at 1 and 2 hours. Measurement of persistence of this inhibition showed that at 12 
hours inhibition was 78 % after subcutaneous flunixin and that the inhibition was 55 % at 
4 hours after subcutaneous tolfenamic acid. These results support the findings of Epinasse 
et al. 1992), who reported that flunixin was significantly more effective than tolfenamic 
acid in inhibiting the production of PGE2 in an experimental inflammatory model in cattle. 
In contrast, the area under the serum TxB2 inhibition versus time curve after subcutaneous 
administration of flunixin and tolfenamic acid was approximately equal.
Examination of platelet numbers throughout each experiment showed that, with the 
exception of the intravenous administration of piroxicam, no consistent trend in platelet 
numbers was apparent This suggests that the reduction in TxB2 concentration seen after 
NSAID administration was due to inhibition of cyclooxygenase, rather than a reduction in 
the platelets which are the primary source of thromboxane. Platelet numbers were 
considerably lower than pre-drug administration numbers, in all dogs, after intravenous 
administration of piroxicam. This effect occurred rapidly (at the first sample time of 0.25 
hours) and persisted, to some extent, throughout the sampling period. Blood disorders, 
including thrombocytopenia, have been recorded as a side effect of piroxicam (Bjomstad 
and Vik, 1986). However, similar reductions in the platelet counts were not observed in 
these dogs after oral administration of piroxicam. In addition, thrombocytopenia has been 
linked with alcoholism in man (Lindenbaum and Hargrove, 1968; Post and Desforges, 
1968b; Cowan and Hines, 1971) and exposure to alcohol vapour in mice (Malik and 
Wickramasinge, 1986). In these cases effects were observed over prolonged periods of 
20 days or more. It therefore seems unlikely that the reduction in platelet numbers was 
associated with administration of piroxicam or ethanol. Furthermore, some increase in 
platelet numbers was seen during the sampling period and this time scale would not be 
consistent with the replacement rate for circulating platelets. The possibility of the 
presence of ethanol interfering with the measurement of platelets also seems unlikely as 
some reduction in platelet number was still apparent at 72 hours.
The concentration of TxB2 in the circulation under normal conditions is generally in the 
nanogram range. The biosynthetic capacity of platelets is 1000 fold greater than the 
normal rate of production in vivo and, as a result, a small residual enzyme activity can
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produce relatively high concentrations of TxB2 (Patrono et al. 1986; Patrono, 1990). 
Toivanen et al (1984) have estimated that only 2.5-10 % of the normal platelet number is 
required to maintain platelet function within the normal range. The relationship between 
NSAID concentration and TxB2 inhibition in clinical situations is highly complex and 
depends on the degree to which the biosynthetic capacity of platelets has been 'stimulated' 
and the IC50 of the NSAID. The in vitro experiments carried out in the present study have 
been standardised by the application of rigid controls to the period of time over which 
blood was permitted to incubate. The incubation time applied in these studies was 90 
minutes. Studies by Lees etal (1987) have shown that concentrations increase erratically 
over a period of 30 to 90 minutes, and that the maximum concentration, which was 
measured at 90 minutes was approximately twice that measured at 30 minutes.
It is interesting to note that the duration of inhibition of serum TxB2 does not appear to 
relate directly to the tV2& of the drug. Ranking the drugs examined in order of and 
apparent duration of action results in
ti/2B
flunixin < tolfenamic acid < cinchophen < piroxicam
Duration of action (intravenous)
tolfenamic acid < cinchophen < flunixin < piroxicam
Duration of action (oral)
cinchophen < flunixin < piroxicam
Duration of action (subcutaneous)
tolfenamic acid < flunixin
This demonstrates that the duration of action is linked to a combination of the tl/2& of the 
drug and the overall ability of the drug to produce inhibition of serum TxB2 at the given 
dose rate. To compare the overall effect of tV2B» maximum TxB2 inhibition and duration 
of inhibition for each drug by each route of administration a factor was devised. This was 
the product of tV2B» maximum mean TxB2 inhibition (TxB2max) and the AUC for TxB2 
inhibition (TxB2AUC) divided by 1000.
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tV2^ x TxB2max x TXB2AUC
Efficacy factor = -------------------------------------
1000
Table 9.1 shows the factor produced for each drug by each route of administration. This 
indicates that piroxicam is the drug of choice for single intravenous and subcutaneous 
administration, whilst tolfenamic acid would be the drug of choice for single oral 
administration. Controlled clinical trials would be required to validate this method of 
assessment.
A general assessment of the efficacy of these drugs can be proposed by comparison of the 
mean of the factors calculated above. Thus
Piroxicam > tolfenamic acid > flunixin > cinchophen
This is in contrast to the findings of Kankaanranta et al (1993) who demonstrated that 
flunixin was approximately ten times more effective than tolfenamic acid (on a molar 
basis) in inhibiting the production of serum TxB2 ex vivo.
In addition to the ex vivo studies which are described for four drugs, an in vitro model 
was used to investigate the inhibition of serum TxB2 by two NSAIDs in different species. 
Solubility difficulties prevented the investigation of the full range of NSAIDs used in the 
in vivo studies. However, it was possible to carry out experiments using two widely 
used drugs (flunixin and meclofenamic acid) in dogs, horses, and goats. Throughout the 
study, concentrations of drug have been expressed primarily as fig/ml, rather than as 
molar concentrations. Although this may complicate inter-drug comparison, it allows ease 
of comparison with other in vivo/ex vivo studies. Where comparison of drug 
concentration was made in the in vitro experiments, values were expressed both as |ig/ml 
and as molar concentrations. For the purposes of comparison, cinchophen and tolfenamic 
acid are of approximately equal molecular weights, piroxicam is approximately 1.3 times 
and flunixin meglumine is approximately 1.9 times the molecular weight of these drugs.
Approximate comparison of the degree of inhibition of serum TxB2 measured ex vivo and 
corresponding drug concentrations, with the inhibition measured in vitro was possible for 
flunixin in the dog. Comparison of drug concentrations which coincided with maximum 
inhibition ex vivo with in vitro inhibitions for the same drug concentration gave values in 
excess of 90% inhibition in vitro. As these inhibitions were produced by drug
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concentrations in serum and plasma which ranged from 2.4 - 8.7pg/ml flunixin, this 
simply illustrates that the concentration required to produce near maximum inhibition is 
less than these concentrations. The last time at which inhibition of TxB2 was 50% or 
greater was also used for comparative purposes. In this case, the ex vivo inhibition was 
compared to that measured for the same drug concentration in vitro. In all but one 
experiment (0.55 mg/kg oral flunixin), the ex vivo inhibition of serum TxB2 was greater 
than that measured in the presence of the same concentration of flunixin in the in vitro 
experiment. As ex vivo inhibition at this stage was measured against a background of 
decreasing concentration of flunixin in plasma, it is likely that the difference is due to 
inhibitory effects caused by the previously higher drug concentrations, the effect of which 
had not been fully reversed. It is possible, however, that the IC50 value of the drug is 
lower ex vivo than in vitro. The potency of fenamates has been shown to be influenced by 
the presence or absence of co-factors (Egan et al. 1978). It is possible that similar factors 
exist which influence the action of flunixin and that such factors were absent or 
diminished in concentration in the in vitro test system.
In vitro experiments demonstrated the existence of inter-species differences (some 
statistically significant) for each drug. In the case of meclofenamic acid, these may be 
attributable to a variation in the presence of co-factors in the blood. Examination of inter- 
species differences in the concentration of known co-factors may have confirmed whether 
inter-species differences in drug potency were related to different co-factor concentrations. 
In such a case a true inter-species comparison of absolute potency of a drug would only 
be possible in the presence of equal concentrations of such co-factors. It would also have 
been of interest to study the effect on in vitro inhibition of serum TxB2 in each species 
after addition of known concentrations of various co-factors.
Experiments were carried out to compare the blood protein binding of flunixin and 
meclofenamic acid in dogs, horses and goats. Large inter-species differences were 
measured, particularly for meclofenamic acid. Based on these figures, estimations of 
unbound drug which might be in the circulation were calculated for a given concentration 
of drug. The differences in unbound drug were particularly large when considered in 
relative terms (eg more than twice the unbound meclofenamate would be circulating in a 
goat than in a dog at normal therapeutic concentrations), although these differences may 
be of little significance if a process of enhanced dissociation of protein bound drugs exists 
(Pardridge, 1985). Also, the situation at the site of inflammation may be of greater 
relevance than that in the circulation. It has been established that an increase in protein
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concentration occurs in inflammatory exudate (Lees and Higgins, 1984). Since NSAIDs 
are principally bound to albumin, it would be of interest to examine the relative 
proportions of the various proteins in exudate. In addition, determination of the extent of 
binding of NSAIDs in exudate of a variety of animal species may give a more complete 
knowledge of whether the increase in plasma/exudate drug ratios observed by Lees and 
Higgins (1984) resulted from the measured increased in protein concentration, or from 
some other, as yet unidentified, mechanism.
If serum TxB2 was only inhibited by unbound NSAID then the in vitro inhibition versus 
drug concentration curve should be displaced to the right for species or drugs where there 
is a higher protein binding. It is of interest to note that this effect is not clearly apparent 
when the results of the in vitro TxB2 and protein binding studies are compared. This may 
simply be due to insufficient data. However, it may also indicate that drug which is bound 
to protein is capable of causing inhibition or may result from the dynamic nature of in vivo 
drug protein binding which may in part explain the clinical effectiveness and ability to 
inhibit serum TxB2 of drugs, such as meclofenamic acid, which are very highly protein 
bound.
Several studies (Hardee and Moore, 1986; Lees et al. 1987) have reported unexplained 
increases in TxB2 compared with pre drug administration concentrations after NSAID 
inhibition. This was also noted for some animals in the present studies. Hardee and 
Moore (1986) proposed several explanations for this observation. They suggested that the 
increase could have resulted from an increase in the number of circulating platelets. Since 
platelet numbers were estimated at a large number of sample times in this present study it 
was possible to examine this theory. Although in some cases TxB2 'rebound' coincided 
with increased platelet numbers this was not observed on a sufficient number of occasions 
to confirm the theory. Other proposed explanations were that cyclooxygenase, Tx 
synthetase or phospholipase activity was enhanced after the inhibitor was removed, or that 
there was a build up of arachidonic acid acid in the membranes as a result of continuing 
phospholipase activity during cyclooxygenase inhibition. It would be of interest to 
examine the relative concentrations of prostaglandins, thromboxane and leukotrienes prior 
to, during and after NSAID administration as this may give some indication of the cause 
of these observations. Lees et al (1987) examined the possibilities of circadian variations 
in TxB2 production. They concluded that although no clear circadian rhythm was apparent 
for TxB2 generation, there were significant variations in the normal TxB2 concentrations
2 1 9
between samples. These observations suggest that ’rebound’ effects which are observed 
are normal variations which have occured by chance at these sample tim es.
With the exception of the studies on piroxicam described earlier, no clear pattern of 
abnormal platelet numbers was seen with any of the NSAIDs studied. Increased bleeding 
times have been widely reported after administration of acetylsalicylic acid in man (Ivy gt 
al, 1941; Meilke et al. 1969) and in horses (Judson and Barton, 1981; Trujillo et al. 
1981). However, prolonged bleeding time was not evident in any of the experiments 
performed in this study, where the measurement used was the time taken for blood to clot. 
This is a comparatively crude test in comparison to the venostasis template technique 
devised by Ivy et al (1941). Kopp et al (1985) used this technique, which was 
standardised for use in humans, to investigate bleeding times in horses after NSAID 
administration. Although a 46% increase was measured after administration of flunixin 
meglumine at a dose rate of 0.5 mg/kg this change was not statistically significant. 
Examination of bleeding times measured prior to drug administration showed a very large 
inter-animal variation (range 2.5-14 minutes). Any study in which a small sample size is 
examined would be unlikely to reveal small underlying effects on bleeding times.
The present study has allowed comparison of the pharmacokinetics of some NSAIDs 
which may be suitable for use in the dog, and has given some insight into their potential to 
control clinical disorders through the inhibition of cyclooxygenase. Many questions about 
the clinical effectiveness and therapeutic differences between these drugs remain 
unanswered, and future studies on the use of NSAIDs in conjunction with appropriate 
models of inflammation will provide further valuable information.
2 2 0
Route of A dm inistration 
Drug In travenous Oral S ubcutanoeus
Flunixin 637.3 1746.5 811.5
Piroxicam 20641.0 12145.1 —
C inchophen 403.3 209.9 —
Tolfenamic Acid 1002.0 1322.6
Table 9.1 Calculated factors for the prediction of the efficacy of four NSAIDs 
in the dog.
Efficacy is predicted to be linearly related to the factor and was 
calculated using the formula:
t V2B x TxB2max x TXB2AUC
Efficacy factor = -------------------------------------
1000
where tl/2B is the intravenous half life of the drug, TxB2max is the 
maximum inhibition of serum thromboxane B2 and TXB2AUC is the area under 
the serum thromboxane B2 versus time curve.
APPENDIX I  
EXTRACTION RECOVERIES OF DRUGS
2 2 2
C o n c e n t r a t i o n  
F lu n i x in  in  
P l a s m a  
( U g /m l )
M e a n  ±  S D  
I n t r a - a s s a y  
R e c o v e r y
 m ____
I n t r a - a s s a y
C o e f f i c i e n t
V a r i a t i o n
M e a n  ±  SD  
I n t e r - a s s a y  
R e c o v e r y
I n t e r - a s s a y
C o e f f i c i e n t
V a r i a t i o n
0.10
0 .5 0
1.00
5 .0 0
92.5 ± 3.9
93.6 ± 1.1
95.2 ± 2.1
90.2 ± 4.7
4.2
1.2 
2.2 
5.2
88.0 ± 6.8 
NS
90.2 ± 6.3
90.2 ± 2.5
7.8 
NS 
7.0
2.8
NS = No sample
Appendix 1.1 Mean (±SD) recovery, intra-assay and inter-assay variation in
recovery of flunixin from plasma fortified at known concentrations.
2 2 3
C o n c e n t r a t i o n  M e a n  ±  S D  I n t r a - a s s a y  M e a n  ±  SD  I n t e r - a s s a y
P i r o x ic a m  in  I n t r a - a s s a y  C o e f f i c i e n t  I n t e r - a s s a y  C o e f f i c i e n t
P l a s m a  R e c o v e r y  V a r i a t i o n  R e c o v e r y  V a r i a t i o n
( l i g / m l ) _____________ {%}________________ {%}________________ {%}________________ ( % )
0 .1 0  70.21± 2.37 2.4 70.33± 6.18 8.8
0 .2 5  NS 69.04± 4.87 7.0
0 .5 0  66.58± 2.51 3.8 72.08±13.46 18.7
1 .0 0  NS 68.49± 6.65 7.4
2 .0  0 72.44± 1.10 1.5 68.49± 6.65 9.7
NS = No sample
Appendix 1.2 Mean (±SD) recovery, intra-assay and inter-assay variation in
recovery of piroxicam from plasma fortified at known concentrations.
2 2 4
C o n c e n t r a t i o n  M e a n  ±  S D  I n t r a - a s s a y  M e a n  ±  SD  I n t e r - a s s a y  
C in c h o p h e n  in  I n t r a - a s s a y  C o e f f i c i e n t  I n t e r - a s s a y  C o e f f i c i e n t
P l a s m a  R e c o v e r y  V a r i a t i o n  R e c o v e r y  V a r i a t i o n
(Hg/ml)_________ {%}____________________  {%}_____ (%)
1 .0  91.99 ± 3.29 3.6 92.20 ± 5.12 5.5
5 .0  NS 86.77 ± 4.18 4.8
10 .0  92.18 ± 5.07 5.5 91.02 ± 1.68 1.8
2 0 .0  NS 92.90 ± 3.30 3.5
5 0 .0  91.70 ± 4.84 5.3 91.40± 6.34 6.9
NS = No sample
Appendix 1.3 Mean (±SD) recovery, intra-assay and inter-assay variation in 
recovery of cinchophen from plasma fortified at known 
concentrations.
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C o n c e n t r a t i o n  
T o l f e n a m i c  
a c id  in  P la s m a  
( u g / m l )
M e a n  ±  SD  
I n t r a - a s s a y  
R e c o v e r y  
<*>
I n t r a - a s s a y
C o e f f i c i e n t
V a r i a t i o n
( * )
M e a n  ±  SD  
I n t e r - a s s a y  
R e c o v e r y
 m ____
I n t e r - a s s a y
C o e f f i c i e n t
V a r i a t i o n
(%)
0 .1 0 65.8 ± 0.5 2.0 66.1 ± 2.4 3.6
0 .2 5 66.8 ± 1.7 6.1 NS NS
0 .5 0 74.7 ± 2.4 7.9 73.06 ± 4.5 6.2
1 .00 71.3 ± 1.1 3.8 NS NS
5 .0 0 77.9 ± 2.4 7.6 76.7 ± 4.6 6.0
NS = No sample
Appendix 1.4 Mean (±SD) recovery, intra-assay and inter-assay variation in
recovery of tolfenamic acid from plasma fortified at known concentrations.
APPENDIX 2 
FLUNIXIN ORAL ADMINISTRATION TABLES
2 27
O ccasion Dose Rate (mg/kg)
____________________ 0jl55______________ 1 A 0 ______________1.65
1 Dog 1 & 2 Dog 3 & 5 Dog 4 & 6
2 Dog 3 & 5 Dog 4 & 6 Dog 1 & 2
3 Dog 4 & 6 Dog 1 & 2 Dog 3 & 5
Appendix 2.1 Dose rate (mg/kg) of flunixin adminisered to each dog on each occasion.
2 2 8
Time Animal Num ber
(h) 1 2 3 4 5 6
Pre 0 0 0 0 0 0
0 .5 0 0 0.11 3.04 2.52 3.69 2.24
1 .0 0 0 2.25 5.23 1.88 3.05 1.99
2 .0 0 0 0.85 4.36 0.61 1.62 1.21
4 .0 0 0.67 0.56 0.35 0.13 1.11 0.46
8 .0 0 0 0.11 1.17 0 0.43 0.20
12 .00 0 0 0.43 0 0.41 0.21
2 4 .0 0 0 0 0 0 0 0
4 8 .0 0 0 0 0 0 0 0
7 2 .0 0 0 0 0 0 0 0
9 6 .0 0 0 0 0 0 0 0
1 68 .00 0 0 0 0 0 0
Appendix 2.2 Concentration (|ig/ml) of flunixin in plasma of dogs after administration
at a dose rate of 0.55 mg/kg by the oral route.
2 2 9
Tim e Animal Num ber
(h) 1 2 3 4 5 6
P re 0 0 0 0 0 0
0 .5 0 4.39 3.07 0.31 0.47 3.38 0.06
1 .0 0 2.89 9.21 2.20 2.15 5.62 5.37
2 .0 0 1.05 4.43 3.42 1.19 3.16 3.74
4 .0 0 0.44 2.05 0.91 0.65 1.03 2.92
8 .0 0 0.10 0.70 0.23 0 0.58 1.05
1 2 .0 0 0 0.14 0 0 0.81 0.35
2 4 .0 0 0 0 0 0 0.10 0
4 8 .0 0 0 0 0 0 0 0
7 2 .0 0 0 0 0 0 0 0
9 6 .0 0 0 0 0 0 0 0
1 68 .00 0 0 0 0 0 0
Appendix 2.3 Concentration (jig/ml) of flunixin in plasma of dogs after
administration at a dose rate of 1.10 mg/kg by the oral route.
2 3 0
Time - Animal Num ber
(h) 1 2 3 4 5 6
Pre 0 0 0 0 0 0
0 .5 0 0.36 6.73 2.07 0.86 7.20 0.40
1 .0 0 1.18 5.79 5.60 7.45 7.91 16.59
2 .0 0 1.47 9.80 4.20 4.91 4.13 5.41
4 .0 0 1.67 2.30 1.59 1.07 1.75 1.46
8 .0 0 0.26 0.71 0.61 0.30 1.11 0.63
12 .0 0 0 0.21 0.19 0.19 0.66 0.63
2 4 .0 0 0 0 0 0 0.25 0.16
4 8 .0 0 0 0 0 0 0 0.10
7 2 .0 0 0 0 0 0 0 0
9 6 .0 0 0 0 0 0 0 0
168 .00 0 0 0 0 0 0
Appendix 2.4 Concentration (pg/ml) of flunixin in plasma of dogs after
administration at a dose rate of 1.65 mg/kg by the oral route.
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0.55mg/kg
T i m e  A n im a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n
P r e 1 .600 1.240 1.440 1.230 0 .9 2 0 1 .1 0 0 1 .362
0 . 5 0 0 .7 6 0 0 .4 4 0 0 .0 1 5 0 .0 1 8 0 .0 1 8 0 .0 4 0 0 .2 1 5
1 . 0 0 0 .6 6 0 0 .0 1 0 0 .0 0 6 0 .0 4 5 0 .013 0 .0 4 0 0 .1 2 7
2 . 0 0 0 .9 6 0 < 0 .2 2 0 0 .0 1 1 0 .0 2 8 0 .0 6 6 0 .2 4 0 < 0 .2 5 4
4 . 0 0 0 .2 5 0 0 .3 4 0 0 .1 2 0 0 .0 2 2 0 .0 9 2 0 .4 8 0 0 .2 1 7
8 . 0 0 0 .3 7 0 0 .8 8 0 0 .0 6 6 0 .0 5 4 0 .164 0 .6 4 0 0 .4 4 5
1 2 . 0 0 1 .1 2 0 0 .4 0 0 0 .1 1 6 0 .9 0 0 0 .1 8 0 0 .6 2 0 0 .6 0 6
2 4 . 0 0 1 .322 0 .6 6 0 0 .6 0 0 0 .6 4 0 0 .5 6 0 1 .040 0 .8 0 3
4 8 . 0 0 1 .040 1.240 1 .1 2 0 1 .360 1.040 1 .240 1.173
7 2 . 0 0 0 .7 7 0 0 .8 8 0 1 .360 0 .7 8 0 2 .0 0 0 0 .7 2 0 1.103
9 6 . 0 0 0 .6 0 0 1.000 1 .480 0 .4 2 0 1 .0 2 0 0 .5 2 0 0 .8 4 0
1 6 8 . 0 0 1 .680 0 .9 2 0 1 .600 0 .3 4 0 1.240 0 .6 2 0 1 .067
1 .1 0  m g /k g
T i m e A n im a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n
Pre 1 .360 1.320 1 .560 0 .8 3 0 2 .0 0 0 1 .600 1 .412
0 .5 0 0 .0 1 2 0 .0 3 0 0 .4 8 0 0 .7 6 0 0 .0 0 4 0 .0 0 5 0 .2 1 5
1 .0 0 0 .0 3 5 0 .004 < 0 .0 0 1 0 .0 2 4 < 0 .0 0 1 0 .0 1 5 < 0 .0 1 3
2 .0 0 0 .1 5 2 0 .0 2 9 0 .0 1 4 0 .2 4 0 0 .0 0 5 0 .0 9 2 0 .0 8 9
4 .0 0 0 .4 4 0 < 0 .0 1 0 0 .1 1 2 0 .0 5 6 0 .0 2 6 0 .0 2 6 < 0 .1 1 0
8 .0 0 0 .7 0 0 0 .3 8 0 0 .4 4 0 1.000 0 .0 4 2 0 .1 6 0 0 .4 5 4
1 2 .0 0 1 .2 0 0 0 .6 8 0 1.640 0 .7 4 0 0 .1 3 2 0 .9 4 0 0 .8 8 8
2 4 .0 0 1 .2 0 0 1.160 1 .040 1.280 0 .8 6 0 0 .6 4 0 1 .030
4 8 .0 0 1 .040 1 .320 1.040 1.480 0 .6 2 0 2 .0 0 0 1.205
7 2 .0 0 0 .8 0 0 0 .8 2 0 0 .8 2 0 1.160 0 .6 8 0 1 .160 0 .9 0 7
9 6 .0 0 0 .4 0 0 0 .4 6 0 0 .9 0 0 1.240 0 .7 4 0 1 .360 0 .8 7 2
168 .00 0 .5 6 0 0 .6 4 0 1 .440 1.230 0 .9 2 0 1 .1 0 0 0 .981
1 .6 5 m g /k g
T i m e A n im a l  N u m b e r
( h ) 1 2 3 4 5 6 M e a n
P r e 1 .680 0 .9 2 0 1 .600 1 .600 1.240 0 .6 2 0 1 .277
0 . 5 0 0 .5 2 0 0 .0 1 0 0 .0 4 4 0 .1 8 4 < 0 .0 0 1 0 .8 2 0 < 0 .2 6 3
1 . 0 0 0 .2 7 0 0 .0 1 1 0 .0 5 5 0 .0 0 1 < 0 .0 0 1 < 0 .0 0 1 < 0 .0 4 8
2 . 0 0 0 .0 1 6 0 .0 0 4 0 .0 1 9 0 .0 0 3 0 .0 0 5 0 .0 2 9 0 .0 1 3
4 . 0 0 0 .1 2 0 0 .0 1 9 0 .0 6 6 0 .1 3 6 < 0 .0 1 0 0 .0 5 2 < 0 .0 6 5
8 . 0 0 0 .3 6 0 0 .1 6 0 0 .2 6 0 0 .3 8 0 0 .0 7 8 0 .2 4 0 0 .2 4 6
1 2 . 0 0 1 .720 0 .5 2 0 0 .8 0 0 0 .3 5 0 0 .2 6 0 0 .6 0 0 0 .7 0 8
2 4 . 0 0 0 .9 8 0 0 .8 8 0 0 .7 8 0 0 .6 8 0 0 .2 5 0 0 .8 8 0 0 .741
4 8 . 0 0 1 .560 0 .9 4 0 1 .040 0 .5 6 0 0 .6 2 0 0 .7 6 0 0 .9 1 3
7 2 . 0 0 0 .6 4 0 1.720 0 .9 8 0 0 .7 2 0 0 .6 2 0 1.000 0 .9 4 7
9 6 . 0 0 1 .720 0 .9 4 0 0 .6 0 0 0 .3 8 0 0 .4 2 0 1 .240 0 .8 8 3
1 6 8 . 0 0 1 .360 1.320 0 .4 8 0 0 .7 0 0 0 .3 4 0 1 .400 0 .9 5 5
Appendix 2.5 Thromboxane B2 concentration (|ig/ml) in serum of dogs after 
administration of flunixin at three dose rates by the oral route.
0.55mg/kg
T i m e
(h) 1 2 3
A n im a l
4
N u m b e r
5 6 M e a n ± S E M
P r e 706 608 358 313 278 40 5 445 ± 70 .5
0.50 6 5 0 514 351 310 265 339 405 ± 59 .9
1.00 531 744 269 319 248 375 414 ± 77 .8
2.00 548 484 267 290 319 310 370 ± 4 7 .6
4.00 694 544 4 0 0 268 31 6 323 42 4 ± 6 6 .8
8.00 4 9 8 434 235 287 340 326 353 ± 39 .5
12.00 648 593 349 2 2 0 314 336 4 1 0 ± 69 .4
24.00 614 802 598 188 308 274 46 4 ± 98 .5
48.00 517 616 229 261 288 275 364 ± 65 .7
72.00 543 509 345 300 4 0 5 369 4 1 2 ± 38 .9
96.00 598 565 4 6 0 300 2 9 2 3 6 2 42 9 ± 54.1
168.00 576 503 382 297 323 41 8 4 1 6 ± 4 3 .6
l . l O m g / k g
T i m e
(h) 1 2 3
A n im a l
4
N u m b e r
5 6 M e a n ± S E M
P r e 564 534 386 300 275 381 4 0 7 ± 4 8 .6
0 .50 547 503 399 233 274 367 387 ± 50 .4
1.00 503 479 402 369 253 337 391 ± 37 .8
2.00 547 523 384 332 295 337 403 ± 43 .4
4.00 655 506 354 257 29 6 4 0 4 4 1 2 + 60 .2
8.00 4 7 2 506 349 504 215 358 401 ± 4 6 .8
12.00 435 439 386 425 299 392 396 ± 21 .4
24.00 449 405 304 419 245 361 364 ± 31 .5
48 .00 44 9 493 379 368 244 294 371 ± 37 .9
72.00 47 9 462 360 245 271 24 0 345 ± 4 4 .2
96.00 4 1 2 547 369 244 268 345 3 6 6 ± 4 3 .6
168.00 513 554 358 271 278 405 4 0 4 ± 4 5 .0
1 . 6 5 m g / k g
T i m e
( h ) 1 2 3
A n im a l
4
N u m b e r
5 6 M e a n ± S E M
P r e 576 503 382 277 323 40 0 4 1 0 ± 4 5 .6
0 . 5 0 561 43 2 389 247 268 368 378 ± 4 6 .9
1 . 0 0 564 485 382 316 326 347 403 ± 40 .7
2 . 0 0 565 551 392 231 291 310 39 0 ± 57 .2
4 . 0 0 579 514 375 256 271 358 392 ± 5 3 .0
8 . 0 0 636 217 349 245 274 329 342 ± 62 .3
1 2 . 0 0 454 509 287 230 245 289 336 ± 4 7 .6
2 4 . 0 0 644 583 N S 301 213 312 411 ± 85.1
4 8 . 0 0 603 463 313 241 3 0 0 329 375 ± 54 .5
7 2 . 0 0 622 566 379 266 323 359 4 1 9 ± 57 .9
9 6 . 0 0 58 437 391 288 389 305 4 1 5 ± 4 8 .8
1 6 8 .0 0 564 534 415 300 323 323 4 1 0 ± 4 7 .0
A p p en d ix  2 .6  Platelet numbers (x 10^/1).in blood o f  dogs after administration o f  
flunixin at three dose rates by the oral route.
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APPENDIX 3
FLUNIXIN INTRAVENOUS ADM INISTRATION TABLES
2 3 4
Time Animal Num ber
(h) 1 2 3 4 5 6
Pre 0 0 0 0 0 0
0 .2 5 10.36 9.91 12.43 16.78 12.76 14.56
0 .5 0 7.61 6.68 8.09 9.76 10.21 9.94
1.00 4.31 4.91 4.45 5.49 6.35 6.16
2 .0 0 1.75 2.26 2.35 1.50 3.02 2.10
4 .0 0 0.53 0.96 1.13 1.44 2.09 0.59
8 .0 0 0 0.34 0.33 0.35 0.59 0.43
12 .00 0 0.31 0 0.19 0.71 0.15
24 .0 0 0 0.13 0 0.16 0.09 0.17
4 8 .0 0 0 0 0 0.13 0 0.14
7 2 .0 0 0 0 0 0.11 0 0
Appendix 3.1 Concentration (Jig/ml) of.flunixin in plasma of dogs after administration
at a dose rate of 1.10 mg/kg by the intravenous route.
2 3 5
rime
(h)
1 2 3
Animal
4
{Number
5 6 Mean ± SEM
0 1.1325 1.0430 1.0930 1.1040 0.8290 1.4880 1.1149 ± 0.0870
0.25 0.0016 0.0008 0.0008 0.0010 0.0003 0.0030 0.0012 ± 0.0004
0.50 0.011 0.0057 0.0013 0.0015 0.0006 0.0040 0.0024 ± 0.0008
1.00 0.0235 0.0032 0.0037 0.0093 0.0010 0.0060 0.0078 ± 0.0033
2.00 0.0390 0.0364 0.0124 0.0436 0.0127 0.0170 0.0268 ± 0.0058
4.00 0.0351 0.0720 0.0615 0.0511 0.0277 0.2636 0.0852 ± 0.0363
6.00 0.1822 0.1420 0.0820 0.1538 0.0585 0.4224 0.1735 ± 0.0532
8.00 0.4833 0.2167 0.1362 0.3680 0.0462 0.3595 0.2683 ± 0.0668
12.00 0.1532 0.0580 0.1347 0.2985 0.0397 0.0860 0.1283 ± 0.0384
24.00 1.0660 1.2230 0.7570 0.8260 0.4440 1.6690 0.9975 ± 0.1732
48.00 1.3460 0.7210 1.2460 0.7590 0.6870 1.4170 1.0293 ± 0.1394
72.00 1.5500 1.3510 1.0620 1.2900 0.9620 1.4910 1.2793 ± 0.0985
A p p e n d ix  3.2 Thromboxane B 2 concentration (fig/ml) in serum o f  dogs after
administration o f  flunixin at at a dose rate o f 1.10 mg/kg by the 
intravenous route.
2 3 6
Tim e Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 326 323 284 210 232 274 274.8 ± 19.2
0 .2 5 405 382 271 245 258 NS 312.2 ± 33.7
0 .5 0 NS 175 280 178 258 271 232.4 ± 23.2
1 .0 0 375 362 248 220 242 251 283.0 ± 27.4
2 .0 0 346 319 280 200 NS 251 279.2 ± 25.7
4 .0 0 326 336 239 191 229 264 2642 ± 23.2
6 .0 0 310 319 293 220 271 287 283.3 ± 14.4
8 .0 0 336 178 251 200 213 172 225.0 + 25.0
1 2 .0 0 293 323 300 166 NS 226 261.6 ± 21.8
2 4 .0 0 NS 326 280 210 232 220 253.6 ± 21.8
4 8 .0 0 352 349 277 188 204 235 217.6 ± 58.2
7 2 .0 0 306 316 277 182 188 242 251.8 ± 23.6
Appendix 3.3 Platelet numbers (xl09/l) in blood of dogs after administration of
flunixin at a dose rate of 1.10 mg/kg by the intravenous route.
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Time Animal Num ber
(h) 1 2 3 4 5 6 Mean
Pre 2.99 3.82 3.71 4.52 4.52 5.00 4.09
1.00 3.68 3.59 3.79 4.08 3.12 2.98 3.54
2 .0 0 3.76 3.52 2.95 3.96 2.64 2.86 3.28
4 .0 0 3.34 4.07 4.23 3.68 4.10 4.10 3.92
6 .0 0 3.34 3.30 3.95 4.14 4.52 3.80 3.84
8 .0 0 0.59 3.22 3.67 3.18 2.70 2.97 2.72
2 4 .0 0 3.65 4.13 3.70 1.58 4.02 2.52 3.27
4 8 .0 0 3.27 3.88 3.48 3.57 3.13 3.66 2.85
7 2 .0 0 4.32 3.39 3.65 4.08 3.48 2.95 3.64
Appendix 3.4 Clotting time (min.) of blood from dogs after administration of flunixin 
at a dose rate of 1.10 mg/kg by the intravenous route.
Tim e
(h).
Pen Number 
2
P re
24 +
48
72
96
168
= Negative
Appendix 3.5 Occult blood in faeces of dogs after administration of flunixin 
at a dose rate of 1.10 mg/kg by the intravenous route.
2 3 9
APPENDIX 4
FLUNIXIN SUBCUTANEOUS ADM INISTRATION TABLES
2 4 0
Tim e Animal Number
(h) 1 2 3 4 5 6
P re 0 0 0 0 0 0
0 .2 5 2.49 3.68 3.79 4.14 2.86 1.94
0 .5 0 4.12 5.04 5.75 7.91 4.95 4.10
1 .0 0 3.82 6.37 6.96 8.55 6.50 5.67
2 .0 0 1.38 4.86 6.29 6.17 3.33 3.20
4 .0 0 0.43 1.80 2.47 2.64 1.00 1.01
8 .0 0 0.15 0.53 0.53 0.50 0.19 0.47
12 .00 0.12 0.29 0.36 0.27 0.08 0.95
2 4 .0 0 0 0 0 0.08 0 0.18
4 8 .0 0 0 0 0 0.07 0 0.11
7 2 .0 0 0 0 0 0 0 0.21
9 6 .0 0 0 0 0 0 0 0.14
1 6 8 .0 0 0 0 0 0 0 0
Appendix 4.1 Concentration (|ig/m l) of.flunixin in plasma o f  dogs
after administration at a dose rate o f 1.10 mg/kg by the 
subcutaneous route body weight.
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T i m e
( h )
1 2 3
A n im a l
4
in u m D e r 
5 6 M e a n ± S E M
0 1 .3200 1 .2600 1 .0 2 2 0 0 .8 0 3 0 0 .9 2 9 0 1 .5830 1 .1528 ± 0 .1 1 7 4
0 . 2 5 0 .0 1 5 0 0 .0025 0 .0 0 1 6 0 .0 0 3 2 0 .0 0 6 9 0 .0 0 9 0 0 .0 0 6 4 ± 0 .0 0 2 1
0 . 5 0 0 .0 1 6 2 0 .0 0 1 2 0 .0007 0 .0 0 1 1 0 .0 0 4 0 0 .0 0 2 3 0 .0 0 4 2 ± 0 .0 0 2 4
1 . 0 0 0 .0 0 2 0 0 .0 0 3 0 0 .0028 0 .0 0 3 2 0 .0 0 2 6 0 .0 0 4 1 0 .0 0 2 9 ± 0 .0003
2 . 0 0 0 .0 8 0 0 0 .0 1 5 0 0 .0 0 1 2 0 .0 0 2 4 0 .0 1 1 0 0 .0 1 0 6 0 .0 2 0 0 ± 0 .0 1 2 2
4 . 0 0 0 .0 9 4 0 0 .0 3 9 0 0 .0073 0 .0 0 8 9 0 .0593 0 .3 5 5 9 0 .0941 ± 0 .0 5 4 0
8 . 0 0 0 .1 7 5 0 0 .1 6 1 4 0 .1 7 5 0 0 .0 8 8 5 0 .3731 0 .2 7 8 7 0 .2 0 8 6 ± 0 .0 4 1 2
1 2 . 0 0 0 .3 3 5 0 0 .2 5 3 3 0 .1 4 0 2 0 .1 2 5 5 0 .4 8 5 3 0 .0 7 1 0 0 .2 7 8 7 ± 0 .0 6 5 4
2 4 . 0 0 0 .9 6 0 0 0 .8 9 3 0 0 .9 3 0 0 0 .4 1 3 5 0 .8 8 8 0 0 .6 5 1 0 0 .7 8 9 7 ± 0 .0 8 7 7
4 8 . 0 0 1 .2470 1 .3160 1 .2080 0 .6 6 8 0 1 .0430 1 .0 2 2 0 1 .0840 ± 0 .0 9 5 6
7 2 . 0 0 1 .1830 1 .1520 1.1710 0 .8 7 0 0 1 .3640 1 .2500 1 .1650 ± 0 .0 6 6 9
9 6 . 0 0 1 .4030 1 .4210 1 .2 0 0 0 0 .7 6 5 0 1 .3500 1 .4090 1 .2580 ± 0 .1041
1 6 8 . 0 0 1 .1780  . 1 .5500 1.3690 0 .7 4 1 0 1 .1 0 0 0 1.1760 1 .1857 ± 0 .1 1 1 3
A ppendix 4 .2  Thromboxane B 2 concentration (|ig/m l) in serum o f  dogs after 
administration o f  flunixin at a dose rate o f  1.10 m g/kg by the 
subcutaneous route.
2 4 2
Time Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 430 370 230 200 380 300 318.3 ± 37.0
0 .2 5 350 340 260 100 190 300 256.7 ± 39.4
0 .5 0 350 370 300 NS 350 310 336.0 ± 13.4
1 .0 0 410 370 280 60 410 270 300.0 ± 54.1
2 .0 0 20 340 260 120 400 300 240.0 ± 58.4
4 .0 0 380 390 260 130 400 170 288.3 ± 48.7
8 .0 0 NS 280 70 240 340 170 220.0 ± 46.7
12 .0 0 250 330 220 130 270 260 243.3 ± 27.0
2 4 .0 0 310 . 330 280 90 340 200 258.3 ± 39.4
4 8 .0 0 310 320 300 150 330 310 286.7 ± 27.6
7 2 .0 0 320 200 230 330 280 160 257.3 ± 27.8
9 6 .0 0 380 280 330 180 370 140 280.0 ± 40.9
168 350 450 290 210 1330 300 48.3 ± 171.3
Appendix 4.3 Platelet numbers in blood o f dogs after administration o f  flunixin at 
a dose rate o f  1.10 m g/kg by the subcutaneous route
2 4 3
Tim e Animal Num ber
(h) 1 2 3 4 5 6 Mean
P re 1.75 2.45 2.63 2.33 2.08 2.58 2.30
0 .2 5 2.77 2.55 3.03 2.54 2.53 1.56 2.50
0 .5 0 0.96 3.68 2.71 1.80 1.67 2.87 2.28
1 .0 0 2.53 3.33 2.31 3.18 2.28 3.08 2.79
2 .0 0 2.89 2.47 3.78 3.22 3.28 3.89 3.26
4 .0 0 2.02 3.19 2.94 2.17 2.83 2.58 2.62
6 .0 0 2.93 4.00 3.33 2.88 3.78 3.99 3.49
8 .0 0 4.00 3.00 4.00 2.00 0.67 1.33 2.50
2 4 .0 0 3.50 4.22 2.02 3.78 3.06 3.03 3.27
4 8 .0 0 3.94 3.85 3.67 4.78 3.70 3.81 3.96
7 2 .0 0 2.67 3.01 3.18 2.31 2.60 3.56 2.89
1 6 8 .0 0 3.07- • 2.23 2.83 1.94 2.85 3.00 2.65
A p p e n d ix  4.4  Clotting time (min.) o f  blood from dogs after administration o f  
flunixin at a dose rate o f 1.10 m g/kg by the subcutaneous route.
2 4 4
Tim e
(h ) . 1
Pen Number 
2 3
P re - / - - / - - / -
24 - / - - / - - / -
4 8 - / - - / - - / -
72 - / - - / - - / -
= Negative
Appendix 4.5 Occult blood in faeces of dogs after administratioon of flunixin at a 
dose rate of 1.10 mg/kg by the subcutaneous route.
APPENDIX 5 
PIROXICAM  INTRAVENOUS TABLES
2 4 6
Animal Num ber 
4
Tim e
(h)
P re
0 .2 5
0 .5 0
1.00
2.00
4 .0 0
6 .00  
8.00
12.00
2 4 .0 0
4 8 .0 0
7 2 .0 0
Appendix
1
0
0.99
0.87
0.86
0.81
0.76
0.83
0.92
0.77
0/51
0.38
0.16
2
0
1.06
0.80
0.90
0.94
0.89
0.87
0.88
0.71
0.79
0.49
0.33
3
0
1.11
0.86
0.85
0.97
1.37
1.29
0.91
0.77
0.97
0.45
0.35
0
1.25
1.06
1.45
1.68
1.71
1.58
1.16
0.92
0.99
0.46
0.42
5
0
0.98
0.75
0.75
0.78
1.15
0.84
0.97
0.87
0.99
0.59
0.30
6
0
1.25
0.84
0.75
0.71
0.84
0.96
0.82
0.67
0.68
0.36
0.22
5.1 Concentration (pg/ml) of piroxicam in plasma of dogs after
administration at a dose rate of 0.3 mg/kg by the intravenous route
Tim e Animal Num ber
(h) 1 2 3 4 5 6 M ean
P re 1.321 0.997 1.380 1.127 0.685 1.202 1.119
0 .2 5 0.087 0.059 <0.007 <0.007 0.026 0.018 <0.034
0 .5 0 0.158 0.092 <0.007 <0.009 0.017 0.028 <0.052
1 .0 0 0.138 0.141 <0.007 0.007 0.014 0.077 <0.064
2 .0 0 0.138 0.392 0.047 0.073 0.024 0.199 0.148
4 .0 0 0.176 <0.009 0.038 0.119 0.043 0.168 <0.092
6 .0 0 0.221 0.197 0.098 0.053 0.017 0.126 0.127
8 .0 0 0.141 0.121 0.107 0.057 0.045 0.126 0.099
1 2 .0 0 0.248 0.181 NS NS NS NS 0.214
2 4 .0 0 0.305 0.319 0.113 0.182 0.141 0.206 0.211
4 8 .0 0 0.492 0.457 0.133 0.205 0.186 0.430 0.317
7 2 .0 0 0.613 . 0.632 0.681 0.506 0.285 0.638 0.558
Appendix 5.2 Thromboxane B2 concentration (|ig/ml) in serum 
of dogs after administration of piroxicam at a dose 
rate of 0.3 mg/kg by the intravenous route.
2 4 8
Time Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
P re 457 419 395 318 269 276 354.0 ± 31.8
0 .2 5 128 144 30 27 21 18 61.3 ± 23.8
0 .5 0 216 235 76 51 48 48 112.3 ± 36.1
1 .0 0 255 239 113 169 91 88 159.2 ± 30.3
2 .0 0 239 300 144 119 76 125 167.2 ± 34.5
4 .0 0 271 319 NS 131 153 NS 218.5 ± 45.5
6 .0 0 258 274 182 131 128 172 190.8 ± 25.4
8 .0 0 147 310 169 116 94 76 152.0 ± 34.5
12 .0 0 150 226 138 119 79 91 133.8 ± 21.5
2 4 .0 0 213 ' 206 128 104 113 150 152.3 ± 19.2
4 8 .0 0 226 249 168 115 85 149 165.3 ± 25.8
7 2 .0 0 226 284 163 122 147 131 178.8 ± 25.8
Appendix 5.3 Platelet numbers (xl09/l).in blood of dogs after
administration of piroxicam at at a dose rate of
0.3 mg/kg by the intravenous route.
2 4 9
Tim e Animal Number
(h ) 1 2 3 4 5 6
P re 2.28 2.75 2.68 3.05 5.01 2.78
0 .5 3.98 2.53 3.93 2.83 2.98 2.43
1 .0 3.7 4.28 3.45 2.83 2.88 2.58
2 .0 2.57 3.28 3.17 1.00 2.97 3.13
4 .0 3.63 4.00 1.38 3.48 3.48 1.52
6 .0 2.93 4.33 3.23 1.17 3.02 3.25
8 .0 3.62 4.72 3.00 1.08 4.82 3.17
2 4 .0 2.15 3.38 2.20 3.28 1.50 3.53
4 8 .0 3.75 4.25 3.65 3.27 2.92 3.98
7 2 .0 3.58 3.98 2.83 3.03 3.03 1.63
Appendix 5.4 Clotting time (min.) of blood from of dogs after
administration of piroxicam at a dose rate of
0.3 mg/kg by the intravenous route.
Mean
3.09
3.11
3.20
2.69
2.91
2.99
3.40
2.67
3.64
3.01
Time
(h ). 1
Pen Num ber 
2 3
Pre -/- -/- -/-
24 -/- -/- -/-
48 -/- -/- -/-
72 -/+ -/-
= Negative 
+ = Definite colour change
Appendix 5.5 . Occult blood in faeces of dogs after administration
of piroxicam at a dose rate of 0.3 mg/kg by the 
intravenous route.
APPENDIX 6 
PIROXICAM ORAL ADMINISTRATION TABLES
2 5 2
Tim e Animal Num ber
(h) 1 2 3 4 5 6
P re 0 0 0 0 0 0
0 .5 0 0.52 0.71 1.27 0.99 0.27 0.87
1 .0 0 0.68 1.17 1.21 1.11 1.26 1.86
2 .0 0 0.88 1.12 1.10 1.24 1.41 1.86
4 .0 0 1.01 0.98 1.11 1.14 1.45 1.81
8 .0 0 0.87 1.29 0.68 0.85 1.10 1.24
1 2 .0 0 0.68 0.74 0.52 0.77 0.83 1.09
2 4 .0 0 0.64 0.76 0.70 0.73 1.00 0.96
4 8 .0 0 0.31 0.49 0.44 0.40 0.52 0.49
7 2 .0 0 0.23 0.45 0.30 0.26 0.56 0.53
A ppendix 6.1 Concentration (jig/ml) of piroxicam in plasma of dogs 
after administration at a dose rate of 0.3 mg/kg 
by the oral route
253
Tim e Animal Number
(h) 1 2 3 4 5 6 Mean ±
P re 1.072 1.796 1.905 1.579 1.377 2.071 1.633 ±
0 .5 0 0.488 0.383 0.531 0.392 0.758 0.768 0.553 ±
1 .0 0 0.391 0.423 0.755 0.341 0.283 0.486 0.448 ±
2 .0 0 0.343 0.378 0.626 0.406 0.314 0.696 0.460 ±
4 .0 0 0.420 0.335 0.661 0.439 0.323 0.643 0.470 ±
8 .0 0 0.301 0.323 0.728 0.355 0.290 0.540 0.423 ±
1 2 .0 0 0.501 0.431 0.675 0.385 0.473 0.804 0.545 ±
2 4 .0 0 0.546 0.616 0.878 0.576 0.445 0.945 0.668 ±
4 8 .0 0 0.525 0.658 1.124 0.593 0.460 0.944 0.717 ±
7 2 .0 0 1.111 1.090 1.073 0.865 0.828 1.164 1.022 ±
Appendix 6.2 Thromboxane B2 concentration (jig/ml) in serum of
dogs after administration of piroxicam at at a dose rate
of 0.3 mg/kg by the oral route.
0.150
0.070
0.068
0.065
0.060
0.072
0.066
0.081
0.106
0.057
2 5 4
Tim e Animal Num ber
(h) 1 2 3 4 5 6 M ean ± SEM
P re 412 415 264 389 306 355 356.8 ± 24.9
0 .5 333 402 395 239 235 310 317.3 ± 28.8
1 .0 398 429 408 251 255 310 341.8 ± 32.6
2 .0 333 369 349 239 268 303 276.8 ± 14.3
4 .0 375 379 429 248 245 313 331.5 ± 30.8
8 .0 210 306 336 194 200 226 245.3 ± 24.6
1 2 .0 316 323 NS 226 300 345 302.0 ± 20.3
2 4 .0 313 329 372 210 255 284 293.8 ± 23.3
4 8 .0 287 389 339 223 264 306 301.3 ± 23.7
7 2 .0 422 395 379 242 290 316 340.7 ± 28.2
Appendix 6.3 Platelet numbers (xl09/l).in blood of dogs after
oral administration of piroxicam at at a dose rate of 0.3 mg/kg 
by the oral route.
255
Tim e Animal Number
(h) 1 2 3 4 5 6
Pre 1.95 3.18 2.40 1.87 3.60 3.03
0 .5 2.11 3.50 2.08 2.08 2.75 2.86
1 .0 2.48 3.53 1.43 2.88 3.28 2.67
2 .0 3.65 3.68 2.83 3.82 1.93 2.15
4 .0 2.27 3.18 2.50 3.32 3.20 2.08
8 .0 3.38 4.08 3.00 3.92 3.72 3.88
2 4 .0 3.26 3.23 3.33 2.52 2.28 3.57
4 8 .0 2.88 3.57 3.52 3.07 3.42 4.29
7 2 .0 2.92 2.50 2.47 2.97 2.77 3.07
Appendix 6.4 Clotting time (min.) of blood from of dogs after
administration of piroxicam at a dose rate of
0.3 mg/kg by the oral route.
Mean
2.67 
2.57 
2.72 
3.02
2.77
3.67 
3.07 
3.50
2.78
Tim e Pen Number
(h ) . 1 2 3
P re -/- -/- -/-
24 -/- -/- -/-
48 -/NS -/- -/NS
72 -/NS -/- -/-
= Negative 
NS = No sample
Appendix 6.5 Occult blood in faeces of dogs after administration 
of piroxicam at a dose rate of 0.3 mg/kg by the 
oral route.
2 5 7
APPENDIX 7
CINCHOPHEN INTRAVENOUS ADMINISTRATION TABLES
2 5 8
Tim e Animal Num ber
(h) 1 2 3 4 5 6
P re 0 0 0 0 0 0
0 .0 8 135.15 143.95 132.47 159.01 89.28 61.58
0 .1 7 116.29 135.33 128.47 155.76 87.20 73.89
0 .3 3 111.60 135.78 117.75 140.51 86.68 82.02
0 .5 0 112.28 111.87 113.88 136.33 91.97 77.79
0 .7 5 96.24 113.15 102.35 138.92 84.48 92.09
1 .0 0 89..41 112.06 90.06 135.31 84.40 88.36
2 .0 0 79.53 94.58 76.51 99.26 67.52 82.59
4 .0 0 50.42 80.28 55.13 77.02 70.36 73.12
8 .0 0 28.95 61.39 35.65 43.99 50.33 53.71
12 .0 0 15.79 35.68 29.13 40.81 32.13 47.36
2 4 .0 0 2.75 13.57 8.96 9.66 12.25 20.35
3 0 .0 0 1.14 8.22 5.48 8.92 7.44 13.79
4 8 .0 0 0.08 1.74 0.92 1.20 1.49 2.60
5 5 .0 0 0 1.04 0.48 0.52 0.94 1.35
Appendix 7.1 Concentration (jig/ml) of cinchophen in plasma of dogs after 
administration at a dose rate of 12.5 mg/kg by the intravenous* 
route.
(* in combination with 0.15 mg/kg prednisolone.)
2 5 9
T i m e  A n im a l  N u m b e r
00 1 2 3 4 5 6 M e a n ± S E M
P r e 1.494 1.157 1.336 0 .6 1 6 0 .8 4 8 0 .9 1 7 1.061 ± 0 .133
0 . 0 8 0 .2 3 9 0 .2 4 7 0 .5 8 9 0 .1 4 0 0 .2 2 6 0 .5 0 4 0 .3 2 4 ± 0 .0 7 2
0 . 1 7 0 .173 0 .2 7 9 0 .237 0 .1 0 4 0 .305 0 .6 0 5 0 .2 8 4 ± 0.071
0 . 3 3 0.381 0 .2 1 5 0 .345 0 .2 0 9 0 .3 1 9 0 .3 8 6 0 .3 0 9 + 0 .0 3 2
0 . 5 0 0 .2 9 2 0 .2 8 0 1.090 0 .1 9 4 0 .2 0 4 0 .6 9 9 0 .4 6 0 ± 0 .1 4 7
0 . 7 5 0 .3 7 2 0 .3 1 7 0 .2 3 8 0 .3 3 8 0 .2 6 5 0 .821 0 .3 9 2 ± 0 .0 8 8
1.00 0 .3 6 2 0 .4 5 6 0 .6 0 9 0 .5 5 6 0 .5 4 6 0 .6 9 4 0 .5 3 7 ± 0 .0 4 7
2.00 0 .6 5 7 0 .4 7 6 0 .5 1 9 0 .2 8 2 0 .4 3 4 0 .5 4 6 0 .4 8 6 ± 0 .051
4 . 0 0 0 .7 2 2 0 .561 0 .5 8 0 0.261 0 .6 3 2 1.050 0 .6 3 4 ± 0 .1 0 4
8.00 0 .6 3 9 0 .9 9 7 0 .4 7 2 0 .2 2 9 0 .603 0 .3 6 2 0 .5 5 0 ± 0 .1 0 9
12.00 0 .9 5 6 1 .146 1.070 0 .5 0 6 0 .975 1.427 1.013 ± 0 .123
2 4 . 0 0 0 .775 1.161 N S 0 .3 2 9 0 .6 1 2 1.911 0 .9 5 4 ± 0 .2 7 4
3 0 . 0 0 1.138 N S 1.367 0 .6 7 9 1.108 1 .930 1 .244 ± 0 .2 0 4
4 8 . 0 0 N S N S N S NS N S 1.367 1.367 ±
Appendix 7.2 Thromboxane B2  concentration (|ig/ml) in serum of dogs after
administration of cinchophen (in combination with 0.15 mg/kg
prednisolone) at a dose rate of 12.5 mg/kg by the intravenous route.
2 6 0
Time Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
P re 460 420 250 210 400 320 343.3 ± 40.7
0 .0 8 390 220 300 190 NS 370 294.0 ± 39.5
0 .1 7 390 330 320 160 380 330 318.3 ± 33.8
0 .3 3 400 350 330 160 380 330 325.0 ± 34.9
0 .5 0 290 320 290 130 320 280 271.7 ± 29.1
0 .7 5 380 370 320 100 360 380 318.3 ± 44.6
1 .0 0 310 330 NS 160 NS 320 280.0 ± 40.2
2 .0 0 350 380 310 150 300 320 301.7 ± 32.6
4 .0 0 250 360 260 200 390 210 278.3 ± 32.2
8 .0 0 460 440 320 180 380 380 360.0 ± 41.3
1 2 .0 0 380 410 350 190 390 150 311.7 ± 45.8
2 4 .0 0 290 320 290 170 340 310 286.7 ± 24.6
3 0 .0 0 360 360 300 160 380 260 303.3 ± 34.0
4 8 .0 0 250 170 310 190 320 320 260.0 ± 27.6
Appendix 7.3 Platelet numbers(xl09/l) in blood of dogs after administration of
cinchophen (in combination with 0.15 mg/kg prednisolone) at a
dose rate of 12.5 mg/kg by the intravenous route.
261
Tim e
(h)
P re
0 .5
1.0
2.0
4 .0
8.0
2 4 .0
3 0 .0
4 8 .0
Animal Number
1 2 3 4 5 6 Mean
3.10 3.75 2.44 2.08 3.08 3.46 2.98
2.42 2.63 3.93 3.30 3.73 3.35 3.23
2.85 4.65 3.10 4.04 4.04 4.42 3.85
3.37 2.95 3.69 3.50 3.73 3.63 3.48
4.26 3.07 3.74 3.23 3.14 4.78 3.70
3.50 1.66 2.75 1.71 3.06 3.53 2.70
3.04 4.12 3.50 1.38 3.50 3.67 3.20
3.00 1.17 3.76 3.37 4.04 3.70 3.17
1:69. 2.00 3.50 2.83 3.33 NS 2.67
Appendix 7.4 Clotting time (min.) of blood from dogs after administration of 
cinchophen (in combination with 0.15 mg/kg prednisolone) at a 
dose rate of 12.5 mg/kg by the intravenous route.
Time
(h). 1
Pen Number 
2 3
Pre -/- -/NS -/NS
24 -/NS -/NS NS/NS
48 -/NS -/- -/NS
= Negative 
NS = No sample
Appendix 7.5 Ocult blood in faeces of dogs after administration 
• of cinchophen (in combination with 0.15 mg/kg 
prednisolone) at a dose rate of 12.5 mg/kg by the 
intravenous route.
APPENDIX 8 
CINCHOPHEN ORAL ADMINISTRATION TABLES
2 6 4
Tim e Animal Num ber
(h) 1 2 3 4 5 6
P re 0 0 0 0 0 0
0 .0 8 0 0.17 0 0.06 0 0
0 .1 7 0.11 12.22 0.07 21.21 0.06 0.14
0 .3 3 0.25 67.35 0.29 69.22 1.14 0.23
0 .5 0 0.48 93.58 75.18 72.80 3.18 0.62
0 .7 5 10.98 94.60 99.56 61.84 4.81 0.97
1 .0 0 66.64 92.02 90.36 62.32 16.33 1.43
2 .0 0 68.78 87.76 74.83 80.29 61.47 78.06
4 .0 0 37.92 72.24 66.35 54.46 38.28 78.53
8 .0 0 25.17 55.91 41.33 18.26 44.74 50.99
1 2 .0 0 10.07 41.45 29.91 21.01 32.56 40.23
2 4 .0 0 1.09 22.52 15.88 4.98 15.31 19.09
3 0 .0 0 1.13 24.41 11.31 2.43 12.28 10.47
4 8 .0 0 0.71 7.37 2.65 0.38 2.33 3.67
5 0 .0 0 0.33 5.41 1.55 0.26 1.44 3.30
Appendix 8.1 Concentration (pg/ml) of cinchophen in plasma of dogs after 
administartion at a dose rate of 12.5 mg.kg by the oral* route. 
(* in combination with 0.15 mg/kg prednisolone.)
2 6 5
Time ANIMAL NUMBER
( h ) 1 2 3 4 5 6 M e a n ± S E M
P r e 1.494 1.404 1.178 1.369 1.345 1.738 1.423 ± 0 .0 7 6
0 . 0 8 1.018 1.550 1.184 0 .9 9 6 1.725 1.517 1.332 ± 0 .1 2 5
0 . 1 7 1.192 1.530 1 .124 1.505 1.060 1.605 1.336 ± 0 .0 9 7
0 . 3 3 1.405 1.080 1.118 0 .513 1.179 2 .0 3 7 1.222 ± 0 .203
0 . 5 0 1.408 0 .9 5 7 0 .6 8 7 0 .8 3 4 1.395 1.534 1.136 ± 0 .1 4 4
0 . 7 5 1.926 0 .5 0 0 0 .345 0 .7 6 5 1.340 1.271 1.024 ± 0 .2 4 3
1.00 0 .7 4 7 0 .507 0.391 1.886 1.268 0.668 0.991 ± 0 .231
2.00 0 .6 2 7 0 .6 4 5 0 .5 2 6 0 .6 2 2 1.153 1.205 0 .7 9 6 ± 0.122
4 . 0 0 0 .9 7 8 1.173 2 .3 4 0 1.647 0 .8 4 3 1.365 1.391 ± 0.222
8.00 0 .8 2 7 1.291 1.264 1.647 0 .7 7 7 2 .0 8 2 1.315 ± 0.020
12.00 1.396 1.525 2 .8 1 0 1.385 0 .833 1.435 1.564 ± 0 .2 6 9
2 4 . 0 0 1.442 L 1 4 7 1.399 1.134 2 .227 1.706 1.509 ± 0 .1 6 7
3 0 . 0 0 1.108 1.475 1.793 0 .9 4 5 1.486 2 .163 1.495 ± 0.181
4 8 . 0 0 1.311 2 .165 1.510 0 .8 2 7 1.184 3 .735 1.789 ± 0 .4 2 9
5 0 . 0 0 1.312 1.494 1.248 1.442 1.203 3 .528 1.704 ± 0 .3 6 7
Appendix 8.2 Thromboxane B2 concentration (pg/ml) in serum of dogs after
administration of cinchophen (in combination with 0.06 mg/kg
prednisolone) at a dose rate of 12.5 mg/kg by the oral route.
2 6 6
Time Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
P re 500 370 310 170 330 390 345.0 ± 44.2
0 .0 8 450 410 370 130 330 NS 338.0 ± 55.6
0 .1 6 420 450 410 200 370 270 353.3 ± 39.9
0 .3 3 430 390 370 240 350 240 336.7 ± 32.4
0 .5 0 420 420 370 210 360 NS 356.0 ± 38.5
0 .7 5 460 400 360 220 300 390 355.0 ± 34.4
1 .0 0 NS 400 260 160 350 310 296.0 ± 41.0
2 .0 0 290 350 370 190 310 350 276.6 ± 25.1
4 .0 0 NS 420 330 220 360 350 336.0 ± 32.6
8 .0 0 350 400 160 200 270 310 281.7 ± 37.0
12 .0 0 400 ' 190 350 250 350 290 305.0 ± 31.4
2 4 .0 0 430 410 320 210 280 280 321.7 ± 34.4
3 0 .0 0 370 410 350 250 320 360 343.3 ± 22.2
4 8 .0 0 360 130 330 220 300 350 281.7 ± 36.6
5 0 .0 0 430 420 360 160 330 240 323.3 ± 43.1
Appendix 8.3 Platelet numbers (xl09A) in blood of dogs after administration of
cinchophen (in combination with 0.06 mg/kg prednisolone) at a
dose rate of 12.5 mg/kg by the oral route.
2 6 7
Animal Number 
3 4 5
Time
(h)
Pre
0 .5
1.0
2.0
4 .0
8 .0
24 .0
30 .0
48 .0
1
2.67 
1.83 
3.55
3.17 
2.33
4.17
1.67 
2.32
2.67
2
2.50 
3.08 
3.78 
4.00 
3.66
3.50 
1.58 
3.32 
2.89
3.92
1.92 
3.57 
3.48 
2.94 
2.67 
2.12 
3.26 
3.42
3.60
2.83
2.92
2.58
4.04
4.17
3.08
3.75
2.50
3.23
3.83
3.27
3.00 
3.46 
3.75
2.00 
3.60 
2.50
6
3.65
2.75
2.50
2.67
3.89
4.00
2.33
2.73
2.61
Mean
3.26
2.71
3.26
3.15 
3.39
3.71 
2.13
3.16 
2.76
Appendix 8.4 Clotting time (min.) of blood from dogs after administration of 
cinchophen (in combination with 0.06 mg/kg prednisolone) at a 
dose rate of 12.5 mg/kg by the oral route.
2 6 8
Time
(h). 1
Pen Number 
2 3
Pre -/NS NS/NS
12 -/- -/- -/-
24 -/- -/- -/-
48 NS/NS NS/NS NS/NS
= Negative 
NS = No sample
Appendix 8.5 Occult blood in faeces of dogs after administration 
of cinchophen (in combination with 0.06 mg/kg 
prednisolone) at a dose rate of 12.5 mg/kg by the oral route.
2 6 9
APPENDIX 9
TOLFENAM IC ACID INTRAVENOUS ADM INISTRATION TABLES
2 7 0
Time Animal Number
(h) 1 2 3 4 5 6
P re 0 0 0 0 0 0
0 .0 8 14.96 23.92 24.47 14.50 30.48 44.13
0 .1 7 8.67 13.07 23.63 11.55 24.05 28.10
0 .3 3 6.65 6.82 12.73 6.23 9.91 17.21
0 .5 0 0.92 2.15 7.34 4.81 5.03 9.66
0 .7 5 1.45 2.25 4.11 3.92 3.07 6.05
1 .0 0 1.25 0.55 2.04 2.14 1.11 2.60
2 .0 0 0 0 0.63 1.32 0.21 0.30
4 .0 0 0 .2 0 , 0.32 1.65 2.34 0.08 0.44.
8 .0 0 0.47 0.43 0.41 1.17 0.16 0.33
1 2 .0 0 0.27 0.34 0.24 0.52 0.08 0.21
2 4 .0 0 0.05 0 0.11 0.20 0 0.06
4 8 .0 0 0 0 0.10 0.12 0 0
7 2 .0 0 0 0 0 0.06 0 0
9 6 ,0 0 0 0 0 0.06 0 0
1 6 8 .0 0 0 0 0 0 0 0
Appendix 9.1 Concentration (pg/ml) of tolfenamic acid in plasma of dogs after
administration at a dose rate of 4.0 mg/kg by the intravenous route.
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Time Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 1.21 1.79 1.35 0.62 1.15 1.43 1.26 ± 0.16
0 .5 0 0.17 0.08 0.07 0.09 0.10 0.08 0.10 ± 0.01
1 .0 0 1.05 0.42 0.36 0.21 0.85 0.41 0.55 ± 0.13
2 .0 0 1.24 0.96 1.55 0.43 0.76 1.04 0.99 ± 0.16
4 .0 0 1.12 0.89 0.40 0.27 1.19 1.34 0.87 ± 0.18
8 .0 0 1.11 0.94 0.84 0.36 1.40 1.14 0.96 ± 0.14
12 .0 0 0.96 0.89 0.67 0.54 1.06 1.20 0.89 ± 0.10
2 4 .0 0 1.28 0.92 1.07 0.48 0.98 1.23 0.99 ± 0.12
4 8 .0 0 0.79 1.35 1.12 0.82 1.49 1.17 1.12 ± 0.11
7 2 .0 0 1.52 1.48 1.43 0.92 0.74 1.05 1.19 ± 0.13
9 6 .0 0 1.06 1.53 1.15 0.92 0.69 0.78 1.02 ± 0.12
16 8 .0 0 1.45 1.90 2.25 1.55 1.42 1.18 1.62 ± 0.16
Appendix 9.2 Thromboxane B2 concentration (jig/ml) in serum of dogs after 
administration of tolfenamic acid at a dose rate of 4.0 mg/kg 
by the intravenous route.
2 7 2
Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 341 190 NS 102 93 207 186.6 ± 44.7
0 .2 5 311 353 317 194 348 227 291.7 ± 26.9
0 .5 0 398 367 299 197 294 253 301.3 ± 30.0
1 .00 342 322 210 196 282 211 260.5 ± 25.8
2 .0 0 361 314 262 150 303 110 250.0 ± 40.4
4 .0 0 388 NS NS NS 328 NS 358.0 ± 30.1
6 .0 0 NS 321 258 92 321 NS 248.0 ± 54.1
8 .0 0 264 153 208 268 221 217 221.8 ± 17.2
12 .00 224 • 350 357 213 391 266 300.2 ± 30.8
2 4 .0 0 349 410 278 245 313 326 320.2 ± 23.4
4 8 .0 0 NS 284 197 NS NS NS 240.5 ± 43.6
7 2 .0 0 293 319 287 185 248 207 256.5 ± 21.4
Appendix 9.3 Platelet numbers (xl09/l) in blood of dogs after administration of
tolfenamic acid at a dose rate of 4.0 mg/kg by the intravenous route.
2 7 3
Tim e Animal Number
(h) 1 2 3 4 5 6 Mean
P re 2.42 3.90 3.72 2.22 2.35 3.99 3.10
0 .5 3.56 3.83 2.78 2.18 4.44 3.48 3.38
1 .0 3.08 4.17 3.44 4.30 3.17 3.50 3.61
2 .0 1.50 2.17 1.50 3.33 3.00 4.33 2.64
4 .0 4.00 2.67 3.83 1.50 3.83 2.00 2.97
8 .0 3.67 3.17 3.83 3.17 3.00 3.83 3.44
2 4 .0 3.68 1.66 3.00 2.88 3.55 4.03 3.13
4 8 .0 2.67 2.78 2.72 2.75 4.19 2.14 2.88
7 2 .0 3.14 4.33 2.75 2.83 2.50 2.75 3.05
9 6 .0 2.83 3.00 1.12 1.67 2.45 3.62 2.45
1 6 8 .0 4.06 3.30 2.50 3.00 2.25 3.64 3.29
Appendix 9.4 Clotting time (min.) of blood from dogs after administration of
tolfenamic acid at a dose rate of 4.0 mg/kg by the intravenous route.
Tim e Pen Number
(h ) . 1 2 3
P re -/- -/- -/-
24 -/- -/- -/-
48 NS -/- -/-
72 -/NS -/NS TR/NS
96 NS NS -/-
168 -/NS -/- -/NS
= Negative 
TR = Trace of colour change 
NS = No sample
Appendix 9.5 Occult blood in faeces of dogs after administration 
of tolfenamic acid at a dose rate of 4.0 mg/kg by the 
intravenous route.
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APPENDIX 10
TOLFENAM IC ACID SUBCUTANEOUS ADMINISTRATION TABLES
2 7 6
Tim e Animal Number
(h) 1 2 4 5 6
P re 0 0 0 0 0
0 .2 5 1.24 2.02 0.05 1.60 0.64
0 .5 0 3.17 2.44 1.27 2.11 1.82
1 .0 0 4.14 4.04 5.73 2.63 3.64
2 .0 0 3.47 3.23 5.76 2.39 5.40
4 .0 0 1.41 0.90 3.05 1.06 1.58
8 .0 0 0.19 0.68 0.33 0.40 0.99
1 2 .0 0 1.81 1.05 1.54 0.15 1.28
2 4 .0 0 0 0.11 0.07 0 0.36
4 8 .0 0 0.06 0 0 0 0.07
7 2 .0 0 0 0 0 0 0
9 6 .0 0 0 0 0 0 0
16 8 .0 0 0 0 0 0 0
Appendix 10.1 Concentration (jig/ml) of tolfenamic acid in plasma of dogs after
administration at a dose rate of 4.0 mg/kg by the
subcutaneous route.
2 7 7
Time Animal Number
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 1.64 1.23 1.44 1.22 1.64 1.74 1.48 ± 0.09
0 .2 5 0.42 0.38 0.31 0.09 0.61 1.18 0.50 ± 0.15
0 .5 0 0.21 0.21 0.14 0.13 0.55 0.79 0.34 ± 0.11
1 .0 0 0.18 0.23 0.22 0.18 0.37 0.74 0.32 ± 0.09
2 .0 0 0.27 0.30 0.31 0.25 0.28 0.30 0.29 ± 0.01
4 .0 0 0.47 0.74 0.53 0.60 0.78 0.79 0.65 ± 0.05
8 .0 0 0.65 0.71 0.78 0.60 1.29 0.85 0.81 ± 0.10
1 2 .0 0 0.67 0.63 1.45 0.71 1.65 1.25 1.06 ± 0.18
2 4 .0 0 1.30 1.11 1.00 0.67 1.50 1.48 1.18 ± 0.13
4 8 .0 0 1.05 0.96 1.22 0.78 1.43 1.97 1.24 ± 0.17
7 2 .0 0 1.16 1.23 1.45 0.96 1.16 1.45 1.24 ± 0.08
9 6 .0 0 0.83 . L 4 2 1.55 1.11 1.81 1.48 1.37 ± 0.14
1 6 8 .0 0 1.29 1.04 1.48 1.19 1.23 1.58 1.30 ± 0.08
A ppendix 10.2 Thromboxane B2 concentration (jig/ml) in serum of dogs after
administration of tolfenamic acid at a dose rate of 4.0 mg/kg by 
the subcutaneous route.
2 7 8
Tim e Animal Num ber
(h) 1 2 3 4 5 6 Mean ± SEM
Pre 419 439 482 NS 464 366 434.0 ± 20.1
0 .2 5 385 303 428 252 430 325 353.8 ± 29.5
0 .5 0 409 411 448 275 412 NS 391.0 ± 29.8
1 .0 0 372 414 444 289 452 118 348.2 ± 52.1
2 .0 0 302 274 280 267 351 318 298.7 ± 13.0
4 .0 0 391 439 361 290 NS 394 375.0 ± 24.6
8 .0 0 379 391 301 257 330 310 328.0 ± 20.5
1 2 .0 0 329 312 421 255 421 209 324.5 ± 35.1
2 4 .0 0 400 - 380 302 NS 341 NS 355.7 ± 21.7
4 8 .0 0 NS 367 312 198 252 265 278.8 ± 28.5
7 2 .0 0 390 374 399 246 394 255 343.0 ± 29.5
9 6 .0 0 242 251 274 175 209 100 208.5 ± 25.9
1 6 8 .0 0 353 391 311 253 382 221 318.5 ± 28.5
Appendix 10.3 Platelet numbers (xl09/l) in blood of dogs after administration of
tolfenamic acid at a dose rate of 4.0 mg/kg by the intravenous route.
2 7 9
Tim e Animal Num ber
(h ) 1 2 3 4 5 6 Mean
P re 2.33 3.33 3.30 2.50 2.78 3.33 2.93
0 .5 3.33 3.67 2.86 3.92 2.37 3.27 3.24
1 .0 1.33 1.66 2.33 3.10 3.48 1.93 2.29
2 .0 2.67 4.08 3.28 3.53 3.17 3.73 3.41
4 .0 2.00 2.92 3.12 2.83 2.50 2.67 2.67
8 .0 3.50 2.67 3.17 3.24 2.98 2.50 3.01
2 4 .0 1.83 3.33 3.07 2.00 2.15 4.13 2.75
4 8 .0 2.17 2.83 2.50 2.83 2.00 3.22 2.59
7 2 .0 2.50 3.52 2.46 2.87 3.07 1.83 2.71
9 6 .0 2.67 2.67 2.62 1.47 2.01 3.17 2.44
1 6 8 .0 4.17 3.00 2.77 2.57 2.20 2.90 2.93
Appendix 10.4 Clotting time (min.) of blood from dogs after administration of
tolfenamic acid at a dose rate of 4.0 mg/kg by the subcutaneous route.
Tim e
(h ). 1
Pen Number 
2 3
Pre -/- -/- -/-
24 -/NS -/NS -/NS
48 -/NS TR/NS +/NS
72 -/- -/- -/-
96 NS NS NS
168 -/- -/- - /-
- = Negative
TR = Trace of colour change 
NS = No sample
Appendix 10.5 Occult blood in faeces of dogs after administration 
of tolfenamic acid at a dose rate of 4.0 mg/kg by the 
subcutaneous route.
APPENDIX 11 
PROTEIN BINDING TABLES
2 8 2
Species
Dog
Sam ple Dialysed Ratio Undialysed Ratio
1 1.29 1.37
2 1.21 1.35
3 1.32 1.36
4 1.30 1.52
5 1.24 1.42
6 1.28 1.29
Mean 1.27 1 .3 8
SEM 0.0 2 0 .0 3
G oat 1
2
3
4
5
6
Mean
SEM
NS
1.22
1.15
1.13
1.13 
1.06
1.14  
0 .0 3
1.18
1.40
1.34
1.30 
1.36
1.31
1.31  
0 .0 3
H o rse 1
2
3
4
5
6
Mean
SEM
1.24 
1.20 
1.22
1.23
1.25
1.24
1.23
0.01
1.47
1.46 
1.37 
1.35 
1.39
1.47
1 .42
0.02
Appendix 11.1 Ratios of sample to standard HPLC peak heights for flunixin 
in dialysed and undialysed serum from three animal species.
Species
Dog
Sam ple
1
2
3
4
5
6
Mean
SEM
Dialysed Ratio
0.91
0.85
0.95
0.92
0.93
0.93
0 .9 1
0.01
Undialysed Ratio
0.97
1.04
1.00 
1.00
1.07
1.01
0 .9 7
0 .0 5
G oat 1
2
3
4
5
6
Mean
SEM
0.82
0.83
0.83
0.87
0.89
0.89
0 .8 5
0.01
1.04
0.89
0.94
1.09
1.06
1.06
1.01
0 .0 3
H orse 1
2 
. 3
4
5
6
Mean
SEM
1.29
1.02
0.99
1.04
1.02
1.10
1 .08
0 .0 4
1.07 
1.14 
1.16 
0.96 
1.13 
1.05
1 .0 8  
0 .0 3
Appendix 11.2 Ratios of sample to standard HPLC peak heights for 
meclofenamic acid in dialysed and undialysed serum 
from three animal species.
2 8 4
APPENDIX 12
IN VITRO INHIBITION OF SERUM THROMBOXANE TABLES
2 8 5
D rug Cone. Animal Num ber
(pg /m l) 1 2 3 4
0 0.588 0.541 0.377 0.495
0 .0 0 0 5 0.491 NS 0.331 0.520
0 .0 0 1 0 0.526 0.446 0.324 0.505
0 .0 0 5 0 0.408 0.386 0.315 0.406
0 .0 0 7 5 0.457 0.448 0.351 0.435
0 .0 1 0 0 0.386 0.437 0.319 0.441
0 .0 2 0 0 0.262 0.489 0.287 0.367
0 .0 2 5 0 0.259 0.347 0.282 0.373
0 .0 5 0 0 0.180 0.263 0.193 0.244
0 .0 7 5 0 0.126 0.357 0.189 0.211
0 .1 0 0 0 0.144 0.217 0.165 0.179
0 .2 0 0 0 0.012 0.104 0.173 0.125
0 .2 5 0 0 0.026 0.139 0.083 0.105
0 .5 0 0 0 0.012 0.057 0.056 0.042
0 .7 5 0 0 0.027 0.064 0.014 0.037
1 .0000 0.011 0.043 0.018 0.037
2 .5 0 0 0 0.007 0.021 0.012 0.017
5 .0 0 0 0 0.005 0.010 0.010 0.011
7 .5 0 0 0 0.005 0.018 0.005 0.013
10 .0000 0.005 0.016 0.009 0.015
NS = No sample
Appendix 12.1 Concentration (|ig/ml) of thromboxane B2 in the serum of dogs.
Blood clotting occured in the presence of flunixin.
2 8 6
Drug Cone
(pg/ml)
0
0.0005
0.0010
0.0050
0.0075
0.0100  
0.0200
0.0250
0.0500
0.0750
0.1000 
0.2000
0.2500
0.5000
0.7500
1.0000
2.5000
5.0000
7.5000  
10.0000
Appendix 12.2
1
0.04247
0.04090
0.03960
0.02555
0.02605
0.02523
0.01715
0.01415
0.00775
0.00640
0.00555
0.00360
0.00353
0.00153
0.00046
0.00067
0.00044
0.00036
0.00041
0.00055
Animal Number 
2
0.05845
0.04930
0.04995
0.03710
0.03365
0.03177
0.02452
0.01402
0.00745
0.00635
0.00400
0.00090
0.00110
0.00035
0.00020
0.00015
0.00005
0.00006
0.00003
0.00011
3
0.03284
0.03080
0.02891
0.01536
0.01707
0.01850
0.00770
0.00468
0.00170
0.00146
0.00071
0.00106
0.00063
0.00028
0.00049
0.00006
0.00009
0.00005
0.00010
0.00008
Concentration (|ig/ml) of thromboxane B2 in the serum of goats.
Blood clotting occured in the presence of flunixin.
2 8 7
>rug Cone. Animal Number
(pg/ml) 1 2 3 4
0 0.0437 0.0110 0.0090 0.0234
0.0005 NS 0.00895 0.0105 0.01975
0.0010 0.0420 0.00802 0.01025 0.01582
0.0050 0.0380 0.00965 0.00777 0.01525
0.0075 NS 0.00875 0.00742 0.01680
0.0100 0.0280 0.00534 0.00628 0.01071
0.0200 NS 0.00456 0.00682 0.00960
0.0250 0.0120 0.00456 0.00553 0.00855
0.0500 0.0085 0.00374 0.00332 0.00403
0.0750 0.003 0.00286 0.00342 0.00488
0.1000 0.0030 0.00183 0.00189 0.00542
0.2500 0.0010 0.00070 0.00845 0.00350
0.5000 0.0012 0.00031 0.00034 0.00674
0.7500 0.0006 0.00020 0.00031 0.00066
1 .0000 0.00073 0.00021 0.00030 0.00057
2.5000 0.00015 NS NS NS
5.0000 0.00014 NS 0.00012 0.00066
10.0000 0.00013 NS 0.00015 0.00050
NS = No sample
Appendix 12.3 Concentration (jig/ml) of thromboxane B2 in the serum of horses.
Blood clotting occured in the presence of flunixin.
rug Cone. Animal Num ber
(pg /m l) 1 2 3
0 0.438 0.408 0.580
0 .0 0 0 5 0.297 0.330 0.452
0 .0 0 1 0 0.281 0.298 0.487
0 .0 0 5 0 NS 0.347 0.384
0 .0 0 7 5 0.309 0.327 0.536
0 .0 1 0 0 0.286 0.325 0.547
0 .0 2 0 0 0.079 0.357 0.439
0 .0 2 5 0 NS NS 0.519
0 .0 5 0 0 NS 0.320 0.479
0 .0 7 5 0 0.341 0.280 0.617
0 .1 0 0 0 0.181 0.305 0.439
0 .2 0 0 0 0.026 0.286 NS
0 .2 5 0 0 0.005 0.277 NS
0 .5 0 0 0 NS 0.144 0.391
0 .7 5 0 0 0.061 0.114 0.318
1 .0000 0.016 NS NS
2 .5 0 0 0 NS 0.073 0.114
5 .0 0 0 0 NS 0.011 0.329
7 .5 0 0 0 NS 0.006 0.136
10 .0000 0.004 0.005 0.065
2 0 .0 0 0 0 NS NS 0.029
3 8 .0 0 0 0 NS NS 0.006
NS = No sample
Appendix 12.4 Concentration (jig/ml) of thromboxane B2 in the serum of dogs.
Blood clotting occured in the presence of meclofenamic acid.
2 8 9
D rug Cone
(pg/m l) 1
0 0.04234
0 .001 0.04195
0 .0 0 5 0.04425
0 .0 1 0 0.04970
0 .0 5 0 0.03218
0 .1 0 0 0.02944
0 .2 0 0 0.03573
0 .2 5 0 0.01509
0 .5 0 0 0.00656
0 .7 5 0 0.00428
1 .000 0.00350
2 .5 0 0 0.00034
5 .0 0 0 0.00017
7 .5 0 0 0.00014
10 .0 0 0 0.00005
2 0 .0 0 0 NS
3 8 .5 5 0 NS
1 3 3 .330 NS
NS = No sample
Animal Num ber
2 3
0.08800 0.07767
0.09295 0.06320
0.08205 0.05035
0.07192 0.07830
0.06789 0.06206
0.04231 0.04715
NS NS
0.02644 0.03096
0.01198 0.01388
0.00850 0.01253
0.00335 0.00478
0.00078 0.00156
0.00023 0.00054
0.00021 0.00039
0.00019 0.00025
0.00016 0.00009
NS 0.00005
NS 0.00005
Appendix 12.5 Concentration (pg/ml) of thromboxane B2 in the serum of goats.
Blood clotting occured in the presence of meclofenamic acid.
2 9 0
D rug Cone.
(pg /m l) 1
0 0.02346
0 .0 0 1 0.01225
0 .0 0 5 0.01190
0 .0 1 0 0.01624
0 .0 2 0 0.01455
0 .0 5 0 0.00993
0 .1 0 0 0.01066
0 .2 5 0 0.00522
0 .5 0 0 0.00255
0 .7 5 0 0.00184
1 .000 0.00117
2 .5 0 0 0.00048
5 .0 0 0 0.00019
7 .5 0 0 0.00020
10 .000 0.00012
2 0 .0 0 0 0.00006
3 8 .5 5 0 NS
1 3 3 .330 NS
NS = No sample
Animal Num ber 
2 3
0.02260 0.05145
0.03040 0.04655
0.02745 0.04425
0.02458 0.04948
0.01390 0.04520
0.01201 0.03892
0.01182 0.03383
0.00612 0.02122
0.00312 0.00956
0.00171 0.00710
0.00009 0.00336
0.00034 0.00130
0.00016 0.00071
0.00032 0.00075
0.00010 0.00043
0.00002 0.00023
0.00002 0.00019
NS 0.00007
Appendix 12.6 Concentration (|ig/ml) of thromboxane B2  in the serum of horses.
Blood clotting occured in the presence of meclofenamic acid.
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D rug Dog G oat H o rse
C oncentration  
(|ig /m l)
0 .0 0 0 5  NS NA NA
0 .0 0 1 0  NS NS NS
0 .0 0 5 0  NS NS <0.05
0 .0 0 7 5  NS NA NA
0 .0 1 0 0  NS NS NS
0 .0 2 0 0  NS NA <0.05
0 .0 2 5 0  NS NA NA
0 .0 5 0 0  NS NA <0.05
0 .0 7 5 0  NS NA NA
0 .1 0 0 0  <0.05 <0.01 <0.05
0 .2 0 0 0  NS NS NA
0 .2 5 0 0  NS <0.01 NS
0 .5 0 0 0  <0.05 NS NS
0 .7 5 0 0  NS <0.01 <0.01
1 .0 0 0 0  NS <0.05 NS
2 .5 0 0 0  <0.01 NS NS
5 .0 0 0 0  NS NS NS
7 .5 0 0 0  NS NS NA
10 .0 0 0 0  NS NS NS
2 0 .0 0 0 0  NA NA NA
3 8 .5 5 0 0  NA NA NA
13 3 .3 3 0 0  NA NA NA
NS = Not significant 
NA = No sample
A ppendix 12.7 Level of significant difference in inhibition of in vitro serum
TxB2 which occured in the presence of flunixin when compared with 
the inhibition which occured in the presence of meclofenamic acid in 
each of three species.
2 9 2
D rug Dog versus Dog versus G oat veri
dncentration G oat H orse H orse
(pg /m l)
0 .0 0 0 5 NS NS NA
0 .0 0 1 0 NS NS NA
0 .0 0 5 0 <0.05 NS <0.05
0 .0 0 7 5 <0.01 NS <0.01
0 .0 1 0 0 <0.05 <0.05 NS
0 .0 2 0 0 <0.05 NS NS
0 .0 2 5 0 <0.05 NS NS
0 .0 5 0 0 <0.01 <0.05 NS
0 .0 7 5 0 <0.05 NS NS
0 .1 0 0 0 <0.01 <0.05 NS
0 .2 0 0 0 NS NA NA
0 .2 5 0 0 NS NS NS
0 .5 0 0 0 NS NS NS
0 .7 5 0 0 <0.05 NS <0.05
1 .0000 <0.05 NS <0.05
2 .5 0 0 0 <0.05 NA NA
5 .0 0 0 0 <0.05 NS NS
7 .5 0 0 0 NS NA NA
1 0 .0000 NS NS NS
NS = Not significant 
NA = No sample
Ap pen di x 12.8 Level of significant difference in inhibition of in vitro serum
TxB2 when each species was compared to another species.
Blood clotting occured in the presence of flunixin.
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D rug Dog versus Dog versus Goat versus
C oncentration
(pg /m l)
G oat H orse H orse
0 .0 0 0 5 NA NA NA
0 .0 0 1 0 NS NS NS
0 .0 0 5 0 NS NS NS
0 .0 0 7 5 NA NA NA
0 .0 1 0 0 NS NS NS
0 .0 2 0 0 NA NS NA
0 .0 2 5 0 NA NA NA
0 .0 5 0 0 NS NS NS
0 .0 7 5 0 NA NA NA
0 .1 0 0 0 NS NS NS
0 .2 0 0 0 NA NA NA
0 .2 5 0 0 NS NS <0.01
0 .5 0 0 0 NS NS NS
0 .7 5 0 0 NS NS <0.05
1 .0 0 0 0 NA NA NS
2 .5 0 0 0 <0.01 <0.01 NS
5 .0 0 0 0 NS NS NS
7 .5 0 0 0 NS NS 0.014
1 0 .0 0 0 0 NS NS NS
2 0 .0 0 0 0 NA NA NS
3 8 .5 5 0 0 NA NA NA
13 3 .3 3 0 0 NA NA NA
NS = Not significant 
NA = No sample
A ppendix 12.9 Level of significant difference in inhibition of in vitro serum 
TxB2 when each species was compared to another species. 
Blood clotting occured in the presence of meclofenamic acid.
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